CLINICAL STUDY PROTOCOL  
 
 
Study ID: [REMOVED] 
 Study Title:  A Retrospective and Prospective, Open -label, Long -term Safety and  Efficacy 
Study of Teduglutide in Pediatric Subjects with Short Bowel  Syndrome Who 
Completed TED -C13-003 
 Study Number:   SHP633 -303 
  Protocol Version  and Date :   
Original Protocol :  11 May 2016  
Amendment 1 :  22 Nov 2016  
Amendment 1.1:  09 Jan 2017  
Amendment 2:   17 Mar  2017 
Amendment 3:   16 May 201 8 
Amendment 4:   [ADDRESS_393253]  2019 
 
PROTOCOL: SHP633 -303
TITLE: A Retrospective and Prospective, Open -label, Long -term Safet y and 
Efficacy  Study  of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED- C13-003
DRUG: Teduglutide
IND: IND# [ADDRESS_393254] NO.: 2016-000863-17
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_393255] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Original Protocol: 11May [ADDRESS_393256] party without the express written consent of Shire.
For non-commercial use only
Shire CONFIDENTIAL 
Protocol SHP633-303 
PROTOCOL SIGNATURE [CONTACT_64783]'s (Shire) Approval 
"-· "''"" ... " ........ ·-·-···· 
Date: Page2 
11 May2016 
Signature: 
··········-··················· 
, MD PhD ..... -··· _ ..... . 
 Clinical Medicine 
. Global Clinical Development 
Investigator's Aclmowledgement 
I have read this protocol for Shire Study SHP633-303. 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-C13-[ADDRESS_393257] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) 
For non-commercial use only

Shire CONFIDENTIAL Page [ADDRESS_393258] IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required b y Protocol within 24 hours to the Shire Global Pharmacovigilance and Risk 
Management Department. Applicable fax numbers and e- mail address can be found on the form 
(sent under sep arate cover). A cop y of this form must also be sent to the contract research 
organization Shire Medical Monitor by  [CONTACT_3719] e -mail using the details below.
, MD PhD
Email: 
Fax: 
For protocol -or safety- related issues during normal business hours ([ADDRESS_393259] Time) ,the investigator must contact [CONTACT_317344]:
, MD PhD,  Clinical Medicine
Phone: 
Mobile: 
Email: 
Fax: 
For protocol -or safety- related issues outside of normal business hours , the investigator 
must contact [CONTACT_319404]:
, MD, 
Phone:  (medical emergencies –[LOCATION_002])
Phone:  (medical emergencies –Global)
Email: 
r on-commercial use only

Shire CONFIDENTIAL Page [ADDRESS_393260] 
(marketed or investigational) does not meet expectations (eg, inadeq uate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs rel ated to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire ([LOCATION_003]) 
For non-commercial use only

Shire CONFIDENTIAL Page [ADDRESS_393261] Background ................................
.................................................................25
2STUDY OBJECTIVES AND PURPOSE ..............................................................................27
2.1 Rationale for the Study .............................................................................................27
2.2 Study  Objectives ......................................................................................................27
2.2.1 Primary  Objectives .................................................................................................27
2.2.2 Secondary  Objectives .............................................................................................27
3STUDY DESIGN ...................................................................................................................28
3.1 Study  Design and Flow Chart ..................................................................................28
3.1.1 Informed Consent/Assent and Eligibility ...............................................................29
3.1.2 Retrospective Data Collection ...............................................................................29
3.1.3 Prospective Data Collection and Treatment ..........................................................30
3.2 Duration and Study  Completion Definition .............................................................31
4STUDY POPUL ATION.........................................................................................................32
4.1 Study  Inclusion Eligibility  Criteria ..........................................................................32
4.2 Study  Exclusion Eligibility  Criteria ................................
.........................................32
4.3 Teduglutide Eligibility  Criteria ................................................................................32
4.4 Teduglutide Treatment Inclusion Criteria ................................................................32
4.5 Teduglutide Treatment Exclusion Criteria...............................................................33
4.6 Follow -up Period Escape Criteria ............................................................................34
4.7 Reproductive Potential .............................................................................................34
4.7.1 Female Contraception ................................
............................................................34
4.8 Discontinuation of Subjects .....................................................................................35
4.8.1 Teduglutide Discontinuation..................................................................................35
4.8.2 Study  Withdrawal ..................................................................................................35
4.8.3 Reasons for Discontinuation ..................................................................................35
For non-commercial use only
Shire CONFIDENTIAL Page 6
Protocol SHP633 -303 11 May 2016
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................[ADDRESS_393262](s) ...........................................................38
6.2.1 Interactive Response Technology  (IRT) for Investigational Product 
Management ...........................................................................................................[ADDRESS_393263] Compliance ..................................................................................................41
7 STUDY PROCEDURES........................................................................................................42
7.1 Study  Schedule .........................................................................................................42
7.1.1 Retrospective Data Collection
...............................................................................42
7.1.2 Screening ................................................................................................................43
7.1.3 Visits for Subjects Not Receiving Teduglutide .....................................................43
7.1.4
Visits for Subjects Receiving Teduglutide Treatment...........................................44
[IP_ADDRESS] Pretreatment Visit ...................................................................................44
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24) .....................................45
[IP_ADDRESS] Site Visits during Teduglutide Treatment Period ...................................45
[IP_ADDRESS] Phone Visits ............................................................................................46
7.1.5 Teduglutide Follow -up Period ...............................................................................46
[IP_ADDRESS] CxW28 ................................
...................................................................46
[IP_ADDRESS] Study  Completion/Earl y Termination Visit (EOS/ET Visit) .................47
7.2 Study  Evaluations and Procedures ...........................................................................47
7.2.1 Retrospective Data Collection ...............................................................................47
[IP_ADDRESS] Growth (Height, Weight, and Head Circumference) ............................. 47
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed ................................ ................ 47
[IP_ADDRESS] Parenteral Support Prescribed ................................ ................................ 47
For non-commercial use only
Shire CONFIDENTIAL Page 7
Protocol SHP633 -303 11 May 2016
[IP_ADDRESS] Adverse Events ................................ ................................ ....................... 48
7.2.2 Prospective Data Collection...................................................................................48
[IP_ADDRESS] Demographics, Medical History , and SBS History ................................48
[IP_ADDRESS] Physical Examination .............................................................................48
[IP_ADDRESS] Vital Signs, Bod y Weight, Height, Head Circumference and Bod y 
Mass I ndex (BMI) ..................................................................................48
[IP_ADDRESS] Clinical L aboratory  Tests .......................................................................49
[IP_ADDRESS] Serum Sampling .....................................................................................51
[IP_ADDRESS] Pregnancy  Testing ..................................................................................51
[IP_ADDRESS] Antibody  Testing ....................................................................................51
[IP_ADDRESS] Volume of Blood ....................................................................................51
[IP_ADDRESS] Gastrointestinal -specific Testing ............................................................52
[IP_ADDRESS] Health-related Quality  of L ife Assessments ...........................................54
8ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................56
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................56
8.1.1 Severity  Categorization ..........................................................................................57
8.1.2 Relationship Categorization ...................................................................................57
8.1.3 Outcome Categorization ................................
........................................................58
8.1.4 Symptoms of the Disease under Study ..................................................................58
8.1.5 Clinical L aboratory  and Other Safet y Evaluations (Prospective Period of 
Observation Onl y)................................
..................................................................58
8.1.6 Pregnancy ...............................................................................................................59
8.1.7 Abuse, Misuse, Overdose, and M edication Error (Prospective Period of 
Observation Onl y)..................................................................................................[ADDRESS_393264] ...........................................................................62
8.4
Dose Interruption and Permanent Discontinuation (Prospective Period of 
Observation Onl y)................................ ................................ ................................ ....63
8.4.1 Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide ( Prospective Period of Observation Only )................................ ......... 63
For non-commercial use only
Shire CONFIDENTIAL Page 8
Protocol SHP633 -303 11 May 2016
8.4.2 Dose Interruption Criteria Based on Drug -Induced L iver Injury  (Prospective 
Period of Observation Only )..................................................................................65
8.5 Early Termination of the Clinical Study  (Prospective Period of Observation 
Only ).........................................................................................................................66
9DATA MANAGEMENT AND STATISTICAL METHODS...............................................67
9.1 Data Collection .........................................................................................................67
9.2 Clinical Data Management .......................................................................................67
9.3 Statistical Analy
sis Process ......................................................................................67
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................67
9.5 Sample Size Calculation and Power Considerations
................................................68
9.6 Study  Population ......................................................................................................68
9.7 Efficacy  Anal yses................................................................
.....................................68
9.7.1 Efficacy  Endpoints ................................................................
.................................68
9.8 Safety  Anal yses........................................................................................................68
9.8.1 Safety  Endpoints ....................................................................................................68
9.9 Other Anal yses.........................................................................................................70
9.9.1 Health- related Quality  of L ife Anal yses................................................................70
10SPONSOR’S AND INVESTI GATOR’S RESPO NSIBILIT IES...........................................71
10.1 Sponsor’s Responsibilities .......................................................................................71
10.1.1 Good Clinical Practice Compliance .......................................................................71
10.1.2 Indemnity /Liability  and Insurance .........................................................................71
10.1.3 Public Posting of Study  Information ................................
......................................71
10.1.4 Submission of Summary  of Clinical Study  Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees ........................71
10.1.5 Study  Suspension, Termination, and Completion
..................................................72
10.2 Investigator’s Responsibilities .................................................................................72
10.2.1 Good Clinical Practice Compliance .......................................................................72
10.2.2 Protocol Adherence and Investigator Agreement ..................................................72
10.2.3 Documentation and Retention of Records .............................................................73
[IP_ADDRESS] Case Report Forms .................................................................................73
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ................................
..............................................................73
[IP_ADDRESS] Audit/I nspection .....................................................................................73
[IP_ADDRESS] Financial Disclosure ...............................................................................[ADDRESS_393265] or Ethics Committee ................................ .................. 74
10.4 Privacy  and Confidentiality ................................ ................................ ...................... 75
10.5 Study  Results / Publication Policy ................................ ................................ ........... [ADDRESS_393266]  OF TABLES
Table 1-1: Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................19
Table 1-2: Schedule of Events for Screening and End of Study  or Earl y 
Termination ...................................................................................................20
Table 1-3: Schedule of Events for No Teduglutide Treatment Period
...........................21
Table 1-4: Schedule of Events for Teduglutide Treatment Period
.................................22
Table 5- 1: Prohibited Treatment .....................................................................................37
Table 7-1: List of Laboratory  Tests ................................................................................50
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................52
Table 7
-3: Developmentally Appropriate PedsQL™Generic Core Scales .....................55
Table 8
-1: CTCAE Criteria for Adverse Events that May  Lead to Dose 
Interruption (Prospective Period of Observation Only ) ................................[ADDRESS_393267]  OF FIGURES
Figure 3 -1: Study  Design Flow Chart ................................
..............................................[ADDRESS_393268] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study report
CTCAE Common Terminology Criteria for A dverse Events
DILI drug-induced livery injury
DMC data monitoring committee
DPP-[ADDRESS_393269]
IRT interactive response technology
IV intravenous
IWRS interactive web -based response system
MedDRA Medical Dictionary for Regulatory Activities
NCI National Cancer Institute
NDA new drug application
For non-commercial use only
Shire CONFIDENTIAL Page 12
Protocol SHP633 -303 11 May 2016
NTT no-teduglutide treatment
PDA patent ductus arteriosus
PedsQL Pediatric Quality of Life Inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once daily
SAE serious adverse event
SAP statistical analysis plan
SBS short bow el syndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_393270] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization -Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page 13
Protocol SHP633 -303 11 May 2016
STUDY  SYNOPSIS
Protocol num ber: SHP633 -303 Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open -label, Long -term Safety and Efficacy Study of 
Teduglutide in Pediatric Patients with Short Bow el Syndrome Who Completed TED -C13-003
Number of subjects (total and for each treatm ent arm):
Approximately [ADDRESS_393271] of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED -C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the [LOCATION_002] (US) and the [LOCATION_008] ([LOCATION_006]) will particip ate in 
this extension study.
Study period (planned):
October 2016 -September 2019Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith short 
bowel syndrome ( SBS)who completed TED -C13-003.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED -C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open -label, long -term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED -C13-[ADDRESS_393272] of care ( SOC )treatment arm in 
TED -C13-003.
Investigational product, dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subj ects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED -C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of specific 
safety and efficacy measures that were completed in the course of the subject’s standard medical care betw een the 
date of the TED -C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and if applicable, 
informed assent) is signed fo r this study. In addition to this retrospective data collection, prospective study 
assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review  and signing of the ICF (and if applicable, i nformed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collec tion only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393273]’s standard medical care betw een the date of the TED -C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collecti on may begin any time after 
informed consent/assent is obtained for this study. The following data w ill be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Growth [height, head circumference (up to 36 months of age), w eight]
End dates for adverse events (AEs) ongoing at the time of TED -013-003
Nonserious treatment -related adverse events (AEs)
All adverse events of special interest ( AESIs)
All serious adverse events (SAEs)
Prospective Data Collection andTreatment
Additional scre ening visit procedures for prospective data collection assessments can be found in Table 1 -2.These 
procedures include but are not limited to, collection of demographics, medical history, and short bow el syndrome 
history. Prescription parenteral support re quirements will be collected at screening. 
Additionally, intake diaries will be dispensed at the screening visit, for collection of actual parenteral support (PS)
volume and hours per day, and actual enteral nutrition (EN) volume per day ( Section [IP_ADDRESS] ). Diary data for 
PN/intravenous ( IV)volume will be collected for at least 2 weeks after the ICF (and if applicable, the informed 
assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no -teduglutide treatment [NTT] perio d), w ill be seen every 
12weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for PN/IV volume will be 
collected for at least [ADDRESS_393274] NTT visit will occur approximately 12 w eeks after the 
screening visit. At any point after screening, including during an NTT period, subjects who meet ≥[ADDRESS_393275], and parent 
or legal guardian agreesto proceed w ith teduglutide therapy .
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28 -week cycle, consisting of 24 w eeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up (no treatment) period ( Figure 3 -1). During 
the 28 -week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
appro ximately 1 week after adjustments in PS during the TED treatment period, betw een Weeks 1 -24, and w eekly 
during the follow -up period, betw een W eeks 24 and 28.
At all site visits and telephone contacts, safety will be monitored and nutritional support will b e reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 w eeks. To m aintain 
consistency across centers, all attempts should be made to follow  the nutritional support adjustment guidelines 
(developed w ith SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation ( Appendix 1 ).
For non-commercial use only
Shire CONFIDENTIAL Page 15
Protocol SHP633 -303 11 May 2016
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured every 12 weeks, but 
subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. Eligible s ubjects 
will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy assessments at 
Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines ). Phone visits are required approximately 1 week after adjustments in 
PS during the intervening weeks between W eeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide at Week 24 
and enter a 4 -week follow -up (no -treatment) period, during which phone visits will be performed weekly ( solid grey lines ). If 
an esca pe criterion is met during the follow -up period, subjects may proceed directly to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet allof the study inclusion criteria. Teduglutide 
treatm ent eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, informed 
assent) to participate in the study before completing any study -related procedures.
2.Subject completed the TED -C13-003 study (including subjects in the standard of care treatment arm).
3.Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligib le for teduglutide treatment if ≥[ADDRESS_393276] (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria :
1.Subject is teduglutide -naïve, receiving PS, and unable to significantly reduce PS or advance ente ral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and during the 
teduglutide pretreatment visit, as assessed by [CONTACT_093]. Transient instability for events such as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of baseline 
prior to the event.
2.Subject w as previously treated w ith teduglutide and at least 1 of the following criteria is satisfied:
a.Increasing PS requirements follow ing teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319405]-commercial use only
Shire CONFIDENTIAL Page 16
Protocol SHP633 -303 11 May 2016
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319360]
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361]
e.Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <10 kg at the pretreatment visit
2.Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.History of cancer in the previous 5 years except surgically curative skin cancers
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections ≤10 
cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle
6.Clinically significant intestinal stricture or obstruction
7.Clinically significant, active or recurrent pancreatic or biliary disease
8.Active, severe, or unstable, clin ically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal d ysfunction shown by [CONTACT_319406] (eGFR) below 
50mL/min/1.[ADDRESS_393277] repair, or patent ductus arteriosus (PDA) ligation
11.Participation in a clinical study using an experimental drug (other than glutamine or Omegaven) within 
3months or 5.5 half -lives of the experimental drug, whichever is longer, prior to the pretreatment visit 
and for the duration of the 28 -week cycle
12.Treatment with analogs of glucagon -like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP -2) (not 
including teduglutide), insulin -like growth factor -1 (IGF -1), or grow th hormon e, within 1 month 
preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_393278], closely -related 
compounds, or any of the stated ingredients
15.Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16.Pregnant or lactating female subjects
17.Sexually active female subjects of child -bearing pot ential unwilling to use approved contraception during 
teduglutide treatment and for 30 days after the treatment period
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents completi on of the study, or interferes with analysis of the study results
Follow -up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interrupted 
and the subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
For non-commercial use only
Shire CONFIDENTIAL Page 17
Protocol SHP633 -303 11 May 2016
2.Deteriorating nutritional status (eg, w eight loss or growth failure) despi[INVESTIGATOR_319363]
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319364]
4.Severe diarrhea related to teduglutide discontinuation
Maximum duration of subject involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple [ADDRESS_393279] has access (as needed) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately [ADDRESS_393280] has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.
Planned duration of retrospective data collection: variable
Planned duration of no -teduglutide treatm ent periods: variable, depending on disease course
Planned duration of the teduglutide pretreatm ent visit: 1-21 days
Planned teduglutide treatment cycle duration :28 w eeks. Each cycle consists of 24 w eeks of 
teduglutide treatment followed by a 4 -week follow -up period (no treatment)
Endpoints and statistical analysis:
The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
The follow ing efficacy endpoints will be analyzed relative to the baseline of the prospective study period, the 
baseline of each teduglutide treatment cycle ,and the baseline of the core study, as applicable, at the following time 
points: 1) 12 -week intervals during the retrospective observation period, 2 ) the end of each prospective teduglutide 
treatment period ( Week 24/ end of treatment [ EOT ]), and 3) each prospective study visit. The derivations of the 
weekly PS volume and baselines will be described in the study statistical analysis plan (SAP) in detail.
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research Endpoints
Health economics and outcomes research endpoints will be analyze d at approximately 12 -week intervals ( Weeks 
12 and 24 of each teduglutide treatment cycle, and every 12 weeks for subjects not on teduglutide), relative to the 
baseline of the prospective study period. The beginning of each treatment cycle (CxD1) will be a n additional 
baseline.
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores:
oFood and drink limits
oDiarrhea
Safety Endpoints
The follow ing safety endpoints will be analyzed from the beginning of the prospective study period:
Adverse events, including those pertaining to GI symptoms
Vital signs, including body temperature, heart rate, and blood pressure
Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)
Urine output
For non-commercial use only
Shire CONFIDENTIAL Page 18
Protocol SHP633 -303 11 May 2016
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy 
and as needed
The follow ing safety endpoints will b e analyzed from the end of the core study ( Week 16/EOS) to the beginning of 
the prospective study period:
 All adverse events related to teduglutide
 All SAEs
 All Adverse Events of Special Interest ( Section 8.3 )
The follow ing safety endpoints will be analyzed relative to the baseline of the core study (TED -C13-003):
 Z-scores for height (or length), w eight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; how ever, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard devia tion , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summariz ed by  [CONTACT_765]. A dverse event s 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_300192].
Sample Size Justification
As this is an extension study, the maximum number of subjects will be dete rmined by [CONTACT_319407] -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 19
Protocol SHP633 -303 11 May 2016
STUDY  SCHEDULES
Table 1-1: Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment Note
Informed consent/assent Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study -
related procedures, including retrospective data collection.Study eligibility
Weight The last representative value for w eight during each [ADDRESS_393281] all available teduglutide prescription start and stop dates and 
corresponding dose levels (mg/kg/day) that were prescribed or planned as part 
of an investigator -initiated trial during the retrospective data collection period.
Parenteral support (PS) 
prescribedThe last stable, representative PS prescription during each 12 -week interval 
throughout the retrospective period and at the beginning and end of any 
teduglutide treatment will be col lected. Data collected should include weekly 
prescribed volume, calories, average hours per day, and days per w eek of 
prescribed PS .
End dates for adverse events 
(AEs) ongoing at the end of 
TED -013-[ADDRESS_393282]
Serious adverse events (SAEs)
Note: Retrospective data is defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED -C13 -003 end of study (EOS) visit and the date the 
informed consent form ( ICF) (and if applicable, informed assent) is signed for this study . Twelve -week intervals of data will be 
collected starting [ADDRESS_393283]’s TED -013- [ADDRESS_393284] data because data are unavailable will not be considered a protocol deviation. For 
subjects who consent only to retrospective data collection, only assessments in this table (Table 1-1) will be completed.
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
For non-commercial use only
Shire CONFIDENTIAL Page 20
Protocol SHP633 -303 11 May 2016
Table 1-2:Schedule of Events for Screening and End of Study or Early Termination
ScreeningEnd of Study or Early 
Termination
Visit Type Site Site
Informed consent/assent X
Study eligibility X
Dem ographics, medical history, SBS historyaX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriabX
Adverse events X X
Concomitant medications and GI procedurescX X
Physical examination and vital signs, including weight X X
Height and head circumferencedX X
Revie w intake and output diarieseX X
Record PS and EN prescriptions, and adjust as neededfX X
Safety laboratory testsgX
PedsQL Generic Core Scale/ PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-ScalesX
Antibodies to teduglutidehX
Fecal occult blood testingi(X)
Colonoscopyj(X)
Pregnancy testingk(X)
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EN=enteral nutrition; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
aIf the subject has any changes to the SBS history that had been collected at the baseline of the TED -C13 -003 study , then the 
updated SBS history will be collected.
bSubjects who meet ≥[ADDRESS_393285], 
and parent or legal guardian agrees to proceed with teduglutide therapy. ( Table 1 -4).
cConcomit ant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies ,and 
associated pathology results.
dHead circumference willbe measured in subjects [ADDRESS_393286] received the equivalent of 2 
treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide will undergo colonoscopy 
at 5 year intervals or more often as needed. See Section [IP_ADDRESS] for details.
kPregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 21
Protocol SHP633 -303 11 May 2016
Table 1-3:Schedule of Events for No Teduglutide Treatment Period
Visit Number NTx
Visit Type Site
Visit Frequency Every 12 weeks
Window (days) ±[ADDRESS_393287] as neededeX
Safety laboratory testsfX
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutideg(X)
Fecal occult blood testinghAnnually
Colonoscopyi(X)
Serum samplejEvery 24 w eeks
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EN=enteral nutrition; PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
aSubjects who meet ≥[ADDRESS_393288], 
and parent or legal guardian agree to proceed with teduglutide therapy ( Table 1 -4).
bConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies ,and 
associated pathology results.
cHead circumference will be measured in subjects [ADDRESS_393289] actual PS volume and hours per day, and actual EN volume per day, completed daily during the 
2weeks preceding each clinic visit (Section [IP_ADDRESS] ). Urine and stool output should be recorded in the output diary over a 48 -hour 
period of PS and EN stability before every clinic visit (see Section [IP_ADDRESS] for more detail).
eParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix [ADDRESS_393290] positive/specific for teduglutide antibodies should have follow -up samples 
collected every [ADDRESS_393291] received the 
equivalent of 2 treatment cycles (48 weeks of study drug exposure) and su bjects who continue to receive teduglutide will undergo 
colonoscopy at 5 -year intervals or more often as needed. See Section [IP_ADDRESS] for details.
j Lack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 22
Protocol SHP633 -303 11 May 2016
Table 1-4:Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Visit Number PxCx
D1Cx
W1Cx
W2
Phone contact [CONTACT_319408] [ADDRESS_393292] is required approximately 1 week after PS adjustmentCxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28
EOS/ET
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhoneaSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  (days) -21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteriaX Xb
Dispense intake 
and output 
diariesX X X X X X X X X X X Xc
Adverse events X X X X X X X X X X X X X
Concomitant 
medications and 
GI
proceduresdX X X X X X X X X X X X X
Physical 
examination and 
vital signs, 
including weightX X X X X X X X X X X X
Height and head 
circumferencee X X X X
Review intake 
and output 
diariesfX X X X X X X X X X X X
Record PS and 
EN Rx, and 
adjust as neededgX X X X X X X X X X X X X
Safety laboratory 
testsh XhX X X X X X X X X X (X) X
PedsQL Generic 
Core Scale/ 
Family Impact 
Module/ GI 
Symptoms 
Module Sub -X X X
For non-commercial use only
Shire CONFIDENTIAL Page 23
Protocol SHP633 -303 11 May 2016
Table 1-4:Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Scales
Antibodies to 
teduglutidei X X X X
Fecal occult 
blood testingj X X X
Colonoscopyk(X) (X) (X)
Pregnancy 
testingl X X X X X X X X X
Serum samplemX X
Evaluate escape 
criterian X X
Dispense study 
drugo X X X X X X X X X
Note: (X) denotes conditional requirement for a given assessment if the subject m eets certain conditions per protocol.
EN=enteral nutrition; eCRFs=electronic case report forms; EOF=end of follow -up; EOS=end of study; EOT=end of treatment; ET=early termination; FOBT=fecal occult blood 
test; FOCBP=females of child -bearing potential; FU=f ollow -up; GI=gastrointestinal; PedsQ L=Pediatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin 
time/international normalized ratio; SBS= short bowel s yndrome; SC=subcutaneous; Scr= screening; TED=teduglutide; Tx=treatment
aPhone visit s are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25-27 (except 
for evaluation of escape criteria).
b Eligibility will need to be reconfirmed prior to the fir st dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
c CxW28 only.
dConcomitant GI pro cedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies ,and associated pathology results.
eHead circumference will be measured in subjects [ADDRESS_393293] actual PS volume and hours per day, and actual EN volume per day. Two weeks of intake diary data are required before drug is administered at CxD1 .
Diaries should be completed daily from Cx D1 up to C xW6 visit during teduglutide t reatment. After C xW6 visit, diaries should be completed daily for a minimum of 2 weeks
immediately prior to each study visit during teduglutide treatment (Section [IP_ADDRESS] ). During the 24 -week teduglutide treatment period, the intake diary will also be comp leted for 1 
week following PS adjustment, and daily during the 4 -week follow -up period. Urine and stool output should be recorded in the output diary over a 48 -hour period of PS and EN 
stability before every clinic visit, and within 1 week of implementing a change in the PS prescription (s ee Section [IP_ADDRESS] for more detail).
gParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance fo r nutrition support adjustment 
provided inAppendix [ADDRESS_393294] PT/INR at the pretreatment 
visit. Additional collection will occur if a potential drug -induced liver injury signal is observed. For pediatric subjects in diapers, urine specimen collection should be attempted as 
part of the safety labs, but lac k of urinalysis will not constitute a protocol deviation.
iSamples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are re ceiving teduglutide (CxW12 and CxW24) must be 
drawn at least [ADDRESS_393295] should be performed on teduglutide -exposed subjects on an annual basis.
For non-commercial use only
Shire CONFIDENTIAL Page 24
Protocol SHP633 -303 11 May 2016
Table 1-4:Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
kThe teduglutide -naïve subjects age 12 and older will undergo colonoscopy at the pretreatment visit if one has not been performed within 1 yea r.Subjects of any age with newly 
positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy prior to receiving teduglutide. 
If newly positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the end of a teduglutide treatment cycle (CxW24/EOT), colo noscopy will 
be performed. The need for colonoscopy in response to positive FOBT results at CxW12 is at the discretion of the inves tigator. Teduglutide -exposed subjects who have received 
the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will undergo colonoscopy. See Section [IP_ADDRESS] for details.
lA serum pregnancy test is performed on all females of child-bearing potential (FOCBP) at the teduglutide pretreatment visit. Urine pregnancy tests will be administered at all 
other visits according to the study schedules, or if pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the stu dy.
mLack of collection of serum samples will not constitute a protocol deviation .
nIf escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investiga tor.
oThe first SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observ ed 
for hypersensitivity reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF.
For non-commercial use only
Shire CONFIDENTIAL Page 25
Protocol SHP633 -303 11 May 2016
1 BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 y ear and older with SBS ( Khan et al. 
2015; Wales et al. 2004 ). Unlike the adult population, the majority of cases of SBS in pediatr ic 
subjects are due to congenital anomalies or catastrophic events that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on par enteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
by 12months of age, and an additional 10% wean off PS by  24 months of age. After this time, 
linear intestinal growth slows. About 60% of pediatric subjects with SBS are able to become 
independent of PS within 5 y ears of the initial diagnosis ( Khan et al. 2015 ). Nevertheless, despi[INVESTIGATOR_115047], many pediatric subjects remain dependent on PS. Complications 
of long -term PS include liver disease, catheter -related blood stream infections, central 
line-associated venous thrombosis and dwindling central venous access. Sepsis is the leading 
cause of death in these patients and quality  of life is poor ( Squires et al. 2012). Accelerating the 
adaptive process and achieving enteral autonom y is an urgent goal for all patients with SBS who 
are dependent on P S (Khan et al. 2015; Squires et al. 2012
).
Intestinal adaptation is driven by  [CONTACT_319409] ( Drucker 
and Yusta 2014). Chief among these is hormones glucagon
-like peptide 2 (GL P-2), which is 
secreted from L- type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Resection of these regions impairs the ada ptive response by  [CONTACT_319410] -2.
1.[ADDRESS_393296] Background
Teduglutide is a novel, recombinant analog of naturally  occurring human GLP -2 that regulates 
the functional and structural integrity  of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33 -
amino acid peptide that differs from native GLP- 2 in the substitution of 
glycine for alanine at the second position at the N -terminus. As a result, teduglutide demonstrates 
resistance to degradation by  [CONTACT_20597] l peptidase 4 (DPP-4) and therefore maintains a longer 
elimination half -life (t 1/2) in adults of approximately 2 hours compared to the native peptide, 
which has a t 1/2 of approximately  7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical tria ls to increase villus height and cry pt depth in the intestinal 
epi[INVESTIGATOR_2130], thereb y increasing the absorptive surface area of the intestines ( Tappenden et al. 
2013; Thymann et al. 2014 ). The European Commission grant ed a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide ( REVESTIVE™) on [ADDRESS_393297] 2012 and a New Drug Application (NDA) for teduglutide (G ATTEX®) was approved by  
[CONTACT_24623] (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide is not currently  
approved for use in pediatric subjects.
For non-commercial use only
Shire CONFIDENTIAL Page 26
Protocol SHP633 -303 11 May 2016
1.3 Clinical Studies with Teduglutide in Pediatric subjects
One Phase 3 stud y, TED -C13-003, was completed in pediatric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1 -17. Thirty -seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for [ADDRESS_393298] of care (SOC) cohort. There were clear dose -dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 0.0125
mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at Week 12 
of 37%, including complete independence from PS support in [ADDRESS_393299], and a reduction of 
3.94 hours per day  infusion time. I n the 0.05 mg/kg/day  cohort there was a reduction in PS 
volume at Week 12 of 39%, including complete independence from PS support in 3 subjects, and 
a reduction of 4.18 hours per day  infusion time. Teduglutide was generall y safe and well 
tolerated b y pediatric subjects in all dosing cohorts. There were no deaths during the stud y and 
no treatment -emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study  were due to adverse events (AEs).
TED -C14-006 is an ongoing study  which includes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arms participate in a [ADDRESS_393300] medical therap y for SBS; while 
those in the teduglutide treatment arm will receive daily  subcutaneous (SC) injections of 
teduglutide (stud y drug) in addition to standard medical therapy . The subjects enrolling in the 
teduglutide treatment arm will be randomized 1:1 in a double- blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day  of teduglutide administered subcutaneously  for 
24weeks.
Alway s refer to the latest version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393301] -time treatment of 
teduglutide -naïve subjects who participa ted in the SOC treatment arm in TED -C13-
003.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED -C13-003.
2.2.2 Seco ndary Objectives
The secondary  objective of this study  is to evaluate the long -term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 28
Protocol SHP633 -303 11 May 2016
3 STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safet y and 
efficacy  of teduglutide in pediatric subjects who completed the TED -C13-003 study  (the core 
study ). At the time of entry  into the TED- C13-[ADDRESS_393302] 30% of their caloric or fluid needs, and 
had not been able to significantly  reduce PS for at least 3 months prior to enrollment. During the 
core stud y, pediatric subjects in the teduglutide treatment arm w ere entered into a 
0.0125 mg/kg/day , 0.025 mg/kg /day, or 0.05 mg/kg /day dose cohort based on the timing of their 
enrollment in the study . The cohorts were filled in a sequential manner.
Approximately  [ADDRESS_393303] meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Rechallenge
Subjects not receiving teduglutide treatment (ie, in a “no teduglutid e treatment period” [NTT] ), 
will be seen every  12 weeks for safet y, parenteral support (PS) requirements, and quality of life. 
At any  point during a nNTT period, subjects who meet ≥[ADDRESS_393304], and parent or 
legal guardian agree sto proceed with teduglutide therap y.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide trea tment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long- term follow -up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving a fter 
discontinuation of teduglutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analy sis suggested that pediatric patients, ages 1 -17years-old, are likel y to require the same 
dose as used in a dults, namely  0.05 mg/kg/day  (Mouksassi et al. 2009 ). In this extension study  to 
TED -C13-003, repeat doses of teduglutide 0.05 mg/kg /day will be administered to eligible 
pediatric subjects.
Rationale: Teduglutide is approved for adult use in the US and EU at a dose of 0.05 mg/kg SC 
once daily. The completed 12-week pediatric study (TED- C13-003) demonstrated that 
teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day was associated with a favorable 
benefit/risk profile. In addition, population pharmacokinetic modeling and simulations were 
conducted to determine the effective dose to be used in pediatric subjects using data from 8adult 
clinical studies including adult Phase 1 studies and Phases 2/3 studies as well as the pediatric 
(core)study (TED -C13-003) and suggested that the dose in pediatric subjects is likely to be same 
as the dose in adults (O'Keefe et al. 2006).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393305] may  be evaluated immediately  for 
additional teduglutide treatment. Subjects who clinically  deteriorate or stop improving at any  
time after the end of the follow- up period will also be assessed for additional treatment .
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED- C13-[ADDRESS_393306]’s standard medical care between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed c onsent form (ICF) (and if 
applicable, informed assent) is signed for this study . In addition to this retrospective data 
collection, prospective study  assessments of safety  and efficacy  will be completed as a part of 
this study .
3.1.1 Informed Consent /Assent and Eligibility
The review and signing of the I CF (and if applicable, informed assent) for this study , must be 
completed before an y other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study ; however subjects may  
consent to retrospective data collection onl y. Subjects may not consent to the prospective data 
collection only . After informed consent/assent is obtained, study  eligibility  will be assessed for 
all subjects.
3.1.[ADDRESS_393307]’s standard medical care between the date of the 
TED -C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study . Retrospe ctive data collection may  begin any  time after informed consent/assent is 
obtained for this study . The following data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Growth [height, head circumference (up to 36 months of age), weight]
End dates for adverse events (AEs) ongoing at the time of TED-013-003
For non-commercial use only
Shire CONFIDENTIAL Page 30
Protocol SHP633 -303 11 May 2016
Nonserious treatment -related adverse events (AEs)
All adverse events of special interest (AESIs)
All serious adverse events (SAEs )
3.1.3 Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, medical 
history , and short bowel sy ndrome history . Prescription pa renteral support requirements will be 
collected at screening. Additionally , intake diaries will be dispensed at the screening visit, for 
collection of actual PS volume and hours per day , and actual enteral nutrition (EN) volume per 
day (Section [IP_ADDRESS]). Diary  data for PN/IV volume will be collected for at least 2 weeks after the 
ICF (and if applicable, the informed assent) is signed for this study .
Subjects not receiving teduglutide treatment (ie, in a nNTT period), will be seen every  12 weeks 
for safety ,PS requirements, and quality  of life. Diary  data for PN/IV volume will be collected 
for at least [ADDRESS_393308] NTT visit will occur approximately  
12weeks after the screening visit. At any  point after screening, including durin g an NTT period, 
subjects who meet ≥[ADDRESS_393309], and parent or legal guardian agree sto proceed with 
teduglutide therap y.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28 -week cy cle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily , follo wed by  a 
4-week follow -up (no treatment) period ( Figure 3 -1). During the 28- week cy cle, clinic visits will 
occur at W eeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately  
1 week after adjustments in PS during the TED treatment period, between Weeks 1 -24, and 
weekl y during the follow -up period, between Weeks 24 and 28.
At all site visits and telephone contacts, safet y will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality  of life assessments w ill be made approximately  every  
12 weeks. To maintain consistency  across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weight 
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation ( Appendix 1 ).
Rationale: Measures of 
long-term safety will include adverse events, growth parameters
, and 
anti-drug antibodies. Measure of long term efficacy will include durability of effect as measured 
by [CONTACT_319411] ( Pediatric Quality of 
Life I nventory [ PedsQL ], PedsQL Family Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary endpoint in pi[INVESTIGATOR_9205] 3 adult 
clinical trials and the completed P hase 3 pediatric study (TED -C13-003), and will be used as an 
endp oint in this extension study. In previous clinical studies, a reduction of this magnitude was 
associated with a reduction in the number of days per week of PS, and increases in enteral 
intake. Reduction in volume and time of PS due to improved enteral abso rption may provide a 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393310] of teduglutide, GI -specific screening tests, 
including fecal occult blood testing and colonoscopy, which are commonly part of the routine 
care of these subje cts, will be performed to ensure safety. This study captures long -term safety 
data on polyps and other colonic mucosal changes in teduglutide-exposed subjects using the 
surveillance strategy proposed in Section [IP_ADDRESS].
Figure 3-1: Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured every 12 weeks, but sub jects 
may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. Eligible subjects will enter 
a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy assessments at Weeks 1, 2, 
4, 6, 9, 12, 16, 20, and 24 (solid black lines ). Phone visits are required approximately 1 week after adjustments in PS during the 
intervening weeks between W eeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide at Week 24 and enter a 4 -week 
follow -
up (no -treatment) period, during which phone visit s will be performed weekly ( solid grey lines ). If an escape criterion is 
met during the follow -up period, subjects may proceed directly to another pretreatment visit.
3.[ADDRESS_393311] has provided signed informed 
consent (and 
if applicable, informed assent), and meets all of the Study  Inclusion Eligibility  
Criteria. The stud y will continue for at least [ADDRESS_393312] has access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be approximately  
[ADDRESS_393313] 
(last safet y contact), whichever is later. The stud y completion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393314] and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before any  study -related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_393315] will not be considered eligible for the study  without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completing any  
study -related procedures. 
2. Subject completed the TED- C13-003 study  (including subjects in the standard of care 
treatment arm).
3.Subject understands and is willing and able to fully  adhere to study  requirements as 
defined in this protocol.
4.2 Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study .
4.3 Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_393316] (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.[ADDRESS_393317] is teduglutide -naïve, receiving PS, and unable to significantl y reduce PS or 
advance enteral feeds (eg, 10% or less change in PS or advance in feeds) for at least 
3 months prior to and during the teduglutide pretreatment visit, as assessed by  [CONTACT_1275]. Transient instability  for events such as interruption of central access or 
treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the 
event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.Increasing PS requirements following teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, followed by  
[CONTACT_319412]
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319366]
d.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319367]
e.Severe diarrhea related to teduglutide discontinuation
For non-commercial use only
Shire CONFIDENTIAL Page 33
Protocol SHP633 -303 11 May 2016
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_393318]
3.History  of cancer in the previous 5 y ears except surgically  curative skin cancers
4.Serial transverse enteroplasty  or other major intestinal surgery  within 3 months 
preceding the teduglutide pretreatment visit. I nsertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week 
cycle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairment or injury , 
including the following laboratory  values at the pretreatment visit:
a.Total bilirubin ≥2× upper limi t of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dy sfunction shown by  [CONTACT_319406] (eGFR) 
below 50 mL /min/1.[ADDRESS_393319] repair, or 
patent ductus arteriosus (PDA) ligation
11.Participation in a clinical study  using an experimental drug (other t han glutamine or 
Omegaven) within 3 months or 5.5 half-lives of the experimental drug, whichever is 
longer, prior to the pretreatment visit and for the duration of the 28 -week cy cle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon -like p eptide -2 
(GLP-2) (not including teduglutide), insulin -like growth factor- 1 (IGF -1), or growth 
hormone, within 1 month preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_393320], 
closely -related compounds, or any  of the stated ingredients
15.Known history  of alcohol or other substance abuse within 1 y ear prior to the 
pretreatme nt visit
16. Pregnant or lactating female subjects 
17.Sexually  active female subjects of child -bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 day s after the treatment period 
For non-commercial use only
Shire CONFIDENTIAL Page 34
Protocol SHP633 -303 11 May 2016
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the study, or interferes with 
analysis of the study  results
4.[ADDRESS_393321] may  
proceed directl y to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation
2. Deteriorating nutritional status (eg, weight loss or growth fail ure) despi[INVESTIGATOR_319369]
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319370]
4.Severe diarrhea related to teduglutide discontinuation
4.[ADDRESS_393322]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects
should be either:
Premenarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta- human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pretreatment visit .Females of 
child- bearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:
Abstinence
Intrauterine devices plus condoms
Double- barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually  active during the study , they  should use 
[ADDRESS_393323] who remains in the study  would enter a n NTT period and could be 
evaluated for subsequent teduglutide treatment eligibility  according to the study  schedules. 
Comments (spontaneous or elicited) or complaints made b y the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case rep ort form (eCRF) and source documents, as 
described in Section 4.8.[ADDRESS_393324] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_319414] -up.
If a subject withdraws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as completely  as possible. 
Subjects who withdraw from the study will not be replaced.
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than [ADDRESS_393325] clinically  relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
Adverse event
Protocol deviation
Lack of efficacy
Physician decision
Withdrawal by  [CONTACT_1130]
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y)
Death
 Other
For non-commercial use only
Shire CONFIDENTIAL Page 36
Protocol SHP633 -303 11 May 2016
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_393326] (office visit or telephone contact). At least [ADDRESS_393327]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations, and return an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page 37
Protocol SHP633 -303 11 May 2016
5 CONCOMITANT TREATMENT
5.1 Concomitant M edications and GI Procedures
Concomitant treatment will be collected for the prospective period onl y and refers to all 
treatment being taken on or after the date the ICF (and if applicable , assent )is signed for this
study . Concomitant treatment informatio n must be recorded on the appropriate eCRF page. 
Concomitant treatments will be assessed at each site visit, and include all nonstudy  treatments 
(medications, herbal treatments, vitamins, invasive and diagnostic procedures). Concomitant GI 
procedures include (but are not limited to) endoscopy , radiographic studies, GI and liver biopsies 
and associated pathology results. Concomitant treatment information must be recorded on the 
appropriate eCRF page. Details of medication changes and/or dosages will be recor ded on the 
eCRF.
The mechanism of action of teduglutide may  increase absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], C OUMADIN®, 
psychotropi[INVESTIGATOR_1102], metronidazole, and digoxin). Accordingl y, due consideration should be given to 
modify ing concomitant medication regimens. Down -titration of concomitant medications should 
be considered when drugs, especiall y those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.[ADDRESS_393328] medical therapy for SBS should be continued.
5.1.2 Prohibited Treatment
The mechanism of action of teduglutide may  increase enteral absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_319371] o f SBS, COUMADIN, 
psychotropi[INVESTIGATOR_1102], metronidazole, digoxin), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narro w therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pre treatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- 1 analog or human growth hormone 1 month
Octreotide or dipeptidyl peptidase 4 inhibitors 3 months
Biological therapy (eg, antitumor necrosis factor) [ADDRESS_393329] is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2) . In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L -histidine, mannitol, monobasic sodium 
phosphate monohy drate, and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.[ADDRESS_393330](s)
6.2.1 Interactive Response Technology (IRT) for Investigational Product 
Management
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory  management and supply  orde ring, investigational product expi[INVESTIGATOR_49093], and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS.
The I WRS will also be used for creating, tracking, and confirming investiga tional product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.[ADDRESS_393331], and/or parent/guardian agree 
to proceed with treatment, a for mal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit ( Table 1-4
).
6.2.[ADDRESS_393332] will start a teduglutide treatment period, consisting of 24 weeks 
of teduglutide treatment at 0.05 mg/kg SC once daily . The initial dose will be calculated based 
on body  weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body  weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered b y SC inje ction once dail y (QD)into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
Teduglutide should be used as soon as possible after reconstitution, but no more than [ADDRESS_393333] 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
Following each [ADDRESS_393334] may  proc eed 
directly  to another Pre treatment visit to assess treatment eligibility  for another cy cle 
(Section 4.6). Following the completion of the 4- week follow -up, the subject will continue in the 
study  off teduglutide. Additional [ADDRESS_393335](s) container.
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing 7 vials of study  drug will be supplied and these will be labeled in 
accordance with app licable regulatory  requirements. Sterile water for injection sy ringes will be 
provided separatel y and will be labeled in accordance with the applicable regulatory 
requirements.
All study  drug used in this study  will be manufactured, tested, labeled, and re leased according to 
current legal requirements and Good Manufacturing Practice.
6.3.2 Packaging
Teduglutide will be provided in a 3 mL  sterile, single -use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL ) will be provided in a prefilled syringe.
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.[ADDRESS_393336] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refrigerated at a temperature between 2 -8°C (35.6 -46.4°F) until dispensed to 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393337], the study  drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2 -25°C, or 35.6- 77°F). Parent/ legal guardian 
will be instructed to keep the subject’s study  drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study  drug may  be refrigerated.
Investigational prod uct must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study  and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrated char t recorder, or b y manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recordi ng. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharmacy or nominated member of the study  
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
6.[ADDRESS_393338] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any  unauthorized situation.
The investigator has overall responsibility  for administering/dispensing investigation al product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study  protocol. All dispensed 
study  medication will be documented in the eCRFs and/or other investigational product record 
For non-commercial use only
Shire CONFIDENTIAL Page 41
Protocol SHP633 -303 11 May 2016
(eg, investigation product accountability  form). The investigator is responsible for assuring the 
retrieval of all study  supplies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. All original containers, whether empt y or containing study drug 
will be retu rned to the pharmacy . Returned study  drugs will NOT be relabeled or reassigned for 
use by  [CONTACT_23837]. Contents of the study  drug containers will not be combined. All used and 
unused vials must be returned to the distribution center according to the sponsor’s instruction. 
No vial/kit may  be destroy ed on site without approval by  [CONTACT_456].
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_393339] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -evident sealed container (eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability  form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 42
Protocol SHP633 -303 11 May 2016
7 STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures and assessments to be performed for subjects throughout the study  are 
outlined in the Schedule of Assessments ( Table 1 -1, Table 1-2, Table 1 -3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing an y study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject ( Table 1-
1).
7.1.1 Retrospective Data Collection
Retrospective data is defined as specific safety  and efficacy  assessments that were completed 
during th e retrospective observation period, defined as the interval between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form (I CF) (and if 
applicable, informed assent) is signed for this study . Twelve -week intervals of da ta will be 
collected starting [ADDRESS_393340]’s TED
-013-[ADDRESS_393341] data because 
data are unavailable will not be considered a protocol deviatio n. For subjects who consent only  
to retrospective data collection, only  assessments in this table ( Table 1-1) will be completed. The 
following data will be collected for the retrospective portion of the study :
Informed consent, and informed assent (if appl icable)
Study eligibility  is determined.
oA screen failure is a subject who has given informed consent and failed to meet 
the study inclusion e ligibility  criteria. Subjects cannot be rescreened once they  
have been designated as a screen failure.
Prior tedug lutide use (as prescribed)
oCollect all available teduglutide prescription start and stop dates, and 
corresponding dose levels (mg/kg/day ), that were prescribed or planned as part of 
an investigator -initiated trial during the retrospective data collection period.
Parenteral support (as prescribed)
oThe last stable, representative PS prescription during each 12 -week interval 
throughout the retrospective period and at the beginning and end of an y 
teduglutide treatment will be collected. Data collected should i nclude weekly  
prescribed volume, calories, average hours per day, and day s per week of 
prescribed PS.
Growth (height, head circumference, and weight)
oThe last representative value for height, during each 12 -week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and y ounger at the time the data 
were collected, if available.
For non-commercial use only
Shire CONFIDENTIAL Page 43
Protocol SHP633 -303 11 May 2016
Adverse events
oAll nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study . The details of data collection and safety  reporting for these events 
can be found in Section 8.
oEnd dates for AEs ongoing at the end of TED -C13-003 will be collected.
7.1.2 Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1
-2, 
and as detailed below:
 Informed consent, and informed assent (if applicable)
 Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the s tudy inclusion eligibility  criteria . Subjects cannot be 
rescreened once they  have been designated as a screen failure.
 Demographics, medical history , and SBS history
 Intake and output diaries are dispensed
 Evaluate teduglutide treatment inclusion criteria
 Adverse events, concomitant medicat ions and concomitant GI  procedures
 Physical examination and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
 Record PS and EN prescriptions, and adjust as needed
The first visit after screening (either a no -tedug lutide treatment visit or a pretreatment visit), 
must occur within 12 weeks of screening.
7.1.3 Visits for Subjects Not Receiving Teduglutide
While outside of the 28- week teduglutide -treatment cy cle, subjects will be followed every  
12weeks for safety  and efficacy  assessments. No- teduglutide treatment visits are numbered 
sequentially  (NT1, NT2, etc.), even if interrupted by  [CONTACT_319415]. Assessments will be 
performed as outlined in Table 1-3 and described below .
 Intake and output diaries are dispensed
 Evaluate teduglutide treatment inclusion criteria
 Adverse events, concomitant medications, and concomitant GI  procedures
 Physical examinati on and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
For non-commercial use only
Shire CONFIDENTIAL Page 44
Protocol SHP633 -303 11 May 2016
 Record PS and enteral nutrition (EN) prescriptions, and adjust as needed
 Safety  laboratory  tests (ie, clinical chemistry , hematology , and urinaly sis)
 PedsQL Generic Core Scale/PedsQL Family  Impact Module/ PedsQL  Gastrointestinal 
Symptoms Module Sub- Scales
 Antibodies to teduglutide, if and when required
 Fecal occult blood testing, as indicated (see Section [IP_ADDRESS])
 Colonoscopy , as indicated (see Section [IP_ADDRESS])
 Serum sample, as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the sub ject may  proceed to the pretreatment visit to determine eligibility . 
The pretreatment visit must occur within 12 weeks of a given NTT visit.
7.1.4 Visits for Subjects Receiving Teduglutide Treatment
[IP_ADDRESS] Pretreatment Visit
Subjects who meet at least [ADDRESS_393342] dose 
administration (CxD1) during an y teduglutide treatment cycle. I n general, pretreatment 
assessments may  occur over a period of up to 21 day s. The teduglutide pretreatment visit (Px) 
assessments and procedures will be performed in Table 1
-4and as described below:
 Evaluate teduglutide eligibility  (treatment inclusion/ex clusion criteria)
 Dispense intake and output diaries
 Adverse events, concomitant medications, and concomitant GI  procedures
 Fecal occult blood testing
 Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as indicated
 Physical examinati on and vital signs, including weight
 Height and head circumference
 Record PS and 
EN prescriptions, and adjust as needed.
 Safety  laboratory  tests
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit include 
prothrombin time [PT] international normalized ratio [I NR]. Subsequent prothrombin 
time/international normalized ratio (PT/I NR) measurement is only  required to evaluate 
for suspected drug -induced liver injury  [DILI]).
For non-commercial use only
Shire CONFIDENTIAL Page 45
Protocol SHP633 -303 11 May 2016
 Pregnancy  testing (serum)
 Serum sample
[IP_ADDRESS] Teduglutide Treatment Period (CxD1- CxW24)
The open- label teduglutide treatment period will comprise [ADDRESS_393343] administration (Visit CxD1).
VISIT CXD1
Assessments and procedures at this visit will be performed as outlined Table 1 -4and as 
described below :
Two weeks of intake diary data are required before drug is administered at CxD1.
 Confirm teduglutide eligibility
 Dispense intake and output diaries
 Adverse events, concomitant medications, and concomitant GI  procedures
 Physical examination and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
 Record PS and EN prescriptions, and adjust as needed
 Safety  laboratory tests
 Quality  of life measurements
 Antibodies to teduglutide
 Pregnancy  testing (urine)
 Dispense study  drug
[IP_ADDRESS] Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cy cle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessm ents and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:
 Dispense and review intake and output diaries
 Physical examination and vital signs, including weight
 Record PS and EN prescriptions, and adjust as needed
 Safety  laboratory  tests
 Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, 
CxW24)
For non-commercial use only
Shire CONFIDENTIAL Page 46
Protocol SHP633 -303 11 May 2016
 Study  drug dispensation (except for CxW24)
 Adverse events, concomitant medications and concomitant GI  procedures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
 Height and head circumference
 Antibodies to teduglutide
 Fecal occult blood testing (FOBT)
 GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated
 Quality  of life measurements
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
[IP_ADDRESS] Phone Visits
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1 -4and described 
below:
 Review intake and output diaries
 Safety  laboratory  tests (clinical chemistry  and urinaly sis)
 Record PS and EN prescriptions, and adjust as needed
 Obtain AEs, concomitant medications, and concomitant GI procedures
 Evaluate escape criteria
7.1.5 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks (Weeks 25 -28 of the cy cle). Phone visits 
will occur on cy cle Weeks 25, 26, and [ADDRESS_393344] may  
proceed directl y to another pretreatment visit at the investigator’s discretion.
[IP_ADDRESS] CxW28
At C ycle Week 28 (CxW28), subjects will return to the study  site. In addition to the assessments 
performed at Weeks 25 -27, the following procedures will be performed at CxW28 only:
 Dispense and review intake and output diaries
 Physical examination and vital signs, including weight
 Antibodies to teduglutide
 Pregnancy  testing (urine)
 Evaluate escape criteria
For non-commercial use only
Shire CONFIDENTIAL Page 47
Protocol SHP633 -303 11 May 2016
[IP_ADDRESS] Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-[ADDRESS_393345] discontinues the study prematurel y, the assessments for the EOS/ET 
visit are to be performed as completel y as possible.
 Adverse events, concomitant medications, and concomitant GI  procedures
 Physical examination and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
 Record PS and EN prescriptions, and adjust as needed
 Safety  laboratory  tests
 Fecal occult blood testing, as indicated
 Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy ,as 
indicated
 Quality  of life measurements
 Antibodies to teduglutide
 Pregnancy  testing, as needed
7.[ADDRESS_393346]'s completion of the TED -C13-003 study  and the 
date the ICF (and if applicable, assent) is signed for the SHP633 -303 study.
[IP_ADDRESS] Growth (Height, Weight, and Head Circumf erence)
Retrospective bod y height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z -score, weight z -score, body  mass index ( BMI ), and BM I z-score will be calculated b y 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the SAP.
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed
Retrospective teduglutide prescription start and stop dates and dose levels will be recorded on the 
appropriate eCRF page, if available, using data from prescriptions filled during the retrospective 
data collection period.
[IP_ADDRESS] Parenteral Support Prescribed
Retrospective parenteral support entries consist o f 1 prescription per 12 -week interval during the 
retrospective period. The prescription should include start and stop dates, and corresponding 
volumes, of prescribed PS, excluding transient instability /interruption(s) for events such as 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393347] stable prescription from the interval should be used. Prescription data 
will be recorded in the eCRF.
[IP_ADDRESS] Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESI s) and all serious adverse events (SAEs) regardless of causal attribution to teduglutide, that 
occurred during the retrospective data collection period will be reported using the sponso r's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safet y reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED- C13-[ADDRESS_393348] baselines 
and completing the treatment -related assessments (including the evaluation of eligibility  for 
teduglutide treatment) of SHP633-303.
[IP_ADDRESS] Demographics, Medical History, and SBS History
Demographics, medical history , and SBS history  will be obtained at screening. Medical history  
for purposes of this extension study  will consist of the following:
 Events that occurred during the period between completion of TED -C13-003 and 
informed consent /assent to SHP633 -
303 with the exception of:  nonserious AEs 
related to teduglutide treatment, and all adverse events of special interest (AESI s) and 
all serious adverse events, regardless of causality  attribution to teduglutide. 
This medical history  information will supplement the medical history  information collected at 
the start of the TED -C13-[ADDRESS_393349] has an y changes to the SBS history  since 
the baseline visit of the TED -C13-003 study , that information (up dated SBS history ) will be 
collected.
[IP_ADDRESS] Physical Examination
Physical examinations will be performed according to the study  schedules. Any  new clinicall y 
significant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF.
[IP_ADDRESS] Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study  schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and b ody temperature 
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same arm, 
and in the same position throughout the stud y).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each s tudy visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit.
For non-commercial use only
Shire CONFIDENTIAL Page 49
Protocol SHP633 -303 11 May 2016
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
[IP_ADDRESS] Clinical Laboratory Tests
Safety  laboratory  tests to be performed at site visits consist of clinical chemistry ,hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1 -2, Table 1-3, and 
Table 1-4). Scheduled laboratory  testing will be processed b y a central lab. All laboratory  assay s 
will be performed according to the central laborat ory’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out-of- range clinical laboratory  
values for clinical significance, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory
 values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical condition, may , at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_393350] of clinical chemistry  and urinal ysis and may  be proce ssed b y the central laboratory 
or a local laboratory . Local lab results will not be entered in the eCRFs; however, if the local lab 
results indicate an y new clinically  significant changes, they  must be reported as an adverse event 
(see Section 8.1). For pe diatric subjects in diapers, urine specimen collection should be 
attempted as part of the safet y labs, but lack of urinalysis will not constitute a protocol deviation.
New clinicall y significant labs should be reported as AEs.
The following clinical labora tory assessments will be performed according to the study  
schedules:
For non-commercial use only
Shire CONFIDENTIAL Page 50
Protocol SHP633 -303 11 May 2016
Table 7-1:List of Laboratory Tests 
Hematology :
Hematocrit 
Hemoglobin 
Platelet count
Red blood cell count 
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio 
Urinalysis : 
Blood
Glucose
Leucocytes
Microscopic analysis
pH and osmolality
Protein
Sodium
Specific gravity
Pregnancy tests (females of childbearing 
potential):
oSerum β -HCG (screening)
oUrine β -HCG (all other visits)Biochemistry :
Albumin 
Alkaline phosphatase 
Alanine aminotransferase 
Amy lase
Aspartate aminotransferase 
Bicarbonate
Bilirubin (total and indirect)
Blood urea nitrogen 
Calcium (total)
Chloride
Cholesterol
C-reactive protein 
Creatinine
Estimated Glomerular Filtration Rate 
(Schwartz formula)
Gamma -glutamyl transferase 
Glucose
Lipase
Magnesium
Phosphorus
Potassium 
Sodium 
Triglycerides
Uric acid
For non-commercial use only
Shire CONFIDENTIAL Page 51
Protocol SHP633 -303 11 May 2016
[IP_ADDRESS] Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times:
 During teduglutide treatment period: at the pretreatment and CxW24 (EOT) visits
 During NTT: Approximately  every  24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sample and/or extracted material will otherwise be stored 
for up to [ADDRESS_393351] their 
sample and/or extracted material destro yed. Any  results alread y generated from the samples will 
not be removed from an y anal yses that have already  been performed.
[IP_ADDRESS] Pregnancy Testing
A serum pregnancy  test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy  tests will be administered at all other visits according to the study schedules, or if 
pregnancy  is suspected, or as specified per protocol upon withdrawal of the subject from the 
study .
[IP_ADDRESS] Antibody Testing
Blood samples will be drawn for the anal ysis of positive/specific an tibodies to teduglutide 
according to the Schedule of Assessments ( Table 1 -2, Table 1-3, and Table 1 -4). Blood samples 
for antibodies may  be drawn from a central line or from peripheral access. The sample drawn on 
CxD1 must be drawn prior to administration of the first dose of teduglutide. Once the subject has 
started teduglutide treatment, samples must be drawn at least [ADDRESS_393352] positive/specific for antibodies to teduglutide will also be tested for neutralizing antibody . 
Subjects who have been previously  treated with teduglutide, and who test positive/specific for 
antibodie s to teduglutide, will have follow- up blood draws for positive/specific antibodies to 
teduglutide every  12weeks while on study  until a negative result is obtained.
[IP_ADDRESS] Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatr ic subjects enrolled 
in this study . The volumes of blood to be drawn from each subject will vary  depending on 
clinical status. Approximate volumes of blood to be drawn from each subject annuall y are shown 
in the following table.
For non-commercial use only
Shire CONFIDENTIAL Page 52
Protocol SHP633 -303 11 May 2016
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment 
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Parameters 1 2 2
Antibodies 2 8 16
Serum storage samples 3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volume): 138
Subjects Not Receiving Teduglutide Treatmentb
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samples 3 2 6
Total mL per 4 “No Teduglutide Treatment” Visits 48 -week period: 24
β-hCG=beta -human chorionic gonadotropin ; NTT= no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bSubjects not receiving TED treatment, but who were exposed to it previously and tested positive for anti -TED antibodies will 
require blood samples for antibody testing every [ADDRESS_393353] negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provi ded by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same t ype of tube, the assessments should be combined. Blood 
volume estimates do not include s afety labs performed after PS adjustment, and anti -teduglutide 
antibody  testing during no- teduglutide treatment.
[IP_ADDRESS] Gastrointestinal- specific Testing
FECAL OCCULT BLOOD TESTING
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week [ADDRESS_393354] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past and 
are therefore not teduglutide -naïve) on a roughl y annual basis (approximately every 48 -60 
weeks). Actions to be taken in response to a positive FOBT are described below.
COLONOSCOPY
Teduglutide -naïve subjects age 12 and older will underg o colonoscop y at the pretreatment visit if 
one has not been performed within 1 y ear.
Subjects of an y age with newly positive FOBT results at the pretreatment visit for which a 
readil y detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscop y prior 
to receiving teduglutide. If newl y positive FOBT results (for which a readily detectable cause 
cannot be identified) are obtained at the end of a teduglutide treatment cy cle (CxW24/EOT), 
colonoscop y will be performed. The need for colonos copy  in response to positive FOBTs at any  
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393355] received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will undergo colonoscopy . While receiving additional teduglutide 
treatment, subjects will undergo colonoscop y at 5 year intervals or more often as needed.
Upper endoscop y ma y be performed along with any colonoscop y at the investigator’ s discretion. 
If a pol yp is found, adherence to current pol yp follow -up guidelines is recommended. Subjects 
with unresected GI pol yps, poly posis conditions, premalignant change or malignancy  in the GI 
tract will be excluded from teduglutide treatment.
NUTR ITIONAL SUPPORT
Nutritional support includes PS, EN, and other food and fluids. Advances in EN and/or 
reductions to PS will be based on clinical status, including weight, linear growth, hy dration 
status, and safet y laboratory  results. Intake and output dia ries will include data to be considered 
in the adjustment of each subject’s nutritional support. Guidelines for nutritional support 
management and weaning algorithms are provided in Appendix [ADDRESS_393356]’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS and enteral nutrition 
(formula) sections of the intake diary  2 weeks prior to ALL scheduled prospective site visits. 
During the 24 -week tedugl utide treatment period, the intake diary  will also be completed for 1 
week following PS adjustments. The intake diary  will also be completed daily  during the 4 -week 
follow -up period. The following data will be captured in the intake diaries:
 Parenteral sup port volume and infusion duration
 Enteral nutrition (formula) volume
 Site personnel will determine the actual PS and EN daily  calories based on diary  
entries
OUTPUT DIARY
Urine and stool output should be recorded in the output diary  over a 48- hour period of PS and 
EN stability  before every clinic visit; in addition, output should be recorded for subjects that are 
in a teduglutide treatment cy cle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
 Toilet -trained subjects (who do not wear diapers)
 Measure and record all urine output in mL  or cc. The subject or parent/legal guardian
will perform dipstick specific gravit y tests on the first urine produced after the daily 
infusions of PS.
Nontoi let-trained subjects (who wear diapers)
 Measure and record the weight of all urine -only diapers. Urine volume will be 
calculated using the following formula: 1 g (scale weight) = [ADDRESS_393357] 
void after the daily  PS infusion to measure specific gravit y.
Stool data (includes diapers with mixed urine and stool):
 Toilet -trained subjects (who do not wear diapers)
oRecord the occurrence of each bowel movement and score the stool consistency  
using the Bristol Stool Form Scale (see Output diary )
 Nontoilet- trained subjects (who wear diapers)
oRecord the weight of diapers containing stool (including diapers with mixed urine 
and stool) as stool output and score the stool consistency  using the Bristol Stool 
Form Scale (see Output diary ). Stool volume will be calculated using the formula: 
1 g (scale weight)=[ADDRESS_393358] to assess clinical status and opportunity  for PS reduction and advance in feeds.
[IP_ADDRESS] Health -related Quality of Life Assessments
Throughout the stud y, he alth-related quality  of life assessments will be performed using the 
PedsQL  Generic Core Scales. Each PedsQL age- appropriate form takes less than [ADDRESS_393359] month, and parent- report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
PEDIATRIC QUALITY OF LIFE GENERIC CORE SCALE (PEDSQL™ ),ACUTE VERSION
The PedsQL Generic Core Scale is designed to measures health- related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed by  [CONTACT_319416] 7
-3at the time points as outlined in Table 1-2, 
Table 1 -3,and Table 1 -4.
For non-commercial use only
Shire CONFIDENTIAL Page 55
Protocol SHP633 -303 11 May 2016
Table 7-3:Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects (ages 
8-12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18) Subject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5 -7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
PEDIATRIC QUALITY OF LIFE FAMILY IMPACT MODULE (PEDSQL™ ),ACUTE VERSION
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-2, Table [ADDRESS_393360] of pediatric chronic health conditions on parents and the family  (Varni et al. 2004 ). 
The 36- item PedsQL Family  Impact Module consists of 6 scales measuring parent self -reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Fun ctioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure parent -
reported f amily  functioning as follows: 1) Dail y Activities (3 items), and 2) Family  Relationships 
(5 items). The PedsQL Family  Impact Module should take the parent or legal guardian 
approximately  5-10 minutes to complete.
PEDSQL GASTROINTESTINAL SYMPTOMS MODULE (PEDSQL™
),ACUTE VERSION
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58
-item module, c omprised 
of 10 different s ymptom scales that assess gastrointestinal sy mptom -related quality  of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The Ped sQL Gastrointestinal Sy mptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
clinically  relevant and appropriate for the s ymptoms experienced in this pediatric study  
population, and therefore, are the onl y scales used in this study . The scales will be completed by  
[CONTACT_319418] [ADDRESS_393361] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
RETROSPECTIVE PERIOD O F OBSERVATION
For the retrospective data collection period (the EOS visit of the core study until signing the ICF 
[and informed assent, if applicable] for SHP633- 303), investigators will be asked if they  are 
aware of an y nonserious AEs possibly  related to teduglutide that occurred during this time and 
any AESIs or any  SAEs, regardless of relationship to tedugl utide, that occurred during this time. 
The following guidance is given for defining a treatment- related event:
The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product .
The event cannot be explained b y the subject’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for th is 
study .
PROSPECTIVE PERIOD OF OBSERVATION
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the defined follow- up period stated in Section 7.1.5. This includes events 
occurring during the scr eening phase of the stud y, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of s ymptoms should be 
recorded. If a diagnosis has not been made, then each s ymptom should be listed individuall y. All 
AEs should be captured on the appropriate AE pages in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investigational product indication 
should also be captured on the AE eCRF.
All prospective AEs must be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the stud y. Closure indicates that an outcome is reached, stabilizati on achieved 
(the investigator does not expect any  further improvement or worsening of the event), or the 
event is otherwise explained. When appropriate, medical tests and examinations are performed 
so that resolution of event(s) can be documented.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393362] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE t hat is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervent ion. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
Note that the severity  of AEs that constitute dose interruption criteria will also be evaluated 
using the National Cancer Institute’s (NCI) Common Terminology  Criteria for Adverse Events 
(CTCAE) grading criteria ( Table 8 -1).
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undete rmined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by  [CONTACT_423]’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393363]’s underl ying medical condition, concomitant therapy , or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse event s that are related to study  drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged b y the investigator.
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline.
8.1.[ADDRESS_393364] be recorded during the course of the study  in the eCRF. Outcomes 
are as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae
 Recovering/Resolving
 Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study ; however, sig nificant worsening of the s ymptoms should be 
recorded as an AE.
8.1.5 Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory  or vital sign can represent an AE if the change is 
clinically  relevant or if, during the study , a shift of a parameter is observed from a normal value 
to an abnormal value, or a further worsening of an alread y abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the d uration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into considerati on.
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the reference range or until a plausib le explanation (eg, concomitant disease) is 
found for the abnormal values.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393365], whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefore represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core stud y until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633- [ADDRESS_393366] be reported within 24 hours to the 
Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy  Report Form (and any  applicable follow -up 
reports) must also be sent to the Shire Medical Monitor using the details specified in the 
emergency  contact [CONTACT_1739]. I n the event a subject becomes pregnant 
after si gning the ICF (and , if applicable, assent), teduglutide administration must be discontinued 
immediately .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. For pregnancy  reports during the prospec tive period of observation, it is 
the responsibility  of the investigator to obtain this information within [ADDRESS_393367] partum. For pregnancies occurring 
during the retrospective pe riod of observation (ie, before signing the informed consent for 
SHP633 -303), the initial notification date will be the date the pregnancy  is recorded for this 
study  and outcome and infant condition information may  be collected any time post partum.
Pregnan cy complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for Serious Adverse Events (SAEs) and Nonserious AEs as Required b y the Protocol. Note: An 
elective abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Adverse Event Form for SAEs and 
Nonseriou s AEs as required by  [CONTACT_319419] I nvestigational and Marketed 
Products Pregnancy  Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medicati on Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633- 303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they  result in an AE/SAE as described in Section 8.2. Note: The 24 -hour reporting 
requirement for SAEs does not a pply to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
For non-commercial use only
Shire CONFIDENTIAL Page 60
Protocol SHP633 -303 11 May 2016
The categories below are not mutually  exclusive; the event can meet more than 1 category .
 Abuse – Persistent or sporadic intentional intake of investigational product when used 
for a nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may  be detrimental to the individual and/or society
 Misuse – Intentional use of investigational product other than as directed or indicated 
at an y dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed b y the protocol)
 Overdose – Administration of a dose greater than the allocated dose of the study  
medication or at a frequency  greater than the dosing interval specified by  [CONTACT_760]
 Medication Error –An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, m edication errors are reportable to the 
sponsor only  as defined below.
 Cases of subjects missing doses of the investigational product are not considered 
reportable as medication errors
 Medication errors should be collected/reported for all products under 
investigation
 The administration and/or use of an expi[INVESTIGATOR_319372] a reportable medication error
All investigational product provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y-authorized represent ative/caregiver.
8.[ADDRESS_393368] awareness 
of the event. Note: The 24- hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless they result in an SAE .
All adverse events of s pecial interest, as defined in Section 8.3, experienced during the 
prospective period of observation must be reported by  [CONTACT_319420] [ADDRESS_393369] complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Nonserious AEs as Required b y Protocol, and verify the accuracy of the informatio n 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global 
Pharmacovigilance and Risk Management Department. A copy  of the completed Shir e Clinical 
For non-commercial use only
Shire CONFIDENTIAL Page 61
Protocol SHP633 -303 11 May 2016
Study  Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as Required 
by [CONTACT_1738] (and any  applicable follow -up reports) must also be sent to the Shire Medical 
Monitor or designee using the details specified in the emergency  contact [CONTACT_319421].
8.2.[ADDRESS_393370] medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 
Results in death
Is life -threatening. Note: The t erm 'life -threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatien t hospi[INVESTIGATOR_1081]. Note: 
Hospi[INVESTIGATOR_602], which are the result of elective or previousl y scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classi fied as SAEs. For example, an admission for a previously scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospi[INVESTIGATOR_230476](s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_10154], 
based upon appropriate medical judgment, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse.
8.2.4 Serious Adverse Event Collec tion Time Frame
For the prospective period of observation, all SAEs (regardless of relationship to study  drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow -up period stated in Section 7.1.5, and must be reported to the Shire Global 
Pharmacovigilance and Risk Management Department andthe Shire Medical Monitor within [ADDRESS_393371] awareness for SAEs collected during the 
retrospective observation period will be the date the event is recorded for this study .
In addition, any SAE(s) considered “related” to the investigational product and discovered by  [CONTACT_10194] y interval after the study has completed must be reported to the Shire Global 
Pharmac ovigilance and Risk Management Department within [ADDRESS_393372]’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previousl y taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action o f “withdrawn” should not be selected solel y as a result of the 
subject’s death.
8.2.[ADDRESS_393373], Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notify ing the 
relevant regulatory  authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notify ing active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
8.[ADDRESS_393374]
An AESI  is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
[CONTACT_230013].
The AEs of special interest that require expedited regulatory  reporting include the following:
 Growth of pre -existing poly ps of the colon
 Benign neoplasia of the GI tract including the hepatobiliary  system
 Tumor -promoting ability (eg, benign and/or malignant n eoplasia of an y kind, not 
limited to those of the GI or hepatobiliary  system)
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393375] awareness as per the SAE notification instructions descr ibed in 
Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4 Dose Interruption and Permanent Discontinuation (Prospective Period of 
Observation Only)
Sections 8.4 and 8.5 apply onl y to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact [CONTACT_103]/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059], incidents of certain AEs, SAEs considered to be related to the 
study  drug, a lapse in investigational product delivery , etc.
Study  drug must be discontinued if any  of the following events occur:
 Pregnancy
 Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319422] y drug. This does not include anti -teduglutide antibodies, mild injection 
site reactions or mild symptoms that according to the investigator do not pose a 
significant risk to the subject.
 An AE listed in ( Table 8-1) that is of NCI CTCAE severit y Grade 3 or 4 and 
considered to be related to study  drug administration
 Confirmed drug -induced liver in jury (DILI) related to teduglutide ( see Section 8.4.2
)
8.4.1 Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only)
The investigational product may  be discontinued if the subject has an AE listed in Table 8-1 that 
is of severit y ≥Grade 3 per the NCI CTCAE. All such AEs should be discussed with Shire’s 
medical monitor as soon as possible. Teduglutide administration must be discontinued if the AE 
is considered related to the investigational product. The l ength of the dose interruption, and 
whether teduglutide administration resumes or is permanentl y discontinued, depends on the 
clinical situation.
Investigators and the data monitoring 
committee (DMC) should be guided by  [CONTACT_319423] 3 and 4 ev ents, as they  relate to known and possible risks associated with the 
administration of teduglutide.
For non-commercial use only
Shire CONFIDENTIAL Page 64
Protocol SHP633 -303 11 May 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observ ation Only)
Adverse Events Grade 3 Description Grade 4 Description
Gastrointestinal Disorders
Colorectal polyps Severe or medically significant but not 
immediately life threatening; 
hospi[INVESTIGATOR_20578]; 
disabling; limiting self -care activities of 
daily livingLife-threatening consequences; urgent 
intervention indicated
Intestinal Obstruction Hospi[INVESTIGATOR_374]; elective 
operative intervention indicated; limiting 
self-care activities of daily living; 
disablingLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder and Bile Duct Disease
Cholecystitis Severe symptoms; radiologic,
endoscopic or elective operative 
intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder perforation Not Applicable Life-threatening consequences; urgent 
intervention indicated
Gallbladder obstruction Symptomatic and severely altered 
gastrointestinal function; tube feeding, 
total parenteral nutrition or 
hospi[INVESTIGATOR_374]; nonemergent 
operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder infection Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic, endoscopic, or operative 
intervention indicatedLife-threatening consequences; urgent 
intervention indicated
Adverse Events Grade 3 Description Grade 4 Description
Alkaline Phosphatase 
increased>5.[ADDRESS_393376] >20.0x ULN
Blood bilirubin increased >3.[ADDRESS_393377] >10.0x ULN
Bile duct stenosis Severely altered gastrointestinal function; 
radiologic, endoscopic or elective 
operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Pancreatic Disease
Pancreatitis Severe pain; vomiting; medical 
intervention indicated (eg, analgesia, 
nutritional support)Life-threatening consequences; urgent 
intervention indicated
Pancreatic duct stenosis Severely altered gastrointestinal function; 
tube feeding or hospi[INVESTIGATOR_374]; 
elective operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Pancreas infection Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic or operative intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated
For non-commercial use only
Shire CONFIDENTIAL Page 65
Protocol SHP633 -303 11 May 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observ ation Only)
Adverse Events Grade 3 Description Grade 4 Description
Serum amylase increaseda>2.[ADDRESS_393378] >5.0x ULN
Lipase increaseda>2.[ADDRESS_393379] >5.0x ULN
Cardiovascular Disease
Heart failure Severe with symptoms at rest or with 
minimal activity or exertion; intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated (eg, continuous 
intravenous therapy or mechanical 
hemodynamic support)
Source: Common Terminology Criteria for Adverse Events, version 4.03, [ADDRESS_393380]=upper limit of normal
a In the setting of clinically acute and symptomatic pancreatitis
8.4.2 Dose Interruption Criteria Based on Drug -Induced Liver Injury 
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may  need to be interrupted if the subject has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following criteria:
 ALT or AST >8x ULN
 ALT or AST >5x ULN and >2x basel ine value for more than 2 weeks
 (ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)
 ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
All laboratory  values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_393381] should be followed closely to determine the trajectory  of the 
laboratory  abnormalities and to evaluate the cause of liver injury . This evaluation may  includ e, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cy tomegalovirus IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultra sound), autoimmune hepatitis 
(anti-nuclear, anti -smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investigator in consultation 
with the Shire Medical M onitor.
Teduglutide administration must be permanentl y discontinued if DILI is confirmed and deemed 
related to stud y drug.
For non-commercial use only
Shire CONFIDENTIAL Page 66
Protocol SHP633 -303 11 May 2016
8.5 Early Terminat ion of the Clinical Study (Prospective Period of Observation Only)
The DMC may  recommend stoppi[INVESTIGATOR_319373]:
 ≥2subjects develop the same event listed in Table 8 -1of severity  CTCAE Grade 3
or
 1subject develops an event listed in Table 8-[ADDRESS_393382] or is not reasonably  related to the underly ing 
disease process
For non-commercial use only
Shire CONFIDENTIAL Page 67
Protocol SHP633 -303 11 May 2016
9 DATA MANAGEMENT AND STATISTICAL M ETHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monitor will visit each site and review retrospective data in accord ance 
with the monitoring plan. Data collection procedures will be discussed with the site at the site 
initiation visit and/or at the investiga tor’s meeting. Unscheduled safet y follow up assessments 
(conducted after EOS) are not required to be collected.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data querie s requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Process
The study  will be analyzed by  [CONTACT_10196]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medicat ions.
9.[ADDRESS_393383] been collected.
A DMC will be involved in the management of this study . The DMC members will review the 
data approximately  every 3 months during the study treatment period (date of the first subject’s 
first dose to date of the last subject’s last dose). The DMC review will include all cumulative 
safet y data (ie, AEs, laboratory assessments, ph ysical examinations, etc.) from study  assessments 
through each cutoff period. Further details regarding the DMC can be found in the DMC charter, 
which will be available prior to the administration of investigational product. 
The DMC for this study  will be conducted in accordance with the FDA Gu idance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
The DMC will be an external, independent board comprised of ph ysicians with relevant training. 
The DMC will be restricted to individu als free of significant conflicts of interest, including, but 
not limited to, financial, scientific, or regulatory  in nature. The DMC will be governed by  a 
Charter agreed to b y members of the Board and the sponsor. Members of the Board may not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hired by  [CONTACT_456], or members of 
For non-commercial use only
Shire CONFIDENTIAL Page 68
Protocol SHP633 -303 11 May 2016
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine whether the study  should be modified or temporaril y or 
permanentl y stopped.
9.5 Sample Size Calculation and Power Considerations
As this is an extension study, the maximum number of subjects will be determined by  [CONTACT_319424] -C13-003.
9.6 Study Population
The safet y population includes all enrolled subjects in the study . The safet y population will be 
used for both safet y and effi cacy anal yses.
9.7 Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1 Efficacy Endpoints
The following efficacy  endpoints will be analy zed relative to the baseline of the prospective 
study  period, the baseline of each teduglutide treatment cy cle, and the baseline of the core study , 
as applicable, at the following time points: 1) 12-week intervals during the retrospective 
observation period, 2) the end of each prospective teduglutide treatment period ( Week 24/EOT), 
and 3) each prospective study  visit . The derivations of the weekl y PS volume and baselines will 
be described in the study  SAP in detail.
 Reduction in PS volume of at least 20%
 Absolute and relative change in PS volume
 Complete weaning off PS
 Change in day s per week of PS
9.8 Safety Analyses
Safety data, including laboratory  tests and vital signs assessments, will be summarized by  [CONTACT_765]. 
Adverse event s will also be collected and summarized. Descriptive statistics will be calculated 
for quantitative safet y data as well as for the difference from baseline, if applicable. Frequency  
counts will be compi[INVESTIGATOR_319374] y data.
9.8.1 Safety Endpoints
The following s afety endpoints will be analy zed from the beginning of the prospective study  
period:
 Adverse events, including those pertaining to GI symptoms
For non-commercial use only
Shire CONFIDENTIAL Page 69
Protocol SHP633 -303 11 May 2016
 Vital signs, including body  temperature, heart rate, and blood pressure
 Laboratory  safet y data (ie, clinical chemistry , hematology , and urinaly sis)
 Urine output
 Stool output
 Antibodies to teduglutide
 Gastrointestinal -specific testing including fetal occult blood testing and colonoscopy  
or sigmoidoscop y, as needed
The following safet y endpoints will be analy zed from the end of the core study  (Week 16/EOS) 
to the beginning of the prospective study  period:
All treatment -related AEs
All SAEs
All AESI s(Section 8.3)
The following safet y endpoints will be analy zed relative to the baseline of the core stud y 
(TED -C13-003):
Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
body  mass index
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA). The number of events, incidence, and percentage of AEs wil l be calculated overall, 
by [CONTACT_319425]. S erious adverse event s will be further 
summarized by  [CONTACT_230535]. Adverse events related to 
investigational product, AEs leading to withdrawal, S AEs, and deaths will be similarly  
summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dictionary  (WHO -DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific p rior medications will be summarized. Medical history  (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by  [CONTACT_6657]. 
For clinical laboratory  tests, vital signs, body  weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to sum marize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive specific or neutralizing 
antibodies to teduglutide will be used to summarize the presence of antibodies. 
Addit ional safet y parameters and measures will include change in bod y weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z -score, BMI, and BMI z -score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
For non-commercial use only
Shire CONFIDENTIAL Page 70
Protocol SHP633 -303 11 May 2016
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses
Health economics and outcomes research endpoints will be analy zed at approximately  12-week 
intervals ( Weeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects 
not on teduglutide), relative to the baselin e of the prospective study  period. The beginning of 
each treatment cy cle (CxD1) will be an additional baseline.
 Change in Pediatric Quality  of Life Inventory  (PedsQL) score
 Change in PedsQL Family  Impact Module score
 Change in PedsQL Gastrointestinal Sy mptoms Module Sub- Scales scores:
Food and drink l imits
Diarrhea
For non-commercial use only
Shire CONFIDENTIAL Page 71
Protocol SHP633 -303 11 May 2016
10 SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_393384] been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH Good Clinical Practice (GCP) Guideline E6 (1996 ), EU 
Direc tive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensure s that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indem nity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appro priate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
10.1.4 Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Mem ber States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GC P. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
For non-commercial use only
Shire CONFIDENTIAL Page 72
Protocol SHP633 -303 11 May 2016
10.1.5 Study Suspensi on, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are n otified as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as requi red b y 
Article 10 (c) of Directive 2001/20/EC.
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_393385] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable re gulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study  
sponsor (or designee) before starting the stud y.
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator i s appointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by  [CONTACT_319426] (single -site study ) or coordinating principal investigator (multicenter 
study ), in compl iance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 (1995). 
10.2.[ADDRESS_393386] met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other stu dy materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by [CONTACT_59761].
Communication with local I RBs/ECs, to ensure accurate an d timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
For non-commercial use only
Shire CONFIDENTIAL Page 73
Protocol SHP633 -303 11 May 2016
multicenter studies, the coordinating principal investigator [INVESTIGATOR_319375].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded di rectly  into the 
eCRF.
Electronic case report forms should be approved by [CONTACT_319427].
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per t he monitoring plan. If the data are unclear or contradictory , queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized represen tatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monito r (and auditors, IRB/EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_10203]/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays etc.). Nonstudy  site personnel will not 
disclose an y personal information or personal medical information .
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
European Medicines Agency  (EMA) , [LOCATION_006] Medicines and Healthcare produ cts Regulatory  
Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data gener ated b y this study must be available 
for inspection upon request by  [CONTACT_1779], for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory  authorities), the 
European Medicines Agency  (EMA), the Medicin es and Healthcare products Regulatory  
For non-commercial use only
Shire CONFIDENTIAL Page 74
Protocol SHP633 -303 11 May 2016
Agency , other regulatory authorities, the sponsor or its representatives, and the I RB/EC for each 
site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_10204] , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.[ADDRESS_393387]’s legall y-authorized representative, as 
applicable, is requested to sign and date the su bject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study  involves, including but not limited to: 
the objective s, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy  of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully executed signature [CONTACT_1787]) must be given to th e subject or the 
subject’s legall y-authorized representative, as applicable. This document may  require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
Within the source documents, site personnel should document instruction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
The pr incipal investigator provides the sponsor with a copy  of the consent form, and assent form 
where applicable, which was reviewed b y the IRB/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the sponsor, prior to the start of the study  unless it is agreed to 
and documented (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally , if the I RB/EC requires modification of the sample subject information and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_393388] or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and al l types of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation .
For non-commercial use only
Shire CONFIDENTIAL Page 75
Protocol SHP633 -303 11 May 2016
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating principal investigator [INVESTIGATOR_10157], according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve an y 
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_1683]/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be d one b y the sponsor, the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_393389] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_317364] (or designee).
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
review their medical records and data collected during the stud y. These records and data may, in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP633; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the study to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identifying num ber, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
For non-commercial use only
Shire CONFIDENTIAL Page 76
Protocol SHP633 -303 11 May 2016
10.5 Study Results / Publication P olicy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase [ADDRESS_393390] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitt ed by  [CONTACT_10206], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  [CONTACT_10207] y publication of study results, or necessa ry for other scholars to verify  such study  
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_393391] publication of the study results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_319377] a nalyzed study  results. If such a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_10209] 18-month period after conclusion, abandonment, 
or termination of the study  at all sites, or after the sponsor confirms there sha ll be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations o f the single -site data being presented.
Unless otherwise required by  [CONTACT_10210], or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer any  rights to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 77
Protocol SHP633 -303 11 May 2016
11 REFERENCES
Drucker, D. J. & Yusta, B. 2014. Phy siology  and pharmacology  of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76,561-83.
Khan, F. A., Squires, R. H., L itman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., 
Sudan, D., Superina, R. A., Teitelbaum, D. H., Venick, R ., Wales, P. W. & Duggan, C. 
2015. Predictors of Enteral Autonomy  in Children with I ntestinal Failure: A Multicenter 
Cohort Study . J Pediatr, 167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cy ran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pedia tric patients using realistic covariates: application to teduglutide, a glucagon -like 
peptide-2 analog in neonates and infants with short- bowel sy ndrome. Clin Pharmacol 
Ther, 86,667-71.
O'Keefe, S. J., Buchman, A. L ., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel sy ndrome and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol, 4
,6-10.
Squires, R. H., Duggan, C., Teitel baum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. 
A., Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs
-Lask y, M. & Belle, S. H. 
2012. Natural hist ory of pediatric intestinal failure: initial report from the Pediatric 
Intestinal Failure Consortium. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel sy ndrome. J Clin 
Gastroenterol, 47,602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon -like peptide 2 
analogue, te duglutide, on intestinal adaptation in short bowel sy ndrome. J Pediatr 
Gastroenterol Nutr, 58
,694-702.
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL  
Family  Impact Module: preliminary  reliability  and validity . 
Health Qual Life Outcomes,
2,55.
Wales, P. W., de Silva, N., Kim, J., L ecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population- based estimates of incidence and mortality  rates. J Pediatr Surg,
39,690-5.
For non-commercial use only
Shire CONFIDENTIAL Page 78
Protocol SHP633 -303 11 May 2016
12 APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 79
Protocol SHP633 -303 11 May 2016
APPENDIX 1 GUIDELINES FOR NUTRITIONAL SUPPORT MANAGEMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical evaluations
Normal serum electrol ytes
Stable blood urea nitrogen /creatinine levels
Decrease in stool frequency  or volume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequenc y increased
Electrol yte changes or imbalance
Skin breakdown 
 Adjustments should be based on the actual nutritional support in volume and calories 
the subject infuses. Subjects should remain compliant with the nutritional support 
prescription in volume and calories during the study .
 Nutritional support constituents may  be adjusted at the discretion of the investigator.
 During the 48 -hour Intake/Output measurement period prior to the subject’s scheduled 
visit, no further changes to the prescribed nutritional support should be made.
 If there is a change in EN or other food or fluid intake, the investigator should consider 
this when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 80
Protocol SHP633 -303 11 May 2016
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 81
Protocol SHP633 -303 11 May 2016
Figure A -2 Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 82
Protocol SHP633 -303 11 May 2016
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
[ADDRESS_393392] 
Lexington 
MA 
[ZIP_CODE] 
[LOCATION_003] 
www.shire.com 
MEMORANDUM 
To: 
Cc: 
From: Investigator 
Study Coordinator 
, MD, PhD 
 
Global Clinical Development 
Date: 25 Aug 2016  
 
Global Clinical Operations 
Re: Protocol SHP633-303 -Protocol Administrative Change Memo #1 
This memorandum clarifies administrative changes made to protocol SHP633-303 dated 11 May 2016. 
The change and rationale are reflected below: 
Change: Remove the collection of all actual and prescribed enteral nutrition data 
Sections finpacted by [CONTACT_48599]: Synopsis; Table 1-2; Table 1-3; Table 1-4; Section 3.1.3; Section 7.1.2; 
Section 7.1.3; Section [IP_ADDRESS]; Section [IP_ADDRESS]; Section [IP_ADDRESS]; Section [IP_ADDRESS]; Section [IP_ADDRESS]; 
Section [IP_ADDRESS] 
Rationale: To reduce the burden on the subjects and investigators. Enteral nutrition data is not required, 
as the efficacy endpoints are limited to parenteral support parameters. 
Change: Remove the collection of urine sodium and urine osmolality 
Sections impacted by [CONTACT_48599]: Synopsis; Table 1-2; Table 1-3; Table 1-4; Table 7-1; Section 7.1.3; 
Section 7.1 .4.1; Section 7.1 .4.2; Section 7.1 .4.3; Section 7.1 .4.4; Section [IP_ADDRESS]; Section 9.8.1 
Rationale: To reduce the burden on subjects and investigators. These tests are not needed to monitor 
hydration status. 
This administrative change does not impact the ccnduct of the study. This change will be documented in a 
subsequent amendment to the protocol. In the meantime, please· submit this memo to your IRB notifying 
them of this change and file this memo in your study file records. Please incorporate these changes once 
you have IRB approvaL 
If you have further questions, please do not hesitate to contact [CONTACT_319429]. 
Thank you, 
 
Global Clinical Development 
cc: SHP633-303 CTMF Main Study File  
 
Global Clinical Operations 
For non-commercial use only

PROTOCOL: SHP633 -303
TITLE: A Retrospective and Prospective, Open -label, Long -term Safet y and 
Efficacy  Study  of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED- C13-003
DRUG: Teduglutide
IND: IND# [ADDRESS_393393] NO.: 2016-000863-17
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_393394] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Amendment 1: 22Nov 2016
Original Protocol: 11May [ADDRESS_393395] party without the express written consent of Shire.
For non-commercial use only
Page2 
Version 2 
PROTOCOL SIGNATURE [CONTACT_64783]'s (Shire) Approval 
Signature: 
,  
 
Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-303. Date: 
 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-Cl3-[ADDRESS_393396] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) Shire CONFIDENTIAL Page 2
Protocol SHP633 -303 Version 2 / 22Nov 2016
For non-commercial use only

Shire CONFIDENTIAL Page 3
Protocol SHP633 -303 Version 2 / 22Nov 2016
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319430].Protocol Signature [CONTACT_319504] [CONTACT_319431] -teduglutide treatment
period, visit swill take place approximately every 12 w eeks.Synopsis
Section s3.1, 3.1.3 , 7.1.3
Figure 3-1
The study design flow chart has been edited for clarity. Synopsis
Figure 3 -1
The collection of all actual and prescribed enteral nutrition data has been 
removed to reduce the burden on the subjects and investigators. Enteral 
nutrition data are not required as the efficacy endpoints are limited to 
parenteral support parameters.Synopsis
Table 1-2,Table 1-3,Table 1-4
Sections 3.1.3 ,7.1.2 ,7.1.3 ,[IP_ADDRESS] , 
[IP_ADDRESS] ,7.1.6 , [IP_ADDRESS] , [IP_ADDRESS]
Exclusion criterion [ADDRESS_393397] been refined : 
exclusion/prohibition of treatment with growth hormone has been 
extended to [ADDRESS_393398] been refined.Table 1-1
Section s7.1.1 ,[IP_ADDRESS] ,[IP_ADDRESS]
Com pletion and review of intake and output diaries have been clarified. 
Also, r eview of diaries has been removed from the screening visit and 
added to the pretreatment visit .Table 1-2,Table 1-3, Table 1-4
Sections 7.1.2 , [IP_ADDRESS] , [IP_ADDRESS] ,  
7.1.6 ,[IP_ADDRESS]
The requirement for urine specimen collection has been revised so that a
lack of urinalysis will not constitute a protocol deviation for any 
pediatric subjects (not only for subjects w earing diapers) .Table 1-2, Table 1-3, Table 1-4
Section [IP_ADDRESS]
Clarification has been made that the first no- teduglutide treatment visit 
after the screening visit will occur within 2 to 12 w eeks of the screening 
(formerly within 12 w eeks of screening) . Synopsis
Table 1-[ADDRESS_393399] been clarified for visits during the no-teduglutide and 
teduglutide treatment periods.Table 1-3, Table 1-4
Section 7.1.3
For non-commercial use only
Shire CONFIDENTIAL Page 4
Protocol SHP633 -303 Version 2 / 22Nov 2016
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_64737]
‘Specific’ has been deleted from ‘positive/specific anti-teduglutide 
antibodies’ to eliminate the redundancy. B y definition, positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise
considered negative .Table 1-3
Section s7.2.2.8 ,9.8.1
For consistency within the protocol , sigmoidoscopy has been added as 
thealternate to colonoscopy throughout the protocol .Table 1-2, Table 1-3, Table 1-4
Section s 3.1.3 ,7.1.3 , [IP_ADDRESS]
Removal of former footnote j on fecal occult blood test for clarity. Table 1-4
Clarification has been made on circumstances when the CxW28 visit 
may be combined with the next pretreatment or EOS/ET visit. Table 1-4
Section 7.1.5
The text on PS support requirements over time in pediatric su bjects w ith 
SBS has been clarified, and text on intestinal adaptation has been refined.Section 1.1
Status of current teduglutide approval sfor use has been updated. Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced w ith ‘additional teduglutide 
treatment’ and ‘PN/IV’ with ‘PS’ for clarity and consistency w ith other 
studies.Synopsis
Sections 3.1, 3.1.[ADDRESS_393400] been clarified.Sections 4.8.1 ,4.8.2
Withdraw al by [CONTACT_7078]/guardian has been added as reason for 
discontinuation.Section 4.8.[ADDRESS_393401] if deemed appropriate to ensure sufficient 
supplies between visits.Also, documentation of all dispensed study drug
has been clarified.Section 6.4
Paragraph on the purpose of prospective data collection has been deleted 
for clarity.Section 7.2.2
Clarification has been made on the collection of medical history and SBS 
history.Synopsis
Sections 3.1.3 , 7.1.2 , [IP_ADDRESS]
A new section which describes the adverse event (AE) c ollection during 
the prospective period has been added to the study evaluations and 
procedures . Section [IP_ADDRESS]
Clarification has been made that local laboratory results are not required 
to be entered in the eCRFs. (form erly Section [IP_ADDRESS])Section [IP_ADDRESS]
Collection of urine sodium and urine osmolality has been removed. Section [IP_ADDRESS]
Clarification has been made that the serum sample will not be collected 
at the pretreatment visit if the subject met a fo llow-up period escape 
criterion. (former ly Section [IP_ADDRESS])Section [IP_ADDRESS]
Nutritional support and diaries (formerly in Section [IP_ADDRESS]) have been Section s7.2.2.11 , [IP_ADDRESS]
For non-commercial use only
Shire CONFIDENTIAL Page 5
Protocol SHP633 -303 Version 2 / 22Nov 2016
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319432] s (Sections [IP_ADDRESS] 1and [IP_ADDRESS] 2,
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that 
only available d iary data will be review ed at each clinic and telephone 
visit.
Performance of dipstick specific gravity tests by [CONTACT_319433] . 
It is now at the discretion of the investigator for all subjects, not just 
those in diapers. This change is to align with standard medical practice.Section [IP_ADDRESS]
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety sections of the protocol. Only 
nonserious AEs related(instead of possibly related ) to teduglutide need 
to be reported. No changes to the protocol w ere made for the reporting of 
allAEs of special interest or any serious adverse events, regardless of 
relations hip to teduglutide, that occurred during the re trospective period.Section 8.[ADDRESS_393402] been made to the language on dose 
interruption.Sections 8.4, 8.4.1
Unscheduled safety follow  up assessments (including visits conducted 
after EOS) are not to be recorded. How ever, clarification has been made 
that they are to be collected whererequested.Section 9.1
Clarification has be en made that the interim analysis will be conducted
on all retrospective data, and other interim analyses may also be 
conducted if needed.Section 9.4
The protocol now refer sto the data monitoring committee (DMC) 
Charter for the schedule of DMC reviews.Section 9.[ADDRESS_393403] been made to the guidelines for nutritional 
support management during the study .Appendix 2
See Appendix 1 for protocol history , including all amendments.
For non-commercial use only
Shire CONFIDENTIAL Page 6
Protocol SHP633 -303 Version 2 / 22Nov [ADDRESS_393404] IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required b y Protocol within 24 hours to the Shire Global Pharmacovigilance and Risk 
Management Department. Applicable fax numbers and e- mail address can be found on the form 
(sent under separate cover). A cop y of this form must also be sent to the Shire Medical Monitor 
by [CONTACT_3719] e -mail using the details below.
, MD PhD
Email: 
Fax:
For protocol -or safety- related issues during normal business hours ([ADDRESS_393405] Time) ,the investigator must contact [CONTACT_317344]:
, MD PhD, 
Phone: 
Mobile: 
Email: 
Fax: 
For protocol -or safety- related issues outside of normal business hours , the investigator 
must contact [CONTACT_319404]:
, MD, 
Phone:  (medical emergencies – [LOCATION_002])
Phone:  (medical emergencies –Global)
Email: 
r n-commercial use only

Shire CONFIDENTIAL Page 7
Protocol SHP633 -303 Version 2 / 22Nov [ADDRESS_393406] 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet the speci fications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality  Complaint:
Origin of Product Quality Complaint E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire ([LOCATION_003]) 
For non-commercial use only

Shire CONFIDENTIAL Page 8
Protocol SHP633 -303 Version 2 / 22Nov [ADDRESS_393407] Background ................................
.................................................................28
2STUDY OBJECTIVES AND PURPOSE ..............................................................................30
2.1 Rationale for the Study .............................................................................................30
2.2 Study  Objectives ......................................................................................................30
2.2.1 Primary  Objectives .................................................................................................30
2.2.2 Secondary  Objectives .............................................................................................30
3STUDY DESIGN ...................................................................................................................31
3.1 Study  Design and Flow Chart ..................................................................................31
3.1.1 Informed Consent/Assent and Eligibility ...............................................................32
3.1.2 Retrospective Data Collection ...............................................................................32
3.1.3 Prospective Data Collection and Treatment ..........................................................33
3.2 Duration and Study  Completion Definition .............................................................34
4STUDY POPUL ATION................................
.........................................................................36
4.1 Study  Inclusion Eligibility  Criteria ..........................................................................36
4.2 Study  Exclusion Eligibility  Criteria .........................................................................36
4.3 Teduglutide Eligibility  Criteria ................................................................................36
4.4 Teduglutide Treatment Inclusion Criteria ................................................................36
4.5
Teduglutide Treatment Exclusion Criteria................................ ............................... 37
4.6 Follow -up Period Escape Criteria ................................ ................................ ............ 38
4.7 Reproductive Potential .............................................................................................38
4.7.1 Female Contraception ............................................................................................38
4.8 Discontinuation of Subjects .....................................................................................39
4.8.1
Teduglutide Discontinuation................................ ................................ .................. 39
4.8.2 Study  Withdrawal ................................ ................................ ................................ ..39
For non-commercial use only
Shire CONFIDENTIAL Page 9
Protocol SHP633 -303 Version 2 / 22Nov 2016
4.8.3 Reasons for Discontinuation ................................ ................................ .................. 39
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................[ADDRESS_393408](s) ...........................................................[ADDRESS_393409] Compliance ..................................................................................................45
7
STUDY PROCEDURES........................................................................................................46
7.1 Study  Schedule .........................................................................................................46
7.1.1 Retrospective Data Collection
...............................................................................46
7.1.2 Screening ................................................................................................................47
7.1.3 Visits for Subjects Not Receiving Teduglutide .....................................................48
7.1.4 Visits 
for Subjects Receiving Teduglutide Treatment...........................................48
[IP_ADDRESS] Pretreatment Visit ...................................................................................48
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24) .....................................49
7.1.5 Teduglutide Follow -up Period ...............................................................................51
7.1.6 Study  Completion/Earl y Termination Visit (EOS/ET Visit) .................................[ADDRESS_393410] ion...............................................................................52
[IP_ADDRESS] Growth (Height, Weight, and Head Circumference) .............................52
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed ................................................52
[IP_ADDRESS] Parenteral Support Prescribed ................................................................52
[IP_ADDRESS] Adverse Events ................................ ................................ ....................... 53
7.2.2 Prospective Data Collection................................ ................................ ................... 53
[IP_ADDRESS] Demographics, Medical History , and SBS History ................................ 53
For non-commercial use only
Shire CONFIDENTIAL Page 10
Protocol SHP633 -303 Version 2 / 22Nov 2016
[IP_ADDRESS] Physical Examination ................................ ................................ ............. 53
[IP_ADDRESS] Adverse Event Collection.......................................................................53
[IP_ADDRESS] Vital Signs, Bod y Weight, Height, Head Circumference and Bod y 
Mass I ndex (BMI) ..................................................................................53
[IP_ADDRESS] Clinical L aboratory  Tests .......................................................................54
[IP_ADDRESS] Serum Sampling .....................................................................................56
[IP_ADDRESS] Pregnancy  Testing ..................................................................................56
[IP_ADDRESS] Antibody  Testing ....................................................................................56
[IP_ADDRESS] Volume of Blood ....................................................................................56
[IP_ADDRESS] Gastrointestinal -specific Testing ............................................................57
[IP_ADDRESS] Nutritional Support ................................
.................................................58
[IP_ADDRESS] Diaries ....................................................................................................58
[IP_ADDRESS] Health- related Quality  of L ife Assessments ...........................................59
8ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................62
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................62
8.1.1 Severity  Categorization ..........................................................................................63
8.1.2 Relationship Categorization ...................................................................................63
8.1.3 Outcome Categorization ........................................................................................64
8.1.4 Symptoms of the Disease under Study ................................
..................................64
8.1.5 Clinical L aboratory  and Other Safet y Evaluations (Prospective Period of 
Observation Onl y)..................................................................................................64
8.1.6 Pregnancy ...............................................................................................................65
8.1.7 Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Onl y)................................................................
..................................[ADDRESS_393411] ................................ ................................ ........... 69
8.4 Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only )................................ ................................ ................................ ......................... 69
8.4.1 Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only ).........................................70
For non-commercial use only
Shire CONFIDENTIAL Page 11
Protocol SHP633 -303 Version 2 / 22Nov 2016
8.4.2 Dose Interruption Criteria Based on Drug -Induced L iver Injury  (Prospective 
Period of Observation Only )..................................................................................72
8.5 Early Termination of the Clinical Study  (Prospective Period of Observation 
Only ).........................................................................................................................73
9DATA MANAGEMENT AND STATISTICAL METHODS...............................................74
9.1 Data Collection .........................................................................................................74
9.2 Clinical Data Management .......................................................................................74
9.3 Statistical Analy
sis Process ......................................................................................74
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................74
9.5 Sample Size Calculation and Power Considerations
................................................75
9.6 Study  Population ......................................................................................................75
9.7 Efficacy  Anal yses................................................................
.....................................75
9.7.1 Efficacy  Endpoints ................................................................
.................................75
9.8 Safety  Anal yses........................................................................................................75
9.8.1 Safety  Endpoints ....................................................................................................76
9.9 Other Anal yses.........................................................................................................77
9.9.1 Health- related Quality  of L ife Anal yses................................................................77
10SPONSOR’S AND I NVEST IGATOR’S RESPONSIBILIT IES...........................................78
10.1 Sponsor’s Responsibilities .......................................................................................78
10.1.1 Good Clinical Practice Compliance .......................................................................78
10.1.2 Indemnity /Liability  and Insurance ................................
.........................................78
10.1.3 Public Posting of Study  Information ......................................................................78
10.1.4 Submission of Summary  of Clinical Study  Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees ........................78
10.1.5 Study  Suspension, Termination, and Completion
..................................................79
10.2 Investigator’s Responsibilities .................................................................................79
10.2.1 Good Clinica l Practice Compliance .......................................................................79
10.2.2 Protocol Adherence and Investigator Agreement ..................................................79
10.2.3 Documentation and Retention of Records .............................................................80
[IP_ADDRESS] Case Report Forms .................................................................................80
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ................................
..............................................................80
[IP_ADDRESS] Audit/I nspection .....................................................................................81
[IP_ADDRESS] Financial Disclosure ...............................................................................[ADDRESS_393412] or Ethics Committee ................................ .................. 82
10.4 Privac y and Confidentiality ................................ ................................ ...................... 82
10.5 Study  Results / Publication Policy ................................ ................................ ........... 83
For non-commercial use only
Shire CONFIDENTIAL Page 12
Protocol SHP633 -303 Version 2 / 22Nov 2016
11REFERENCES ................................ ................................ ................................ ....................... 85
12APPENDI CES ........................................................................................................................86
For non-commercial use only
Shire CONFIDENTIAL Page 13
Protocol SHP633 -303 Version 2 / 22Nov [ADDRESS_393413]  OF TABLES
Table 1-1: Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................22
Table 1-2: Schedule of Events for Screening and End of Study or Earl y 
Termination ...................................................................................................23
Table 1-3: Schedule of Events for No Teduglutide Treatment Period
...........................24
Table 1-4: Schedule of Events for Teduglutide Treatment Period .................................25
Table 5
-1: Prohibited Treatment .....................................................................................41
Table 7-1: List of Laboratory  Tests ................................................................................55
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject 
Annually ................................
........................................................................57
Table 7
-3: Developmentally Appropriate PedsQL™Generic Core Scales .....................60
Table 8
-1: CTCAE Criteria for Adverse Events that May Lead to Dose 
Interruption (Prospective Period of Observation Only ) ................................[ADDRESS_393414]  OF FIGURES
Figure 3 -1: Study  Design Flow Chart ................................
..............................................[ADDRESS_393415]  OF APPENDICES
Appendix 1 Protocol History................................
.............................................................87
Appendix 2 Guidelines for Nutritional Support Management During the Study .............88
For non-commercial use only
Shire CONFIDENTIAL Page 14
Protocol SHP633 -303 Version 2 / 22Nov [ADDRESS_393416] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body  mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study  report
CTCAE Common Terminology Criteria for Adverse E vents
DILI drug-induced livery  injury
DMC data monitoring committee
DPP-[ADDRESS_393417]
IV intravenous
For non-commercial use only
Shire CONFIDENTIAL Page 15
Protocol SHP633 -303 Version 2 / 22Nov 2016
IWRS interactive web -based response sy stem
MedDRA Medical Dictionary  for Regulatory  Activities
NCI National Cancer Institute
NDA new drug application
NTT no-teduglutide treatment
PDA patent ductus arteriosus
PedsQL Pediatric Quality  of Life Inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once dail y
SAE serious adverse event
SAP statistical analy sis plan
SBS short bowel sy ndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_393418] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization- Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page 16
Protocol SHP633 -303 Version 2 / 22Nov 2016
STUDY  SYNOPSIS
Protocol num ber: SHP633 -303 Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open -label, Long -term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bow el Syndrome Who Completed TED -C13-003
Number of subjects (total and for each treatm ent arm):
Approximately [ADDRESS_393419] of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED -C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the [LOCATION_002] (US) and the [LOCATION_008] ([LOCATION_006]) will participate in 
this extension study.
Study period (planned):
October 2016 -September 2019Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith short 
bowel syndrome ( SBS)who completed TED -C13-003.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED -C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open -label, long -term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED -C13-[ADDRESS_393420] of care ( SOC )treatment arm in 
TED -C13-003.
Investigational product, dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subj ects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED -C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of 
specific s afety and efficacy measures that were completed in the course of the subject’s standard medical care 
betw een the date of the TED -C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) is signed fo r this study. In addition to this retrospective data collection, prospective 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review  and signing of the ICF (and if applicable, i nformed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collec tion only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only
Shire CONFIDENTIAL Page 17
Protocol SHP633 -303 Version 2 / 22Nov [ADDRESS_393421]’s standard medical care betw een the date of the TED -C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after
informed consent/assent is obtained for this study. The following retrospective data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Growth (height, head circumference [ up to 36 months of age ], weight )
End dates for adverse events (AEs) ongoing at the time of TED -C13-003
All n onserious AEsrelated to teduglutide treatment
All adverse events of special interest ( AESIs)
All serious adverse events (SAEs)
Prospective Data Collection andTreatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1 -2.These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. Prescription parenteral support requirements will be collected at screening. 
Additionally, intake diaries will be dispensed at the screening visit for collection of actual parenteral support (PS)
volume and hours per day ( Section [IP_ADDRESS] ). Diary data for PSvolume will be collected fo r at least 2 w eeks after 
the ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no -teduglutide treatment [NTT] period), w ill be seen 
approximately every  12weeks for safety, parente ral support (PS) requirements, and quality of life. Diary data for 
PSvolume will be collected for at least [ADDRESS_393422] NTT visit after the screening visit 
will occur within 2 to 12 w eeks ofthe screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥[ADDRESS_393423], and parent or legal guardian agree sto proceed with teduglutide therapy .
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28 -week cycle, consisting of 2 4 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up (no treatment) period ( Figure 3 -1). During 
the 28 -week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and w eekly during the follow -up period (betw een Weeks 24 and 28 ).
At all site visits and telephone contacts, safety will be monitored and nutrition al support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 w eeks. To m aintain 
consistency across centers, all attempts should be made to follow  the nutritional support adjustment guidelines 
(develope d with SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a proto col deviation ( Appendix 2 ).
For non-commercial use only
Shire CONFIDENTIAL Page 18
Protocol SHP633 -303 Version 2 / 22Nov 2016
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy.
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are requir ed approximately 
1week after adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects 
discontinue teduglutide at Week 24 and enter a 4 -week follow-up (no -treatment) period, during which phone visits will be 
performed weekly ( solid grey lines ). If an escape criterion is met during the follow -up period, subjects may proceed directly 
to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet allof the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study -related procedures.
2.Subject completed the TED -C13-003 study (including subjects in the standard of care treatment arm).
3.Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligib le for tedugluti de treatment if ≥[ADDRESS_393424] (and/or parent or 
legal guardian, as appropriate) must agree to proceed wit h treatment.
Teduglutide Treatment Inclusion Criteria :
1.Subject is teduglutide -naïve, receiving PS, and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and during t he 
teduglutide pretreatment visit, as assessed by [CONTACT_093]. Transient instability for events such as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of 
baseline prior to the event.
2.Subject w as previ ously treated w ith teduglutide and at least 1 of the following criteria is satisfied:
a.Increasing PS requirements follow ing teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319434] t eduglutide discontinuation
For non-commercial use only
Shire CONFIDENTIAL Page 19
Protocol SHP633 -303 Version 2 / 22Nov 2016
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319360]
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361]
e.Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <10 kg at the pretreatment visit
2.Unresected gastrointestinal (GI) polyp, known p olyposis condition, premalignant change, or malignancy, 
in the GI tract
3.History of cancer in the previous 5 years except surgically curative skin cancers
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglu tide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle
6.Clinically s ignificant intestinal stricture or obstruction
7.Clinically significant, active or recurrent pancreatic or biliary disease
8.Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_319406] (eGFR) below 
50mL/min/1.[ADDRESS_393425] repair, or patent ductus arteriosus (PDA) ligation
11.Participation in a clinical study using an experimental drug (other than glutamine ,Omegaven , or 
Smoflipid) within 3 months or 5.5 half -lives of the experimental drug, whichever is longer, prior to the 
pretreatment visit and for the duration of the 28 -week cycle
12.Treatment w ith analogs of glucagon -like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP -2) (not 
including teduglutide), insulin -like growth factor -1 (IGF -1), or grow th hormone, within 3months
preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_393426], closely -related 
compounds, or any of the stated ingredients
15.Known history of alcoho l or other substance abuse within 1 year prior to the pretreatment visit
16.Pregnant or lactating female subjects
17.Sexually active female subjects of child -bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents completion of the study, or interferes with analysis of the study results
Follow -up Period Escape Cr iteria: At the discretion of the investigator, the follow -up period may be interrupted 
and the subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
For non-commercial use only
Shire CONFIDENTIAL Page 20
Protocol SHP633 -303 Version 2 / 22Nov 2016
2.Deteriorating nutritional status (eg, w eight loss or growth failure) despi[INVESTIGATOR_319363]
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319364]
4.Severe diarrhea related to teduglutide discontinuation
Maximum duration of subject involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple [ADDRESS_393427] has access (as needed) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately [ADDRESS_393428] has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.
Planned duration of no -teduglutide treatm ent periods: variable, depending on disease course
Planned duration of the t eduglutide pretreatm ent visit: 1-21 days
Planned teduglutide treatment cycle duration :28 w eeks. Each cycle consists of 24 w eeks of 
teduglutide treatment followed by a 4 -week follow -up period (no treatment)
Endpoints and statistical analysis:
The safety p opulation includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED -C13-003) and/or first exposure to 
teduglutide. The following efficacy endpoints will be analyzed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research Endpoints
Health economics and outcomes research endpoints will be analyzed at approximately 12 -week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, an d every 12 w eeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period. The beginning of each treatment cycle (CxD1) w ill be an 
additional baseline.
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores:
oFood and drink limits
oDiarrhea
Safety Endpoints
The follow ing safety endpoints will be analyzed from the beginning of the prospective study period:
Adverse events
Vital signs, including body temperature, heart rate, and blood pressure
Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
Antibodies to teduglutide
For non-commercial use only
Shire CONFIDENTIAL Page 21
Protocol SHP633 -303 Version 2 / 22Nov 2016
Gastrointestinal -specific testing, includ ing fetal occult blood testing and colon oscopy or sigmoidoscopy
The follow ing safety endpoints will be analyzed from the end of the core study ( TED -C13-003) to the beginning of 
the prospective study period:
 Adverse events related to teduglutide
 All SAEs
 All Adverse Events of Special Interest ( Section 8.3 )
The follow ing safety endpoints will be analyzed relative to the baseline of the core study (TED -C13-003):
 Z-scores for height (or length), w eight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; how ever, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Saf ety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by [CONTACT_765]. A dverse event s 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the d ifference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_300192].
Sample Size Justification
As this is an extension study, the maximum number of subjects wasdetermined by [CONTACT_319435] -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 22
Protocol SHP633 -303 Version 2 / 22Nov 2016
STUDY  SCHEDULES
Table 1-1: Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment Note
Informed consent/assent Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study -
related procedures, including retrospective data collection.Study eligibility
WeightaThe last representative value for w eight during each [ADDRESS_393429] all teduglutide prescription sduring the retrospective data collection 
period , including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator -initiated trials, 
compassionate use, an d named -patient access programs .
Parenteral support (PS) 
prescribedaThe last representative PS presc ription during each 12 -week interval 
throughout the retrospective period and at the beginning and end of any 
teduglutide treatment will be collected. Data collected should include weekly 
prescribed volume, calories, average hours per day, and days per w eekof 
prescribed PS .
End dates for adverse events 
(AEs) ongoing at the end of 
TED -C13-[ADDRESS_393430]
Serious adverse events (SAEs)
Note: Retrospective data aredefined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED -C13 -003 end of study (EOS) visit and the date the 
informed consent form ( ICF) (and if applicable, informed assent) is signed for this study . Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospecti ve data 
collection, only assessments in this table will be completed. See Section 7.1.1 for further details on collection of retrospective 
data.
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
a The first 12 -week interval begins at TED -C13 -003 EOS visit.
For non-commercial use only
Shire CONFIDENTIAL Page 23
Protocol SHP633 -303 Version 2 / 22Nov 2016
Table 1-2:Schedule of Events for Screening and End of Study or Early Termination
ScreeningEnd of Study or Early 
Termination
Visit Type Site Site
Informed consent/assent X
Study eligibility X
Dem ographics, medical history, SBS historyaX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriabX
Adverse events X X
Concomitant medications and GI procedurescX X
Physical examination and vital signs, including weight X X
Height and head circumferencedX X
Revie w intake and output diarieseX
Record PS prescription and adjust as neededfX X
Safety laboratory testsgX
PedsQL Generic Core Scale/ PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-ScalesX
Antibodies to teduglutidehX
Fecal occult blood testingi(X)
Colonoscopy or sigmoidoscopyj(X)
Pregnancy testingk(X)
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EOS =end of study ;ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child -bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
aIf the subject has any changes to the medical history and SBS history that had been collected at the baseline of the TED-C13 -
003study , then the updated medical history and SBS history will be collected.
bSubjects who meet ≥[ADDRESS_393431], 
and parent or legal guardian agrees to proceed with teduglutide therapy ( Table 1-4).
cConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies ,and 
associated pathology results.
dHead circumference willbe measured in subjects 36 months of age and younger.
eThe intake diary should b e completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be 
completed daily over a 48 -hour period of nutritional stability before the EOS/ET visit.
fParenteral support prescription will be collected at the screening vi sit. Parenteral support adjustments should be made after 
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix [ADDRESS_393432] of clinical chemistry, hematology, and urinalysis, with results pro cessed 
by a central laboratory. U rine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a protocol deviation.
h Required for all teduglutide -exposed subjects.
i Fecal occult blood testing should be performed on teduglutide -exposed subjects on an annual basis, approximately every 48 -
60weeks at a minimum.
j The need for colonoscopy /sigmoidoscopy in response to a po sitive FOBT result during a no -teduglutide treatment period is at 
the discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy /sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of stu dy drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscopy /sigmoidoscopy at 5 year intervals or more often as needed. See Section [IP_ADDRESS] for details.
kPregnancy testing is required for FOCBP at an ET visit if the subjec t has not had a pregnancy test at least 30 days after study 
drug discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 24
Protocol SHP633 -303 Version 2 / 22Nov 2016
Table 1-3:Schedule of Events for No Teduglutide Treatment Period
Visit Number NTx
Visit Type Site
Visit FrequencyaEvery 12 weeks
Window (days)b±[ADDRESS_393433] as neededgX
Safety laboratory testshX
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutidei(X)
Fecal occult blood testingjAnnually
Colonoscopy or sigmoidoscopyk(X)
Serum samplelEvery 24 w eeks
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
aThe first NTx visit after the screening visit must occur within [ADDRESS_393434] NTx visit in the current no -teduglutide treatment period.
c Subjects who meet ≥[ADDRESS_393435], 
and parent or legal guardian agree to proceed with teduglutide therapy ( Table 1-4).
dConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies ,and 
associated pathology results.
eHead circumference will be measured in subjects [ADDRESS_393436] actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool output should be recorded in the output diary over a 48 -hour period of nutritional stabi lity before every clinic 
visit. S ee Section [IP_ADDRESS] for more detail.
gParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix [ADDRESS_393437] follow -up samples collected 
every 12 weeks during the study until a negative result is obtained.
jFecal occult blood testing should be performed on teduglutide -exposed subjects on an annual basis, approximately every 
48-60weeks at a minimum.
kThe need for colonoscopy /sigmoidoscopy in response to a positive fecal occult blood test during a no -teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy /sigmoidoscopy after 
they have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receiv e 
teduglutide will undergo colonoscopy /sigmoidoscopy at 5-year intervals or more often as needed. See Section [IP_ADDRESS] for 
details.
lLack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 25
Protocol SHP633 -303 Version 2 / 22Nov 2016
Table 1-4:Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Visit Number PxCx
D1Cx
W1Cx
W2
Phone contact [CONTACT_319408] [ADDRESS_393438] is required approximately 1 week after PS adjustmentCxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28b
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhoneaSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  (days)c-21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteriaX Xd
Dispense intake 
and output diariesX X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant 
medications and 
GI
procedureseX X X X X X X X X X X X X
Physical 
examination and 
vital signs, 
including weightX X X X X X X X X X X X
Height and head 
circumferencef X X X X
Review intake 
and output 
diariesgX X X X X X X X X X X X X
Record PS Rx 
and adjust as 
neededhX X X X X X X X X X X X X
Safety laboratory 
testsi XiX X X X X X X X X X (X) X
PedsQL Generic 
Core Scale/ 
Family Impact 
Module/ GI 
Symptoms 
Module Sub -X X X
For non-commercial use only
Shire CONFIDENTIAL Page 26
Protocol SHP633 -303 Version 2 / 22Nov 2016
Table 1-4:Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Scales
Antibodies to 
teduglutidej X X X X
Fecal occult 
blood testingX X X
Colonoscopy /
Sigmoidoscopyk (X) (X) (X)
Pregnancy 
testingl X X X X X X X X X
Serum samplemX X
Evaluate escape 
criterian X X
Dispense study 
drugo X X X X X X X X X
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
eCRFs=electronic case report forms; EOS=end of study; EOT=end of treatment; ET = early termination; FOBT=fecal occult blood test; FOCBP=females of child -bearing 
potential; FU=follow -up; GI=gastrointestinal; PedsQ L=Ped iatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin time/international normalized ratio;
SBS= short bowel s yndrome; SC=subcutaneous; Scr=screening; TED=teduglutide; Tx=treatment
aPhone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25 -27 (except 
for evaluation of escape criteria).
bThe investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur 
within [ADDRESS_393439] is completing the study at the CxW28 visit, the EOS/ET visit (Table 1-2)will take place in lieu of the CxW28 visit.
cVisit windows are relative to the CxD1 visit.
d Eligibility will need to be reconfirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of othe r labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
eConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies ,and associated pathology results.
fHead circumference will be measured in subjects [ADDRESS_393440] actual PS volume and hours per day. Intake d iaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except 
atpretreatment visit), for 1 week following PS adjustment, and daily during the 4-week follow -up period. Urine and stool output should be recorded in the output diary over a 48 -
hour period of nutritional stability before every clinic visit, and within 1 wee k of implementing a change in the PS prescription . See Section [IP_ADDRESS] for more detail.
hParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance fo r nutrition support a djustment 
provided in Appendix [ADDRESS_393441] PT/INR at the pretreatment 
visit. Additional collection will occur if a potential drug -induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
of urinalysis w ill not constitute a protocol deviation.
jSamples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are re ceiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
For non-commercial use only
Shire CONFIDENTIAL Page 27
Protocol SHP633 -303 Version 2 / 22Nov 2016
Table 1-4:Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
kThe teduglutide -naïve subjects age 12 and older will undergo colonoscopy /sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a 
colonoscopy /sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) ar e obtained at the end of a 
teduglutide treatment cycle (CxW24/EOT), colonoscopy /sigmoidoscopy will be performed. The n eed for colonoscopy /sigmoidoscopy in response to positive FOBT results at 
CxW12 is at the discretion of the investigator. Teduglutide -exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will 
undergo col onoscopy /sigmoidoscopy. See Section [IP_ADDRESS] for details.
lA serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be adminis tered at all other visits according to the study 
schedules, or if pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the study.
mLack of collection of serum samples will not constitute a protocol deviation .
nIf escape criteria are met, the subject may proceed directly to another pretrea tment visit at the discretion of the investigator.
oThe first SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observ ed 
for hypersensitivity rea ctions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF .See 
Section 6.2.3 for dose adjustment.
For non-commercial use only
Shire CONFIDENTIAL Page 28
Protocol SHP633 -303 Version 2/ 22Nov 2016
1 BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 y ear and older with SBS ( Khan et al. 
2015; Wales et al. 2004 ). Unlike the adult population, the majority  of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids ( parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12months of the initial insult , and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 y ears of the initial diagnosis ( Khan et al. 2015). 
Nevertheless, despi[INVESTIGATOR_3062], many  pediatric subjects remain dependent 
on PS. Complications of long -term PS include liver disease, catheter -related blood stream 
infections, central line- associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality  of life is poor ( Squires et al. 
2012). Accelerating the adaptive process and achieving enteral autonomy  isan urgent goal for all 
patients with SBS who are dependent on PS ( Khan et al. 2015; Squires et al. 2012).
Intestinal adaptation is driven by  [CONTACT_319436] ( Drucker 
and Yusta 2014
). Chief among these is hormones glucagon- like peptide 2 (GL P
-2), which is 
secret ed from L -type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Resection of these regions may impair the adaptive response b y limiting endogenous 
production of GLP -2.
1.[ADDRESS_393442] Background
Teduglutide is a novel, recombinant analog of naturally occurring human GLP -
2 that regulates 
the functional and structural integrity  of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33 -amino acid peptide that differs from native GLP- 2 in the substitution of 
glycine for alanine at the second position at the N-terminus. As a result, teduglutide demonstrates 
resistance to degradation by  [CONTACT_20597] l peptidase 4 (DPP -4) and therefore maintains a longer 
elimination half -life (t 1/2) in adults of approximately 2 hours compare d to the native peptide, 
which has a t 1/2 of approximately  7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and cry pt depth in the intestinal 
epi[INVESTIGATOR_2130], thereb y increasing the absorptive surface area of the intestines ( Tappenden et al. 
2013; Thymann et al. 2014). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide ( REVESTIVE™) on [ADDRESS_393443] 2012 and a New Drug Application (NDA) for teduglutide (G ATTEX®) was approved by  
[CONTACT_24623] (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide hasalsobeen 
approved for use in adult patients with SBS in Canada and Switzerland . On 29 Jun 2016, the 
For non-commercial use only
Shire CONFIDENTIAL Page 29
Protocol SHP633 -303 Version 2/ 22Nov 2016
European Commission granted an extension of the Market Authorization for teduglutide 
(REV ESTIVE ™) for the treatment of patients a ged 1 y ear and above with SBS; patients should be 
stable following a period of intestinal adaptation.
1.3 Clinical Studies with Teduglutide in Pediatric subjects
One Phase 3 stud y, TED -C13-003, was completed in pedia tric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1 -17. Thirty -seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for [ADDRESS_393444] of care (SOC) cohort. There were clear dose -dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 0.0125 
mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at Week 12 
of 37%, including complete independence from PS support in [ADDRESS_393445], and a reduction of 
3.94 hours per day  infusion time. I n the 0.05 mg/kg/day  cohort there was a reduction in PS 
volume at Week 12 of 39%, including complete independence from PS support in 3 subjects, and 
a reduction of 4.18 hours per day  infusion time. Teduglutide was generall y safe and well 
tolerated b y pediatric subjects in all dosing cohorts. There were no deaths durin g the stud y and 
no treatment -emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study  were due to adverse events (AEs).
TED -C14-006 is an ongoing study  which includes 2 treatment arms: a teduglutide trea tment arm 
and a standard of care treatment arm. Subjects in both arms participate in a [ADDRESS_393446] medical therap y for SBS; while 
those in the teduglutide treatment arm will receive daily  subcutaneous (SC) injections of 
teduglutide (stud y drug) in addition to sta ndard medical therapy. The subjects enrolling in the 
teduglutide treatment arm will be randomized 1:1 in a double- blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day  of teduglutide administered subcutaneousl y for 
24weeks.
Alway s refer to the latest version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633).
For non-commercial use only
Shire CONFIDENTIAL Page 30
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393447] -time treatment of 
tedu
glutide -naïve subjects who participated in the SOC treatment arm in TED- C13-003.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED -C13-003.
2.2.2 Secondary Objectives
The secondary  objective of this study  is to evaluate the long -term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 31
Protocol SHP633 -303 Version 2/ 22Nov 2016
3 STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safet y and 
efficacy  of teduglutide in pediatric subjects who completed the TED -C13-003 study  (the core 
study ). At the time of entry  into the TED- C13-[ADDRESS_393448] 30% of their caloric or fluid needs, and 
had not been able to significantly  reduce PS for at least [ADDRESS_393449] s in the teduglutide treatment arm were entered into a 
0.0125 mg/kg/day , 0.025 mg/kg /day, or 0.05 mg/kg /day dose cohort based on the timing of their 
enrollment in the study . The cohorts were filled in a sequential manner.
Approximately  [ADDRESS_393450] meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT] ), 
will be seen approximately  every  12 weeks for safety , parenteral support (PS) requirements, and 
quality  of life. At any  point during a nNTT period, subjects who meet ≥[ADDRESS_393451], and 
parent or legal guardian agree sto proceed with teduglutide therapy .
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long- term follow -up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric sub jects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analy sis suggested that pediatric patients, ages 1 -17years-old, are lik ely to require the same 
dose as used in adults, namely  0.05 mg/kg/day  (Mouksassi et al. 2009 ). In this extension study  to 
TED -C13-003, repeat doses of teduglutide 0.05 mg/kg /day will be administered to eligible 
pediatric subjects.
Rationale: Teduglutide is approved for adult use in the US and EU , and for pediatric use in the 
EU,at a dose of 0.05 mg/kg SC once daily. The completed 12 -week pediatric study (TED- C13-
003) demonstrate d that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day was 
associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
For non-commercial use only
Shire CONFIDENTIAL Page 32
Protocol SHP633 -303 Version 2/ 22Nov 2016
studies as well as the pediatric (core)study (TED -C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults ( O'Keefe et al. 2006 ).
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED -C14-[ADDRESS_393452] may  be evaluated immediately  for 
additional teduglutide treatment. Subjects who clinically  deteriorate or stop improving at any  
time after the end of the follow-up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED- C13-[ADDRESS_393453]’s standard medical care between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form ( ICF) (and if 
applicable, informed assent) is signed for this study . In addition to this retrospective data 
collection, prospective study  assessments of safety  and efficacy  will be completed a s a part of 
this study .
3.1.1 Informed Consent /Assent and Eligibility
The review and signing of the I CF (and if applicable, informed assent) for this study , must be 
completed before an y other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study ; however subjects may  
consent to retrospective data collection onl y. Subjects may not consent to the prospective data 
collection only . After informed consent/assent is obtained, study  eligibility will be assessed for 
all subjects.
3.1.[ADDRESS_393454]’s standard medical care between the date of the 
TED -C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study . Retrospective data collection may  begin any  time after informed consent/assent is 
obtained for this study . The following data will be collected:
For non-commercial use only
Shire CONFIDENTIAL Page 33
Protocol SHP633 -303 Version 2/ 22Nov 2016
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Growth ( height, head circumference [up to 36 months of age ], weight)
End dates for adverse events (AEs) ongoing at the time of TED -C13-003
All n onserious AEs related to teduglutide
All adverse events of special interest ( AESIs)
All serious adverse events (SAEs )
3.1.3 Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history  and short bowel sy ndrome history . Prescription parenteral support 
requirements will be collected at screening. Additionally , intake diaries will be dispensed at the 
screening visit for collection of actual PS volume and hours per day  (Section [IP_ADDRESS]). Diary  
data for PSvolume will be collected for at least 2 weeks after the ICF (and if applicable, the 
informed assent) is signed for this study .
Subjects not receiving teduglutide treatment (ie, in a nNTT period), will be seen approximately  
every  [ADDRESS_393455] NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any  point after screening, including 
during an NTT period, subjects who meet ≥[ADDRESS_393456], and pa rent or legal 
guardian agree sto proceed with teduglutide therapy .
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28 -week cycle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily , followed by  a 
4-week follow -up (no treatment) period ( Figure 3 -1). During the 28- week cy cle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately  
1
week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 
24), and weekl y during the follow -up period (between W
eeks 24 and 28).
At all site visits and telephone contacts, safet y will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality  of life assessments will be made approximately  every  
12 weeks. To maintain consistency  across centers, all attempts should be made to follow the 
nutritional support adjustme nt guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weight 
gain, urine and stool output, and clinical stability . Departure from the guidelines, however, is not 
considered a protocol deviation ( Appendix 2 ).
Rationale: Measures of 
long-term safety will include adverse events, growth parameters, and 
anti-drug antibodies. Measure of long term efficacy will include durability of effect as measured 
For non-commercial use only
Shire CONFIDENTIAL Page 34
Protocol SHP633 -303 Version 2/ 22Nov 2016
by [CONTACT_319411] (Pediatric Quality of 
Life I nventory [ PedsQL ], PedsQL Family Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary endpoint in pi[INVESTIGATOR_9205] 3 adult 
clinical trials and the completed Phase 3 pediatric study (TED -C13-003), and will be used as an 
endpoint in this extension study. In previous clinical studies, a reduction of this magnitude was 
associated with a reduction in the number of days per week of PS, and increases in enteral 
intake. Reduction in volume and time of PS due to improved enteral absorption may provide a 
pediatric subject with opportunities for more age -appropriate activities including oral 
rehabilitation. Quality of life assessments will be performed in this study to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient population and the pharmacologic effect of teduglutide, GI -specific screening tests,
including fecal occult blood testing and colonoscopy /sigmoidoscopy , which are commonly part 
of the routine care of these subjects, will be performed to ensure safety. This study captures long -
term safety data on polyps and other colonic mucosal changes in teduglutide -exposed subjects 
using the surveillance strategy proposed in Section [IP_ADDRESS] .
Figure 3-1: Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutid e treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid blac k lines ). Phone visits are required approximately 1 week after 
adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide 
at Week 24 and enter a 4 -week follow -up (no-treatment) period, during which phone visits will be performed weekly ( solid grey 
lines ). If an escape criterion is met during the follow -up period, subjects may proceed directly to another pretreatment visit.
3.[ADDRESS_393457] has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study  Inclusion Eligibility  
Criteria. The stud y will continue for at least [ADDRESS_393458] has access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be approximately 
[ADDRESS_393459] has not withd rawn early  from the study  for an y 
reason prior to completing the EOS visit.
For non-commercial use only
Shire CONFIDENTIAL Page 35
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393460] 
(last safet y contact), whichever is later. The stud y completion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page 36
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393461] and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before any  study -related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_393462] will n ot be considered eligible for the study  without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completing any  
study -related procedures. 
2. Subject completed the TED- C13-003 study  (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully  adhere to study  requirements as 
defined in this protocol.
4.2 Study Exclusion El igibility Criteria
There are no exclusion criteria for this study .
4.3 Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_393463] (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.[ADDRESS_393464] is teduglutide -naïve, receiving PS, and unable to significantl y reduce PS or 
advance enteral feeds (eg, 10% or less change in PS or advance in feeds) for at least 
3months prior to and during the teduglutide pretreatment visit, as assessed by  [CONTACT_1275]. T ransient instability  for events such as interruption of central access or 
treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the 
event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criter ia is 
satisfied:
a.Increasing PS requirements following teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, followed by  
[CONTACT_319412]
c.Deteriorating nutritional status ( eg, weig ht loss or growth failure) despi[INVESTIGATOR_319366]
d.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319378]-commercial use only
Shire CONFIDENTIAL Page 37
Protocol SHP633 -303 Version 2/ 22Nov 2016
e.Severe diarrhea related to teduglutide discontinuation
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_393465]
3.History  of canc er in the previous 5 y ears except surgically  curative skin cancers
4.Serial transverse enteroplasty  or other major intestinal surgery  within 3 months 
preceding the teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic 
ulcer repair, minor i ntestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week 
cycle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurr ent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairment or injury , 
including the following laboratory  values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransfe rase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dy sfunction shown by  [CONTACT_319406] (eGFR) 
below 50 mL /min/1.[ADDRESS_393466] repair, or 
patent ductus arteriosus (PDA) ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine ,
Omegaven , or Smoflipid ) within 3 months or 5.5 half -lives of the experimental drug, 
whichever is longer, prior to the pretreatment visit and for the duration of the 28 -week 
cycle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon -like peptide -2 
(GLP-2) (not including teduglutide), insulin -like growth factor- 1 (IGF -1), or growth 
hormone, within 3 month s preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_393467], 
closely -related compounds, or any  of the stated ingredients
15.Known history  of alcohol or other substance abuse within 1 y ear prior to the 
pretreatment visit
16. Pregnant or lactating female subjects 
For non-commercial use only
Shire CONFIDENTIAL Page 38
Protocol SHP633 -303 Version 2/ 22Nov 2016
17.Sexually  active female subjects of child -bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 day s after the treatment period 
18.Any condition, disease, illness, or circumsta nce that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the study, or interferes with 
analysis of the study  results
4.[ADDRESS_393468] may  
proceed directl y to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation
2. Deteriorating nutritional status (eg, weight loss or growth failure) desp ite maximal 
tolerated enteral nutrition following teduglutide discontinuation
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319370]
4.Severe diarrhea related to teduglut ide discontinuation
4.[ADDRESS_393469]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:
Premenarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta
-human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pretreatment visit .Females of 
child- bearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:
Abstinence
Intrauterine devices plus condoms
Double- barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
For non-commercial use only
Shire CONFIDENTIAL Page 39
Protocol SHP633 -303 Version 2/ 22Nov 2016
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually  active dur ing the study , they  should use [ADDRESS_393470] wishes to remain in the study, the evaluations listed for the EOT visit are to be 
performed. A 4-week follow -up period will ensue, consisting of weekl y telephone visits 
(CxW25 -27) an d the week 28 clinic visit (CxW28). The subject would then enter a nNTT period 
and could be evaluated for subsequent teduglutide treatment eligibility  according to the study  
schedules. 
Comments (spontaneous or elicited) or complaints made b y the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic c ase report form (eCRF) and source documents, as 
described in Section 4.8.[ADDRESS_393471] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_319437] t he interim period between EOT and ET for safety  follow -up.
If a subject withdraws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completel y as possible. 
Subjects who withdraw from the study  will not be replaced.
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is wi thdrawn for more than [ADDRESS_393472] clinically  relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
Adverse event
For non-commercial use only
Shire CONFIDENTIAL Page 40
Protocol SHP633 -303 Version 2/ 22Nov 2016
Protocol deviation
Lack of efficacy
Physician decision
Withdrawal by  [CONTACT_1130]
Withdrawal by  [CONTACT_7078]/guardian
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y)
Death
Other
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_393473] (office visit or telephone contact). At least [ADDRESS_393474]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations, and return an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page 41
Protocol SHP633 -303 Version 2/ 22Nov 2016
5 CONCOMITANT TREATMENT
5.1 Concomitant M edications and GI Procedures
Concomitant treatment will be collected for the prospective period onl y and refers to all 
treatment being taken on or after the date the ICF (and if applicable , assent )is signed for this
study . Concomitant treatment information must be recorded on the appropriate eCRF page. 
Concomitant treatments will be assessed at each site visit, and include all nonstudy  treatments 
(medications, herbal treatments, vitamins, invasive and diagnostic proc edures). Concomitant GI 
procedures include (but are not limited to) endoscopy , radiographic studies, GI and liver biopsies 
and associated pathology results. Concomitant treatment information must be recorded on the 
appropriate eCRF page. Details of medicat ion changes and/or dosages will be recorded on the 
eCRF.
The mechanism of action of teduglutide may  increase absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole , and digoxin). Accordingly, due consideration should be given to 
modify ing concomitant medication regimens. Down -titration of concomitant medications should 
be considered when drugs, especiall y those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.[ADDRESS_393475] medical therapy for SBS should be continued.
5.1.2 Prohibited Treatment
The mechanism of action of teduglutide may  increase enteral absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, digoxin), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when dru gs, especially  those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pre treatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- 1 analog or human growth hormone 3month s
Octreotide or dipeptidyl peptidase 4 inhibitors 3 months
Biological therapy (eg, antitumor necrosis factor) 6 months
For non-commercial use only
Shire CONFIDENTIAL Page 42
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393476] is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2) . In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L -histidine, mannitol, monobasic sodium 
phosphate monohy drate, and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.[ADDRESS_393477](s)
6.2.[ADDRESS_393478] Management
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory  management and supply  ordering, investigational product expi[INVESTIGATOR_49093], and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS.
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.[ADDRESS_393479], and/or parent/guardian agree 
to proce ed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit ( Table 1-4
).
6.2.[ADDRESS_393480] will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body  weight measured at the teduglutide pretreatment visit, and ad justed as needed, based on 
body  weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered b y SC injection once dail y (QD)into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
Teduglutide shoul d be used as soon as possible after reconstitution, but no more than 3 hours 
later.
For non-commercial use only
Shire CONFIDENTIAL Page 43
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393481] 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
Following each [ADDRESS_393482] may  proceed 
directly  to another Pre treatment visit to assess treatment eligibility  for another cy cle 
(Section 4.6). Following the completion of the 4- week follow -up, the subject will continue in the 
study  off teduglutide. Additional [ADDRESS_393483](s) container.
The study  drug will be packaged, labeled, and shipped to t he study  site by  [CONTACT_98634]. Kits containing 7 vials of study  drug will be supplied and these will be labeled in 
accordance with applicable regulatory  requirements. Sterile water for injection sy ringes will also 
be provided separatel y and will be labeled in accordance with the applicable regulatory  
requirements.
All study  drug used in this study  will be manufactured, tested, labeled, and released according to 
current legal requirements and Good Manufacturing Practice.
6.3.2 Packaging
Teduglutide will be provided in a 3 mL  sterile, single -use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL ) will be provided in a prefilled s yringe.
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
For non-commercial use only
Shire CONFIDENTIAL Page 44
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393484] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refrigerated at a temperature between 2 -8°C (35.6 -46.4°F) until dispensed to 
a subject. Onc e dispensed to a subject, the study  drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2 -25°C, or 35.6- 77°F). Parent/ legal guardian 
will be instructed to keep the subject’s study  drug and sterile water diluent at co ntrolled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study  drug may  be refrigerated. The study  drug is for single use onl y, and should be used within 
[ADDRESS_393485] is maintained within an established temperature range. The investigator is respon sible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrat ed chart recorder, or b y manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharma cy or nominated member of the study  
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
6.[ADDRESS_393486] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be recorde d and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any  unauthorized situation.
For non-commercial use only
Shire CONFIDENTIAL Page 45
Protocol SHP633 -303 Version 2/ 22Nov 2016
The investigator has overall responsibility  for administering/dispensing investigati onal product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicabl e study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
for teduglutide treatmen t following the procedures set out in the study  protocol. All dispensed 
study  medication will be documented in the interactive response technology system and/or other 
investigational product record (eg, investigation product accountability  form). The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator o r his/her designee may  
dispense the unused study  drug vials to the same subject. All original containers, whether empty  
or containing stud y drug will be returned to the pharmacy. Returned stud y drugs will NOT be 
relabeled or reassigned for use b y other subjects. Contents of the study  drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may  be destroy ed on site without approval by  [CONTACT_456].
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_393487] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -evident sealed container (eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability  form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 46
Protocol SHP633 -303 Version 2/ 22Nov 2016
7 STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures and assessments to be performed for subjects throughout the study  are 
outlined in the Schedule of Assessments ( Table 1 -1, Table 1-2, Table 1 -3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing an y study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject ( Table 1-
1).
7.1.1 Retrospective Data Collection
Retrospective data aredefined as specific safet y and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED -C13-
003 e nd of study  (EOS) visit and the date the informed consent form (I CF) (and if 
applicable, informed assent) is signed for this study . Retrospective PS and growth data will be 
captured in [ADDRESS_393488] retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent onl y to retrospecti ve data collection, only  
assessments in Table 1-1 will be completed. The following data will be collected for the 
retrospective portion of the study :
Informed consent, and informed assent (if applicable)
Study eligibility  is determined
oA screen failure is a subject who has given informed consent and failed to meet 
the study inclusion 
eligibility  criteria. Subjects cannot be rescreened once they  
have been designated as a screen failure.
Prior teduglutide use (as prescribed)
oCollect all te duglutide prescription sduring the retrospective data collection 
period, including start and stop dates, dose, route, and frequency . Prescription 
data includes teduglutide treatment in investigator- initiated trials, compassionate 
use, and named -patient acc ess programs.
oCollect start and end dates when asubject’s teduglutide use was interrupted . 
Parenteral support (as prescribed)
oThe last representative PS prescription during each 12- week interval throughout 
the retrospective period and at the beginning and end of any  teduglutide treatment 
will be collected. Usuall y, the prescription at the end of theinterval will represent
the status of intestinal adaptation. However, transient alterations in PS related to 
loss of central venous access or acute illness are not representative of intestinal 
adaptation. When such events occur at the end of a 12 -week interval, earlier, more 
representa tive PS prescription data shou ld be recorded.
For non-commercial use only
Shire CONFIDENTIAL Page 47
Protocol SHP633 -303 Version 2/ 22Nov 2016
Data collected should include weekl y prescribed volume, calories, average hours 
per day , and day s per week of prescribed PS. H ours per day  should be aver aged 
over the day s where PS is prescribed.
Growth (height, head circumference, and weight)
oThe last representative value for height, during each 12 -week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and y ounger at the time the data 
were collected, if available.
The investigator should u se his/her clinical judgment to select values that reflect 
the true growth trajectory .
Adverse events
oAll nonserious AEs related to teduglutide treatment, as well as all adve rse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study . The details of data collection and safety  reporting for these ev ents 
can be found in Section 8.
oEnd dates for AEs ongoing at the end of TED -C13-003 will be collected.
7.1.2 Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1-2, 
and as detailed below:
Informed consent, and informed assent (if applicable)
Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the s tudy inclusion e ligibility  criteria. Subjects cannot be 
rescreened once they  have been designated as a scre en failure.
Demographics, updates to medical history  and SBS history
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomitant medications and concomitant GI  procedures
Physical examination and vi tal signs, including weight
Height and head circumference
Record PS prescription and adjust as needed
The first visit after screening must occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit .
For non-commercial use only
Shire CONFIDENTIAL Page 48
Protocol SHP633 -303 Version 2/ 22Nov 2016
7.1.3 Visits for Subjects Not Receiving Teduglutide
While outside of the 28- week teduglutide -treatment cy cle, subjects will be followed 
approximately  every  12weeks for safety  and efficacy  assessments. No -teduglutide treatment 
visits are numbered sequentially  (NT1, NT2, etc.), even if interrupted by  [CONTACT_319415]. 
The visit w indow (±7days) is relative to the first NTx visit in the current NTT period.
Assessments will be performed as outlined in Table 1 -3and described below .
 Intake and output diaries are dispensed
 Evaluate teduglutide treatment inclusion criteria
 Adverse events, concomitant medications, and concomitant GI  procedures
 Physical examination and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
 Record PS  prescription and adjust as needed
 Safety  laboratory  tests (ie, clinical chemistry , hematology , and urinaly sis)
 PedsQL  Generic Core Scale/PedsQL Family  Impact Module/ PedsQL  
Gastrointestinal Sy
mptoms Module Sub- Scales
 Antibodies to teduglutide, if and when required
 Fecal occult blood testing, as indicated (see Section [IP_ADDRESS] )
 Colonoscopy /sigmoidoscopy , as indicated (see Section [IP_ADDRESS])
 Serum sample, as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may  proceed to the pretreatment visit immediately  to determine 
eligibility . 
7.1.4 Visits for Subjects Receiving Tedugl utide Treatment
[IP_ADDRESS] Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may  proceed to the pretreatment visit immediately . Similarly , 
subjects who meet escape crite ria during the teduglutide follow -up period may  proceed to the 
pretreatment visit immediately .
In general, pretreatment assessments may  occur over a period of up to 21 day s. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performed as in Table 1-4 and as 
described below:
 Evaluate teduglutide eligibility  (treatment inclusio n/exclusion criteria)
 Dispense intake and output diaries
For non-commercial use only
Shire CONFIDENTIAL Page 49
Protocol SHP633 -303 Version 2/ 22Nov 2016
 Adverse events, concomitant medications, and concomitant GI  procedures
 Fecal occult blood testing
 Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as 
indicated
 Physical exami nation and vital signs, including weight
 Height and head circumference
 Review intake and output diaries 
 Record PS prescription and adjust as needed.
 Safety  laboratory  tests
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit
include prothrombin time [PT] international normalized ratio [I NR]. 
Subsequent prothrombin time/international normalized ratio (PT/I NR) 
measurement is only required to evaluate for suspected drug -induced liver 
injury  [DILI ]).
 Pregnancy  testing (serum)
 Serum sample
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open- label teduglutide treatment period will comprise [ADDRESS_393489] administration (Visit CxD1).
VISIT CXD1
Assessments and proce dures at this visit will be performed as outlined Table 1 -4and as described 
below :
Two weeks of intake diary data are required before drug is administered at CxD1.
 Confirm teduglutide treatment eligibility
 Dispense intake and output diaries
 Adverse events , concomitant medications ,and concomitant GI  procedures
 Physical examination and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
 Record PS 
prescription and adjust as needed
 Safety  laboratory  tests
For non-commercial use only
Shire CONFIDENTIAL Page 50
Protocol SHP633 -303 Version 2/ 22Nov 2016
 Quality  of life measurements
 Antibodies to teduglutide
 Pregnancy  testing (urine)
 Dispense study  drug
SITE V ISITS DURING TEDUGLUTIDE TREATMENT PERIOD
Subjects will return for clinic visits on cy cle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedure s at these visits will be performed as outlined in Table 1-4 and as 
described below:
 Dispense and review intake and output diaries (every effort should be made to 
complete 2 weeks of intake diary  entries prior to each clinic visit and to 
complete 48 hours of output diary  entries during a period of nutritional stability
prior to each clinic visit)
 Physical examination and vital signs, including weight
 Record PS prescription and adjust as needed
 Safety  laboratory  tests
 Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, 
CxW24)
 Study  drug dispensation (except for CxW24)
 Adverse events, concomitant medications and concomitant GI  procedures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
 Height and he ad circumference
 Antibodies to teduglutide
 Fecal occult blood testing (FOBT)
 GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated
 Quality  of life measurements
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
PHONE VISITS
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1 -4and described 
below:
 Review intake and output diaries
For non-commercial use only
Shire CONFIDENTIAL Page 51
Protocol SHP633 -303 Version 2/ 22Nov 2016
 Safety  laboratory  tests (clinical chemistry  and urinaly sis)
 Record PS prescription a nd adjust as needed
 Obtain AEs, concomitant medications, and concomita nt GI  procedures
 Evaluate escape criteria
7.1.5 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks (Weeks 25 -28 of the cy cle). Phone visits 
will occur on cy cle Weeks 25, 26, and [ADDRESS_393490] may  
proceed directl y to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is 
met at the CxW28 visit, and the pretreatment assessments occur within [ADDRESS_393491] is completing the stud y at the CxW28 visit, the EOS/ET visit (Section 7.1.6) 
will take place in lieu of the CxW28 visi t.Otherwise, following completion of the [ADDRESS_393492] will proceed to an NTT visit within approximately  12 weeks.
At C ycle Week 28 (CxW28), subjects will return to the study  site. In addition to the assessments 
performed at Weeks 25 -27, the following procedures will be performed at CxW28 only:
 Dispense and review intake and output diaries
 Physical examination and vital signs, including weight
 Antibodies to teduglutide
 Pregnancy  testing (urine)
 Evaluate escape criteria
7.1.6 Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will 
return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-
2and as 
described here. If a subject discontinues the study prematurel y, the assessments for the EOS/ET 
visit are to be performed as completel y as possible (see Section 4.8.2 ).
 Adverse events, concomitant medications, and concomitant GI  procedures
 Physical examination and vital signs, including weight
 Height and head circumference
For non-commercial use only
Shire CONFIDENTIAL Page 52
Protocol SHP633 -303 Version 2/ 22Nov 2016
 Review intake and output diaries (the intake diary should be completed daily  
for a minimum of 2 weeks prior to the EOS/ET visit. The output diary  should 
be completed dail y over a 48-hour period of nutritional stability before the 
EOS/ET visit)
 Record PS prescription andadjust as needed
 Safety  laboratory  tests
 Fecal occult blood testing, as indicated
 Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy ,as 
indicated
 Quality  of life measurements
 Antibodies to teduglutide
 Pregnancy  testing, as needed
7.[ADDRESS_393493]'s completion of the TED -C13-003 study  and the 
date the ICF (and if applicable, assent) is signed for the SHP633 -303 study.
[IP_ADDRESS] Growth (Height, Weight, and Head Circumference)
Retrospective bod y height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm fo r subjects ≤36 months of age) will also be recorded. A 
height z -score, weight z -score, body  mass index ( BMI ), and BM I z-score will be calculated b y 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be descri bed as needed in the statistical analy sis plan (SAP) .
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed
Any retrospective teduglutide prescription start and stop dates, dose, route, and frequency will be 
recorded on the appropriate eCRF page.
[IP_ADDRESS] Parenteral Support Presc ribed
Retrospective parenteral support entries consist of 1prescription per12-week interval during the 
retrospective period. If the subject has multiple PS prescriptions in a [ADDRESS_393494] 
representative prescription from the interval should be used (see Section 7.1.1 ).In addition, PS 
prescriptions at the beginning and end of an y retrospective teduglutide treatment must be 
recorded. The PS prescription includes weekl y volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
For non-commercial use only
Shire CONFIDENTIAL Page 53
Protocol SHP633 -303 Version 2/ 22Nov 2016
[IP_ADDRESS] Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESI s) and all serious adverse events (SAEs) ,regardless of causal attribution to teduglutide, 
that occurred during the ret rospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safet y reporting are provided in Section 8.
The end dates for AEs that were ongoing at th e end of TE D-C13-003 will be collected.
7.2.2 Prospective Data Collection
[IP_ADDRESS] Demographics, Medical History, and SBS History
Demographics, updates to medical history , and updates to SBS history  will be obtained at 
screening. Medical history  for purposes of this extension study  will consist of updates to the 
medical history  collected at the start of the TED- C13-[ADDRESS_393495] ha sany 
changes to the SBS history  since the baseline visit of the TED -C13-003 study , that information 
(updated SBS history ) will also be collected.
[IP_ADDRESS]
Physical Examination
Physical examinations will be performed according to the study  schedules. Any  new clinicall y 
significant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF.
[IP_ADDRESS] Adverse Event Collection
At each study  visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had any  health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (seeSection 8, Adverse 
and Serious Adverse Events Assessment.)
[IP_ADDRESS] Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study  schedules. Measurements will incl ude 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body  temperature 
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same arm, 
and in the same position throughout the stud y).
Body weight will als o be recorded in the eCRF; subjects should be weighed on the same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit.
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
For non-commercial use only
Shire CONFIDENTIAL Page 54
Protocol SHP633 -303 Version 2/ 22Nov 2016
[IP_ADDRESS] Clinical Laboratory Tests
Safety laboratory  tests to be performed at site visits consist of clinical chemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1 -2, Table 1-3, and 
Table 1-4). Scheduled laboratory  testing will be processed b y a central lab. All laboratory  assay s 
will be performed according to the central laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out-of- range clinical laboratory  
values for clinical significance, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical conditi on, may , at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_393496] of clinical chemistry  and urinal ysis and may  be processed by  [CONTACT_319438] a local laboratory
. Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate an y new clinicall y significant changes, they must be reported as an 
adverse event (see Section 8.1). Urine specimen collection should be attempted as part of the 
safet y labs, but lack of urinalysis will not constit ute a protocol deviation.
New clinicall y significant labs should be reported as AEs.
The following clinical laboratory
 assessments will be performed according to the study  
schedules:
For non-commercial use only
Shire CONFIDENTIAL Page 55
Protocol SHP633 -303 Version 2/ 22Nov 2016
Table 7-1:List of Laborat ory Tests 
Hematology :
Hematocrit
Hemoglobin
Platelet count
Red blood cell count
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio
Urinalysis :
Blood
Glucose
Leuk ocytes
Microscopic analysis
pH
Protein
Specific gravity
Pregnancy tests (females of childbearing potential):
Serum β -HCG (screening)
Urine β -HCG (all other visits)Biochemistry :
Albumin
Alkaline phosphatase
Alanine aminotransferase
Amy lase
Aspartate aminotransferase
Bicarbonate
Bilirubin (total and indirect)
Blood urea nitrogen
Calcium (total)
Chloride
Cholesterol
C-reactive protein
Creatinine
Estimated Glomerular Filtration Rate
(Schwartz formula)
Gamma -glutamyl transferase
Glucose
Lipase
Magnesium
Phosphorus
Potassium
Sodium
Triglycerides
Uric acid
For non-commercial use only
Shire CONFIDENTIAL Page 56
Protocol SHP633 -303 Version 2/ 22Nov 2016
[IP_ADDRESS] Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times:
 At the pretreatment visit. If the subject met a follow- up period escape criterion, 
the serum sample will not be collected at the pretreatment visit
 At the CxW24 (EOT) visit
 During NTT: Approximately  every  24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sample and/or extracted material will otherwise be stored 
for up to [ADDRESS_393497] their 
sample and/or extracted material destro yed. An y results alread y generated from the samples will 
not be removed from an y anal yses that have already  been pe rformed.
[IP_ADDRESS] Pregnancy Testing
A serum pregnancy  test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy  tests will be administered at all other visits according to the study  schedules, or if 
pregnancy  is suspected, or as specifie d per protocol upon withdrawal of the subject from the 
study .
[IP_ADDRESS] Antibody Testing
Blood samples will be drawn for the anal ysis of antibodies to teduglutide according to the 
Schedule of Assessments ( Table 1-2, Table 1 -3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least [ADDRESS_393498] follow- up blood draws for antibodies to teduglutide every  12 weeks while 
on study  until a negative result is obtained.
[IP_ADDRESS]
Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study . The volumes of blood to be drawn from each subject will vary  depending on 
clinical status. Approximate volumes of blood to be drawn from each sub ject annuall y are shown 
in Table 7-2.
For non-commercial use only
Shire CONFIDENTIAL Page 57
Protocol SHP633 -303 Version 2/ 22Nov 2016
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Parameters 1 2 2
Antibodies 2 8 16
Serum storage samples 3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volum e): 138
Subjects Not Receiving Teduglutide Treatmentb
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samples 3 2 6
Total mL per 4 “No Teduglutide Treatment” Visits 48 -week period: 24
β-hCG=beta -human chorionic gonadotropin ; NTT= no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bSubjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti -teduglutide 
antibodies will require blood samples for antibody testing every [ADDRESS_393499] negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same t ype of tube, the assessments should be combined. Blood 
volume estimates do not include safet y labs performed after PS adjustment, and anti -teduglutide 
antibody  testing during no- teduglutide treatment.
[IP_ADDRESS] Gastrointestinal- specific Testing
FECAL OCCULT BLOOD TESTING
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week [ADDRESS_393500] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutid e any time in the past and 
are therefore not teduglutide -naïve) on a roughl y annual basis (approximately every 48 -60 
weeks). Actions to be taken in response to a positive FOBT are described below.
COLONOSCOPY OR SIGMOIDOSCOPY
Teduglutide -naïve subjects age 12 and older will undergo colonoscopy or sigmoidoscopy at the 
pretreatment visit if one has not been performed within 1 y ear.
Subjects of an y age with newly positive FOBT results at the pretreatment visit for which a 
readil y detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy or 
sigmoidoscop yprior to receiving teduglutide. If newly  positive FOBT results (for which a 
readil y detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (C xW24/EOT), colonoscopy or sigmoidoscopy will be performed. The need for 
For non-commercial use only
Shire CONFIDENTIAL Page 58
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393501] received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will undergo colonoscopy or sigmoidoscopy . While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy or sigmoidos copyat 5 y ear intervals or 
more often as needed.
Upper endoscop y ma y be performed along with any colonoscop yor sigmoidoscopy at the 
investigator’s discretion. If a pol yp is found, adherence to current pol yp follow -up guidelines is 
recommended. Subjects w ith unresected GI pol yps, poly posis conditions, premalignant change 
or malignancy  in the GI tract will be excluded from teduglutide treatment.
[IP_ADDRESS] Nutritional Support
Nutritional support includes PS, enteral nutrition , and other food and fluids. Advances in enteral 
nutrition and/or reductions to PS will be based on clinical status, including weight, linear growth, 
hydration status, and safety  laboratory  results. Intake and output diaries will include data to be 
considered in the adjustment of each subject’s nutritional support. Guidelines for nutritional 
support management and weaning algorithms are provided in Appendix 2 .
[IP_ADDRESS] Diaries
STUDY DRUG ADMINISTRA TION DIARY
A study  drug administration diary  will record administration of teduglutide. This diary  should be 
completed by [CONTACT_423] (or parent/legall y authorized representative, as applicable) daily  during 
the teduglutide treatment period (between visits CxD1 and CxW24).
INTAKE DIARY
Intake diaries will be used to collect and evaluate each subject’s nutritional su pport. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary  
2 weeks prior to ALL scheduled prospective site visits (except at pretreatment visit) . During the 
24-week teduglutide treatment period, the intake diary  will also be completed for 1 week 
following PS adjustments. The intake diary  will also be completed dail y during the 4 -week 
follow -up period. The following data will be captured in the intake diaries:
 Parenteral support volume and infusion duration
 Site personnel will determine the actual PS daily  calories based on diary  entries
OUTPUT DIARY
Urine and stool output should be recorded in the output diary  over a 48-hour period of nutritional 
stability  before every  clinic visit; in addition, output shoul d be recorded for subjects that are in a 
teduglutide treatment cy cle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
 Toilet -trained subjects (who do not wear diapers)
Measure and recor d all urine output in mL  or cc
For non-commercial use only
Shire CONFIDENTIAL Page 59
Protocol SHP633 -303 Version 2/ 22Nov 2016
 Nontoilet- trained subjects (who wear diapers)
Measure and record the weight of all urine -only diapers. Urine volume will be 
calculated using the following formula: 1 g (scale weight) = 1 mL or 1 cc
 At the discretion of the investigator, the parent or legal guardian may be asked 
to collect the first void after the dail y PS infus ion to measure specific gravity
Stool data (includes diapers with mixed urine and stool):
 Toilet -trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool 
consistency  using the Bristol Stool Form Scale (see Output diary )
 Nontoilet- trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed 
urine and stool) as stool output and score the stool consistency  using the Bristol 
Stool Form Scale (see Output diary ). Stool volume will be calculated using the 
formula: 1 g (scale weight)=[ADDRESS_393502] ed. Ostomy  output will not be scored using the 
Bristol scale.
All available diar y data will be reviewed b y the investigator or their designee at each clinic and 
telephone visit to assess clinical status and opportunity  for PS reduction and advance in feeds.
[IP_ADDRESS] Health -related Quality of Life Assessments
Throughout the stud y, health -related quality  of life assessments will be performed using the 
PedsQL  Generic Core Scales. Each PedsQL age- appropriate form takes less than [ADDRESS_393503] month, and parent- report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
For non-commercial use only
Shire CONFIDENTIAL Page 60
Protocol SHP633 -303 Version 2/ 22Nov 2016
PEDIATRIC QUALITY OF LIFE GENERIC CORE SCALE (P EDSQL ™),ACUTE VERSION
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed by [CONTACT_319416] 7 -3at the time points as outlined in Table 1-2, Table 1 -3,and Table 1 -4.
Table 7-3: Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects 
(ages 8 -12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18) Subject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5 -7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
PEDIATRIC QUALITY OF LIFE FAMILY IMPACT MODULE (PEDSQL™ ),ACUTE VERSION
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-2, Table [ADDRESS_393504] of pediatric chronic health conditions on parents and the family  (Varni et al. 2004 ). 
The 36-i tem PedsQL Family  Impact Module consists of 6 scales measuring parent self -reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure parent -
reported f amily  functioning as follows: 1) Dail y Activities (3 items), and 2) Family  Relationships 
(5 items). The PedsQL Family  Impact Module should take the parent or legal guardian 
approximately  5-10 minutes to complete.
PEDS
QLGASTROINTESTINAL SYMPTOMS MODULE (PEDSQL
™),ACUTE VERSION
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58
-item module, comprised 
of 10 different s ymptom scales that assess gastrointestinal sy mptom -related quality  of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Sy mptom s 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
For non-commercial use only
Shire CONFIDENTIAL Page 61
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393505] as indicated in Table 7 -3at the time points 
outlined in Table 1-2, Table 1 -3,and Table 1 -4.
For non-commercial use only
Shire CONFIDENTIAL Page 62
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393506] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
RETROSPECTIVE PERIOD O F OBSERVATION
For the retrospective data collection period ( the interval between the EOS visit of the core study  
until signing the ICF [and informed assent, if applicable] for SHP633- 303), investigators will be 
asked if they  are aware of any  nonserious AEs related to teduglutide that occurred during this 
time and an y AESIs or any SAEs, regardless of relationship to teduglutide, that occu rred during 
this time. The following guidance is given for defining a treatment -related event:
The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response patt ern to that 
product .
The event cannot be explained b y the subject’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this study
in the eCRF .
PROSPECTIVE PERIOD OF OBSERVATION
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the defined follow
-up period stated in Section 7.1.5. This includes events 
occurring during the screening phase of the stud y, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of s ymptoms should be 
recorded. If a diagnosis has not been made, then each s ymptom should be listed individually . All 
AEs should be captured on the appropriate AE pages in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investigational product indication 
should also be captured on the AE eCRF.
All prospective AEs must be f ollowed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the stud y. Closure indicates that an outcome is reached, stabilization a chieved 
(the investigator does not expect any  further improvement or worsening of the event), or the 
event is otherwise explained. When appropriate, medical tests and examinations are performed 
so that resolution of event(s) can be documented.
For non-commercial use only
Shire CONFIDENTIAL Page 63
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393507] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE tha t is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl yaffects 
clinical status, or may  require intensive therapeutic intervention.
Note that the severity  of AEs that constitute dose interruption criteria will also be evaluated 
using the National Cancer Institute’s (NCI) Common Terminology  Criteria for Adverse Events 
(CTCAE) grading criteria ( Table 8 -1).
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, ther e is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response patter n to that product, and the event cannot be 
explained by  [CONTACT_423]’s medical condition, other therapi[INVESTIGATOR_014], or 
For non-commercial use only
Shire CONFIDENTIAL Page 64
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393508]’s underl ying medical condition, concomitant therapy ,or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse event s that are related to study  drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, a s judged b y the investigator.
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline.
8.1.[ADDRESS_393509] be recorded during the course of the study  in the eCRF. Outcomes 
are as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study ; however, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.5 Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory  or vital sign can represent an AE if the change is
clinically  relevant or if, during the study , a shift of a parameter is observed from a normal value 
to an abnormal value, or a further worsening of an alread y abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consid eration.
For non-commercial use only
Shire CONFIDENTIAL Page 65
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393510] ausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y signi ficant and 
therefore represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core stud y until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633- [ADDRESS_393511] be r eported within 24 hours to the 
Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy Report Form (and a ny applicable follow -up 
reports) must also be sent to the Shire Medical Monitor using the details specified in the 
emergency  contact [CONTACT_1739]. I n the event a subject becomes pregnant 
after signing the ICF (and , if applicable, assent), teduglutide administration must be discontinued 
immediately .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. For pregnancy  reports during the prospective period of observation, it is 
the responsibility  of the investigator to obtain this information within [ADDRESS_393512] partum. For pregnancies occurring 
during the retrospective period of observation (ie, before signin g the informed consent for 
SHP633 -303), the initial notification date will be the date the pregnancy  is recorded for this 
study  and outcome and infant condition information may  be collected any time post partum.
Pregnancy  complications such as spontaneous a bortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for Serious Adverse Events (SAEs) and Nonserious AEs as Required b y the Protocol. Note: An 
elective abortion is not con sidered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Adverse Event Form for SAEs and 
Nonserious AEs as required b y the Protocol as w ell as the Shire I nvestigational and Marketed 
Products Pregnancy  Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
For non-commercial use only
Shire CONFIDENTIAL Page 66
Protocol SHP633 -303 Version 2/ 22Nov 2016
8.1.7 Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633- 303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they  result in an AE/SAE as described in Section 8.2. Note: The 24 -hour reporting 
requirement for SAEs does not apply  to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually  exclusive; the event can meet more than 1 category .
 Abuse – Persistent or sporadic intentional intake of investigational product 
when used for a nonmedical purpose (eg, to alter one’s state of consciousness or 
get high) in a manner that may  be detrimental to the individual and/or society
 Misuse –Intentional use of investigational product other than as directed or 
indicated at an y dose (Note: this includes a situation where the investigational 
product is not used as directed at the dose prescribed by  [CONTACT_760])
 Overdose – Administration of a dose greater than the allocated dose of the study  
medication or at a frequency  greater than the dosing interval specified by  [CONTACT_12695]
 Medication Error –An error made in prescribing, dispensing, administration, 
and/or use of an investigational product. For studies, m edication errors are 
reportable to the sponsor only  as defined below.
 Cases of subjects missing doses of the investigational product are not 
considered reportable as medication errors
 Medication errors should be collected/reported for all products under 
inves tigation
 The administration and/or use of an expi[INVESTIGATOR_319379] a reportable medication error
All investigational product provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y-authorized representati ve/caregiver.
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference for safet y information for this study  is the investigator brochure which the sponsor 
has provided under separate cover to all investigators.
For non-commercial use only
Shire CONFIDENTIAL Page 67
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393513] awareness 
of the event. Note: The 24- hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless they result in an SAE .
All adverse events of s pecial interest, as defined in Section 8.3, experienced during the 
prospective period of observation must be reported by  [CONTACT_319420] [ADDRESS_393514] complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Nonserious AEs as Required b y Protocol, and verify  the accuracy  of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global 
Pharmacovigilance and Risk Management Department. A copy  of the completed Shire Clinical 
Study  Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as Required 
by [CONTACT_1738] (and any  applicable follow -up reports) must also be sent to the Shire Medical 
Monitor or designee usin g the details specified in the emergency  contact [CONTACT_319421].
8.2.[ADDRESS_393515] medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 
Results in death
Is life -threatening. Note: The term 'life -threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatient hospi[INVESTIGATOR_1081]. Note: 
Hospi[INVESTIGATOR_602], which are the result of elective or previousl y scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously  scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospi[INVESTIGATOR_38860](s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
For non-commercial use only
Shire CONFIDENTIAL Page 68
Protocol SHP633 -303 Version 2/ 22Nov 2016
Is an important medical event. Note: I mportant medical events that may  not resu lt in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based upon appropriate medical judgment, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in thi s 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependenc y or 
drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
For the retrospective data collection period (the interval between the EOS visit of the core stud y 
until signing the ICF [and informed assent, if applicable] for SHP633 -303), investigators will be 
asked if they  are aware of any  SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is record ed for this study  in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Pharmacovigilance and Risk Management Department and the Shire Medical 
Monitor within [ADDRESS_393516] awareness of the ev ent, and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to study  drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow -up peri od stated in Section 7.1.5. These SAEs must be reported to the Shire 
Global Pharmacovigilance and Risk Management Department andthe Shire Medical Monitor 
within [ADDRESS_393517] awareness of the event , as per Section 8.2.2. 
In addition, any  SAE(s) c onsidered “related” to the investigational product and discovered b y the 
investigator at an y interval after the study has completed must be reported to the Shire Global 
Pharmacovigilance and Risk Management Department within [ADDRESS_393518]’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For non-commercial use only
Shire CONFIDENTIAL Page 69
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393519]’s death or any ongoing events at the time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solel y as a result of the 
subject’s death.
8.2.[ADDRESS_393520], Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notify ing the 
relevant regulatory  authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notify ing active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notify ing the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
8.[ADDRESS_393521]
An AESI  is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
[CONTACT_230013].
The AEs of special interest that require expedited regulatory  reporting include the fo llowing:
 Growth of pre -existing poly ps of the colon
 Benign neoplasia of the GI tract including the hepatobiliary  system
 Tumor -promoting ability (eg, benign and/or malignant neoplasia of any kind, 
not limited to those of the GI or hepatobiliary  system)
For AESIs experienced during the retrospective or prospective period of observation, the sponsor 
must be informed within [ADDRESS_393522] awareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4 Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 
8.5apply onl y to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing regimen is in terrupted. Attempts should be made to contact [CONTACT_103]/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059] ,AEs, a lapse in investigational product delivery , etc.
Study  drug must be di scontinued if any  of the following events occur:
For non-commercial use only
Shire CONFIDENTIAL Page 70
Protocol SHP633 -303 Version 2/ 22Nov 2016
 Pregnancy
 Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319439]. This does not include the presence of anti-teduglutide 
antibodies, mild injection site react ions or mild symptoms that according to the 
investigator do not pose a significant risk to the subject.
 An AE listed in ( Table 8-1) that is of NCI CTCAE severit y Grade 3 or 4 and 
considered to be related to study  drug administration
 Confirmed drug -induced liver injury  (DILI) related to teduglutide ( see Section 
8.4.2)
8.4.1 Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only)
The investigational product may be discontinued if the subject has an AE listed in Table 8-1 that 
is of severit y ≥Grade 3 per the NCI CTCAE. All such AEs should be discussed with Shire’s 
medical monitor or designee as soon as possible. Teduglutide administration must be 
discontinued if the AE is considered related to the investigat
ional product. The length of the dose 
interruption, and whether teduglutide administration resumes or is permanently  discontinued, 
depends on the clinical situation.
Investigators and the data monitoring c ommittee (DMC) should be guided by  [CONTACT_319423] 3 and 4 events, as they  relate to known and possible risks associated with the 
administration of teduglutide.
For non-commercial use only
Shire CONFIDENTIAL Page 71
Protocol SHP633 -303 Version 2/ 22Nov 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events Grade 3 Description Grade 4 Description
Gastrointestinal Disorders
Colorectal polyps Severe or medically significant but not 
immediately life threatening; 
hospi[INVESTIGATOR_20578]; 
disabling; limiting self -care activities of 
daily livingLife-threatening consequences; urgent 
intervention indicated
Intestinal Obstruction Hospi[INVESTIGATOR_374]; elective 
operative intervention indicated; limiting
self-care activities of daily living; 
disablingLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder and Bile Duct Disease
Cholecystitis Severe symptoms; radiologic,
endoscopic or elective operative 
intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder perforation Not Applicable Life-threatening consequences; urgent 
intervention indicated
Gallbladder obstruction Symptomatic and severely altered 
gastrointestinal function; tube feeding, 
total parenteral nutrition or 
hospi[INVESTIGATOR_374]; nonemergent 
operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder infection Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic, endoscopic, or operative 
intervention indicatedLife-threatening consequences; urgent 
intervention indicated
Adverse Events Grade 3 Description Grade 4 Description
Alkaline Phosphatase 
increased>5.[ADDRESS_393523] >20.0x ULN
Blood bilirubin increased >3.[ADDRESS_393524] >10.0x ULN
Bile duct stenosis Severely altered gastrointestinal function; 
radiologic, endoscopic or elective 
operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Pancreatic Disease
Pancreatitis Severe pain; vomiting; medical 
intervention indicated (eg, analgesia, 
nutritional support)Life-threatening consequences; urgent 
intervention indicated
Pancreatic duct stenosis Severely altered gastrointestinal function; 
tube feeding or hospi[INVESTIGATOR_374]; 
elective operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Pancreas infection Intravenous antibiotic, antifungal, or 
antiviral inte rvention indicated; 
radiologic or operative intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated
For non-commercial use only
Shire CONFIDENTIAL Page 72
Protocol SHP633 -303 Version 2/ 22Nov 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events Grade 3 Description Grade 4 Description
Serum amylase increaseda>2.[ADDRESS_393525] >5.0x ULN
Lipase increaseda>2.[ADDRESS_393526] >5.0x ULN
Cardiovascular Disease
Heart failure Severe with symptoms at rest or with 
minimal activity or exertion; intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated (eg, continuous 
intravenous therapy or mechanical 
hemodynamic support)
Source: Common Terminology Criteria for Adverse Events, version 4.03, [ADDRESS_393527]=upper limit of normal
a In the setting of clinically acute and symptomatic pancreatitis
8.4.2 Dose Interruption Criteria Based on Drug -Induced Liver Injury
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may  need to be interrupted if the subject has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following criteria:
 ALT or AST >8x ULN
 ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
 (ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN 
or INR>1.5)
 ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, 
nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)
All laboratory  values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_393528] should be followed closely to determine the trajectory  of the 
laboratory  abnormal ities and to evaluate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cy tomegaloviru s IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti -smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investigator in consultation 
with the Shire Medical M onitor.
For non-commercial use only
Shire CONFIDENTIAL Page 73
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393529] be permanentl y discontinued if DILI is confirmed and deemed 
related to stud y drug.
8.5 Early Termination of the Clinical Study (Prospective Period of Observation Only)
The DMC may  recommend stoppi[INVESTIGATOR_319373]:
 ≥2subjects develop the same event listed in Table 8 -1of seve rity CTCAE 
Grade 3
or
 1subject develops an event listed in Table 8-[ADDRESS_393530] or is not reasonabl y related to
the underl ying disease process
For non-commercial use only
Shire CONFIDENTIAL Page 74
Protocol SHP633 -303 Version 2/ 22Nov 2016
9 DATA MANAGEMENT AND STATISTICAL M ETHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monitor will visit each site and review retrospective data in accord ance 
with the monitoring plan. Data collection procedures w ill be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safet y follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissio ns, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical databas e, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Process
The study  will be anal yzed by  [CONTACT_10196]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, d emographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4 Planned Interim Analysis, and Data Monitoring Committee
An interim anal ysis of all retrospective data will be conducted. Other interim analy ses may  also 
be conducted if needed.
A DMC will be involved in the management of this study . The DMC members will review the 
data approximately  every 3 months according to the DMC Charter . The DMC review will 
include all cumulative safety  data (ie, AEs, laboratory  assessments, phy sical examinations, etc.) 
from study  assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product. 
The DMC for this study  will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only
Shire CONFIDENTIAL Page 75
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393531] may  not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hired by  [CONTACT_456], or members of 
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine whether the study  should be modified or temporaril y or 
perma nentl y stopped.
9.5 Sample Size Calculation and Power Considerations
As this is an extension study , the maximum number of subjects wasdetermined by  [CONTACT_319407] -C13-003.
9.6 Study Population
The safet y population includes all enrolled subjects in the study . The safet y population will be 
used for both safet y and efficacy anal yses.
9.7 Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assesse d on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1 E fficacy Endpoints
Efficacy  endpoints will be anal yzed at the end of each teduglutide treatment period (Week 2 4or 
EOT), and at each stud y visit, relative to the baseline of the core study  (TED -C13-003) and/or 
first exposure to teduglutide. The following ef ficacy  endpoints will be analy zed:
 Reduction in PS volume of at least 20%
 Absolute and relative change in PS volume
 Complete weaning off PS
 Change in day s per week of PS
9.8 Safety Analyses
Safety data, including laboratory  tests and vital signs assessments, will be summarized by  [CONTACT_765]. 
Adverse event s will also be collected and summarized. Descriptive statistics will be calculated 
for quantitative safet y data as well as for the difference from baseline, if applicable. Frequency  
counts will be compi[INVESTIGATOR_319380] y data.
For non-commercial use only
Shire CONFIDENTIAL Page 76
Protocol SHP633 -303 Version 2/ 22Nov 2016
9.8.1 Safety Endpoints
The following safet y endpoints will be analy zed from the beginning of the prospective study  
period:
 Adverse events
 Vital signs, including body  temperature, heart rate, and blood pressure
 Laboratory  safet y data (ie, clinical chemistry , hematology , and urinaly sis)
 Urine output
 Stool output
 Antibodies to teduglutide
 Gastrointestinal -specific testing including fetal occult blood testing and 
colonoscopy or sigmoidoscopy
The following safet y endpoints will be analy zed from the end of the core study  (TED -C13-003) 
to the beginning of the prospective study  period:
 Adverse events related to teduglutide
 All SAEs
 All AESI s(Section 8.3)
The following safet y endpoints will be analy zed relative to the baseline of the core stud y 
(TED -C13-003):
 Z-scores for height (or length), weigh
t, head circumference (up to 36 months of age), 
and body  mass index
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA). The number of events, inci dence, and percentage of AEs will be calculated overall, 
by [CONTACT_319425]. S erious adverse event s will be further 
summarized by  [CONTACT_230535]. Adverse events related to 
investigational produ ct, AEs leading to withdrawal, SAEs, and deaths will be similarly  
summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dictionary  (WHO -DD) with regard to drug class and drug name. The number and percen tage of 
subjects with specific prior medications will be summarized. Medical history  (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by  [CONTACT_6657]. 
For clinical laboratory  tests, vital signs, body  weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
For non-commercial use only
Shire CONFIDENTIAL Page 77
Protocol SHP633 -303 Version 2/ 22Nov 2016
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of an tibodies. 
Additional safet y parameters and measures will include change in bod y weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z -score, BMI, and BMI z -score. Descriptive st atistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses
Health economics and outcomes research endpoints will be analy zed at approximately  12-week 
intervals ( Weeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective study  period. The beginning of 
each treatment cy cle (CxD1) will be an additional baseline.
Change in Pediatric Quality  of Life Inventory  (PedsQL) score
Change in PedsQL Family  Impact Module score
Change in PedsQL Gastroi ntestinal Sy mptoms Module Sub- Scales scores:
Food and drink l imits
Diarrhea
For non-commercial use only
Shire CONFIDENTIAL Page 78
Protocol SHP633 -303 Version 2/ 22Nov 2016
10 SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_393532] been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH Good Clinical Practice (GCP) Guideline E6 (1996 ), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are con ducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)natio nal government regulations and guidelines. Records and data may  additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nom inated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
10.1.4 Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member St ates Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. Thi s requirement will be fulfilled within 6 months of the end of 
For non-commercial use only
Shire CONFIDENTIAL Page 79
Protocol SHP633 -303 Version 2/ 22Nov 2016
the study  completion date for pediatric studies and within 1 y ear for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
10.1.5 Study Suspension, Te rmination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notifie d as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as required b y
Article 10 (c) of Directive 2001/20/EC.
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_393533] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulato ry requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant st udy-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator [CONTACT_832] a ppointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by  [CONTACT_319426] (single -site study ) or coordinating principal investigator (multicenter 
study ), in complian ce with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 (1995). 
10.2.[ADDRESS_393534] met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 80
Protocol SHP633 -303 Version 2/ 22Nov 2016
If the investigator suspends o r terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materia ls to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by [CONTACT_59761].
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observ ations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
Electronic case report forms should be approved by [CONTACT_319427].
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory , queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor ( and auditors, IRB/EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_10203]/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays etc.). Nonstudy  site personnel will not 
disclose an y personal information or personal medical information.
For non-commercial use only
Shire CONFIDENTIAL Page 81
Protocol SHP633 -303 Version 2/ 22Nov [ADDRESS_393535] be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
European Medicines Agency  (EMA) , [LOCATION_006] Medicines and Healthcare products Regulatory  
Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generate d by [CONTACT_319440], for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory  authorities), the 
European Medicines Agency  (EMA), the Medicines and Healthcare products Regulatory  
Agency , other regulatory authorities, the sponsor or its representatives, and the I RB/EC for each 
site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_10204] , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from th e sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor o r subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.[ADDRESS_393536]’s legall y-authorized representative, as 
applicable, is requested to sign and date the su bject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study  involves, including but not limited to: 
the objective s, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy  of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully executed signature [CONTACT_1787]) must be given to th e subject or the 
subject’s legall y-authorized representative, as applicable. This document may  require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
Within the source documents, site personnel should document instruction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
For non-commercial use only
Shire CONFIDENTIAL Page 82
Protocol SHP633 -303 Version 2/ 22Nov 2016
The pr incipal investigator provides the sponsor with a copy  of the consent form, and assent form 
where applicable, which was reviewed b y the IRB/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the sponsor, prior to the start of the study  unless it is agreed to 
and documented (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally , if the I RB/EC requires modification of the sample subject information and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_393537] or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and al l types of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation .
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinati ng principal investigator [INVESTIGATOR_10157], according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_1683]/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_393538] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_317364] (or designee).
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
review their medical records and data collected during the stud y. These records and data may, in 
For non-commercial use only
Shire CONFIDENTIAL Page 83
Protocol SHP633 -303 Version 2/ 22Nov 2016
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP633; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the recor ds and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identifying number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, rele vant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. T he purpose of any such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres t o external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase [ADDRESS_393539] undergo appropriate technical and 
intellectual propert yreview, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_319441], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_319381] e sponsor a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and pos ters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other for m.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  [CONTACT_10207] y publication of study results, or necessary for other scholars to verify  such study  
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
For non-commercial use only
Shire CONFIDENTIAL Page 84
Protocol SHP633 -303 Version 2/ 22Nov 2016
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be give n to the sponsor for review at least [ADDRESS_393540] publication of the study results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_64663] s tudy results. If such a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_10209] 18-month period after conclusion, abandonment, 
or termination of the study  at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the sin gle-site data being presented.
Unless otherwise required by  [CONTACT_10210], or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 85
Protocol SHP633 -303 Version 2/ 22Nov 2016
11 REFERENCES
Drucker, D. J. & Yusta, B. 2014. Phy siology  and pharmacology  of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76,561-83.
Khan, F. A., Squires, R. H., L itman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., Sudan, 
D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wal es, P. W. & Duggan, C. 2015. Predictors 
of Enteral Autonom y in Children with I ntestinal Failure: A Multicenter Cohort Study . J Pediatr,
167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cy ran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric p atients using realistic covariates: application to teduglutide, a glucagon -
like peptide-2 
analog in neonates and infants with short- bowel s yndrome. Clin Pharmacol Ther, 86,667-71.
O'Keefe, S. J., Buchman, A. L ., Fishbein, T. M., Jeejeebhoy , K. N., Jeppese n, P. B. & Shaffer, J. 
2006. Short bowel sy ndrome and intestinal failure: consensus definitions and overview. Clin 
Gastroenterol Hepatol, 4
,6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mer cer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. A., 
Kocoshis, S., Superina, R., L awlor, S., Haller, T., Kurs -Lask y, M. & Belle, S. H. 2012. Natural 
history  of pediatric intestinal failure: initial report from the Pediatric Inte stinal Failure 
Consortium. 
J Pediatr, 161,723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel sy ndrome. J Clin Gastroenterol, 47,
602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon -like peptide 2 analogue, 
teduglutide, on intestinal adaptation in short bowel sy ndrome. J Pediat r Gastroenterol Nutr, 58,
694-702.
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL  
Family  Impact Module: preliminary  reliability  and validity . Health Qual Life Outcomes, 2,55.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population- based estimates of incidence and mortality  rates. J Pediatr Surg, 39,690-
5.
For non-commercial use only
Shire CONFIDENTIAL Page 86
Protocol SHP633 -303 Version 2/ 22Nov 2016
12 APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 87
Protocol SHP633 -303 Version 2/ 22Nov 2016
APPENDIX 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol 11 May 2016 Global
Amendment 1 22Nov 2016 Global
For non-commercial use only
Shire CONFIDENTIAL Page 88
Protocol SHP633 -303 Version 2/ 22Nov 2016
APPENDIX 2 GUIDELINES FOR NUTRI TIONAL SUPPORT MANAG EMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered f or managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical evaluations
Serum electrol ytes
Blood urea nitrogen /creatinine levels
Changes in s tool frequency  orvolume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte changes or imbalance
Skin breakdown 
Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the stud y.
Nutritional support constituents m ay be adjusted at the discretion of the investigator.
During the [ADDRESS_393541]’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.
If there is a change in enteral nutrition ( EN) or other food or fluid intake, the investigator 
should consider this when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 89
Protocol SHP633 -303 Version 2/ 22Nov 2016
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 90
Protocol SHP633 -303 Version 2/ 22Nov 2016
Figure A -2 Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 91
Protocol SHP633 -303 Version 2/ 22Nov 2016
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
PROTOCOL: SHP633 -303
TITLE: A Retrospective and Prospective, Open -label, Long -term Safet y and 
Efficacy  Study  of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED- C13-003
DRUG: Teduglutide
IND: IND# [ADDRESS_393542] NO.: 2016-000863-17
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_393543] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Amendment 1.1: 09Jan 2017 ([LOCATION_008] -Specific)
Amendment 1: 22 Nov 2016
Original Protocol: [ADDRESS_393544] party without the express written consent of Shire.
For non-commercial use only
Sponsor's (Shire) Approval 
Signature: 
, MD PhD 
 
Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-303. 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-Cl3-[ADDRESS_393545] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) Shire CONFIDENTIAL Page 2
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
For non-commercial use only

Shire CONFIDENTIAL Page 3
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1.1 Amendment Date
09Jan 2017United -Kingdom -Specific
Description of Change and Rationale Section(s) Affected by [CONTACT_319442] a contraceptive method in the 
study protocol as requested by [CONTACT_319443] ([LOCATION_006]) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.Section 4.7.[ADDRESS_393546] IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required b y Protocol within 24 hours to the Shire Global Pharmacovigilance and Risk 
Management Department. Applicable fax numbers and e- mail address can be found on the form 
(sent under separate cover). A cop y of this form must also be sent to the Shire Medical Monitor 
by [CONTACT_3719] e -mail using the details below.
, MD PhD
Email: 
Fax: 
For protocol -or safety- related issues during normal business hours ([ADDRESS_393547] Time) ,the investigator must contact [CONTACT_317344]:
, MD PhD, 
Phone: 
Mobile: 
Email: 
Fax: 
For protocol -or safety- related issues outside of normal business hours , the investigator 
must contact [CONTACT_319404]:
, MD, 
Phone:  (medical emergencies – [LOCATION_002])
Phone:  (medical emergencies –Global)
Email: 
r n-commercial use only

Shire CONFIDENTIAL Page [ADDRESS_393548] 
(marketed or investigational) does not meet expectations (eg, inadeq uate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs rel ated to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire ([LOCATION_003]) 
For non-commercial use only

Shire CONFIDENTIAL Page [ADDRESS_393549] Background ................................
.................................................................26
1.3 Clinical Studies with Teduglutide in Pediatric Subjects ..........................................27
2STUDY OBJECTIVES AND PURPOSE ..............................................................................28
2.1 Rationale for the Study .............................................................................................28
2.2 Study  Objectives ......................................................................................................28
2.2.1 Primary  Objectives .........................................................................................28
2.2.2 Secondary  Objectives .....................................................................................28
3STUDY DESIGN ................................
...................................................................................29
3.1 Study  Design and Flow Chart ..................................................................................29
3.1.1 Informed Consent/Assent and Eligibility .......................................................30
3.1.2 Retrospective Data Collection ........................................................................30
3.1.3 Prospective Data Collection and Treatment ...................................................31
3.2 Duration and Study  Completion Definition .............................................................32
4STUDY POPUL ATION.........................................................................................................34
4.1 Study  Inclusion Eligibility  Criteria ..........................................................................34
4.2 Study  Exclusion Eligibility  Criteria
.........................................................................34
4.3 Teduglutide Eligibility  Criteria ................................ ................................ ................ 34
4.4 Teduglutide Treatment Inclusion Criteria ................................ ................................ 34
4.5 Teduglutide Treatment Exclusion Criteria ...............................................................35
4.6 Follow -up Period Escape Criteria ............................................................................36
4.7 Reproductive Potential .............................................................................................36
4.7.1 Female Contraception .....................................................................................36
4.8
Discontinuation of Subjects ................................ ................................ ..................... 37
For non-commercial use only
Shire CONFIDENTIAL Page 7
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
4.8.1 Teduglutide Discontinuation ..........................................................................37
4.8.2 Study  Withdrawal ...........................................................................................37
4.8.3 Reasons for Discontinuation ...........................................................................37
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................[ADDRESS_393550](s) ...........................................................[ADDRESS_393551] Compliance ..................................................................................................43
7
STUDY PROCEDURES........................................................................................................44
7.1 Study  Schedule .........................................................................................................44
7.1.1 Retrospective Data Collection
........................................................................44
7.1.2 Screening ........................................................................................................45
7.1.3 Visits for Subjects Not Receiving Teduglutide ..............................................46
7.1.4 Visits 
for Subjects Receiving Teduglutide Treatment....................................46
[IP_ADDRESS] Pretreatment Visit ...................................................................................46
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24) ................................ .....47
7.1.5 Teduglutide Follow -up Period ........................................................................49
7.1.6 Study  Completion/Earl y Termination Visit (EOS/ET Visit) ..........................49
7.2 Study  Evaluations and Procedures ...........................................................................50
7.2.1 Retrospective Data Collection ........................................................................50
[IP_ADDRESS] Growth (Height, Weight, and Head Circumference) ............................. 50
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed ................................ ................ 50
[IP_ADDRESS] Parenteral Support Prescribed ................................ ................................ 51
For non-commercial use only
Shire CONFIDENTIAL Page 8
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
[IP_ADDRESS] Adverse Events .......................................................................................51
7.2.2 Prospective Data Collection ...........................................................................51
[IP_ADDRESS] Demographics, Medical History , and SBS History ................................51
[IP_ADDRESS] Physical Examination .............................................................................51
[IP_ADDRESS]
Adverse Event Collection.......................................................................51
[IP_ADDRESS] Vital Signs, Bod y Weight, Height, Head Circumference and Bod y 
Mass I ndex (BMI) ..................................................................................51
[IP_ADDRESS] Clinical L aboratory  Tests .......................................................................52
[IP_ADDRESS] Serum Sampling .....................................................................................54
[IP_ADDRESS] Pregnancy  Testing ..................................................................................54
[IP_ADDRESS] Antibody  Testing ....................................................................................54
[IP_ADDRESS] Volume of Blood ....................................................................................54
[IP_ADDRESS] Gastrointestinal -specific Testing ............................................................55
[IP_ADDRESS] Nutritional Support ................................
.................................................56
[IP_ADDRESS] Diaries ....................................................................................................56
[IP_ADDRESS] Health- related Quality  of L ife Assessments ...........................................57
8ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................60
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................60
8.1.1 Severity  Categorization ................................
..................................................61
8.1.2 Relationship Categorization ............................................................................61
8.1.3 Outcome Categorization .................................................................................62
8.1.4 Symptoms of the Disease under Study ...........................................................62
8.1.5 Clinical L aboratory  and Other Safet y Evaluations (Prospective Period 
of Observation Only ) ......................................................................................62
8.1.6 Pregnancy .......................................................................................................63
8.1.7 Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Onl y)..........................................................................................[ADDRESS_393552] ................................ ................................ ........... 67
For non-commercial use only
Shire CONFIDENTIAL Page 9
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
8.4 Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only ).........................................................................................................................67
8.4.1 Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only ) .................................68
8.4.2 Dose Interruption Criteria Based on Drug -Induced L iver Injury  
(Prospective Period of Observation Onl y)......................................................70
8.5 Early Termination of the Clinical Study  (Prospective Period of Observation 
Only ).........................................................................................................................70
9DATA MANAGEMENT AND STATISTICAL METHODS...............................................71
9.1 Data Collection ................................................................
.........................................71
9.2 Clinical Data Management .......................................................................................71
9.3 Statistical Analy
sis Process ......................................................................................71
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................71
9.5 Sample Size Calculation and Power Considerations
................................................72
9.6 Study  Population ......................................................................................................72
9.7 Efficacy  Anal yses................................................................
.....................................72
9.7.1 Efficacy  Endpoints ..........................................................................................72
9.8 Safety  Anal yses................................
........................................................................72
9.8.1 Safety  Endpoints .............................................................................................73
9.9 Other Anal yses.........................................................................................................74
9.9.1 Health- related Quality  of L ife Anal yses.........................................................74
10SPONSOR’S AND I NVEST IGATOR’S RESPONSIBILIT IES...........................................75
10.1 Sponsor’s Responsibilities .......................................................................................75
10.1.1 Good Clinical Practice Compliance ................................................................75
10.1.2 Indemnity /Liability  and Insurance ..................................................................75
10.1.3 Public Posting of Study  Information ..............................................................75
10.1.4 Submission of Summary  of Clinical Study  Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees ................75
10.1.5 Study  Suspension, Termination, and Completion ..........................................76
10.2
Investigator’s Responsibilities .................................................................................76
10.2.1 Good Clinica l Practice Compliance ................................ ................................ 76
10.2.2 Protocol Adherence and Investigator Agreement ...........................................76
10.2.3 Documentation and Retention of Records ......................................................77
[IP_ADDRESS] Case Report Forms .................................................................................77
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................77
[IP_ADDRESS] Audit/I nspection ................................ ................................ ..................... 78
[IP_ADDRESS] Financial Disclosure ................................ ................................ ............... [ADDRESS_393553] or Ethics Committee ...........................................79
10.4 Privac y and Confidentiality ......................................................................................79
10.5 Study  Results / Publication Policy ...........................................................................[ADDRESS_393554]  OF TABLES
Table 1-1: Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ................................ ................................ ........... 20
Table 1-2: Schedule of Events for Screening and End of Study or Earl y 
Termination ...................................................................................................21
Table 1-3: Schedule of Events for No Teduglutide Treatment Period ...........................22
Table 1-4: Schedule of Events for Teduglutide Treatment Period .................................23
Table 5
-1: Prohibited Treatment .....................................................................................39
Table 7-1: List of Laboratory  Tests ................................................................................53
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject 
Annually ................................
........................................................................55
Table 7
-3: Developmentally Appropriate PedsQL™Generic Core Scales .....................58
Table 8
-1: CTCAE Criteria for Adverse Events that May Lead to Dose 
Interruption (Prospective Period of Observation Only ) ................................[ADDRESS_393555]  OF FIGURES
Figure 3 -1: Study  Design Flow Chart ................................
..............................................[ADDRESS_393556] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study report
CTCAE Common Terminology Criteria for Adverse Events
DILI drug-induced livery injury
DMC data monitoring committee
DPP-[ADDRESS_393557]
IV intravenous
IWRS interactive web -based response system
MedDRA Medical Dictionary for Regulatory Activities
NCI National Cancer Institute
NDA new drug application
NTT no-teduglutide treatment
For non-commercial use only
Shire CONFIDENTIAL Page 13
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
PDA patent ductus arteriosus
PedsQL Pediatric Quality of Life Inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once daily
SAE serious adverse event
SAP statistical analysis plan
SBS short bow el syndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_393558] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization -Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page 14
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
STUDY  SYNOPSIS
Protocol num ber: SHP633 -303 Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open -label, Long -term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bow el Syndrome Who Completed TED -C13-003
Number of subjects (total and for each treatm ent arm):
Approximately [ADDRESS_393559] of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED -C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the [LOCATION_002] (US) and the [LOCATION_008] ([LOCATION_006]) w ill participate in 
this extension study.
Study period (planned):
October 2016 -September 2019Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith short 
bowel syndrome (SBS) who completed TED -C13-003.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED -C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open -label, long -term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED -C13-[ADDRESS_393560] of care (SOC) treatment arm in 
TED -C13-003.
Investigational product, dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible ped iatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED -C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of
specific safety and efficacy measures that were completed in the course of the subject’s standard medical care 
betw een the date of the TED -C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) i s signed for this study. In addition to this retrospective data collection, prospective 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review  and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393561]’s standard medical care betw een the date of the TED -C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after 
informed consent/assent is obtained for this study. The following retrospective data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Grow th (height, head circumference [up to 36 months of age], w eight)
End dates for adverse events (AEs) ongoing at the time of TED -C13-003
All nonserious AEs related to teduglutide treatment
All adverse events of special interest ( AESIs)
All serious adverse events (SAEs)
Prospective Data Collection andTreatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1 -2.These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. Prescription par enteral support requirements will be collected at screening. 
Additionally, intake diaries will be dispensed at the screening visit for collection of actual parenteral support (PS) 
volume and hours per day (Section [IP_ADDRESS]). Diary data for PS volume will be collected for at least 2 w eeks after 
the ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no -teduglutide treatment [NTT] period), w ill be seen 
approximately every 12 weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for 
PS volume will be collected for at least [ADDRESS_393562] NTT visit after the screening visit 
will occur within 2 to 12 w eeks of the screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥[ADDRESS_393563], and parent or legal guardian agrees to proceed wit h teduglutide therapy .
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28 -week cycle, consisting of 24 weeks of teduglutid e 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up (no treatment) period (Figure 3 -1). During 
the 28 -week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week af ter adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and w eekly during the follow -up period (betw een Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored and nutritional support will be re viewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 w eeks. To m aintain 
consistency across centers, all attempts should be made to follow  the nutritional support adjustment guidelines 
(developed w ith SBS expert inp ut and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation (Append ix 2).
For non-commercial use only
Shire CONFIDENTIAL Page 16
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone vis its are required approximately 
1week after adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects 
discontinue teduglutide at Week 24 and enter a 4 -week follow-up (no -treatment) period, during which phone visits will be 
performed weekly ( solid grey lines ). If an escape criterion is met during the follow -up period, subjects may proceed directly 
to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they m eet allof the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study -related procedures.
2.Subject completed the TED -C13-003 study (including subjects in the standard of care treatment arm).
3.Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_393564] (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria :
1.Subject is teduglutide -naïve, receivin g PS, and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and during the 
teduglutide pretreatment visit, as assessed by [CONTACT_093]. Transient instability for events such as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of 
baseline prior to the event.
2.Subject w as previously treated w ith teduglutide and at least 1 of the following criteria is satisfied:
a.Increas ing PS requirements follow ing teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319444]-commercial use only
Shire CONFIDENTIAL Page 17
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
improvement after teduglutide discontinuation
c.Deteriorating nutritional status (eg, w eight loss or growth failur e) despi[INVESTIGATOR_319360]
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361]
e.Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <10 kg at the pretreatment visit
2.Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.History of cancer in t he previous 5 years except surgically curative skin cancers
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestin al resections 
≤10cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle
6.Clinically significant intestinal stricture or obstruction
7.Clinically significant, active or recurrent pan creatic or biliary disease
8.Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_319406] (eGFR) below 
50mL/min/1.[ADDRESS_393565] repair, or patent ductus arteriosus (PDA) ligation
11.Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, or 
Smoflipid) w ithin 3 months or 5.5 half -lives of the experimental drug, whichever is longer, prior to the 
pretreatment visit and for the duration of the 28 -week cycle
12.Treatment with analogs of glucagon -like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP -2) (not 
including ted uglutide), insulin -like growth factor -1 (IGF -1), or grow th hormone, within 3 months 
preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_393566], closely -related 
compounds, or any of the stated ingredients
15.Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16.Pregnant or lactating female subjects
17.Sexually active female subjects of child -bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period
18.Any condition, disease, illness, or circumstance that in the investig ator’s opi[INVESTIGATOR_319362], prevents completion of the study, or interferes with analysis of the study results
Follow -up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interrupted 
and the s ubject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
For non-commercial use only
Shire CONFIDENTIAL Page 18
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
1.Increasing PS requirements follow ing teduglutide discontinuation
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319382] e nteral 
nutrition following teduglutide discontinuation
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319364]
4.Severe diarrhea related to teduglutide discontinuation
Maximum duration of subject involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple [ADDRESS_393567] has access (as needed) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately [ADDRESS_393568] has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.
Planned duration of no -teduglutide treatm ent periods: variable, depending on disease course
Planned duration of the teduglutide pretreatm ent visit: 1-21 days
Planned teduglutide treatment cycle duration :28 w eeks. Each cycle consists of 24 w eeks of 
teduglutide treatment followed by a 4 -week follow -up period (no treatm ent)
Endpoints and statistical analysis:
The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED -C13-003) and/or first exposure to 
teduglutide. The following efficacy endpoints will be analyzed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research Endpoints
Health economics and outcomes research endpoints will be analyzed at approximately 12- week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 w eeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period. The beginning of each treatment cycle (CxD1) w ill be an 
additional baseline.
Change in Pedi atric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores:
oFood and drink limits
oDiarrhea
Safety Endpoints
The follow ing safety endpoints will be analyzed from the beginning of the prospective study period:
Adverse events
Vital signs, including body temperature, heart rate, and blood pressure
Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
For non-commercial use only
Shire CONFIDENTIAL Page 19
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Antibodies to teduglutide
Gastrointestinal -specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy
The follow ing safety endpoints will be analyzed from the end of the core study (TED -C13-003) to the beginning of 
the prospective study peri od:
 Adverse events related to teduglutide
 All SAEs
 All Adverse Events of Special Interest (Section 8.3)
The follow ing safety endpoints will be analyzed relative to the baseline of the core study (TED -C13-003):
 Z-scores for height (or length), w eight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; how ever, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by [CONTACT_765]. Adverse events 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_300192].
Sample Size Justification
As this is an extension study, the maximum number of subjects wa s determined by [CONTACT_319435] -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 20
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
STUDY  SCHEDULES
Table 1-1: Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment Note
Informed consent/assent Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study -related 
procedures, including retrospective data collection.Study eligibility
WeightaThe last representative value for w eight during each [ADDRESS_393569] all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator -initiated trials, 
compassionate use, and named -patient access programs.
Parenteral support (PS) 
prescribedaThe last representative PS prescription during each 12 -week interval throughout 
the retrospective period and at the beginning and end of any teduglutide 
treatment will be collected. Data collected should include weekly prescribed 
volume, calories, average hours per day, and days per w eek of prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED -C13-[ADDRESS_393570]
Serious adverse events (SAEs)
Note: Retrospective data are defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED -C13 -003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent) is signed fo r this study. Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospective data
collection, only assessments in this table will be completed. See Section 7.1.1for further details on collection of retrospective 
data.
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
a  The first 12 -week interval begins at TED -C13 -003 EOS vi sit.
For non-commercial use only
Shire CONFIDENTIAL Page 21
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Table 1-2: Schedule of Events for Screening and End of Study or Early Termination
ScreeningEnd of Study or Early 
Termination
Visit Type Site Site
Informed consent/assent X
Study eligibility X
Dem ographics, medical history, SBS historyaX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriabX
Adverse events X X
Concomitant medications and GI procedurescX X
Physical examination and vital signs, including weight X X
Height and head circumferencedX X
Revie w intake and output diarieseX
Record PS prescription and adjust as neededfX X
Safety laboratory testsgX
PedsQL Generic Core Scale/ PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-ScalesX
Antibodies to teduglutidehX
Fecal occult blood testingi(X)
Colonoscopy or sigmoidoscopyj(X)
Pregnancy testingk(X)
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EOS =end of study; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child -bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
aIf the subject has any changes to the medical history and SBS history that had been collected at the baseline of the TED -C13 -
003 study, then the updated medical history and SBS history will be collected.
bSubjects who meet ≥[ADDRESS_393571], 
and parent or legal guardian agrees to proceed with teduglutide therapy ( Table 1-4).
cConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
dHead circumference willbe measured in subjects 36 months of age and younger.
eThe intake diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary shou ld be 
completed daily over a 48 -hour period of nutritional stability before the EOS/ET visit.
fParenteral support prescription will be collected at the screening visit. Parenteral support adjustments should be made after
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix [ADDRESS_393572] of clinical chemistry, hematology, and urinalysis, with results pro cessed
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis wil l not 
constitute a protocol deviation.
h Required for all teduglutide -exposed subjects.
i Fecal occult blood testing should be per formed on teduglutide -exposed subjects on an annual basis, approximately every 48 -
60weeks at a minimum.
j The need for colonoscopy/sigmoidoscopy in response to a positive FOBT result during a no -teduglutide treatment period is at 
the discretion of the inv estigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscop y/sigmoidoscopy at 5 year intervals or more often as needed. See Section [IP_ADDRESS] for details.
kPregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 22
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Table 1-3: Schedule of Events for No Teduglutide Treatment Period
Visit Number NTx
Visit Type Site
Visit FrequencyaEvery 12 weeks
Window (days)b±[ADDRESS_393573] as neededgX
Safety laboratory testshX
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutidei(X)
Fecal occult blood testingjAnnually
Colonoscopy or sigmoidoscopyk(X)
Serum samplelEvery 24 w eeks
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
aThe first NTx visit after the screening visit must occur within [ADDRESS_393574] NTx visit in the current no -teduglutide treatment period.
c Subjects who meet ≥[ADDRESS_393575], 
and parent or legal guardian agree to proceed with teduglutide therapy ( Table 1-4).
dConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver bi opsies, and 
associated pathology results.
eHead circumference will be measured in subjects [ADDRESS_393576] actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool output should be recorded in the output diary over a 48-hour period of nutritional stability before every clinic 
visit. See Section [IP_ADDRESS] for more detail.
gParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix [ADDRESS_393577] positive for teduglutide antibodies should hav e follow -up samples collected 
every 12 weeks during the study until a negative result is obtained.
j Fecal occult blood testing should be performed on teduglutide -exposed subjects on an annual basis, approximately every 
48-60weeks at a minimum.
k The need for colonoscopy /sigmoidoscopy in response to a positive fecal occult blood test during a no -teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy /sigmoidoscopy after 
they have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive 
teduglutide will undergo colonoscopy /sigmoidoscopy at 5-year intervals or more often as needed. See Section [IP_ADDRESS] for 
details.
l Lack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 23
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Visit Number PxCx
D1Cx
W1Cx
W2
Phone contact [CONTACT_319408] [ADDRESS_393578] is required approximately 1 week after PS adjustmentCxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28b
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhoneaSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  (days)c-21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteriaX Xd
Dispense intake 
and output diariesX X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant 
medications and 
GI
procedureseX X X X X X X X X X X X X
Physical 
examination and 
vital signs, 
including weightX X X X X X X X X X X X
Height and head 
circumferencef X X X X
Review intake 
and output 
diariesgX X X X X X X X X X X X X
Record PS Rx 
and adjust as 
neededhX X X X X X X X X X X X X
Safety laboratory 
testsi XiX X X X X X X X X X (X) X
PedsQL Generic 
Core Scale/ 
Family Impact 
Module/ GI 
Symptoms X X X
For non-commercial use only
Shire CONFIDENTIAL Page 24
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Module Sub -
Scales
Antibodies to 
teduglutidej X X X X
Fecal occult 
blood testingX X X
Colonoscopy /
Sigmoidoscopyk (X) (X) (X)
Pregnancy 
testingl X X X X X X X X X
Serum samplemX X
Evaluate escape 
criterian X X
Dispense study 
drugo X X X X X X X X X
Note: (X) denotes conditional requirement for a given assessment if the subject meet s certain conditions per protocol.
eCRFs=electronic case report forms; EOS=end of study; EOT=end of treatment; ET = early termination; FOBT=fecal occult blood t est; FOCBP=females of child -bearing 
potential; FU=follow -up; GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin time/international normalized ratio; 
SBS=short bowel syndrome; SC=subcutaneous; Scr=screening; TED=teduglutide; Tx=treatment
aPhone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25-27 (except 
for evaluation of escape criteria).
bThe investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur 
within [ADDRESS_393579] is completing the study at the CxW28 visit, the EOS/ET visit ( Table 1-2) will take place in lieu of the CxW28 visit.
cVisit windows are relative to the CxD1 visit.
d Eligibility will need to be reconfirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
eConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and associ ated pathology results.
fHead circumference will be measured in subjects [ADDRESS_393580] actual PS volume and hours per day. Intake diaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except 
at pretreatment visit), for 1 week following P S adjustment, and daily during the 4-week follow -up period. Urine and stool output should be recorded in the output diary over a 48 -
hour period of nutritional stability before every clinic visit, and within 1 week of implementing a change in the PS prescri ption. See Section [IP_ADDRESS] for more detail.
hParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment 
provided in Appendix [ADDRESS_393581] PT/INR at the pretreatment 
visit. Additional collection will occur if a potential drug -induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
of urinalysis will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 25
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Table 1-4: Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
j Samples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are rec eiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
k The teduglutide -naïve subjects age 12 and olde r will undergo colonoscopy /sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a 
colonoscopy /sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) ar e obtained at the end of a 
teduglutide treatment cycle (CxW24/EOT), colonoscop y/sigmoidoscopy will be performed. The need for colonoscopy /sigmoidoscopy in response to positive FOBT results at 
CxW12 is at the discretion of the investigator. Teduglutide -exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will 
undergo colonoscopy /sigmoidoscopy. See Section [IP_ADDRESS] for details.
l A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be adminis tered at all other visits according to the study 
schedules, or if pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the study.
m Lack of collection of serum samples will not constitute a protocol deviation.
n If escape criteria are met, the su bject may proceed directly to another pretreatment visit at the discretion of the investigator.
o The first SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subj ect will be observed 
for hypersensitivity reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. Se e 
Section 6.2.3 for dose adjustment.
For non-commercial use only
Shire CONFIDENTIAL Page 26
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
1 BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 y ear and older with SBS ( Khan et al. 
2015; Wales et al. 2004 ). Unlike the adult population, the majority  of cases of SBS in pediatric 
subje cts are due to congenital anomalies or catastrophic events that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 years of the initial diagnosis ( Khan et al. 2015). 
Nevertheless, despi[INVESTIGATOR_3062], many  pediatric subjects remain dependent 
on PS. Complications of long -term PS include liver disease, catheter -related blood stream 
infections, centra l line -associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality  of life is poor ( Squires et al. 
2012). Accelerating the adaptive process and achieving enteral autonomy  is an urgent goal for all 
patients with SBS who are depend ent on PS ( Khan et al. 2015; Squires et al. 2012).
Intestinal adaptation is driven by  [CONTACT_319409] ( Drucker 
and Yusta 2014). Chief among these is hormones glucagon- like peptide 2 (GL P
-2), which is 
secreted from L- type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Resection of these regions may  impair the adaptive response b y limiting endogenous 
production of GLP -2.
1.[ADDRESS_393582] Background
Teduglutide is a novel, recombinant analog of naturally  occurring human GLP -2 that regulates 
the functional and structural integrity  of the cells lining the gastrointestinal ( GI) tract. 
Teduglutide is a 33 -
amino acid peptide that differs from native GLP- 2 in the substitution of 
glycine for alanine at the second position at the N -terminus. As a result, teduglutide demonstrates 
resistance to degradation by  [CONTACT_20597] l peptidase 4 (DPP -4) and therefore maintains a longer 
elimination half -life (t 1/2) in adults of approximately 2 hours compared to the native peptide, 
which has a t 1/2 of approximately  7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical t rials to increase villus height and cry pt depth in the intestinal 
epi[INVESTIGATOR_2130], thereb y increasing the absorptive surface area of the intestines ( Tappenden et al. 
2013; Thymann et al. 2014 ). The European Commission grant ed a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide (R EVESTIVE™) on [ADDRESS_393583] 2012 and a New Drug Application (NDA) for teduglutide (G ATTEX®) was approved by  
[CONTACT_24623] (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide has also been 
approved for use in adult patients with SBS in Canada and Switzerland. On 29 Jun 2016, the 
For non-commercial use only
Shire CONFIDENTIAL Page 27
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
European Commission granted an extension of the Market Authorization for teduglutide 
(REVESTIVE ™) for the treatment of patients aged 1 year and above with SBS; patients should be 
stable following a period of intestinal adaptation.
1.3 Clinical Studies with Teduglutide in Pediatric S ubjects
One Phase 3 study , TED -C13-003, was completed in pediatric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1 -17. Thirty -seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for [ADDRESS_393584] of care (SOC) cohort. There were clear dose -dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 0.0125 
mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at Week 12 
of 37%, including complete independence from PS support in [ADDRESS_393585], and a reduction of 
3.94 hours per day  infusion time. I n the 0.05 mg/kg/day  cohort there was a reduction in PS 
volume at Week 12 of 39%, including complete independence from PS support in 3 subjects, and 
a reduction of 4.18 hours per day  infusion time. Teduglutide was generall y safe and well 
tolerated b y pediatric subjects in all dosing cohorts. There were no deaths during the stud y and 
no treatment -emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study  were due to adverse events (AEs).
TED -C14-006 is an ongoing study  which inc ludes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arms participate in a [ADDRESS_393586] medical therap y for SBS; while 
those in the teduglutide treatment arm will receive daily  subcutaneous (SC) injections of 
teduglutide (stud y drug) in addition to standard medical therap y. The subjects enrolling in the 
teduglutide treatment arm will be randomized 1:1 in a double- blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day  of teduglutide administered subcutaneousl y for 
24weeks.
Alway s refer to the latest version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393587] -time treatment of 
teduglutide -naïve subjects who participated in the SOC treatment arm in TED- C13-003.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED -C13-003.
2.2.2 Secondary Objectives
The secondary  objective of this study  is to evaluate the long -term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 29
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
3 STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safet y and 
efficacy  of teduglutide in pediatric subjects who completed the TED -C13-003 study  (the core 
study ). At the time of entry  into the TED- C13-[ADDRESS_393588] 30% of their caloric or fluid needs, and 
had not been able to significantly  reduce PS for at least 3 months prio r to enrollment. During the 
core stud y, pediatric subjects in the teduglutide treatment arm were entered into a 
0.0125 mg/kg/day , 0.025 mg/kg/day , or 0.05 mg/kg/day  dose cohort based on the timing of their 
enrollment in the study . The cohorts were filled i n a sequential manner.
Approximately  [ADDRESS_393589] meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusio n criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen approximately  every  12 weeks for safety , parenteral support (PS) requirements, and 
quality  of life. A t any point during an NTT period, subjects who meet ≥[ADDRESS_393590], and 
parent or legal guardian agrees to proceed with teduglutide therap y.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long -term follow -up without additional teduglutide treatment may b e appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analy sis suggeste d that pediatric patients, ages 1- 17 years-old, are likel y to require the same 
dose as used in adults, namely  0.05 mg/kg/day  (Mouksassi et al. 2009 ). In this extension study  to 
TED -C13-003, repeat doses of teduglutide 0.05 mg/kg/day  will be administered to eligible 
pediatric subjects.
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily. The completed 12 -week pediatric study (TED- C13-
003) demonstrated that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day was 
associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determin e the effective dose to be used in pediatric 
For non-commercial use only
Shire CONFIDENTIAL Page 30
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
studies as well as the pediatric (core) study (TED -C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults ( O'Keefe et al. 2006 ).
Duration of Treatment
The duration of teduglutide treatment in thi s study mirrors that of the TED -C14-[ADDRESS_393591] may  be evaluated immediately  for 
additional teduglutide treatment. Subjects who clinically  deteriorate or stop improving at any  
time after the end of the follow- up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED- C13-[ADDRESS_393592]’s standard medical care between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form (I CF) (and if 
applicable, informed assent) is signed for this study . In addition to this retrospective data 
collection, prospective study  assessments of safety  and efficacy  will be completed as a part of 
this study .
3.1.1 Informed Consent/Assent and Eligib ility
The review and signing of the I CF (and if applicable, informed assent) for this study , must be 
completed before an y other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this stu dy; however subjects may  
consent to retrospective data collection onl y. Subjects may not consent to the prospective data 
collection only . After informed consent/assent is obtained, study  eligibility  will be assessed for 
all subjects.
3.1.[ADDRESS_393593]’s standard medical care between the date of the 
TED -C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
For non-commercial use only
Shire CONFIDENTIAL Page 31
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
this study . Retrospective data collection may  begin any  time after informed consent/assent is 
obtained for this study . The following data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Growth (height, head circumference [up to 36 months of age], weight)
End dates for adverse events (AEs) ongoing at the time of TED- C13-003
All nonserious AEs related to teduglutide
All adverse events of special interest (AESIs)
All serious adverse events (SAEs )
3.1.3 Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history  and short bowel sy ndrome history .Prescription parenteral support 
requirements will be collected at screening. Additionally , intake diaries will be dispensed at the 
screening visit for collection of actual PS volume and hours per day  (Section [IP_ADDRESS]). Diary  
data for PS volume will be collected for at least 2 weeks after the ICF (and if applicable, the 
informed assent) is signed for this study .
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen approximately  
every  [ADDRESS_393594] NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any  point after screening, including 
during an N TT period, subjects who meet ≥[ADDRESS_393595], and parent or legal 
guardian agrees to proceed with teduglutide therapy .
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28 -week cy cle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily , followed by a 
4-week follow -up (no treatment) period ( Figure 3 -1). During the 28- week cy cle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately 
1week after adjustments in PS during the teduglutide treatme nt period (between Weeks 1 and 
24), and weekl y during the follow -up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safet y will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality  of life asses sments will be made approximately  every  
12 weeks. To maintain consistency  across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regar ding PS reduction and advances in enteral feeds based on weight 
For non-commercial use only
Shire CONFIDENTIAL Page 32
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation ( Appendix 2 ).
Rationale: Measures of long -term safety  will include adverse events, growth parameters, and 
anti-drug antibodies. Measure of long term efficacy  will include durability of effect as measured 
by [CONTACT_319411] (Pediatric Quality  of 
Life Inventory  [PedsQL ], PedsQL  Famil y Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary endpoint in pi[INVESTIGATOR_9205] 3 adult clinical 
trials and the completed Phase 3 pediatric stud y (TED -C13-003), and will be used as an endpoint 
in this extension study . In previous clinical studies, a reduction of this magnitude was associated 
with a reduction in the number of days per week of PS, and increases in enteral intake. Reduction 
in volume and time of PS due to improved ente ral absorption may  provide a pediatric subject 
with opportunities for more age -appropriate activities including oral rehabilitation. Quality  of life 
assessments will be performed in this study to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient population and the pharmacologic effect of teduglutide, GI -specific screening tests, 
including fecal occult blood testing and colonoscopy /sigmoidoscopy , which are commonl y part 
of the routi ne care of these subjects, will be performed to ensure safet y. This study  captures long -
term safet y data on polyps and other colonic mucosal changes in teduglutide -exposed subjects 
using the surveillance strategy  proposed in Section [IP_ADDRESS] .
Figure 3-1: Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 (solid black lines ). Phone visits are required approximately 1 week after 
adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide 
at Week 24 and enter a 4 -week follow -up (no-treatment) period, during which phone visits will be performed weekly ( solid grey 
lines ). If an escape criterion is met during the follow -up period, subjects may proceed directly to another pretreatment visit.
3.[ADDRESS_393596] has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study Inclusion Eligibility  
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393597] h as access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be approximately  
[ADDRESS_393598] 
(last safet y contact), whichever is later. The stud y completion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393599] and/or parent or legal guardian must review and si gn the informed consent (and if 
applicable, informed assent) before an y stud y-related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_393600] will not be considered eligible for the study  without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completin g any stud y-
related procedures. 
2. Subject completed the TED- C13-003 study  (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully  adhere to study  requirements as defined 
in this protocol.
4.2 Study Exclus ion Eligibility Criteria
There are no exclusion criteria for this study .
4.3 Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_393601] (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.[ADDRESS_393602] is teduglutide -naïve, receiving PS, and unable to signi ficantl y reduce PS or advance 
enteral feeds (eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to 
and during the teduglutide pretreatment visit, as assessed b y the investigator. Transient 
instability  for events such as interrupt ion of central access or treatment for sepsis is allowed 
if the PS returns to within 10% of baseline prior to the event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.Increasing PS requirements follo wing teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, followed by  
[CONTACT_319412]
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319383]
d.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319367]
e.Severe diarrhea related to teduglutide discontinuation
For non-commercial use only
Shire CONFIDENTIAL Page 35
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_393603]
3.History  of cancer in the previous 5 y ears except surgically  curative skin cancers
4.Serial transverse enteroplasty  or other major intestinal surgery  within 3 months preceding the 
teduglutide pretreatment visit. I nsertion of a feeding tube, anastomotic ulcer repair, minor 
intestinal resections ≤10 cm, and endoscopic procedure s are allowed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cy cle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairment or injury , including the 
following laboratory  values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7× ULN
9.Renal dy sfunction shown by  [CONTACT_319406] (eGFR) below 
50 mL /min/1.[ADDRESS_393604] repair, or patent ductus 
arteriosus (PDA) ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine, 
Omegaven, or Smoflipid) within 3 months or 5.5 half -lives of the experimental drug, 
whichever is longer, prior to the pretreatment visit and for the duration of the 28 -week cy cle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon -like peptide -2 (GLP -
2) (not including teduglutide), insulin -like growth factor -1 (IGF -1), or growth hormone, 
within 3 months preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_393605], closely -
related compounds, or any  of the stated ingredients
15.Known history  of alcohol or other substance abuse within 1 y ear prior to the pretreatment 
visit
16. Pregnant or lactating female subjects 
17.Sexually  active female subjects of child-bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 day s after the treatment period 
For non-commercial use only
Shire CONFIDENTIAL Page 36
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_20567] y undue ri sk, prevents completion of the study , or interferes with analy sis of the 
study  results
4.[ADDRESS_393606] may  
proceed directl y to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319384]
3.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319385]
4. Severe diarrhea related to teduglutide discontinuation
4.[ADDRESS_393607]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:
Premenarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta- human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pretreatment visit .Females of 
child- bearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:
True abstinence: Abstention of sexual activity  that is in line with the preferred and usual 
lifesty le of the subject. (Periodic abstinence [e g, calendar, ovulation, sy mptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception).
Intrauterine devices plus condoms
Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
For non-commercial use only
Shire CONFIDENTIAL Page 37
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Hormonal contrace ptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually  active during the study , they  should use [ADDRESS_393608] w ishes to remain in the study , the evaluations listed for the EOT visit are to be 
performed. A 4- week follow -up period will ensue, consisting of weekl y telephone visits 
(CxW25 -27) and the week 28 clinic visit (CxW28). The subject would then enter an NTT per iod 
and could be evaluated for subsequent teduglutide treatment eligibility  according to the study  
schedules. 
Comments (spontaneous or elicited) or complaints made b y the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case report form (eCRF) and source documents, as 
described in Section 4.8.[ADDRESS_393609] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_319445] -up.
If a subject with draws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completel y as possible. 
Subjects who withdraw from the study will not be replaced.
4.8.3 Reasons for Discontinuation
The reason(s) for permanent di scontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than [ADDRESS_393610] clinically  relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
For non-commercial use only
Shire CONFIDENTIAL Page 38
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Adverse event
Protocol deviation
Lack of efficacy
Physician decision
Withdrawal by  [CONTACT_1130]
Withdrawal by  [CONTACT_7078] /guardian
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y)
Death
Other
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_393611] (office visit or telephone contact). At least [ADDRESS_393612]’s last 
known address via courier or mail (with an acknowledgement of receipt request) aski ng that they  
return to the site for final safet y evaluations, and return an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page 39
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
5 CONCOMITANT TREATMENT
5.1 Concomitant Medications and GI Procedures
Concomitant treatment will be collected for the prospective period onl y and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this 
study . Concomitant treatment information must be recorded on the appropriate eCRF page. 
Concomitant treatments will be assessed at each site visit, an d include all nonstudy treatments 
(medications, herbal treatments, vitamins, invasive and diagnostic procedures). Concomitant GI 
procedures include (but are not limited to) endoscopy , radiographic studies, GI and liver biopsies 
and associated pathology res ults. Concomitant treatment information must be recorded on the 
appropriate eCRF page. Details of medication changes and/or dosages will be recorded on the 
eCRF.
The mechanism of action of teduglutide may  increase absorption of drugs (eg, motility  
medicati on including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, and digoxin). Accordingl y, due consideration should be given to 
modify ing concomitant medication regimens. Down -titration of concomitant medications should 
be considered when drugs, especiall y those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.[ADDRESS_393613] medical therapy for SBS should be continued.
5.1.2 Prohibited Treatment
The mechanism of action of teduglutide may  increase enteral absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, digoxin), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- 1 analog or human growth hormone 3 months
Octreotide or dipeptidyl peptidase 4 inhibitors 3 months
Biological therapy (eg, antitumor necrosis factor) [ADDRESS_393614] is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2). In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L -histidine, mannitol, monobasic sodium 
phosphate monohy drate, and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.[ADDRESS_393615](s)
6.2.[ADDRESS_393616] Management
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recordi ng subject visits, investigational product supply  dispensation and management, 
inventory  management and supply  ordering, investigational product expi[INVESTIGATOR_49093], and return of investigational product. Please refer to the Study Manual for
additional details regarding the IWRS.
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personne l will receive training.
6.2.[ADDRESS_393617], and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit ( Table 1-4).
6.2.[ADDRESS_393618] will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily . The initial dose wil l be calculated based on 
body  weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body  weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discuss ed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered b y SC injection once dail y (QD) into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For subjects with a 
stoma, the quadrant of the abdomen containing the stoma should not be used. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393619] 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
Following each [ADDRESS_393620] may  proceed 
directly  to another Pretreatment visit to assess treatment eligibility  for another cy cle 
(Section 4.6). Following the completion of the 4- week follow -up, the subject will continue in the 
study  off teduglutide. Additional [ADDRESS_393621](s) container.
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing 7 vials of study  drug will be supplied and these will be labeled in 
accordance with applicable regulatory  requirements. Sterile water for injection sy ringes will also 
be provided separatel y and will be labeled in accordance with the applic able regulatory  
requirements.
All study  drug used in this study  will be manufactured, tested, labeled, and released according to 
current legal requirements and Good Manufacturing Practice.
6.3.2 Packaging
Teduglutide will be provided in a 3 mL  sterile, single -use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL ) will be provided in a prefilled s yringe.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393622] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refrigerated at a temperature between 2 -8°C (35.6 -46.4°F) until dispensed to 
a subject. Once dispensed to a subject, the study  drug c an be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2 -25°C, or 35.6- 77°F). Parent/legal guardian 
will be instructed to keep the subject’s study  drug and sterile water diluent at controlled room 
temperature. If there are co ncerns that the controlled room temperature cannot be maintained, the 
study  drug may  be refrigerated. The study  drug is for single use onl y, and should be used within 
[ADDRESS_393623] is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study  and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  [CONTACT_10179], suc h that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified im mediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will p rovide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharmacy or nominated member of the stud y 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
6.[ADDRESS_393624] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any  unauthorized situation.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study  protocol. All dispensed 
study  medication will be documented in the interactive response technology  system and/or other 
investigational product record (eg, investigation product accountability  form). The investigator is 
responsible for assuring the re trieval of all study  supplies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may  
dispense the unused study  drug vials to the same subject. All original containers, whether empty  
or containing stud y drug will be returned to the pharmacy. Returned stud y drugs will NOT be 
relabeled or reassigned for use b y other subjects. Contents of the study drug containe rs will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may  be destroy ed on site without approval by  [CONTACT_456].
Please see the Pharmacy Manual for additional infor mation.
6.[ADDRESS_393625] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -evident sealed container (eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability  form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 44
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
7 STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures a nd assessments to be performed for subjects throughout the stud y are 
outlined in the Schedule of Assessments ( Table 1 -1, Table 1-2, Table 1 -3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to pe rforming an y study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject ( Table 1-1
).
7.1.1 Retrospective Data Collection
Retrospective data are defined as specific safet y and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form (I CF) (and if 
applicable, informed assent) is signed for this study . Retrospective PS and growth data will be 
captured in [ADDRESS_393626] retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent onl y to retrospective data collection, only 
assessments in Table 1-1 will be completed. The following data will be collected for the 
retrospective portion of the study :
Informed consent, and informed assent (if applicable)
Study  eligibility  is determined
oA screen failure is a subject who has given informed cons ent and failed to meet 
the study  inclusion eligibility  criteria. Subjects cannot be rescreened once they  
have been designated as a screen failure.
Prior teduglutide use (as prescribed)
oCollect all teduglutide prescriptions during the retrospective data col lection 
period, including start and stop dates, dose, route, and frequency . Prescription 
data includes teduglutide treatment in investigator- initiated trials, compassionate 
use, and named -patient access programs.
oCollect start and end dates when a subject’ s teduglutide use was interrupted. 
Parenteral support (as prescribed)
oThe last representative PS prescription during each 12- week interval throughout 
the retrospective period and at the beginning and end of any  teduglutide treatment 
will be collected. Usuall y, the prescription at the end of the interval will represent 
the status of intestinal adaptation. However, transient alterations in PS related to 
For non-commercial use only
Shire CONFIDENTIAL Page 45
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
loss of central venous access or acute illness are not representative of intestinal 
adaptation. When such events occur at the end of a 12 -week interval, earlier, more 
representative PS prescription data should be recorded.
Data collected should include weekl y prescribed volume, calories, average hours 
per day , and day s per week of prescribed PS. Hours per d ay should be averaged 
over the day s where PS is prescribed. 
Growth (height, head circumference, and weight)
oThe last representative value for height, during each 12 -week interval throughout 
the retrospective data collection period will be captured. Head c ircumference 
should be provided for subjects 36 months of age and y ounger at the time the data 
were collected, if available.
The investigator should use his/her clinical judgment to select values that reflect 
the true growth trajectory.
Adverse events
oAll nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study . The details of data collection and safety  reporting for these events 
can be found in Section 8.
oEnd dates for AEs ongoing at the end of TED -C13-003 will be collected.
7.1.2 Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1-2, 
and as detailed below:
Informed consent, and informed assent (if applicable)
Study  eligibility  is determined. A screen failure is a subject who has given infor med 
consent and failed to meet the study  inclusion eligibility  criteria. Subjects cannot be 
rescreened once they  have been designated as a screen failure.
Demographics, updates to medical history  and SBS history
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomitant medications and concomitant GI  procedures
Physical examination and vital signs, including weight
Height and head circumference
Record PS prescription and adjust as needed
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393627] occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
7.1.3 Visits for Subjects Not Receiving Teduglutide
While outside of the 28- week teduglutide -treatment cy cle, subjects will be followed 
approximately  every  12weeks for safety  and efficacy  assessments. No -teduglutide treatment 
visits are numbered sequentially  (NT1, NT2, etc.), even if interrupted by  [CONTACT_319415]. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outlined in Table 1 -3and described below.
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomitant medications, and concomitant GI  procedures
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
Record PS  prescription and adjust as needed
Safety  laboratory  tests (ie, clinical chemistry , hematology , and urinaly sis)
PedsQL  Generic Core Scale/PedsQ L Family  Impact 
Module/PedsQL Gastrointestinal Symptoms Module Sub -Scales
Antibodies to teduglutide, if and when required
Fecal occult blood testing, as indicated (see Section [IP_ADDRESS])
Colonoscopy /sigmoidoscopy , as indicated (see Section [IP_ADDRESS])
Serum sample, as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may  proceed to the pretre atment visit immediately  to determine 
eligibility . 
7.1.4 Visits for Subjects Receiving Teduglutide Treatment
[IP_ADDRESS] Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may  proceed to the pretreatment visit immediately . Similarly , 
subjects who meet escape criteria during the teduglutide follow- up period may  proceed to the 
pretreatment visit immediately . 
For non-commercial use only
Shire CONFIDENTIAL Page 47
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
In general, pretreatment assessments may  occur over a period of up to 21 days. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performed as in Table 1-4 and as 
described below:
Evaluate teduglutide eligibility  (treatment inclusion/exclusion criteria)
Dispense intake and output diaries
Adverse events, concomitant medications, and concomitant GI  procedures
Fecal occult blood testing
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as indicated
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries 
Record PS prescription and adjust as needed.
Safety  laboratory  tests
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit include 
prothrombin time [PT] international normalized ratio [I NR]. Sub sequent prothrombin 
time/international normalized ratio (PT/I NR) measurement is only  required to evaluate 
for suspected drug -induced liver injury  [DILI]).
Pregnancy  testing (serum)
Serum sample
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open- label tedug lutide treatment period will comprise [ADDRESS_393628] administration (Visit CxD1).
VISIT CXD1
Assessments and procedures at this visit will be performed as outlined Table 1 -4and as 
descr ibed below:
Two weeks of intake diary data are required before drug is administered at CxD1.
Confirm teduglutide treatment eligibility
Dispense intake and output diaries
Adverse events, concomitant medications, and concomitant GI  procedures
Physical examination and vital signs, including weight
For non-commercial use only
Shire CONFIDENTIAL Page 48
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed
Safety  laboratory  tests
Quality  of life measurements
Antibodies to teduglutide
Pregnancy  testing (urine )
Dispense study  drug
SITE V ISITS DURING TEDUGLUTIDE TREATMENT PERIOD
Subjects will return for clinic visits on cy cle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:
Dispense and review intake and output diaries (every  effort should be made to complete 2 
weeks of intake diary  entries prior to each clinic visit and to complete 48 hours of output 
diary  entries during a period of nutritional stability  prior to each clinic visit)
Physical examination and vital signs, including weight
Record PS prescription and adjust as needed
Safety  laboratory  tests
Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)
Study  drug dispensation (except for CxW24)
Adverse events, concomitant medications and concomitant GI  procedures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
Height and head circumference
Antibodies to teduglutide
Fecal occult blood testing (FOBT)
GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated
Quality  of life measurements
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 49
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
PHONE VISITS
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1 -4and described 
below:
Review intake and output diaries
Safety  laboratory  tests (clinical chemistry  and urinaly sis)
Record PS prescription and adjust as needed
Obtain AEs, concomitant medications, and concomitant GI procedures
Evaluate escape criteria
7.1.5 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks (Weeks 25 -28 of the cy cle). Phone visits 
will occur on cy cle Weeks 25, 26, and [ADDRESS_393629] may  
proceed directl y to another pretreatment visit a t the investigator’s discretion. The investigator 
may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is 
met at the CxW28 visit, and the pretreatment assessments occur within [ADDRESS_393630] is completing the stud y at the CxW28 visit, the EOS/ET visit (Section 7.1.6) 
will take place in lieu of the CxW28 visit. Otherwise, following completion of the [ADDRESS_393631] will proceed to an NTT visit within approximately  12 weeks.
At Cy cle Week 28 (CxW28), subjects will return to the study  site. In addition to the assessments 
performed at Weeks 25 -27, the following procedures will be performed at CxW28 only :
Dispense and review intake and output diaries
Physical examination and vi tal signs, including weight
Antibodies to teduglutide
Pregnancy  testing (urine)
Evaluate escape criteria
7.1.6 Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET ). 
Assessments and procedures at this visit will be performed as outlined in Table 1-[ADDRESS_393632] discontinues the study prematurel y, the assessments for the EOS/ET 
visit are to be performed as completel y as possible (see Section 4.8.2).
Adverse events, concomitant medications, and concomitant GI  procedures
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries (the intake diary should be completed daily  for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary should be completed 
daily  over a 48- hour period of nutritional stability  before the EOS/ET visit)
Record PS prescription and adjust as needed
Safety  laboratory  tests
Fecal occult blood testing, as indicated
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy , as indicated
Quality  of life measurements
Antibodies to teduglutide
Pregnancy  testing, as needed
7.[ADDRESS_393633]'s completion of the TED -C13-003 study  and the 
date the ICF (and if applicable, assent) is signed for the SHP633 -303 study.
[IP_ADDRESS] G rowth (Height, Weight, and Head Circumference)
Retrospective bod y height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z -score, we ight z-score, bod y mass index (BMI), and BM I z-score will be calculated b y 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the statistical analy sis plan (SAP) .
[IP_ADDRESS] Prior Teduglutide T reatment Prescribed
Any retrospective teduglutide prescription start and stop dates, dose, route, and frequency  will be 
recorded on the appropriate eCRF page.
For non-commercial use only
Shire CONFIDENTIAL Page 51
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
[IP_ADDRESS] Parenteral Support Prescribed
Retrospective parenteral support entries consist of [ADDRESS_393634] 
representative prescription from the interval should be used (see Section 7.1.1 ). In addition, PS 
prescriptions at the beginn ing and end of an y retrospective teduglutide treatment must be 
recorded. The PS prescription includes weekl y volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
[IP_ADDRESS] Adverse Events
Nonserious AEs related to tedugl utide treatment and all adverse events of special interest 
(AESI s) and all serious adverse events (SAEs), regardless of causal attribution to teduglutide, 
that occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safet y reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED- C13-003 will be collected.
7.2.2 Prospective Data Collection
[IP_ADDRESS] Demographics, Medical History, and SBS History
Demographics, updates to medical history , and updates to SBS history  will be obtained at 
screening. Medical history  for purposes of this extension study  will consist of updates to the 
medical history  collected at the start of the TED -C13-[ADDRESS_393635] has an y 
changes to the SBS history  since the baseline visit of the TED -C13-003 study , that information 
(updated SBS history ) will also be collected.
[IP_ADDRESS] Physical Examination
Physical examinations will be performed according to the stud y schedules. Any new clinicall y 
significant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF.
[IP_ADDRESS] Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way  to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had an y health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (see Section 8, Adverse 
and Serious Adverse Events Assessment.)
[IP_ADDRESS] Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study  schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body  temperature 
For non-commercial use only
Shire CONFIDENTIAL Page 52
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same arm, 
and in the same position throughout the stud y).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit.
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
[IP_ADDRESS] Clinical Laboratory Tests
Safety  laboratory  tests to be performed at site visits consist of clinical c hemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1 -2, Table 1-3, and 
Table 1-4). Scheduled laboratory  testing will be processed b y a central lab. All laboratory  assay s 
will be performed according to the centra l laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out-of- range clinical laboratory  
values for clinical significance, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical condition, may , at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolve d.
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_393636] of clinical chemistry  and urinal ysis and may be processed by  [CONTACT_319438] a local laboratory . Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate an y new clinicall y significant changes, they must be reported as an 
adverse event (see Section 8.1
). Urine specimen collection should be attempted as part of the 
safet y labs, but lack of urinalysis will not constitute a protocol deviation.
New clinicall y significant labs should be reported as AEs.
The following clinical laboratory  assessment s will be performed according to the study  
schedules:
For non-commercial use only
Shire CONFIDENTIAL Page 53
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Table 7-1: List of Laboratory Tests 
Hematology :
Hematocrit
Hemoglobin
Platelet count
Red blood cell count
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio
Urinalysis :
Blood
Glucose
Leukocytes
Microscopic analysis
pH
Protein
Specific gravity
Pregnancy tests (females of childbearing potential):
Serum β -HCG (screening)
Urine β -HCG (all other visits)Biochemistry :
Albumin
Alkaline phosphatase
Alanine aminotransferase
Amy lase
Aspartate aminotransferase
Bicarbonate
Bilirubin (total and indirect)
Blood urea nitrogen
Calcium (total)
Chloride
Cholesterol
C-reactive protein
Creatinine
Estimated Glomerular Filtration Rate 
(Schwartz formula)
Gamma -glutamyl transferase
Glucose
Lipase
Magnesium
Phosphorus
Potassium
Sodium
Triglycerides
Uric acid
For non-commercial use only
Shire CONFIDENTIAL Page 54
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
[IP_ADDRESS] Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times:
At the pretreatment visit. If the subject met a follow-up period escape criterion, the serum 
sample will not be collected at the pretreatment visit
At the CxW24 (EOT) visit
During NTT: Approximately  every  24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sampl e and/or extracted material will otherwise be stored 
for up to [ADDRESS_393637] their 
sample and/o r extracted material destro yed. An y results alread y generated from the samples will 
not be removed from an y anal yses that have already  been performed.
[IP_ADDRESS] Pregnancy Testing
A serum pregnancy  test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy  tests will be administered at all other visits according to the study  schedules, or if 
pregnancy  is suspected, or as specified per protocol upon withdrawal of the subject from the 
study .
[IP_ADDRESS] Antibody Testing
Blood samples will be drawn for the analysis of antibodies to teduglutide according to the 
Schedule of Assessments ( Table 1-2, Table 1 -3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least [ADDRESS_393638] follow- up blood draws for antibodies to teduglutide every  12 weeks while 
on study  until a negative result is obtained.
[IP_ADDRESS] Volume of B lood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study . The volumes of blood to be drawn from each subject will vary  depending on 
clinical status. Approximate volumes of blood to be drawn from each sub ject annuall y are shown 
in Table 7-2
.
For non-commercial use only
Shire CONFIDENTIAL Page 55
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Parameters 1 2 2
Antibodies 2 8 16
Serum storage samples 3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volum e): 138
Subjects Not Receiving Teduglutide Treatmentb
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samples 3 2 6
Total mL per 4 “No Teduglutide Treatment” Visits 48 -week period: 24
β-hCG=beta -human chorionic gonadotropin; NTT= no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bSubjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti -teduglutide 
antibodies will require blood samples for antibody testing every [ADDRESS_393639] negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/p eriod, if they  require the same t ype of tube, the assessments should be combined. Blood 
volume estimates do not include safet y labs performed after PS adjustment, and anti -teduglutide 
antibody  testing during no- teduglutide treatment.
[IP_ADDRESS] Gastrointestinal- speci fic Testing
FECAL OCCULT BLOOD TESTING
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week [ADDRESS_393640] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past and 
are therefore not teduglutide -naïve) on a roughl y annual basis (approximately every 48 -60 
weeks). Actions to be taken in response to a positive FOBT are described below.
COLONOSCOPY OR SIGMOI DOSCOPY
Teduglutide -naïve subjects age 12 and older will undergo colonoscopy  or sigmoidoscopy  at the 
pretreatment visit if one has not been performed within 1 y ear.
Subjects of an y age with newly positive FOBT results at the pretreatment visit for which a 
readil y detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscop y or 
For non-commercial use only
Shire CONFIDENTIAL Page 56
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
sigmoidoscop y prior to receiving teduglutide. If newly positive FOBT results (for which a 
readil y detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy  or sigmoidoscopy  will be performed. The need for 
colonoscop y or sigmoidoscopy in response to positive FOBTs at an y other point during the 
study , or to reevaluate persistently  positive FOBTs is at th e discretion of the investigator.
Teduglutide -exposed subjects who have received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will undergo colonoscopy  or sigmoidoscopy . While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy  or sigmoidoscopy at 5 y ear intervals or 
more often as needed.
Upper endoscop y ma y be performed along with any colonoscop y or sigmoidoscopy at the 
investigator’s discretion. If a pol yp is found, adherence to current pol yp follow -up guidelines is 
recommended. Subjects with unresected GI pol yps, poly posis conditions, premalignant change 
or malignancy  in the GI tract will be excluded from teduglutide treatment.
[IP_ADDRESS] Nutritional Support
Nutritional support includes PS, enteral nutrition, and ot her food and fluids. Advances in enteral 
nutrition and/or reductions to PS will be based on clinical status, including weight, linear growth, 
hydration status, and safety  laboratory  results. Intake and output diaries will include data to be 
considered in t he adjustment of each subject’s nutritional support. Guidelines for nutritional 
support management and weaning algorithms are provided in Appendix 2 .
[IP_ADDRESS] Diaries
STUDY DRUG ADMINISTRA TION DIARY
A study  drug administration diary  will record administration of te duglutide. This diary  should be 
completed b y the subject (or parent/legally authorized representative, as applicable) dail y during 
the teduglutide treatment period (between visits CxD1 and CxW24).
INTAKE DIARY
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary  
2 weeks prior to ALL scheduled prospective site visits (except at pretreatment visit). During the 
24-week tedug lutide treatment period, the intake diary  will also be completed for 1 week 
following PS adjustments. The intake diary  will also be completed dail y during the 4 -week 
follow -up period. The following data will be captured in the intake diaries:
Parenteral su pport volume and infusion duration
Site personnel will determine the actual PS daily  calories based on diary  entries
OUTPUT DIARY
Urine and stool output should be recorded in the output diary  over a 48- hour period of nutritional 
stability  before every  clinic visit; in addition, output should be recorded for subjects that are in a 
For non-commercial use only
Shire CONFIDENTIAL Page 57
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
teduglutide treatment cy cle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
Toilet -trained subjects (who do not wear diapers)
Measure and record all urine output in mL  or cc 
Nontoilet- trained subjects (who wear diapers)
Measure and record the weight of all urine -only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL or 1 cc
At the discretion of the investigator, the parent or legal guardian may  be asked to collect 
the first void after the daily  PS infusion to measure specific gravit y
Stool data (includes diapers with mixed urine and stool):
Toilet -trained subjects (w ho do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency  using the 
Bristol Stool Form Scale (see Output diary )
Nontoilet- trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed urine and 
stool) as stool output and score the stool consistency  using the Bristol Stool Form Scale 
(see Output diary ). Stool volume will be calculated using the formula: 1 g (scale 
weight)=1 mLor 1 cc
All ostomy  output volum e should be recorded. Ostomy  output will not be scored using the 
Bristol scale.
All available diary  data will be reviewed by  [CONTACT_319446] d advance in feeds.
[IP_ADDRESS] Health -related Quality of Life Assessments
Throughout the stud y, health -related quality  of life assessments will be performed using the 
PedsQL  Generic Core Scales. Each PedsQL age- appropriate form takes less than [ADDRESS_393641] month, and parent -report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
PEDIATRIC QUALITY OF LIFE GENE RIC CORE SCALE (PEDSQL™), ACUTE VERSION
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed b y either the parent or legal guardian and subject 
as indicated in Table 7 -3at the time points as outlined in Table 1-2, Table 1 -3,and Table 1 -4.
Table 7-3: Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects 
(ages 8 -12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18) Subject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5 -7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
PEDIATRIC QUALITY OF LIFE FAMILY IMPACT MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-2, Table [ADDRESS_393642] of pediatric chronic health conditions on parents and the family  (Varni et al. 2004 ). 
The 36- item PedsQL Family  Impact Module consists of 6 scales measuring parent self -reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Fun ctioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure parent -
For non-commercial use only
Shire CONFIDENTIAL Page 59
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
reported family  functioning as follows: 1) Dail y Activities (3 items), and 2) Family  Relationships 
(5 items). The PedsQL Family  Impact Module should take the parent or legal guardian 
approximately  5-10 minutes to complete.
PEDSQL GASTROINTESTINAL SYMPTOMS MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58- item module, c omprised 
of 10 different s ymptom scales that assess gastrointestinal sy mptom -related quality  of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The Ped sQL Gastrointestinal Sy mptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
clinically  relevant and appropriate for the s ymptoms experienced in this pediatric study  
population, and therefore, are the onl y scales used in this study . The scales will be completed by  
[CONTACT_319418] [ADDRESS_393643] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
RETROSPECTIVE PERIOD OF OBSERVATION
For the retrospective data collection period (the interval between the EOS visit of the core study  
until signing the ICF [and informed assent, if applicable] for SHP633 -303), investigators will be 
asked if they  are aware of any  nonserious AEs related to teduglutide that occurred during this 
time and an y AESIs or any SAEs, regardless of relationsh ip to teduglutide, that occurred during 
this time. The following guidance is given for defining a treatment -related event:
The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a know n or suspected response pattern to that 
product.
The event cannot be explained b y the subject’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this stud y 
in the eCRF.
PROSPECTIVE PERIOD OF OBSERVATION
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the defined follow- up period stated in Section 7.1.5. This includes even ts 
occurring during the screening phase of the stud y, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of s ymptoms should be 
recorded. If a diagnosis has not been made, then each s ymptom s
hould be listed individually . All 
AEs should be captured on the appropriate AE pages in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investigational product indication 
should also be captured on the AE eCRF .
All prospective AEs must be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the stud y. Closure indicates that an outc ome is reached, stabilization achieved 
For non-commercial use only
Shire CONFIDENTIAL Page 61
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
(the investigator does not expect any  further improvement or worsening of the event), or the 
event is otherwise explained. When appropriate, medical tests and examinations are performed 
so that resolution of event(s) can be documented.
8.1.[ADDRESS_393644] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more fre quent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
Note that the severity  of AEs that constitute dose interruption criteria will also be evaluated 
using the National Cancer Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) grading criteria ( Table 8 -1).
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her m edical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documente d in the source document.
The following additional guidance may  be helpful:
Term Relationship Definition
Related The temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393645]’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Not RelatedThe event can be readil y explained by  [CONTACT_11260]’s underl ying medical condit ion, concomitant therapy , or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study  drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged by  [CONTACT_093].
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline.
8.1.[ADDRESS_393646] be recorded during the course of the study  in the eCRF. Outcomes 
are as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study ; however, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.5 Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory  or vital sign can represent an AE if the change is 
clinically  relevant or if, during the study , a shift of a parameter is observed from a normal value 
to an abnormal value, or a further worsening of an alread y abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393647] be taken into consideration.
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the referen ce range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefore represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core stud y until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633 -[ADDRESS_393648] be reported within 24 hours to the 
Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy  Report Form (and any  applicable follow -up 
reports) must also be sent to the Shire Medical Monitor using the details specified in the 
emergency  contact [CONTACT_1739]. I n the event a subject becomes pregnant 
after si gning the ICF (and, if applicable, assent), teduglutide administration must be discontinued 
immediately .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. For pregnancy  reports during the prospec tive period of observation, it is 
the responsibility  of the investigator to obtain this information within [ADDRESS_393649] partum. For pregnancies occurring 
during the retrospective pe riod of observation (ie, before signing the informed consent for 
SHP633 -303), the initial notification date will be the date the pregnancy  is recorded for this 
study  and outcome and infant condition information may  be collected any time post partum.
Pregnan cy complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for Serious Adverse Events (SAEs) and Nonserious AEs as Required b y the Protocol. Note: An 
elective abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Adverse Event Form for SAEs and 
Nonseriou s AEs as required by  [CONTACT_319419] I nvestigational and Marketed 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393650] positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medicati on Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633- 303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they  result in an AE/SAE as described in Section 8.2. Note: The 24 -hour reporting 
requirement for SAEs does not a pply to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse – Persistent or sporadic intentional intake of investigational p roduct when used 
for a nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may  be detrimental to the individual and/or society
Misuse –Intentional use of investigational product other than as directed or indicated 
at any dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed b y the protocol)
Overdose –Administration of a dose greater than the allocated dose of the study  
medication or at a frequency  grea ter than the dosing interval specified by  [CONTACT_760]
Medication Error – An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, medication errors are reportable to the 
sponsor only  as defined below .
 Cases of subjects missing doses of the investigational product are not 
considered reportable as medication errors
 Medication errors should be collected/reported for all products under 
investigation
 The administration and/or use of an expi[INVESTIGATOR_319386] a reportable medication error
All investigational product provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y-authorized representative/caregiver.
8.[ADDRESS_393651] awareness 
of the event. Note: The 24-hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless they result in an SAE.
All adverse events of special interest, as defined in Section 8.3, experienced during the 
prospecti ve period of observation must be reported by  [CONTACT_319420] [ADDRESS_393652] complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Nonserious AEs as Required b y Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global 
Pharmacovigilance and Risk Management Department. A copy  of the completed Shire Clinical 
Study  Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as Required 
by [CONTACT_1738] (and any  applicable follow -up reports) must also be sent to the Shire Medical 
Monitor or designee using the details specified in the emergency  contact [CONTACT_319421].
8.2.[ADDRESS_393653] medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 
Results in death
Is life -threatening. Note: The term 'life -threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatient hospi[INVESTIGATOR_233003]. Note: 
Hospi[INVESTIGATOR_602], which are the result of elective or previousl y scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previous ly scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospi[INVESTIGATOR_230476](s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
For non-commercial use only
Shire CONFIDENTIAL Page 66
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based u pon appropriate medical judgment, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive tre atment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
For the retrospective data collection period (the interval between the EOS visit of the core study  
until signing the ICF [and informed assent, if applicable] for SHP633 -303), investigators will be 
asked if they  are aware of any  SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is recorded for this study  in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Pharmacovigilance and Risk Management Department and the Shire Medical 
Monitor within [ADDRESS_393654] awareness of the event, and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to study  drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow -up period stated in Section 7.1.5. These SAEs must be reported to the Shire 
Global Pharmacovigilance and Risk Management Department and the Shire Medical Monitor 
within [ADDRESS_393655] awareness of the event, as per Section 8.2.2. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by  [CONTACT_10194] y interv al after the study  has completed must be reported to the Shire Global 
Pharmacovigilance and Risk Management Department within [ADDRESS_393656]’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393657]’s death or any ongoing events at t he time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solel y as a result of the 
subject’s death.
8.2.[ADDRESS_393658], Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notify ing the 
relevant regulatory  authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinica l CRO is responsible for notify ing active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
8.[ADDRESS_393659]
An AESI  is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by  
[CONTACT_230013].
The AEs of special interest that require expedited regulatory  reporting include the following:
Growth of pre -existing poly ps of the colon
Benign neoplasia of the GI tract including the hepatobiliary  system
Tumor -promoting ability (eg, benign and/or malignant neoplasia of any  kind, not limited 
to those of the GI or hepatobiliary  system)
For AESIs experienced during the retrospective or prospective period of observation, the sponsor 
must b e informed within [ADDRESS_393660] awareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4 Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 8.5apply onl y to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact [CONTACT_103]/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059], AEs, a lapse in investigational product delivery , etc.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393661] be discontinued if any  of the following events occur:
Pregnancy
Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319447]. This does not include the presence of anti- teduglutide antibodies, mild
injection site reactions or mild sy mptoms that according to the investigator do not pose a 
significant risk to the subject.
An AE listed in ( Table 8-1) that is of NCI CTCAE severit y Grade 3 or 4 and considered 
to be related to stud y drug administration
Confirmed drug -induced liver injury  (DILI) related to teduglutide (see Section 8.4.2)
8.4.1 Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide (Prospective Period of Observation Only)
The investigational product may  be discontinued if the subject has an AE listed in Table 8-1 that 
is of severit y ≥Grade 3 per the NCI CTCAE. All such AEs should be discussed with Shire’s 
medical monitor or designee as soon as possible. Teduglutide administration must be 
discontinued if the AE is considered rel ated to the investigational product. The length of the dose 
interruption, and whether teduglutide administration resumes or is permanently  discontinued, 
depends on the clinical situation.
Investigators and the data monitoring committee (DMC) should be guid ed by  [CONTACT_319423] 3 and 4 events, as they  relate to known and possible risks associated with the 
administration of teduglutide.
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events Grade 3 Description Grade 4 Description
Gastrointestinal Disorders
Colorectal polyps Severe or medically significant but not 
immediately life threatening; 
hospi[INVESTIGATOR_20578]; 
disabling; limiting self -care activities of 
daily livingLife-threatening consequences; urgent 
intervention indicated
Intestinal Obstruction Hospi[INVESTIGATOR_374]; elective 
operative intervention ind icated; limiting 
self-care activities of daily living; 
disablingLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder and Bile Duct Disease
Cholecystitis Severe symptoms; radiologic,
endoscopic or elective operative 
intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder perforation Not Applicable Life-threatening consequences; urgent 
For non-commercial use only
Shire CONFIDENTIAL Page 69
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption 
(Prospective Period of Observation Only)
Adverse Events Grade 3 Description Grade 4 Description
intervention indicated
Gallbladder obstruction Symptomatic and severely altered 
gastrointestinal function; tube feeding, 
total parenteral nutrition or 
hospi[INVESTIGATOR_374]; nonemergent 
operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder infection Intravenous antibio tic, antifungal, or 
antiviral intervention indicated; 
radiologic, endoscopic, or operative 
intervention indicatedLife-threatening consequences; urgent 
intervention indicated
Adverse Events Grade 3 Description Grade 4 Description
Alkaline Phosphatase 
increased>5.[ADDRESS_393662] >20.0x ULN
Blood bilirubin increased >3.[ADDRESS_393663] >10.0x ULN
Bile duct stenosis Severely altered gastrointestinal function; 
radiologic, endoscopic or elective 
operative intervention indicatedLife-threatening consequences ; urgent 
operative intervention indicated
Pancreatic Disease
Pancreatitis Severe pain; vomiting; medical 
intervention indicated (eg, analgesia, 
nutritional support)Life-threatening consequences; urgent 
intervention indicated
Pancreatic duct stenosis Severely altered gastrointestinal function; 
tube feeding or hospi[INVESTIGATOR_374]; 
elective operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Pancreas infection Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic or operative intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated
Serum amylase increaseda>2.[ADDRESS_393664] >5.0x ULN
Lipase increaseda>2.[ADDRESS_393665] >5.0x ULN
Cardiovascular Disease
Heart failure Severe with symptoms at rest or with 
minimal activity or exertion; intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated (eg, continuous 
intravenous therapy or mechanical 
hemodynamic suppo rt)
Source: Common Terminology Criteria for Adverse Events, version 4.03, [ADDRESS_393666]=upper limit of normal
a In the setting of clinically acute and symptomatic pancreatitis
For non-commercial use only
Shire CONFIDENTIAL Page 70
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
8.4.2 Dose Interruption Criteria Based on Drug -Induced Liver Injury
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may  need to be interrupted if the subject has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following criteria:
ALT or AST >8x ULN
ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)
ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory  values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_393667] should be followed closely to determine the trajectory  of the 
laboratory  abnormal ities and to evaluate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cy tomegaloviru s IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti -smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investigator in consultation 
with the Shire Medical Monitor.
Teduglutide administration must be permanentl y disconti nued if DILI is confirmed and deemed 
related to stud y drug.
8.5 Early Termination of the Clinical Study (Prospective Period of Observation Only)
The DMC may  recommend stoppi[INVESTIGATOR_319373]:
≥2subjects develop the same event listed in Table 8 -1of severity  CTCAE Grade 3
or
1subject develops an event listed in Table 8-[ADDRESS_393668] or is not reasonably  related to the underlying 
disease process
For non-commercial use only
Shire CONFIDENTIAL Page 71
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
9 DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection procedu res will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safet y follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for o missions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical d atabase, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Process
The study  will be anal yzed by  [CONTACT_10196]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or hig her.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject dispositi on, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4 Planned Interim Analysis, and Data Monitoring Committee
An interim anal ysis of all retrospective data will be conducted. Other interim a nalyses may  also 
be conducted if needed.
A DMC will be involved in the management of this study . The DMC members will review the 
data approximately  every 3 months according to the DMC Charter. The DMC review will 
include all cumulative safety  data (ie, AEs, laboratory  assessments, phy sical examinations, etc.) 
from study  assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product. 
The DMC for this study  will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393669] may  not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hired by  [CONTACT_456], or members of 
regulatory  agenc ies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine whether the study  should be modified or temporaril y or 
permanentl y stopped.
9.[ADDRESS_393670] udy. The safet y population will be 
used for both safet y and efficacy anal yses.
9.7 Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those as sessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentag es.
9.7.1 Efficacy Endpoints
Efficacy  endpoints will be anal yzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each stud y visit, relative to the baseline of the core study  (TED -C13-003) and/or 
first exposure to teduglutide. The followi ng efficacy  endpoints will be analy zed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Complete weaning off PS
Change in day s per week of PS
9.8 Safety Analyses
Safety data, including laboratory  tests and vital signs assessments, will be summarized by  [CONTACT_765]. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
For non-commercial use only
Shire CONFIDENTIAL Page 73
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
for quantitative safet y data as well as for the difference from baseline, if applicable. Frequency  
counts will be compi[INVESTIGATOR_319374] y data.
9.8.1 Safety Endpoints
The following safet y endpoints will be analy zed from the beginning of the prospective study  
period:
Adverse events
Vital signs, including body  temperature, heart rate, and blood pressure
Laboratory  safet y data (ie, clinical chemistry , hematology , and urinaly sis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing including fetal occult blood testing and colonoscopy  or 
sigmoidoscop y
The following safet y endpoints will be analy zed from the end of the core study  (TED -C13-003) 
to the beginning of the prospective study  period:
Adverse events related to teduglutide
All SAEs
All AESI s (Section 8.3)
The following safet y endpoints will be analyzed relative to the ba seline of the core stud y 
(TED -C13-003):
Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
body  mass index
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by [CONTACT_319425]. Serious adverse events will be further 
summarized by  [CONTACT_230535]. Adverse events related to 
investigati onal product, AEs leading to withdrawal, SAEs, and deaths will be similarly  
summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dictionary  (WHO -DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history  (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by  [CONTACT_319448]. 
For non-commercial use only
Shire CONFIDENTIAL Page 74
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
For clinical laboratory  tests, vital signs, body  weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified ca tegories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the pres ence of antibodies. 
Additional safet y parameters and measures will include change in bod y weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z -score, BMI, and BMI z -score. Desc riptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses
Health economics and outcomes research endpoints will be analy zed at approximately  12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective study  period. The beginning of 
each treatment cy cle (CxD1) will be an additional baseline.
Change in Pediatric Quality  of Life Inventory  (PedsQL) score
Change in PedsQL Family  Impact Module score
Change in PedsQ L Gastrointestinal Sy mptoms Module Sub- Scales scores:
Food and drink limits
Diarrhea
For non-commercial use only
Shire CONFIDENTIAL Page 75
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
10 SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_393671] been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH Good Clinical Practice (GCP) Guideline E6 (1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionall y be 
reviewed b y auditors or by  [CONTACT_319449].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropr iate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance cert ificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating inves tigators’ names 
and contact [CONTACT_3031].
10.1.4 Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent author ity of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
For non-commercial use only
Shire CONFIDENTIAL Page 76
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated pub lic website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as required b y 
Article 10 (c) of Directive 2001/20/EC.
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_393672] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  train ed 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications neces sary to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should , with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator [INVESTIGATOR_319387]. Agreement with the final CSR is documented by  [CONTACT_319450] (single -site study ) or coordinating principal investigator (multicenter 
study ), in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 (1995). 
10.2.[ADDRESS_393673] met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 77
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final r eports and summaries as required b y international regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
multice nter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or desig nee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
Electronic case report forms should be approved by [CONTACT_319451] r equirements.
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory , queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access , and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_10203]/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory  reports, X -rays etc.). Nonstudy  site personnel will not 
disclose an y personal information or personal medical information.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393674] be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized re presentative of any  regulatory  agency  (eg, the US FDA, 
European Medicines Agency  (EMA), [LOCATION_006] Medicines and Healthcare products Regulatory  
Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy edwithout written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  [CONTACT_1779], for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory  authorities), the 
European Medicines Agency  (EMA), the Medicines and Healthcare products Regulatory  
Agency , other regulatory authorities, the sponsor or its representatives, and the I RB/EC for each 
site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_319452] y, or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.[ADDRESS_393675]’s legally-authorized representative, as 
applicable, is requested to sign and date the subject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been rea d) the written subject 
information and received an explanation of what the study  involves, including but not limited to: 
the objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy  of the informed cons ent and assent documentation (ie, a complete set of 
subject information sheets and fully  executed signature [CONTACT_1787]) must be given to the subject or the 
subject’s legall y-authorized representative, as applicable. This document may  require translation 
into th e local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
For non-commercial use only
Shire CONFIDENTIAL Page 79
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Within the source documents, site personnel should document instruction of and understanding 
by [CONTACT_7071]/legall y-authorize d representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
The principal investigator [INVESTIGATOR_1682] a cop y of the consent form, and assent form 
where applicable, which was rev iewed by  [CONTACT_1201]/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the sponsor, prior to the start of the study  unless it is agreed to 
and documented (ab iding by [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally , if the I RB/EC requires modification of the sample subject inf ormation and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_393676] or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to s ubmit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation .
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating principal investigator [INVESTIGATOR_10157], according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is d efined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_1683]/EC apprised of the 
progress of the study  and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicenter 
studies the coordinating principal investigator, according to national provi sions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_393677] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_317364] (or designee).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393678] consented to take part in the study , the sponsor and/or its representatives 
review their medical records and data collected during the stud y. These re cords and data may , in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP633; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that laborat ory results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase [ADDRESS_393679] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s p roprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_10206], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her pu blications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publ ication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, el ectronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393680] the right to publish the 
study  results, and any background information provided by  [CONTACT_10207] y publication of study results, or necessary for other scholars to verify such stud y 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_393681] publication of the study results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163]. If such a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_10209] 18-m onth period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the spe cific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwise required by  [CONTACT_10210], or the forum in w hich 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 82
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
11 REFERENCES
Drucker, D. J. & Yusta, B. 2014. Phy siology  and pharmacology  of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76,561-83.
Khan, F. A., Squires, R. H., L itman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S ., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., Sudan, 
D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. & Duggan, C. 2015. Predictors 
of Enteral Autonom y in Children with I ntestinal Failure: A Multicenter Cohort Study . J Pediatr,
167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cy ran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon -
like peptide-2 
analog in neonates and infants with short -bowel s yndrome. Clin Pharmacol Ther, 86,667-71.
O'Keefe, S. J., Buchman, A. L ., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel sy ndrome and intestinal failure: consensus definitions and overview. Clin 
Gastroente rol Hepatol, 4
,6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. A., 
Kocoshis, S., Superina, R., L awlor, S., Hall er, T., Kurs -Lask y, M. & Belle, S. H. 2012. Natural 
history  of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure 
Consortium. 
J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel sy ndrome. J Clin Gastroenterol, [ADDRESS_393682], N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. A cute effects of the glucagon -like peptide 2 analogue, 
teduglutide, on intestinal adaptation in short bowel sy ndrome. J Pediatr Gastroenterol Nutr, 58,
694-702.
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL  
Family Impact Module: preliminary  reliability  and validity . Health Qual Life Outcomes, 2,55.
Wales, P. W., de Silva, N., Kim, J., L ecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population- based estimates of incidence and mortality  rates. J Pediatr Surg, 39,690-
5.
For non-commercial use only
Shire CONFIDENTIAL Page 83
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
12 APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 84
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
APPENDIX 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol 11 May 2016 Global
Amendment 1 22 Nov 2016 Global
Amendment 1.1 09Jan 2017 [LOCATION_006] Specific
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319453].Protocol Signature [CONTACT_319504] [CONTACT_319431] -teduglutide treatment 
period, visits will take place approximately every 12 w eeks.Synopsis
Sections 3.1, 3.1.3 , 7.1.3
Figure 3 -1
The study design flow chart has been edited for clarity. Synopsis
Figure 3 -1
The collection of all actual and prescribed enteral nutrition data has 
been removed to reduce the burden on the subjects and investigators. 
Enteral nutrition data are not required as the efficacy endpoints are 
limited to parenteral support parameters.Synopsis
Table 1 -2, Table 1 -3, Table 1 -4
Sections 3.1.3 , 7.1.2, 7.1.3, [IP_ADDRESS], 
[IP_ADDRESS], 7.1.6, [IP_ADDRESS], [IP_ADDRESS]
Exclusion criterion [ADDRESS_393683] been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to [ADDRESS_393684] been refined.Table 1 -1
Sections 7.1.1, [IP_ADDRESS], [IP_ADDRESS]
Com pletion and review of intake and output diaries have been clarified. 
Also, review of diaries has been removed from the screening visit and 
added to the pretreatment visit.Table 1 -2, Table 1 -3, Table 1 -4
Sections 7.1.2, [IP_ADDRESS], [IP_ADDRESS], 7.1.6, 
[IP_ADDRESS]
For non-commercial use only
Shire CONFIDENTIAL Page 85
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319454] 
a lack of urinalysis will not constitute a protocol deviation for any 
pediatric subjects (not only for subjects w earing diapers).Table 1 -2, Table 1 -3, Table 1 -4
Section [IP_ADDRESS]
Clarification has been made that the first no -teduglutide treatment visit 
after the screening visit will occur within 2 to 12 w eeks of the screening 
(formerly within 12 w eeks of s creening). Synopsis
Table [ADDRESS_393685] been clarified for visits during the no -teduglutide and 
teduglutide treatment periods.Table 1 -3, Table 1 -4
Section 7.1.3
‘Specific’ has been deleted from ‘positive/specific anti -teduglutide 
antibodies’ to eliminate the redundancy. By [CONTACT_108], positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative. Table 1 -3 
Sections [IP_ADDRESS], 9.8.1
For consistency within the protocol, sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol. Table 1 -2, Table 1 -3, Table 1 -4
Sections 3.1.3, 7.1.3, [IP_ADDRESS]
Removal of former footnote j on fecal occult blood t est for clarity. Table 1 -4
Clarification has been made on circumstances when the CxW28 visit 
may be combined with the next pretreatment or EOS/ET visit.  Table 1 -4
Section 7.1.5
The text on PS support requirements over time in pediatric subjects 
with SBS has been clarified, and text on intestinal adaptation has been 
refined.Section 1.1
Status of current teduglutide approvals for use has been updated. Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced w ith ‘additional teduglutide 
treatment’ and ‘PN/IV’ with ‘PS’ for clarity and consistency w ith other 
studies.Synopsis
Sections 3.1, 3.1.[ADDRESS_393686] been clarified.Sections 4.8.1, 4.8.2
Withdraw al by [CONTACT_7078]/guardian has been added as reason for 
discontinuation.Section 4.8.[ADDRESS_393687] if deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study 
drug has been clarified.Section 6.4
Paragraph on the purpose of prospective data collection has been 
deleted for clarity.Section 7.2.2
Clarification has been made on the collection of medical history and 
SBS history.Synopsis
Sections 3.1.3, 7.1.2, [IP_ADDRESS]
For non-commercial use only
Shire CONFIDENTIAL Page 86
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_64737]
A new section which describes the adverse event (AE) collection during 
the prospective period has been added to the study evaluations and 
procedures. Section [IP_ADDRESS]
Clarification has been made that local laboratory results are not 
requir ed to be entered in the eCRFs. (formerly Section [IP_ADDRESS])Section [IP_ADDRESS]
Collection of urine sodium and urine osmolality has been removed. Section [IP_ADDRESS]
Clarification has been made that the serum sample will not be collected 
at the pretreatment visit if the subject met a follow -up period escape 
criterion. (formerly Section [IP_ADDRESS])Section [IP_ADDRESS]
Nutritional support and diaries (formerly in Section [IP_ADDRESS]) have been 
moved under separate sections (Sections [IP_ADDRESS] and [IP_ADDRESS], 
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that 
only available diary data will be review ed at each clinic and telephone 
visit.Sections [IP_ADDRESS] ,[IP_ADDRESS] 
Performance of dipsti ck specific gravity tests by [CONTACT_319455]. It is now at the discretion of the investigator for all subjects, 
not just those in diapers. This change is to align with standar d medical 
practice.Section [IP_ADDRESS]
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety sections of the protocol. Only 
nonserious AEs related (instead of possibly related ) to teduglutide need 
to be reported. No changes to the protocol w ere made for the reporting 
of all AEs of special interest or any serious adverse events, regardless 
of relationship to teduglutide, that occurred during the retrospective 
period.Section 8.[ADDRESS_393688] been made to the language on dose 
interruption.Sections 8.4, 8.4.1
Unscheduled safety follow  up assessments (including visits conducted 
after EOS) are not to be recorded. How ever, clarification has been made 
that they are to be collected where requested.Section 9.1
Clarification has been made that the interim analysis will be conducted 
onall retrospective data, and other interim analyses may also be 
conducted if needed.Section 9.4
The protocol now  refers to the data monitoring committee (DMC) 
Charter for the schedule of DMC reviews.Section 9.[ADDRESS_393689] been made to the g uidelines for nutritional 
support management during the study.Appendix 2
For non-commercial use only
Shire CONFIDENTIAL Page 87
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
APPENDIX 2 GUIDELINES FOR NUTRI TIONAL SUPPORT MANAG EMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical evaluations
Serum electrol ytes
Blood urea nitrogen /creatinine levels
Changes in stool frequency  or volume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL /kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte changes or imbalance
Skin breakdown 
Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects sh ould remain compliant with the nutritional support prescription in 
volume and calories during the stud y.
Nutritional support constituents may  be adjusted at the discretion of the investigator.
During the [ADDRESS_393690]’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.
If there is a change in enteral nutrition (EN) or other food or fluid intake, the investigator 
should consider this when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 88
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 89
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Figure A -2 Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 90
Protocol Am endment 1.1
SHP633 -303 09 Jan 2017
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
PROTOCOL: SHP633 -303
TITLE: A Retrospective and Prospective, Open -label, Long -term Safet y and 
Efficacy  Study  of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED- C13-003
DRUG: Teduglutide
IND: IND# [ADDRESS_393691] NO.: 2016-000863-17
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_393692] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Amendment 2: 17Mar 2017
Amendment 1.1: 09Jan 2017 ([LOCATION_008] -Specific)
Amendment 1: 22 Nov 2016
Original Protocol: [ADDRESS_393693] party without the express written consent of Shire.
For non-commercial use only
PAGE 
Sponsor's (Shire) Approval - _ _J 
Andrew Grim 1 
I r 1 
II 
L evelopment 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-303. 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-Cl3-[ADDRESS_393694] fully discussed the objective(s) of this study and the contents ofthis protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) Shire CONFIDENTIAL Page 2
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
PROTOCOL  SIGNA TURE P AGE
For non-commercial use only

Shire CONFIDENTIAL Page 3
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2 Amendment Date
17Mar 2017Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319456] . Emergency Contact [CONTACT_7171] ; 
Section 8.1.6 ; Section 8.2.2 ; Section 
8.2.4
Revised teduglutide treatment inclusion criterion #[ADDRESS_393695] been enough to assess efficacy are eligible to receive
treatment in Study SHP633 -303.Study Synopsis ; Section 4.4
Revised t eduglutide treatment exclusion c riteri on#[ADDRESS_393696] of experimental drugs exempt of a washout period 
before initiating teduglutide treatment in Study SHP633 -303. Study Synopsis ; Section 4.5; Section 
5.1.[ADDRESS_393697] pretreatment visit (P1) follows the screening visit , it must 
occur within 12 w eeks of screening .Table 1-4
To qualify the lang uage on abstinence as a contraceptive method in the 
study protocol as requested by [CONTACT_319443] ([LOCATION_006]) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.Section 4.7.1
Clarification that ancillary components, in addition to s terile w ater for 
injection syringes ,will also be provided and labeled in accordance w ith 
the applicable regulatory requirements.Section 6.3.1
A footnote was added in Table 7 -3 to clarify that subjects older than 
18years of a gewill continue to use t he Child Self Report and Parent 
Prox y-Report for Teens (ages 13 -18) when completing the Pediatric 
Quality o f Life Generic Core Scale (PEDSQL™) .Section [IP_ADDRESS] (Table 7-3)
Revised the text on severity categorization to specify th at a severe 
treatment -emergent adverse event ( TEAE )that might lead to dose 
interruption (Section 8.4.1 ) or early te rmination of the study 
(Section 8.5) will also be graded according to the National Cancer 
Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) severity grading criteria, in addition to the standard severity 
categorization .These events are no longer limited to only the events 
descr ibed in Table 8 -1, entitled “CTCAE Criteria for Adverse Events 
that May Lead to Dose Interruption (Prospective Period of Observation 
Only). Therefore ,Table 8 -1 has been deleted.Section 8.1.1 ; Section 8.4; Section 
8.4.1 ;Table 8 -1 (deleted)
Revised the criteria forearly termination of the study as requested by 
[CONTACT_319457] 06 Jan 2017: stoppi[INVESTIGATOR_3418] w ere 
extended to all NCI CTCAE Grade [ADDRESS_393698], and nolonger limited to the 
events described in Table 8 -1, entitled “CTCAE Criteria for Adverse 
Events that May Lead to Dose Interruption (Prospective Period of Section 8.5
For non-commercial use only
Shire CONFIDENTIAL Page 4
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2 Amendment Date
17Mar 2017Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319458]).
See Appendix [ADDRESS_393699] INFORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required b y Protocol within 24 hours to the Shire Glo bal Drug Safet y Department. Applicable 
fax numbers and e -mail address can be found on the form (sent under separate cover). A copy  of 
this form must also be sent to the Shire Medical Monitor by  [CONTACT_3719] e -mail using the details 
below.
, MD PhD
Email: 
Fax: 
For protocol -or safety- related issues ,the investigator must contact [CONTACT_319459] :
Primary contact [CONTACT_319460]
, MD, 
Mobile: 
US Toll Free number: 
Phone:  (medical emergencies –US)
Email: 
Primary contact [CONTACT_319461] b ackup contact [CONTACT_319462]
, MD, 
Mobile: 
Phone: 
Phone:  (medical emergencies –[LOCATION_006])
Email: 
In addition, the investigator may also contact [CONTACT_317344]:
, MD Ph D, 
Phone: 
Mobile: 
Email: 
- mer al use only

Shire CONFIDENTIAL Page [ADDRESS_393700] 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire ([LOCATION_003]) 
For non-commercial u  only

Shire CONFIDENTIAL Page [ADDRESS_393701] Background ................................
.................................................................27
1.3 Clinical Studies with Teduglutide in Pediatric Subjects ..........................................28
2STUDY OBJECTIVES AND PURPOSE ..............................................................................29
2.1 Rationale for the Study .............................................................................................29
2.2 Study  Objectives ......................................................................................................29
2.2.1 Primary  Objectives .........................................................................................29
2.2.2 Secondary  Objectives .....................................................................................29
3STUDY DESIGN ...................................................................................................................30
3.1 Study  Design and Flow Chart ..................................................................................30
3.1.1 Informed Consent/Assent and Eligibility .......................................................31
3.1.2 Retrospective Data Collection ........................................................................31
3.1.3 Prospective Data Collection and Treatment ...................................................32
3.2 Duration and Study  Completion Definition .............................................................34
4STUDY POPUL ATION.........................................................................................................35
4.1 Study  Inclusion Eligibility  Criteria ................................ ................................ .......... 35
4.2 Study  Exclusion Eligibility  Criteria .........................................................................35
4.3 Teduglutide Eligibility  Criteria ................................................................................35
4.4 Teduglutide Treatment Inclusion Criteria ................................................................35
4.5 Teduglutide Treatment Exclusion Criteria...............................................................36
4.6 Follow -up Period Escape Criteria ............................................................................37
4.7 Reproductive Potential ................................ ................................ ............................. 37
4.7.1 Female Contraception ................................ ................................ ..................... 37
For non-commercial use only
Shire CONFIDENTIAL Page 8
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
4.8 Discontinuation of Subjects .....................................................................................38
4.8.1 Teduglutide Discontinuation ..........................................................................38
4.8.2 Study  Withdrawal ...........................................................................................38
4.8.3 Reasons for Discontinuation ...........................................................................39
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................[ADDRESS_393702](s) ...........................................................[ADDRESS_393703] Compliance ..................................................................................................45
7
STUDY PROCEDURES........................................................................................................46
7.1 Study  Schedule .........................................................................................................46
7.1.1 Retrospective Data Collection
........................................................................46
7.1.2 Screening ........................................................................................................47
7.1.3 Visits for Subjects Not Receiving Teduglutide ................................ .............. 48
7.1.4 Visits for Subjects Receiving Teduglutide Treatment....................................48
[IP_ADDRESS] Pretreatment Visit ...................................................................................48
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24) .....................................49
7.1.5 Teduglutide Follow -up Period ........................................................................51
7.1.6 Study  Completion/Earl y Termination Visit (EOS/ET Visit) ..........................51
7.2 Study  Evaluations and Procedures
...........................................................................52
7.2.1
Retrospective Data Collection ................................ ................................ ........ 52
[IP_ADDRESS] Growth (Height, Weight, and Head Circumference) ............................. 52
For non-commercial use only
Shire CONFIDENTIAL Page 9
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed ................................................52
[IP_ADDRESS] Parenteral Support Prescribed ................................................................53
[IP_ADDRESS] Adverse Events .......................................................................................53
7.2.2 Prospective Data Collection ...........................................................................53
[IP_ADDRESS] Demographics, Medical History , and SBS History ................................53
[IP_ADDRESS] Physical Examination ................................
.............................................53
[IP_ADDRESS] Adverse Event Collection.......................................................................53
[IP_ADDRESS] Vital Signs, Bod y Weight, Height, Head Circumference and Bod y 
Mass I ndex (BMI) ................................
..................................................53
[IP_ADDRESS] Clinical L aboratory  Tests .......................................................................54
[IP_ADDRESS] Serum Sampling .....................................................................................56
[IP_ADDRESS] Pregnancy  Testing ..................................................................................56
[IP_ADDRESS] Antibody  Testing ................................
....................................................56
[IP_ADDRESS] Volume of Blood ....................................................................................56
[IP_ADDRESS] Gastrointestinal -specific Testing ............................................................57
[IP_ADDRESS] Nutritional Support .................................................................................58
[IP_ADDRESS] Diaries ....................................................................................................58
[IP_ADDRESS] Health- related Quality  of L ife Assessments ...........................................59
8ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................62
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................62
8.1.1 Severity  Categorization ..................................................................................63
8.1.2 Relationship Categorization ............................................................................63
8.1.3 Outcome Categorization .................................................................................64
8.1.4 Symptoms of the Disease under Study ...........................................................64
8.1.5 Clinical L aboratory  and Other Safet y Evaluations (Prospective Period 
of Observation Only )
......................................................................................64
8.1.6 Pregnancy .......................................................................................................65
8.1.7 Abuse, Misuse, Overdose, and Medication Error (Prospective Peri
od of 
Observation Onl y)..........................................................................................[ADDRESS_393704] ...........................................................................69
8.4 Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only ).........................................................................................................................[ADDRESS_393705] (Prospective Period of 
Observation Onl y)................................
..........................................................70
8.4.2 Dose Interruption Criteria Based on Drug -Induced L iver Injury  
(Prospective Period of Observation Onl y)......................................................70
8.5 Early Termination of the Clinical Study  (Prospective Period of Observation 
Only )................................
.........................................................................................71
9DATA MANAGEMENT AND STATISTICAL METHODS...............................................72
9.1 Data Collection .........................................................................................................72
9.2 Clinical Data Management .......................................................................................72
9.3 Statistical Analysis Process ......................................................................................72
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................72
9.5 Sample Size Calculation and Power Considerations
................................................73
9.6 Study  Population ......................................................................................................73
9.7 Efficacy  Anal yses.....................................................................................................73
9.7.1 Efficacy  Endpoints ................................
..........................................................73
9.8 Safety  Anal yses........................................................................................................73
9.8.1 Safety  Endpoints .............................................................................................74
9.9 Other Anal yses.........................................................................................................75
9.9.1 Health- related Quality  of L ife Anal yses.........................................................75
10SPONSOR’S AND I NVEST IGATOR’S RESPONSIBILIT IES...........................................76
10.1 Sponsor’s Responsibilities .......................................................................................76
10.1.1 Good Clinical Practice Compliance ................................................................76
10.1.2 Indemnity /Liability  and Insurance ..................................................................76
10.1.3 Public Posting of Study  Information ..............................................................76
10.1.4 Submission of Summary  of Clinical Study  Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees ................77
10.1.5 Study  Suspension, Termination, and Completion ..........................................77
10.2
Investigator’s Responsibilities ................................ ................................ ................. 77
10.2.1 Good Clinical Practice Compliance ................................................................77
10.2.2 Protocol Adherence and Investigator Agreement ...........................................78
10.2.3 Documentation and Retention of Records ......................................................78
[IP_ADDRESS] Case Report Forms .................................................................................78
For non-commercial use only
Shire CONFIDENTIAL Page 11
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................78
[IP_ADDRESS] Audit/I nspection .....................................................................................79
[IP_ADDRESS] Financial Disclosure ...............................................................................[ADDRESS_393706] or Ethics Committee ...........................................80
10.4 Privacy  and Confidentiality ......................................................................................81
10.5 Study  Results / Publication Policy ...........................................................................[ADDRESS_393707]  OF TABLES
Table 1-1 Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................[ADDRESS_393708] 
Annually ........................................................................................................57
Table 7
-3 Developmentally Appropriate PedsQL™Generic Core Scales .....................[ADDRESS_393709] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study report
CTCAE Common Terminology Criteria for Adverse Events
DILI drug-induced livery injury
DMC data monitoring committee
DPP-[ADDRESS_393710]
IV intravenous
IWRS interactive web -based response system
MedDRA Medical Dictionary for Regulatory Activities
NCI National Cancer Institute
NDA new drug application
For non-commercial use only
Shire CONFIDENTIAL Page 14
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
NTT no-teduglutide treatment
PDA patent ductus arteriosus
PedsQL Pediatric Quality of Life Inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once daily
SAE serious adverse event
SAP statistical analysis plan
SBS short bow el syndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_393711] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization -Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page 15
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
STUDY  SYNOPSIS
Protocol num ber: SHP633 -303 Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open -label, Long -term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bow el Syndrome Who Completed TED -C13-003
Number of subjects (total and for each treatm ent arm):
Approximately [ADDRESS_393712] of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED -C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the [LOCATION_002] (US) and the [LOCATION_008] ([LOCATION_006]) w ill participate in 
this extension study.
Study period (planned):
October 2016 -September 2019Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith short 
bowel syndrome (SBS) who completed TED -C13-003.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects wi th SBS who completed 
TED -C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open -label, long -term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED -C13-[ADDRESS_393713] of care (SOC) treatment arm in 
TED -C13-003.
Investigational product, dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once da ily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subj ects who completed the TED -C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of 
specific safety and efficacy measures that were completed in the course of the subject’s standard medical care 
betw een the date of the TED -C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) is signed for this study. In addition to this retrospective data collection, prospective 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review  and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; h owever subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393714]’s standard medical care betw een the date of the TED -C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retros pective data collection may begin any time after 
informed consent/assent is obtained for this study. The following retrospective data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Grow th (height, head circumference [ up to 36 months of age], w eight)
End dates for adverse events (AEs) ongoing at the time of TED -C13-003
All nonserious AEs related to teduglutide treatment
All adverse events of special interest ( AESIs)
All serious adverse events (SAEs)
Prospective Data Collection andTreatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1 -2.These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. The parenteral support prescription willalso be collected at screening. 
Additionally, intake diaries will be dispensed at the screening visit for collection of actual parenteral support (PS) 
volume and hours per day (Section [IP_ADDRESS]) . Diary data for PS volume will be collected for at least 2 w eeks after 
the ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no -teduglutide treatment [NTT] period), w ill be seen 
approximately every 12 weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for 
PS volume will be collected for at least [ADDRESS_393715] NTT visit after the screening visit 
will occur within 2 to 12 w eeks of the screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥[ADDRESS_393716], and parent or lega l guardian agrees to proceed with teduglutide therapy .
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28 -week cycle, cons isting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up (no treatment) period (Figure 3 -1). During 
the 28 -week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and w eekly during the follow -up period (betw een Weeks 24 and 28).
At all site visits and telephone contacts, safety will be monitored an d nutritional support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 w eeks. To m aintain 
consistency across centers, all attempts should be made to follow  the nutritional support adjustment guideline s 
(developed w ith SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not conside red a protocol deviation (Appendix 2).
For non-commercial use only
Shire CONFIDENTIAL Page 17
SHP633 -303 Protocol Amendment 2
Teduglutide 17 Mar 2017
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approximately 
1week after adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects 
discontinue teduglutide at Week 24 and enter a 4 -week follow-up (no -treatment) period, during which phone visits will be 
performed weekly ( solid grey lines ). If an escape criterion is met during the follow -up period, subjects may proceed directly 
to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligibl e for the study if they meet allof the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study -related procedures.
2.Subject completed the TED -C13-003 study (including subjects in the standard of care treatment arm).
3.Subject understands and is willing and able to fully adhere to study requirements a s defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_393717] (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria :
1.Subject is receiving PS and unable to significantly reduce PS or advance enteral feeds (eg, 10% or less 
change in PS or advance in feeds) for at least 3 months prior to and during the teduglutide pretreatment 
visit, as assessed by [CONTACT_093]. Transient instability for e vents such as interruption of central access 
or treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the event.
2.Subject w as previously treated w ith teduglutide and at least 1 of the following criteria is satisfied:
a.Increasin g PS requirements follow ing teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319444]-commercial use only
Shire CONFIDENTIAL Page 18
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
improvement after teduglutide discontinuation
c.Deteriorating nutritional status (eg, w eight loss or growth failure) despi[INVESTIGATOR_319360]
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361]
e.Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <10 kg at the pretreatment visit
2.Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.History of cancer in t he previous 5 years except surgically curative skin cancers
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestin al resections 
≤10cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle
6.Clinically significant intestinal stricture or obstruction
7.Clinically significant, active or recurrent pan creatic or biliary disease
8.Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_319406] (eGFR) below 
50mL/min/1.[ADDRESS_393718] repair, or patent ductus arteriosus (PDA) ligation
11.Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, Smoflipid , 
or teduglut ide) within 3 months or 5.5 half -lives of the experimental drug, whichever is longer, prior to 
the pretreatment visit and for the duration of the 28 -week cycle
12.Treatment with analogs of glucagon -like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP -2) (not
including teduglutide), insulin -like growth factor -1 (IGF -1), or grow th hormone, within 3 months 
preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_393719], closely -related 
compounds, or any of the stated ingredients
15.Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16.Pregnant or lactating female subjects
17.Sexually active female subjects of child -bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents completion of the study, or interferes with analysis of the study results
For non-commercial use only
Shire CONFIDENTIAL Page 19
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Follow -up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interr upted 
and the subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
2.Deteriorating nutritional status (eg, w eight loss or growth failure) despi[INVESTIGATOR_319388]
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319364]
4.Severe diarrhea related to teduglutide disc ontinuation
Maximum duration of subject involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple [ADDRESS_393720] has access (as needed) to teduglutide. The subject’s maximum duration of participation is expect ed to be 
approximately [ADDRESS_393721] has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) visit.
Planned duration of no -teduglutide treatm ent perio ds:variable, depending on disease course
Planned duration of the teduglutide pretreatm ent visit: 1-21 days
Planned teduglutide treatment cycle duration :28 w eeks. Each cycle consists of 24 w eeks of 
teduglutide treatment followed by a 4 -week follow -up peri od (no treatment)
Endpoints and statistical analysis:
The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED -C13-003) and/or first exposure to 
teduglutide. The following efficacy endpoints will be analyzed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research Endpoints
Health economics and outcomes research endpoints will be analyzed at approximately 12- week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 w eeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period. The beginning of each treatment cycle (CxD1) w ill be an 
additional baseline.
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores:
oFood and drink limits
oDiarrhea
Safety Endpoints
The follow ing safety endpoints will be analyzed from the beginning of the prospective study period:
Adverse events
Vital signs, including body temperature, heart rate, and blood pressure
For non-commercial use only
Shire CONFIDENTIAL Page 20
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy
The follow ing safety endpoints will be analyzed from the end of the core study (TED -C13-003) to the beginning of 
the prospect ive study period:
 Adverse events related to teduglutide
 All SAEs
 All Adverse Events of Special Interest (Section 8.3)
The follow ing safety endpoints will be analyzed relative to the baseline of the core study (TED -C13-003):
 Z-scores for height (or length), weight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; how ever, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include nu mber of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by [CONTACT_765]. Adverse events 
will also be collected and summarized. Descriptive statistics wil l be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_300192].
Sample Size Justification
As this is an extension study, the maximum n umber of subjects was determined by [CONTACT_319435] -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 21
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
STUDY  SCHEDULES
Table 1-1 Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment Note
Informed consent/assent Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study -related 
procedures, including retrospective data collection.Study eligibility
WeightaThelast representative value for w eight during each [ADDRESS_393722] all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator -initiated trials, 
compassionate use, and named -patient access programs.
Parenteral support (PS) 
prescribedaThe last representative PS prescription during each 12 -week interval throughout 
the retrospective period and at the beginning and end of any tedugl utide 
treatment will be collected. Data collected should include weekly prescribed 
volume, calories, average hours per day, and days per w eek of prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED -C13-[ADDRESS_393723]
Serious adverse events (SAEs)
Note: Retrospective data are defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED -C13 -003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent) is signed for this study. Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospective data
collection, only assessments in this table will be completed. See Section 7.1.1 for further details on collection of retrospective 
data.
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
a  The first 12 -week interval begins at TED -C13 -003 EOS vis it.
For non-commercial use only
Shire CONFIDENTIAL Page 22
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Table 1-2 Schedule of Events for Screening and End of Study or Early Termination
ScreeningEnd of Study or Early 
Termination
Visit Type Site Site
Informed consent/assent X
Study eligibility X
Dem ographics, medical history, SBS historyaX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriabX
Adverse events X X
Concomitant medications and GI procedurescX X
Physical examination and vital signs, including weight X X
Height and head circumferencedX X
Revie w intake and output diarieseX
Record PS prescription and adjust as neededfX X
Safety laboratory testsgX
PedsQL Generic Core Scale/ PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-ScalesX
Antibodies to teduglutidehX
Fecal occult blood testingi(X)
Colonoscopy or sigmoidoscopyj(X)
Pregnancy testingk(X)
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
EOS =end of study; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child -bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
aIf the subject has any changes to the medical history and SBS history that had been collected at the baseline of the TED -C13 -
003 study, then the updated medical history and SBS history will be collected.
bSubjects who meet ≥[ADDRESS_393724], 
and parent or legal guardian agrees to proceed with teduglutide therapy ( Table 1-4).
cConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies, and 
associated pathology results.
dHead circumference willbe measured in subjects 36 months of age and younger.
eThe intake diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary shoul d be 
completed daily over a 48 -hour period of nutritional stability before the EOS/ET visit.
fParenteral support prescription will be collected at the screening visit. Parenteral support adjustments should be made after
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix [ADDRESS_393725] of clinical chemistry, hematology, and urinalysis, with results pro cessed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis wil l not 
constitute a protocol deviation.
h Required for all teduglutide -exposed subjects.
i Fecal occult blood testing should be performed on teduglutide-exposed subjects on an annual basis, approximately every 48 -
60weeks at a minimum.
j The need for colonoscopy/sigmoidoscopy in response to a positive FOBT result during a no -teduglutide treatment period is at 
the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonos copy/sigmoidoscopy at 5 year intervals or more often as needed. See Section [IP_ADDRESS] for details.
kPregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 23
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Table 1-3 Schedule of Events for No Teduglutide Treatment Period
Visit Number NTx
Visit Type Site
Visit FrequencyaEvery 12 weeks
Window (days)b±[ADDRESS_393726] as neededgX
Safety laboratory testshX
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutidei(X)
Fecal occult blood testingjAnnually
Colonoscopy or sigmoidoscopyk(X)
Serum samplelEvery 24 w eeks
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
aThe first NTx visit after the screening visit must occur within [ADDRESS_393727] NTx visit in the current no -teduglutide treatment period.
c Subjects who meet ≥[ADDRESS_393728], 
and parent or legal guardian agree to proceed with teduglutide therapy ( Table 1-4).
dConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver bio psies, and 
associated pathology results.
eHead circumference will be measured in subjects [ADDRESS_393729] actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool output should be recorded in the output diary over a 48 -hour period of nutritional stability before every clinic 
visit. See Section [IP_ADDRESS] for more detail.
gParenteral support adjustments should be made after review of the intake and output d iaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix [ADDRESS_393730] follow -up samples collected 
every 12 weeks during the study until a negative result is obtained.
j Fecal occult blood testing should be performed on teduglutide -exposed subjects on an annual basis, approximately every 
48-60weeks at a minimum.
k The need for colonoscopy /sigmoidoscopy in response to a positive fecal occult blood test during a no -teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy /sigmoidoscopy after 
they have r eceived the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive 
teduglutide will undergo colonoscopy /sigmoidoscopy at 5-year intervals or more often as needed. See Section [IP_ADDRESS] for 
details.
l Lack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393731] is required approximately 1 week after PS adjustmentCxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  (days)d-21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteriaX Xe
Dispense intake 
and output diariesX X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant 
medications and 
GI
proceduresfX X X X X X X X X X X X X
Physical 
examination and 
vital signs, 
including weightX X X X X X X X X X X X
Height and head 
circumferenceg X X X X
Review intake 
and output 
diarieshX X X X X X X X X X X X X
Record PS Rx 
and adjust as 
needediX X X X X X X X X X X X X
Safety laboratory 
testsj XjX X X X X X X X X X (X) X
PedsQL Generic 
Core Scale/ 
Family Impact 
Module/ GI 
Symptoms X X X
For non-commercial use only
Shire CONFIDENTIAL Page 25
SHP633 -303Protoco l Am endment 2
Teduglutide 17 Mar 2017
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Module Sub -
Scales
Antibodies to 
teduglutidek X X X X
Fecal occult 
blood testingX X X
Colonoscopy /
Sigmoidoscopyl (X) (X) (X)
Pregnancy 
testingm X X X X X X X X X
Serum samplenX X
Evaluate escape 
criteriao X X
Dispense study 
drugp X X X X X X X X X
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
eCRFs=electronic case report forms; EOS=end of study; EOT=end of treatment; ET = early termination; FOBT=fecal occult blood t est; FOCBP=females of child -bearing 
potential; FU=follow -up; GI=gastrointestinal; PedsQL=Ped iatric Quality of Life Inventory; PS=parenteral support; PT/INR= prothrombin time/international normalized ratio; 
SBS=short bowel syndrome; SC=subcutaneous; Scr=screening; TED=teduglutide; Tx=treatment
aIf the first pretreatment visit (P1) follows the screening visit, it must occur within 12 weeks of screening .
b Phone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are t he same as those described for CxW25 -27 (except 
for evaluation of esca pe criteria).
cThe investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur 
within [ADDRESS_393732] is completing th e study at the CxW28 visit, the EOS/ET visit ( Table 1-2) will take place in lieu of the CxW28 visit.
dVisit windows are relative to the CxD1 visit.
eEligibility will need to be reconfirmed prior to the first dose in the cycle. Negative urine pregnancy te st is required prior to the first dose of teduglutide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
fConcomitant GI procedures include (but are not limited to) endoscopy, radiographi c studies, GI and liver biopsies, and associated pathology results.
gHead circumference will be measured in subjects [ADDRESS_393733] actual PS volume and hours per day. Intake diaries should be completed daily f or a minimum of 2 weeks immediately prior to each clinic visit (except 
at pretreatment visit), for 1 week following PS adjustment, and daily during the 4-week follow -up period. Urine and stool output should be recorded in the output diary over a 48 -
hour pe riod of nutritional stability before every clinic visit, and within 1 week of implementing a change in the PS prescription. S ee Section [IP_ADDRESS] for more detail.
iParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment 
provided in Appendix [ADDRESS_393734] PT/INR at the pretreatment 
visit. Additional collection will occur if a potential drug -induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393735] administration of teduglutide. Samples collected while subjects are receiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
lThe teduglutide -naïve subjects age 12 and older will undergo colonoscopy /sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a 
colonoscopy /sigmoid oscopy prior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) ar e obtained at the end of a 
teduglutide treatment cycle (CxW24/EOT), colonoscopy /sigmoidoscopy will be performed. The need fo r colonoscopy /sigmoidoscopy in response to positive FOBT results at 
CxW12 is at the discretion of the investigator. Teduglutide -exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will 
undergo colonosco py/sigmoidoscopy. See Section [IP_ADDRESS] for details.
mA serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be adminis tered at all other visits according to the study 
schedules, or if pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the study.
nLack of collection of serum samples will not constitute a protocol deviation.
oIf escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investigator.
pThe first SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observ ed 
for hypersensitivity reaction s for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. Se e 
Section 6.2.3 for dose adjustment.
For non-commercial use only
Shire CONFIDENTIAL Page 27
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
1 BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 y ear and older with SBS ( Khan et al., 
2015; Wales et al., 2004 ). Unlike the adult population, the majority  of cases of SBS in pedia tric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on p arenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 y ears of the initial diagnosis ( Khan et al., 2015).
Nevertheless, despi[INVESTIGATOR_3062], many  pediatric subjects remain dependent 
on PS. Complications of long -term PS include liver disease, catheter -related blood stream 
infec tions, central line -associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality  of life is poor ( Squires et al., 
2012). Accelerating the adaptive process and achieving enteral autonomy  is an urgent goal for all 
patients with SBS who are dependent on PS ( Khan et al., 2015; Squires et al., 2012 ).
Intestinal adaptation is driven by  [CONTACT_319436] (Drucker 
and Yusta, 2014 )
.Chief among these is hormones glucagon -like pepti de 2 (GL P-2), which is 
secreted from L- type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Resection of these regions may  impair the adaptive response by  [CONTACT_319410] -2.
1.[ADDRESS_393736] Background
Teduglutide is a novel, recombinant analog of naturally occurring human GLP -2 that regulates 
the functional and structural integrity  of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33 -amino acid peptide that differs from native GLP- 2 inthe substitution of 
glycine for alanine at the second position at the N -
terminus. As a result, teduglutide demonstrates 
resistance to degradation by  [CONTACT_20597] l peptidase 4 (DPP -4) and therefore maintains a longer 
elimination half -life (t 1/2) in adults of approximately  2 hours compared to the native peptide, 
which has a t 1/2 of approximately  7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and cry pt depth in the intestinal 
epi[INVESTIGATOR_2130], there by [CONTACT_319463] ( Tappenden et al., 
2013; Thymann et al., 2014). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide ( REVESTIVE™) on [ADDRESS_393737] 2012 and a New Drug Application (NDA) for teduglutide (G ATTEX®) was approved by  
[CONTACT_24623] (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide has also been 
For non-commercial use only
Shire CONFIDENTIAL Page 28
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
approved for use in adult patients with SBS in Canada and Switzerland. On 29 Jun 2016, the 
European Commission granted an extension of the Market Authorization for teduglutide 
(REVESTIVE ™) for the treatment of patients aged 1 y ear and above with SBS; patients should be 
stable following a period of intestinal adaptation.
1.3 Clinical Studies with Teduglutide in Pediatric S ubjects
One Phase 3 stud y, TED -C13-003, was completed in pediatric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1 -17. Thirty -seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for [ADDRESS_393738] of care (SOC) cohort. There were clear dose- dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 0.0125 
mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at Week 12
of 37%, including complete independence from PS support in [ADDRESS_393739], and a reduction of 
3.94 hours per day  infusion time. I n the 0.05 mg/kg/day  cohort there was a reduction in PS 
volume at Week 12 of 39%, including complete independence from PS support i n 3 subjects, and 
a reduction of 4.18 hours per day  infusion time. Teduglutide was generall y safe and well 
tolerated b y pediatric subjects in all dosing cohorts. There were no deaths during the stud y and 
no treatment -emergent serious adverse events (TESAEs ) related to teduglutide were reported. No 
discontinuations from study  were due to adverse events (AEs).
TED -C14-006 is an ongoing study  which includes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arm s participate in a 2-week minimum 
screening period, a [ADDRESS_393740] medical therap y for SBS; while 
those in the teduglutide treatment arm will receive daily  subcutaneous (SC) injections of 
teduglutide (stud y drug) in addition to standard medical therap y. The subjects enrolling in the 
teduglutide tre atment arm will be randomized 1:1 in a double -blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day  of teduglutide administered subcutaneousl y for 
24weeks.
Alway s refer to the latest version of the investigator’s brochure for the o verall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393741] -time treatment of 
teduglutide -naïve subjects who participated in the SOC treatment arm in TED -C13-003.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED -C13-003.
2.2.2 Secondary Objectives
The secondary  objective of this study  is to evaluate the long -term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 30
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
3 STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safet y and 
efficacy  of teduglutide in pediatric subjects who completed the TED -C13-003 study  (the core 
study ). At the time of entry  into the TED- C13-[ADDRESS_393742] 30% of their caloric or fluid needs, and 
had not been able to significantly  reduce PS for at least 3 months prior to enrollment. During the 
core stud y, pediatric subjects in the teduglutide treatment arm were entered into a 
0.0125 mg/kg/ day, 0.025 mg/kg/day , or 0.05 mg/kg/day  dose cohort based on the timing of their 
enrollment in the study . The cohorts were filled in a sequential manner.
Approximately  [ADDRESS_393743] meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen approximately  every  12 weeks for safety , parenteral support (PS) requirements, and 
quality  of life. At any  point during an NTT period, subjects who meet ≥[ADDRESS_393744], and 
parent or legal guardian agrees to proceed with teduglutide therap y.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatment in this extension 
study and thus long -term follow -up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of tedug lutide treatment. In these pediatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analy sis suggested that pediatric patients, ages 1 -17 years-old, are likel y to require the same 
dose as used in adults, namely  0.05 mg/kg/day  (Mouksassi e t al., 2009). In this extension study  
to TED -C13-003, repeat doses of teduglutide 0.05 mg/kg/day  will be administered to eligible 
pediatric subjects.
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0
.05 mg/kg SC once daily. The completed 12 -week pediatric study (TED- C13-
003) demonstrated that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day was 
associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
For non-commercial use only
Shire CONFIDENTIAL Page 31
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
studies as well as the pediatric (core) study (TED -C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults ( O'Keefe et al., 2006 ).
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED -C14-[ADDRESS_393745] may  be evaluated immediately  for 
additional teduglutide treatment. Subjects who clinically d eteriorate or stop improving at an y 
time after the end of the follow- up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED- C13-[ADDRESS_393746]’s standard medical care between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form (I CF) (and if 
applicable, informed assent) is signed for this study . In addition to this retrospective data 
collection, p rospective study  assessments of safety  and efficacy  will be completed as a part of 
this study .
3.1.1 Informed Consent/Assent and Eligibility
The review and signing of the I CF (and if applicable, informed assent) for this study , must be 
completed before an y other study  procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study ; however subjects may  
consent to retrospective data collection onl y. Subjects may not consent to the prospective data 
collec tion only . After informed consent/assent is obtained, study  eligibility  will be assessed for 
all subjects.
3.1.[ADDRESS_393747]’s standard medical care be tween the date of the 
For non-commercial use only
Shire CONFIDENTIAL Page 32
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
TED -C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study . Retrospective data collection may  begin any  time after informed consent/assent is 
obtained for this study . The following data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Growth (height, head circumference [up to 36 months of age], weight)
End dates for adverse events (AEs) ongoing at the time of TED- C13-003
All nonserious AEs related to ted uglutide
All adverse events of special interest (AESIs)
All serious adverse events (SAEs )
3.1.3 Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history  and short bowel sy ndrome history . 
The parenteral support prescription will 
also be collected at screening. Additionally , intake diaries will be dispen sed at the screening visit 
for collection of actual PS volume and hours per day  (Section [IP_ADDRESS]). Diary  data for PS 
volume will be collected for at least 2 weeks after the I CF (and if applicable, the informed 
assent) is signed for this study .
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen approximately  
every  [ADDRESS_393748] NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At any  point after screening, including 
during an NTT period, subjects who meet ≥[ADDRESS_393749], and parent or legal 
guardian agrees to proceed with teduglutide therapy .
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28- week cy cle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily , followed by  a 
4-week follow -up (no treatment) period ( Figure 3 -1
). During the 28- week cy cle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately  
1
week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 
24), and weekl y during the follow -up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safet y will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality  of life assessments will be made approximately  every  
12 weeks. To maintain consistency across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
For non-commercial use only
Shire CONFIDENTIAL Page 33
SHP633 -303 Protocol Amendment 2
Teduglutide 17 Mar 2017
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weight 
gain, urine and stool output, and clinical stability. Dep arture from the guidelines, however, is not 
considered a protocol deviation ( Appendix 2 ).
Rationale: Measures of long -term safety  will include adverse events, growth parameters, and 
anti-drug antibodies. Measure of long term efficacy  will include durabilit y of effect as measured 
by [CONTACT_319411] (Pediatric Quality  of 
Life Inventory  [PedsQL ], PedsQL  Famil y Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary  endpoint in pi[INVESTIGATOR_9205] 3 adult clinical 
trials and the completed Phase 3 pediatric stud y (TED -C13-003), and will be used as an endpoint 
in this extension study . In previous clinical studies, a reduction of this magnitude was associated 
with a r eduction in the number of day s per week of PS, and increases in enteral intake. Reduction 
in volume and time of PS due to improved enteral absorption may provide a pediatric subject 
with opportunities for more age -appropriate activities including oral reha bilitation. Quality  of life 
assessments will be performed in this study to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient population and the pharmacologic effect of teduglutide , GI-specific screening tests, 
including fecal occult blood testing and colonoscopy /sigmoidoscopy , which are commonl y part 
of the routine care of these subjects, will be performed to ensure safet y. This study  captures long -
term safet y data on polyps and ot her colonic mucosal changes in teduglutide -exposed subjects 
using the surveillance strategy  proposed in Section [IP_ADDRESS] .
Figure 3-1Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approximately 1 week after 
adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide 
at Week 24 and enter a 4 -week follow -up (no-treatment) period, during which phone visits will be performed weekly ( solid grey 
lines ). If an escape criterion is met during the follow -up period, subjects may proceed directly to another pretreatment visit.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393750] has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study  Inclusion Eligibility  
Criteria. The stud y will continue for at least [ADDRESS_393751] has access (as needed) 
to teduglutide. The subject’s maximum duration of participation is expected to be appro ximately  
[ADDRESS_393752] 
(last safet y contact), whichever is later. The stud y completion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393753] and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before an y stud y-related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_393754] will not be considered eligible for the study  without meeting all of the criteria below:
1.Subject provides wri tten informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completing any  
study -related procedures. 
2. Subject completed the TED- C13-003 study  (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully  adhere to study  requirements as 
defined in this protocol.
4.2 Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study .
4.3 Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_393755] (and/or parent or legal guardian, as appropri ate) must agree to proceed with 
treatment.
4.[ADDRESS_393756] is receiving PS and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and
during the teduglutide pretreatment visit, as assessed by  [CONTACT_093]. Transient 
instability  for events such as interruption of central access or treatment for sepsis is 
allowed if the PS returns to within 10% of baseline prior to the event.
2. Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.Increasing PS requirements following teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, followed by  
[CONTACT_319412]
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319366]
d.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319378]-commercial use only
Shire CONFIDENTIAL Page 36
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
e.Severe diarrhea related to teduglutide discontinuation
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_393757]
3.History  of cancer in the previous 5 y ears except surgically  curative skin cancers
4.Serial transverse enteroplasty  or other major intestinal surgery  within 3 months 
preceding the teduglutid e pretreatment visit. I nsertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week 
cycle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairment or injury , 
including the following laboratory  values at the pre treatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dy sfunction shown by  [CONTACT_319406] (eGFR) 
below 50 mL /min/1.[ADDRESS_393758] repair, or 
patent ductus arteriosus (PDA) ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine, 
Omegaven, S moflipid , or teduglutide ) within 3 months or 5.5 half -lives of the 
experimental drug, whichever is longer, prior to the pretreatment visit and for the 
duration of the 28- week cy cle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon -like peptide -2 
(GLP-2) (not including teduglutide), insulin -like growth factor
-1 (IGF -1), or growth 
hormone, within 3 months preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_393759], 
closely -related compounds, or any  of the stated ingr edients
15.Known history  of alcohol or other substance abuse within 1 y ear prior to the 
pretreatment visit
For non-commercial use only
Shire CONFIDENTIAL Page 37
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
16. Pregnant or lactating female subjects 
17.Sexually  active female subjects of child -bearing potential unwilling to use approved 
contraception during teduglu tide treatment and for 30 day s after the treatment period 
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the study, or interferes with 
analysis of the study  results
4.[ADDRESS_393760] may  
proceed directl y to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319369]
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319389] l fluid and 
electrol yte intake following teduglutide discontinuation
4. Severe diarrhea related to teduglutide discontinuation
4.[ADDRESS_393761]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:
Premenarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta-human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pretreatment visit .Females of 
child- bearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable methods of contraception .
Acceptable methods of contraception are:
For non-commercial use only
Shire CONFIDENTIAL Page 38
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
True abstinence: Abstention of sexual activity  that is in line with the preferred and usual 
lifesty le of the subject. (Periodic abstinence [eg, calendar, ovulation, sy mptothermal, 
post-ovulation methods] and withd rawal are not acceptable methods of contraception). 
Intrauterine devices plus condoms
Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized fo r at 
least 30 day s prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually  active during the study , they  should use [ADDRESS_393762] wishes to remain in the study , the evaluations listed for the EOT visit are to be 
performed. A 4- week follow -up period will ensue, consisting of weekl y telephone visits 
(CxW25 -27) and the week 28 clinic visit (CxW28). The subject would then enter an NTT period 
and could be evaluated for subsequent teduglutide treatment eligibi lity according to the study  
schedules. 
Comments (spontaneous or elicited) or complaints made b y the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case report form (eCRF) and source documents, as 
described in Section 4.8.[ADDRESS_393763] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_319445] -up.
If a subject withdraws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completel y as possible. 
Subjects who withdraw from the study will not be replaced.
For non-commercial use only
Shire CONFIDENTIAL Page 39
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than [ADDRESS_393764] clinically  relevant reason should be e ntered in the eCRF.
Reasons for discontinuation include, but are not limited to:
Adverse event
Protocol deviation
Lack of efficacy
Physician decision
Withdrawal by  [CONTACT_1130]
Withdrawal by  [CONTACT_7078]/guardian
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y)
Death
Other
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_393765] (office visit or telephone contact). At least [ADDRESS_393766]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluatio ns, and return an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page 40
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
5 CONCOMITANT TREATMENT
5.1 Concomitant Medications and GI Procedures
Concomitant treatment will be collected for the prospective period onl y and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this 
study . Concomitant treatment information must be recorded on the appropriate eCRF page. 
Concomitant treatments will be assessed at each site visit, and include all nonstudy  treatments 
(medications, herbal tre atments, vitamins, invasive and diagnostic procedures). Concomitant GI 
procedures include (but are not limited to) endoscopy , radiographic studies, GI and liver biopsies 
and associated pathology results. Concomitant treatment information must be recorded o n the 
appropriate eCRF page. Details of medication changes and/or dosages will be recorded on the 
eCRF.
The mechanism of action of teduglutide may  increase absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, and digoxin). Accordingl y, due consideration should be given to 
modify ing concomitant medication regimens. Down -titration of concomitant medications should 
be considered when drugs, especiall y those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.[ADDRESS_393767] medical therapy for SBS should be continued.
5.1.2 Prohibited Treatment
At the time of screening, any teduglutide treatment being received through any  mec hanism other 
than participation in this study  (eg,by [CONTACT_78150]-label prescription, participation in an investigator -
initiated trial, com passionate access program, etc) must be discontinued. I n such cases, there is 
no minimum duration of interruption of teduglutide treatment before pretreatment evaluations 
can be performed.
The mechanism of action of teduglutide may  increase enteral absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102] , metronidazole, digoxin), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
For non-commercial use only
Shire CONFIDENTIAL Page 41
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Table 5-1 Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- 1 analog or human growth hormone 3 months
Octreotide or dipeptidyl peptidase 4 inhibitors 3 months
Biological therapy (eg, antitumor necrosis factor) [ADDRESS_393768] is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for inje ction (Section 6.3.2). In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L -histidine, mannitol, monobasic sodium 
phosphate monohy drate, and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is 
provided in th e current SHP633 investigator’s brochure.
6.1.[ADDRESS_393769](s)
6.2.[ADDRESS_393770] Management
An interactive web-based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory  management and supply  ordering, investigational product expi[INVESTIGATOR_49093], and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS.
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.[ADDRESS_393771], and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclus ion criteria will 
be performed at the pretreatment visit ( Table 1-4
).
6.2.[ADDRESS_393772] will start a teduglutide treatment period, consis ting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body  weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body  weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered b y SC injection once dail y (QD) into 
1 of the 4 quadrants of the ab domen (in subjects without a stoma) or into either the thigh or arm. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393773] 
4 hours during their initial dosing visit. The site of ad ministration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
Following eac h 24- week teduglutide treatment period, subjects will enter a [ADDRESS_393774] may  proceed 
directly  to another Pretreatment visit to assess treatment eligibility  for another cy cle 
(Section 4.6). Following the completion of the 4- week follow -up, the subject will continue in the 
study  off teduglutide. Additional [ADDRESS_393775](s) container.
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing 7 vials of study  drug will be supplied and these will be labeled in 
accordance wi th applicable regulatory  requirements. Sterile water for injection sy ringes and 
other ancillary  components will also be provided separately  and will be labeled in accordance 
with the applicable regulatory  requirements.
All study  drug used in this study  will be manufactured, tested, labeled, and released according to 
current legal requirements and Good Manufacturing Practice.
6.3.2 Packaging
Teduglutide will be provided in a 3 mL  sterile, single -use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL ) will be provided in a prefilled s yringe.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393776] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refrigerated at a temperature between 2 -8°C (35.6 -46.4°F) until dispensed to 
a subject. Once dispensed to a subject, the study  drug can be stored refrigerated or up to a 
controlled room temperature (a cceptable range of 2-25°C, or 35.6- 77°F). Parent/legal guardian 
will be instructed to keep the subject’s study  drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, t he 
study  drug may  be refrigerated. The study  drug is for single use onl y, and should be used within 
[ADDRESS_393777] is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records a re maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  [CONTACT_10179], such that both minimum and maximum thermometric values over a specifi c time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established ran ge. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstanc es should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharmacy or nominated member of the stud y 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
6.[ADDRESS_393778] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no cas e will 
clinical supplies be used in any  unauthorized situation.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_10180] y 
delegation of authorit y form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study  protocol. All dispensed 
study  medication will be documented in the interactive response technology  system and/or other 
investigational product record (eg, investigation product accountability  form). The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may  
dispense the unused study  drug vials to the same subject. All original containers, wh ether empty  
or containing stud y drug will be returned to the pharmacy. Returned stud y drugs will NOT be 
relabeled or reassigned for use b y other subjects. Contents of the study drug containers will not 
be combined. All used and unused vials must be returne d to the distribution center according to 
the sponsor’s instruction. No vial/kit may  be destroy ed on site without approval by  [CONTACT_456].
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_393779] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -eviden t sealed container (eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability  form.
Of those subjects eligible for teduglutide treatment, subj ects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 46
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
7 STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures and assessments to be performed for subjects throughout the study  are 
outlin ed in the Schedule of Assessments ( Table 1 -1, Table 1-2, Table 1 -3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing an y study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject ( Table 1-1
).
7.1.1 Retrospective Data Collection
Retrospective data are defined as specific safet y and efficacy  assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form (I CF) (and if 
applicable, informed assent) is signed for this study . Retrospective PS and growth data will be 
captured in [ADDRESS_393780] retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent onl y to retrospective data collection, only 
assessments in Table 1-1 will be completed. The following data will be collected for the 
retrospective portion of the study :
Informed consent, and informed assent (if applicable)
Study  eligibility  is determined
A screen failure is a subject who has given informed consent and failed to meet 
the study  inclusion eligibility  criteria. Subject s cannot be rescreened once they  
have been designated as a screen failure.
Prior teduglutide use (as prescribed)
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency . Prescription 
data includes teduglutide treatment in investigator- initiated trials, compassionate 
use, and named -patient access programs.
Collect start and end dates when a subject’s teduglutide use was interrupted. 
Parenteral support (as prescr ibed)
The last representative PS prescription during each 12- week interval throughout 
the retrospective period and at the beginning and end of any  teduglutide treatment 
will be collected. Usuall y, the prescription at the end of the interval will represent 
For non-commercial use only
Shire CONFIDENTIAL Page 47
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
the status of intestinal adaptation. However, transient alterations in PS related to 
loss of central venous access or acute illness are not representative of intestinal 
adaptation. When such events occur at the end of a 12 -week interval, earlier, more 
representative PS prescription data should be recorded.
Data collected should include weekl y prescribed volume, calories, average hours 
per day , and day s per week of prescribed PS. Hours per day  should be averaged 
over the day s where PS is prescribed. 
Growth (height, head circumference, and weight)
The last representative value for height, during each 12 -week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and y ounger at the time the data 
were collected, if available.
The investigator should use his/her clinical judgment to select values that reflect 
the true growth trajectory.
Adverse events
All nonserious AEs related to teduglutide treatment, as well as all adve rse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study . The details of data collection and safety  reporting for these ev ents 
can be found in Section 8.
End dates for AEs ongoing at the end of TED -C13-003 will be collected.
7.1.2 Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1
-2, 
and as detailed below:
Informed consent, and informed assent (if applicable)
Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the study  inclusion eligibility  criteria. Subjects cannot be 
rescreened once they  have been designated as a scre en failure.
Demographics, updates to medical history  and SBS history
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomitant medications and concomitant GI  procedures
Physical examination and vi tal signs, including weight
Height and head circumference
For non-commercial use only
Shire CONFIDENTIAL Page 48
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Record PS prescription and adjust as needed
The first visit after screening must occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
7.1.3 Visits for Subjects Not Receiving Teduglutide
While outside of the 28- week teduglutide -treatment cy cle, subjects will be followed 
approximately  every  12weeks for safety  and efficacy  assessments. No -teduglutide treatment 
visits are numbered sequentially  (NT1, NT2, etc.), even if interrupted by  [CONTACT_319415]. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outlined in Table 1 -3and described below.
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomitant medications, and concomitant GI  procedures
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
Record PS  prescription and adjust as needed
Safety  laboratory  tests (ie, clinical chemistry , hematology , and urinaly sis)
PedsQL  Generic Core Scale/PedsQ L Family  Impact 
Module/PedsQL Gastrointestinal Symptoms Module Sub -Scales
Antibodies to teduglutide, if and wh en required
Fecal occult blood testing, as indicated (see Section [IP_ADDRESS])
Colonoscopy /sigmoidoscopy , as indicated (see Section [IP_ADDRESS])
Serum sample, as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investig ator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may  proceed to the pretreatment visit immediately  to determine 
eligibility . 
7.1.4 Visits for Subjects Receiving Teduglut ide Treatment
[IP_ADDRESS] Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may  proceed to the pretreatment visit immediately . Similarly , 
subjects who meet escape criteri a during the teduglutide follow -up period may  proceed to the 
pretreatment visit immediately . 
For non-commercial use only
Shire CONFIDENTIAL Page 49
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
In general, pretreatment assessments may  occur over a period of up to 21 day s. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performe d as in Table 1-4 and as 
described below:
Evaluate teduglutide eligibility  (treatment inclusion/exclusion criteria)
Dispense intake and output diaries
Adverse events, concomitant medications, and concomitant GI  procedures
Fecal occult blood testing
Gastroi ntestinal- specific testing, including colonoscopy  or sigmoidoscopy  as indicated
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries 
Record PS prescription and adjust as needed.
Safety  laboratory tests
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit include 
prothrombin time [PT] international normalized ratio [I NR]. Subsequent prothrombin 
time/international normalized ratio (PT/I NR) measurement is only  required to evaluate 
for suspected drug -induced liver injury  [DILI]).
Pregnancy  testing (serum)
Serum sample
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open- label teduglutide treatment period will comprise [ADDRESS_393781] administration (Visit CxD1).
VISIT CXD1
Assessments and procedures at this visit will be performed as outlined Table 1 -4and as 
described below:
Two weeks of intake diary data are required before drug is administered a t CxD1.
Confirm teduglutide treatment eligibility
Dispense intake and output diaries
Adverse events, concomitant medications, and concomitant GI  procedures
Physical examination and vital signs, including weight
For non-commercial use only
Shire CONFIDENTIAL Page 50
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed
Safety  laboratory  tests
Quality  of life measurements
Antibodies to teduglutide
Pregnancy  testing (urine)
Dispense study  drug
SITE V ISITS DURING TEDUGLUTIDE TREATMENT PERIOD
Subjects will return for clinic visits on cy cle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:
Dispense and review intake and output diaries (every  effort should be made to complete 2 
weeks of intake diary  entries prior to each clinic visit and to complete 48 hours of output 
diary  entries during a period of nutritional stability  prior to each clinic visit)
Physical examination and vital signs, including weight
Record PS prescription and adjust as needed
Safety  laboratory  tests
Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)
Study  drug dispensation (except for CxW24)
Adverse events, concomitant medications and concomitant GI  procedures
In addi tion, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
Height and head circumference
Antibodies to teduglutide
Fecal occult blood testing (FOBT)
GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated
Quality  of life measurements
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 51
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
PHONE VISITS
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1 -4and described 
below:
Review intake and output diaries
Safety  laboratory  tests (clinical chemistry  and urinaly sis)
Record PS prescription and adjust as needed
Obtain AEs, concomitant medications, and concomitant GI procedures
Evaluate escape criteria
7.1.5 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks (Weeks 25 -28 of the cy cle). Phone visits 
will occur on cy cle Weeks 25, 26, and [ADDRESS_393782] may  
proceed directl y to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is 
met at the CxW28 visit, and the pretreatment assessments occur within [ADDRESS_393783] is completing the stud y at the CxW28 visit, the EOS/ET visit (Section 7.1.6) 
will take place in lieu of the CxW28 visit. Otherwise, following completion of the [ADDRESS_393784] will proceed to an NTT visit within approximately  12 weeks.
At Cy cle Week 28 (CxW28), subjects will return to the study  site. In addition to the assessments 
performed at Weeks 25 -27, the following procedures will be performed at CxW28 only :
Dispense and review intake and output diaries
Physical examination and vital signs, including weight
Antibodies to teduglutide
Pregnancy  testing (urine)
Evaluate escape criteria
7.1.6 Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-
2and as 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393785] discontinues the study prematurel y, the assessments for the EOS/ET 
visit are to be performed as completel y as possible (see Section 4.8.2).
Adverse events, concomitant medications, and concomitant GI  procedures
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries (the intake diary should be completed daily  for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary  should be completed 
daily  over a 48- hour period of nutritional stability  before the EOS/ET visit)
Record PS prescription and adjust as needed
Safety  laboratory  tests
Fecal occult blood testing, as indicated
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy , as indicated
Quality  of life measurements
Antibodies to teduglutide
Pregnancy  testing, as needed
7.[ADDRESS_393786]'s completion of the TED -C13-003 study  and the 
date the ICF (and if applicable, assent) is signed for the SHP633 -303 study.
[IP_ADDRESS] Growth (Height, Weight, and Head Circumference)
Retrospective bod y height (or lengt h [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z -score, weight z -score, bod y mass index (BMI), and BM I z-score will be calculated b y 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the statistical analy sis plan (SAP) .
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed
Any retrospective teduglutide prescription start and stop date s, dose, route, and frequency  will be 
recorded on the appropriate eCRF page.
For non-commercial use only
Shire CONFIDENTIAL Page 53
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
[IP_ADDRESS] Parenteral Support Prescribed
Retrospective parenteral support entries consist of [ADDRESS_393787] 
representative prescription from the interval should be used (see Section 7.1.1 ). In addition, PS 
prescriptions at the beginning and end of an y retrospective teduglutide treatment must be 
recorded. The PS pr escription includes weekl y volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
[IP_ADDRESS] Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESI s) and all serious adverse events (SAEs), regardless of causal attribution to teduglutide, 
that occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE col lection and 
safet y reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED
-C13-003 will be collected.
7.2.2 Prospective Data Collection
[IP_ADDRESS] Demographics, Medical History, and SBS History
Demographics, updates to medical history , and updates to SBS history  will be obtained at 
screening. Medical history  for purposes of this extension study  will consist of updates to the 
medical history  collected at the start of the TED- C13-[ADDRESS_393788] has an y 
changes to the SBS history  since the baseline visit of the TED -C13-003 study , that information 
(updated SBS history ) will also be collected.
[IP_ADDRESS] Physical Examination
Physical examinations will be performed according to the study  schedules. Any  new clinicall y 
significant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF.
[IP_ADDRESS] Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had an y health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (see Section 8, Adverse 
and Serious Adverse Events Assessment.)
[IP_ADDRESS] Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study  schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body  temperature 
For non-commercial use only
Shire CONFIDENTIAL Page 54
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
(°C/°F). Blood pressure should be determined b y cuff (using th e same method, the same arm, 
and in the same position throughout the stud y).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit.
New clinicall y significant vital sign abnorm alities should be recorded on the appropriate AE 
page of the eCRF.
[IP_ADDRESS] Clinical Laboratory Tests
Safety  laboratory  tests to be performed at site visits consist of clinical chemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1 -2, Table 1-3, and 
Table 1-
4). Scheduled laboratory  testing will be processed b y a central lab. All laboratory  assay s 
will be performed according to the central laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_319464]. The investigator should assess out-of- range clinical laboratory  
values for clinical significance, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical condition, may , at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_393789] of clinical chemistry  and urinal ysis and may  be processed by  [CONTACT_319438] a local laboratory . Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate an y new clinicall y significant changes, they must be reported as an 
adverse event (see Section 8.1). Urine specimen collection should be attempted as part of the 
safet y labs, but lack of urinaly sis will not constitute a protocol deviation.
New clinicall y significant labs should be reported as AEs.
The following clinical laboratory assessments will be performed according to the study  
schedules:
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393790] of Laboratory Tests 
Hematology :
Hematocrit
Hemoglobin
Platelet count
Red blood cell count
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio
Urinalysis :
Blood
Glucose
Leukocytes
Microscopic analysis
pH
Protein
Specific gravity
Pregnancy tests (females of childbearing potential):
Serum β -HCG (screening)
Urine β -HCG (all other visits)Biochemistry :
Albumin
Alkaline phosphatase
Alanine aminotransferase
Amy lase
Aspartate aminotransferase
Bicarbonate
Bilirubin (total and indirect)
Blood urea nitrogen
Calcium (total)
Chloride
Cholesterol
C-reactive protein
Creatinine
Estimated Glomerular Filtration Rate 
(Schwartz formula )
Gamma -glutamyl transferase
Glucose
Lipase
Magnesium
Phosphorus
Potassium
Sodium
Triglycerides
Uric acid
For non-commercial use only
Shire CONFIDENTIAL Page 56
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
[IP_ADDRESS] Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times:
At the pretreatment visit. If the subject met a follow -up period escape criterion, the serum 
sample will not be collected at the pretreatment visit
At the CxW24 (EOT) visit
During NTT: Approximately  every  24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sample and/or extracted material will otherwise be stored 
for up to [ADDRESS_393791] their 
sample and/or extracted material destro yed. An y results alread y generated from the samples will 
not b e removed from an y anal yses that have already  been performed.
[IP_ADDRESS] Pregnancy Testing
A serum pregnancy  test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy  tests will be administered at all other visits according to the study  schedules, or if 
pregnancy  is suspected, or as specified per protocol upon withdrawal of the subject from the 
study .
[IP_ADDRESS] Antibody Testing
Blood samples will be drawn for the anal ysis of antibodies to teduglutide according to the 
Schedule of Assessments ( Table 1-2, Table 1 -3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least [ADDRESS_393792] follow- up blood draws for antibodies to teduglutide every  12 weeks while 
on study  until a negative result is obtained.
[IP_ADDRESS] Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study . The volumes of blood to be drawn from each subject will vary  depending on 
clinical status. Approximate volumes of blood to be drawn from each sub ject annuall y are shown 
in Table 7-
2.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393793] Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Parameters 1 2 2
Antibodies 2 8 16
Serum storage samples 3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volum e): 138
Subjects Not Receiving Teduglutide Treatmentb
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samples 3 2 6
Total mL per 4 “No Teduglutide Treatment” Visits 48 -week period: 24
β-hCG=beta -human chorionic gonadotropin; NTT= no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bSubjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti -teduglutide 
antibodies will require blood samples for antibody testing every [ADDRESS_393794] negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/p eriod, if they  require the same t ype of tube, the assessments should be combined. Blood 
volume estimates do not include safet y labs performed after PS adjustment, and anti -teduglutide 
antibody  testing during no- teduglutide treatment.
[IP_ADDRESS] Gastrointestinal- speci fic Testing
FECAL OCCULT BLOOD TESTING
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week [ADDRESS_393795] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past and 
are therefore not teduglutide -naïve) on a roughl y annual basis (approximately every 48 -60 
weeks). Actions to be taken in response to a positive FOBT are described below.
COLONOSCOPY OR SIGMOI DOSCOPY
Teduglutide -naïve subjects age 12 and older will undergo colonoscopy  or sigmoidoscopy  at the 
pretreatment visit if one has not been performed within 1 y ear.
For non-commercial use only
Shire CONFIDENTIAL Page 58
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Subjects of an y age with newly positive FOBT results at the pretreatment visit for which a 
readil y detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscop y or 
sigmoidoscop y prior to receiving teduglutide. If newly positive FOBT results (for which a 
readil y detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy  or sigmoidoscopy  will be performed. The need for 
colonoscop y or sigmoidoscopy in response to positive FOBTs at an y other point during the 
study , or to reevaluate persistently  positive FOBTs is at th e discretion of the investigator.
Teduglutide -exposed subjects who have received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will undergo colonoscopy  or sigmoidoscopy . While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy  or sigmoidoscopy at 5 y ear intervals or 
more often as needed.
Upper endoscop y ma y be performed along with any colonoscop y or sigmoidoscopy at the 
investigator’s discretion. If a pol yp is found, adherence to current pol yp follow -up guidelines is 
recommended. Subjects with unresected GI pol yps, poly posis conditions, premalignant change 
or malignancy  in the GI tract will be excluded from teduglutide treatment.
[IP_ADDRESS] Nutritional Support
Nutritional support includes PS, enteral nutrition, and ot her food and fluids. Advances in enteral 
nutrition and/or reductions to PS will be based on clinical status, including weight, linear growth, 
hydration status, and safety  laboratory  results. Intake and output diaries will include data to be 
considered in t he adjustment of each subject’s nutritional support. Guidelines for nutritional 
support management and weaning algorithms are provided in Appendix 2 .
[IP_ADDRESS] Diaries
STUDY DRUG ADMINISTRA TION DIARY
A study  drug administration diary  will record administration of te duglutide. This diary  should be 
completed b y the subject (or parent/legally authorized representative, as applicable) dail y during 
the teduglutide treatment period (between visits CxD1 and CxW24).
INTAKE DIARY
Intake diaries will be used to collect and eva
luate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary  
2 weeks prior to ALL scheduled prospective site visits (except at pretreatment visit). During the 
24-week tedug lutide treatment period, the intake diary  will also be completed for 1 week 
following PS adjustments. The intake diary  will also be completed dail y during the 4 -week 
follow -up period. The following data will be captured in the intake diaries:
Parenteral su pport volume and infusion duration
Site personnel will determine the actual PS daily  calories based on diary  entries
For non-commercial use only
Shire CONFIDENTIAL Page 59
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
OUTPUT DIARY
Urine and stool output should be recorded in the output diary  over a 48- hour period of nutritional 
stability  before every  clinic visit; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cy cle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
Toilet -trained subjects (who do not wear diapers)
Measure and record all urine output in mL  or cc 
Nontoilet- trained subjects (who wear diapers)
Measure and record the weight of all urine -only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL or 1 cc
At the discretion of the investigator, the parent or legal guardian may  be asked to collect 
the first void after the daily  PS infusion to measure specific gravit y
Stool data (includes diapers with mixed urine and stool):
Toilet -trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency  using the 
Bristol Stool Form Scale (see Output diary )
Nontoilet- trained subjects (who wear diapers)
Record the weight of diapers containing stool (includ ing diapers with mixed urine and 
stool) as stool output and score the stool consistency  using the Bristol Stool Form Scale 
(see Output diary ). Stool volume will be calculated using the formula: 1 g (scale 
weight)=1 mLor 1 cc
All ostomy  output volume shoul d be recorded. Ostomy  output will not be scored using the 
Bristol scale.
All available diary  data will be reviewed by  [CONTACT_319465].
[IP_ADDRESS] Health -related Quality of Life Assessments
Throughout the stud y, health -related quality  of life assessments will be performed using the 
PedsQL  Generic Core Scales. Each PedsQL age- appropriate form takes less than [ADDRESS_393796] month, and parent- report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
PEDIATRIC QUALITY OF LIFE GENERIC CORE SCALE (PEDSQL™), ACUTE VERSION
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed b y either the parent or legal guardian and subject 
as indicated in Table 7 -3at the time points as outlined in Table 1-2, Table 1 -3,and Table 1 -4.
Table 7-3 Developmentally Appropriate PedsQL™Gener ic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects 
(ages 8 -12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18)aSubject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
a The Child Self Report and Parent Proxy -Report for Teens (ages 13 -18)will also be completed for subjects older 
than 18 years of age
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5-7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393797] MODULE (PEDSQL™), ACUTE VERSION
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-2, Table [ADDRESS_393798] of pediatric chronic health conditions on parents and the family  (Varni et al., 2004 ).
The 36- item PedsQL Family  Impact Module consists of 6 scales measuring parent self -reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioni ng (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure parent -
reported family  functioning as follows: 1) Dail y Ac
tivities (3 items), and 2) Family  Relationships 
(5 items). The PedsQL Family  Impact Module should take the parent or legal guardian 
approximately  5-
10minutes to complete.
PEDSQL GASTROINTESTINAL SYMPTOMS MODULE (PEDS
QL™), ACUTE VERSION
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58- item module, comprised 
of 10 different s ymptom scales that assess gastrointestinal sy mptom -related quality  of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas a nd 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Sy mptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) w ere identified as 
clinically  relevant and appropriate for the s ymptoms experienced in this pediatric study  
population, and therefore, are the onl y scales used in this study . The scales will be completed by  
[CONTACT_319418] [ADDRESS_393799] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding ), symptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
RETROSPECTIVE PERIOD OF OBSERVATION
For the retrospective data co llection period (the interval between the EOS visit of the core study  
until signing the ICF [and informed assent, if applicable] for SHP633 -303), investigators will be 
asked if they  are aware of any  nonserious AEs related to teduglutide that occurred durin g this 
time and an y AESIs or any SAEs, regardless of relationship to teduglutide, that occurred during 
this time. The following guidance is given for defining a treatment -related event:
The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product.
The event cannot be explained b y the subject’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this stud y 
in the eCRF.
PROSPECTIVE PERIOD OF OBSERVATION
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the de fined follow -up period stated in Section 7.1.5. This includes events 
occurring during the screening phase of the stud y, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of s ymptoms should be 
recorded. If a diagnosis has not been made, then each s ymptom should be listed individually . All 
AEs should be captured on the appropriate AE pages in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investi gational product indication 
should also be captured on the AE eCRF.
All prospective AEs must be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject i s still 
participating in the stud y. Closure indicates that an outcome is reached, stabilization achieved 
For non-commercial use only
Shire CONFIDENTIAL Page 63
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
(the investigator does not expect any  further improvement or worsening of the event), or the 
event is otherwise explained. When appropriate, medical te sts and examinations are performed 
so that resolution of event(s) can be documented.
8.1.[ADDRESS_393800] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of inves tigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Sever e: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
In consideration of whether a treatment -emergent adverse event ( TEAE ) might lead to dose 
interruption (Section 8.4.1) or early  termination of the study  (Section 8.5), severe TEAEs will 
also be graded according to the National Cancer Institute’s (NCI) Common Terminology  Criteria 
for Adverse Events (CTCAE) severit y grading criteria (US Department of Health and Human 
Services et al., 2010 ).
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relatio nship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurre nce 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may  be helpful:
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393801] is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by  [CONTACT_423]’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Not RelatedThe event can be readil y explained by  [CONTACT_11260]’s underl ying medical condition, concomitant therapy , or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged b y the investigator.
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline.
8.1.[ADDRESS_393802] be recorded during the course of the study  in the eCRF. Outcomes 
are as follows:
Fatal
NotRecovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study; however, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.5 Clinical Laboratory and Other Safety Evaluations (Prospective Per iod of 
Observation Only)
A change in the value of a clinical laboratory  or vital sign can represent an AE if the change is 
clinically  relevant or if, during the study , a shift of a parameter is observed from a normal value 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393803] be taken into consideration.
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefore represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported for the retrospective observation period from t he EOS visit of 
the core stud y until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633 -[ADDRESS_393804] be reported within 24 hours to the 
Shire Global Drug Safety Department using the Shire Investigational and Marketed Products 
Pregnancy  Report Form. A copy  of the Shire Investigational and Marketed Products Pregnancy 
Report Form (and an y applicable follow -up reports) must also be sent to the Shire Medical 
Monitor using the details specified in the emergency  contact [CONTACT_319466] t he protocol. 
In the event a subject becomes pregnant after signing the ICF (and, if applicable, assent), 
teduglutide administration must be discontinued immediately .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
cond ition of the infant. For pregnancy  reports during the prospective period of observation, it is 
the responsibility  of the investigator to obtain this information within [ADDRESS_393805] partum. For pregnancies occurring 
during the retrospective period of observation (ie, before signing the informed consent for 
SHP633 -303), the initial notification date will be the date the pregnancy  is recorded for this 
study  and outcome and infant condit ion information may  be collected any time post partum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for Serious Adverse Events (SAEs) and Nonserious AEs as Required b y the Protocol. Note: An 
elective abortion is not considered an SAE.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393806] positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633-303 will not be co llected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they  result in an AE/SAE as described in Section 8.2. Note: The 24 -hour reporting 
requirement for SAEs does not apply  to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse – Persistent or sporadic intentional intake of investigational product when used 
for a nonmedical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may  be detrimental to the individual and/or society
Misuse –Intentional use of investigational product other than as directed or indicated 
at an y dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed b y the protocol)
Overdose –Administration of a dose greater than th e allocated dose of the study  
medication or at a frequency  greater than the dosing interval specified by  [CONTACT_760]
Medication Error –
An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, medica tion errors are reportable to the 
sponsor only  as defined below.
 Cases of subjects missing doses of the investigational product are not 
considered reportable as medication errors
 Medication errors should be collected/reported for all products under 
investi gation
 The administration and/or use of an expi[INVESTIGATOR_319379] a reportable medication error
All investigational product provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y-authorized representative/caregiver.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393807] awareness of the event. N ote: The 24- hour 
reporting requirement for SAEs does not apply  to reports of abuse, misuse, overdose, or 
medication errors (see Section 8.1.7) unless they  result in an SAE.
All adverse events of special interest, as defined in Section 8.3, experienced duri ng the 
prospective period of observation must be reported by  [CONTACT_319467] [ADDRESS_393808] complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Nonserious AEs as Required b y Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (No te: Source documents are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global Drug Safet y
Department. A cop y of the completed Shire Clinical Study Adverse Event Form for Serious 
Adverse Events (SAEs) and Nonserious AEs as Required by  [CONTACT_1738] (and any  applicable 
follow -up reports) must also be sent to the Shire Medical Monitor or designee using the details 
specified in the emergency  contact [CONTACT_1739].
8.2.[ADDRESS_393809] medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 
Results in death
Is life -threatening. Note: The term 'life -threatening' in the definition of "serious" refers to 
an event in which t he subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatient hospi[INVESTIGATOR_1081]. Note: 
Hospi[INVESTIGATOR_48181], which are the result of elective or previousl y scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously  scheduled ventral 
For non-commercial use only
Shire CONFIDENTIAL Page 68
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
hernia r epair would not be classified as an SAE; however, complication(s) resulting from 
a hospi[INVESTIGATOR_230476](s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based upon appropriate medical judgm ent, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
For the retrospective data collection period (the interval between the EOS visit of the core study  
until signing the ICF [and informed assent, if applicable] for SHP633 -303), investigators will be 
asked if they  are aware of any  SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is recorded for this study  in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Drug Safety Department and the Shire Medical Monitor within [ADDRESS_393810] 
awareness of the event, and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to study  drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow -up period stated in Section 7.1.5. These SAEs must be reported to the Shire 
Global Drug Safet yDepartment and the Shire Medical Monitor within [ADDRESS_393811] 
awareness of the event, as per Section 8.2.2. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by  [CONTACT_10194] y interval after the study has completed must be reported to the Shire Global 
Drug Safet yDepartment within [ADDRESS_393812]’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be se lected solel y as a result of the 
subject’s death.
8.2.[ADDRESS_393813], Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notify ing the 
relevant regulatory  authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notify ing active sites of all related, unexpected 
SAEs occurring during all interv entional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
8.[ADDRESS_393814]
An AESI  is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
[CONTACT_230013].
The AEs of special interest that req uire expedited regulatory  reporting include the following:
Growth of pre -existing poly ps of the colon
Benign neoplasia of the GI tract including the hepatobiliary  system
Tumor -promoting ability (eg, benign and/or malignant neoplasia of any  kind, not limite d 
to those of the GI or hepatobiliary  system)
For AESIs experienced during the retrospective or prospective period of observation, the sponsor 
must be informed within [ADDRESS_393815] awareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
For non-commercial use only
Shire CONFIDENTIAL Page 70
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
8.4 Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 8.5apply onl y to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing regimen is in terrupted. Attempts should be made to contact [CONTACT_103]/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059], AEs, a lapse in investigational product delivery , etc.
Study  drug must be di scontinued if any  of the following events occur:
Pregnancy
Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319447]. This does not include the presence of anti- teduglutide antibodies, mild 
injection site reactions or mild sy mptoms that according to the investigator do not pose a 
significant risk to the subject.
An AE that is of NCI CTCAE severit y Grade 3 or 4 and considered to be related to study 
drug administration
Confirmed drug -induced liver injury  (DILI) re lated to teduglutide (see Section 8.4.2)
8.4.[ADDRESS_393816] (Prospective Period of Observation 
Only)
The investigational product must be discontinued if the subject experi enced an AE that is of 
severit y ≥Grade [ADDRESS_393817] . 
In consideration of whether a TEAE might lead to dose interruption, severe TEAEs will also be 
graded according to the NCI CTCAE severit y grading criteria (US Department of Health and 
Human Services et al., 2010 ). All such TEAEs should be discussed with the Shire M edical 
Monitor or designee as soon as possible. The length of the dose interruption, and whether 
teduglutide administration resumes or is permanently  discontinued, depends on the clinical 
situation.
8.4.2 Dose Interruption Criteria Based on Drug -Induced Liver I njury 
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may  need to be interrupted if the subject has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identifie d by [CONTACT_4868]:
ALT or AST >8x ULN
ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
For non-commercial use only
Shire CONFIDENTIAL Page 71
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)
ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory  values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_393818] should be followed closely to determine the trajectory  of the 
labora tory abnormalities and to evaluate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, c ytomegalovirus IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti -smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, ca rdiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investigator in consultation 
with the Shire Medical Monitor.
Teduglutide administration must be permane ntly discontinued if DILI is confirmed and deemed 
related to stud y drug.
8.5 Early Termination of the Clinical Study (Prospective Period of Observation Only)
The DMC may  recommend stoppi[INVESTIGATOR_319390] :
≥2subjects devel op the same event of CTCAE severity  Grade 3that is reported asrelated 
to the investigational product
or
[ADDRESS_393819]
For non-commercial use only
Shire CONFIDENTIAL Page 72
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
9 DATA MANAGEMENT AND STATISTICAL METHO DS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection proc edures will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safet y follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Process
The study  will be anal yzed by  [CONTACT_10196]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4 Planned Interim Analysis, and Data Monitoring Committee
An interim anal ysis of all retrospective data will be conducted. Other interim analy ses may  also 
be conducted if needed.
A DMC will be involved in the management of this study . The DMC members will review the 
data approximately  every 3 months according to the DMC Charter. The DMC revie w will 
include all cumulative safety  data (ie, AEs, laboratory  assessments, phy sical examinations, etc.) 
from study  assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product. 
The DMC for this study  will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393820] may not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hi red by  [CONTACT_456], or members of 
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine wheth er the study  should be modified or temporaril y or 
permanentl y stopped.
9.5 Sample Size Calculation and Power Considerations
As this is an extension study , the maximum number of subjects was determined by  [CONTACT_319407] -C13-003.
9.6 Study Population
The safet y population includes all enrolled subjects in the study . The safet y population will be 
used for both safet y and efficacy anal yses.
9.7 Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summa ries will include 
number of subjects and percentages.
9.7.1 Efficacy Endpoints
Efficacy  endpoints will be anal yzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each stud y visit, relative to the baseline of the core study  (TED -C13-003) and/or 
first exposure to teduglutide. The following efficacy  endpoints will be analy zed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Complete weaning off PS
Change in day s per week of PS
9.8 Safety Analyses
Safety  data, i ncluding laboratory  tests and vital signs assessments, will be summarized by  [CONTACT_765]. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
For non-commercial use only
Shire CONFIDENTIAL Page 74
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
for quantitative safet y data as well as for the difference from baseline, if applicable. Frequency  
counts will be compi[INVESTIGATOR_319374] y data.
9.8.1 Safety Endpoints
The following safet y endpoints will be analy zed from the beginning of the prospective study  
period:
Adverse events
Vital signs, including body  temperature, heart rate, and blood pressure
Laboratory  safet y data (ie, clinical chemistry , hematology , and urinaly sis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing including fetal occult blood testing and colonoscopy  or 
sigmoidoscop y
The following safet y endpoints will be analy zed from the end of the core study  (TED -C13-003) 
to the beginning of the prospective study  period:
Adverse events related to teduglutide
All SAEs
All AESI s (Section 8.3)
The following safet y endpoints will be analy zed relative to the baseline of the core study  
(TED -C13-003):
Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
body  mass index
Adverse events will be coded using the Medical Dictionary  for Reg ulatory  Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by [CONTACT_319425]. Serious adverse events will be further 
summarized by  [CONTACT_230535]. Adverse events related to 
investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly 
summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dictionary  (WHO -DD) with re gard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history  (including 
For non-commercial use only
Shire CONFIDENTIAL Page 75
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with speci fic histories will be summarized by  [CONTACT_6657]. 
For clinical laboratory  tests, vital signs, body  weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the numb er and 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies. 
Additional safet y parameters and measures will include change in bod y weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z -score, BMI, and BMI z -score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change fro m baseline at each 
scheduled visit.
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses
Health economics and outcomes research endpoints will be analy zed at approximately  12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective stud y period. The beginning of 
each treatment cy cle (CxD1) will be an additional baseline.
Change in Pediatric Quality  of Life Inventory  (PedsQL) score
Change in PedsQL Family  Impact Module score
Change in PedsQL Gastrointestinal Sy mptoms Module Sub- Scales scores:
Food and drink limits
Diarrhea
For non-commercial use only
Shire CONFIDENTIAL Page 76
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
10 SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibi lities
10.1.[ADDRESS_393821] been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulatio ns, ICH Good Clinical Practice (GCP) Guideline E6 (1996 ), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managi ng the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation o f receipt of any  regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharm aceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
For non-commercial use only
Shire CONFIDENTIAL Page 77
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
10.1.4 Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clin ical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the stud y, at any time for an y reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as required b y 
Article 10 (c) of Directive 2001/20/EC.
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_393822] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suit able subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator [INVESTIGATOR_319387]. Agreement with the f inal CSR is documented by  [CONTACT_319426] (single -site study ) or coordinating principal investigator (multicenter 
study ), in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 (1995). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393823] met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by [CONTACT_59761].
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_78269], applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The inves tigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report for ms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
Electronic case report forms should be approved by [CONTACT_20616] r per study  specifications and 
data deliverable requirements.
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory , queries are sent for 
corre ctions or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be recorded in the subject’s medical records.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393824] permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authoritie s, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_10203]/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medica l file, 
appointment books, original laboratory reports, X -rays etc.). Nonstudy  site personnel will not 
disclose an y personal information or personal medical information.
These records must be made available within reasonable times for inspection and duplic ation, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
European Medicines Agency  (EMA), [LOCATION_006] Medicines and Healthcare products Regulatory  
Agency ) or an auditor.
Essential documents must be maintained according t o ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  [CONTACT_1779], for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory  authorities), the 
European Medicines Agency  (EMA), the Medicines and Healthcare products Regulatory  
Agency , other regulatory authorities, the sponsor or its representatives, and the I RB/EC for each 
site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_10204] , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in t he form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.[ADDRESS_393825]’s legall y-authorized representative, as 
applicable, is requested to sign and date the subject informed consent form or a certified 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393826] has received and read (or been read) the written subject 
information and received an explanation of what the study  involves, including but not limited to: 
the objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibi lities. A copy  of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully  executed signature [CONTACT_1787]) must be given to the subject or the 
subject’s legall y-authorized representative, as applicable. This docum ent may  require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
Within the source documents, site personnel should document instruction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
The principal investigator [INVESTIGATOR_1682] a cop y of the consent form, an d assent form 
where applicable, which was reviewed b y the IRB/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the sponsor, prior to the start of the study  unless it is agreed to 
and documented (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally , if the I RB/EC re quires modification of the sample subject information and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_393827] or Ethics Committee
For sites outside the EU, it i s the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation .
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating principal investigator [INVESTIGATOR_10157], according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless the re is a 
subject safet y issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For sites outside the EU, the investigator is responsible for keepi [INVESTIGATOR_1683]/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicenter 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393828] also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_393829] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_317364] (or designee).
The confidentialit y of records that may  be able to identify  subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
review their medical records and data collected during the stud y. These records and data may, in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP633; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accu racy of the data (eg, to confirm 
that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recor ded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a public ation steering committee, which is done for 
large, multicenter Phase [ADDRESS_393830] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
For non-commercial use only
Shire CONFIDENTIAL Page 82
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_10206], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have th e right to publish the 
study  results, and any  background information provided by  [CONTACT_10207] y publication of study results, or necessary for other scholars to verify such stud y 
results. Notwithstanding the foregoing, no p ublication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_393831] publication of the study  results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163]. If such a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_10209] 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may  indivi duall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwise required by [CONTACT_319468], or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 83
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
11 R EFERENCES
Drucker, D. J. & Yusta, B. 2014. Phy siology  and pharmacology  of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Phy siol, 76, 561-83.
Khan, F. A., Squires, R. H., L itman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., Sudan, 
D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wal es, P. W. & Duggan, C. 2015. Predictors 
of Enteral Autonom y in Children with I ntestinal Failure: A Multicenter Cohort Study . J Pediatr,
167, 29- 34.e1.
Mouksassi, M. S., Marier, J. F., Cy ran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon -like peptide-2 
analog in neonates and infants with short- bowel s yndrome. Clin Pharmacol Ther, 86, 667-71.
O'Keefe, S. J ., Buchman, A. L ., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel sy ndrome and intestinal failure: consensus definitions and overview. Clin 
Gastroenterol Hepatol, 4,
6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. A., 
Kocoshis, S., Superina, R., L awlor, S., Haller, T., Kurs -Lask y, M. & Belle, S. H. 2012. Natural 
history  of pedia tric intestinal failure: initial report from the Pediatric Intestinal Failure 
Consortium. J Pediatr, 161, 723- 8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients wi th short bowel sy ndrome. J Clin Gastroenterol, 47,
602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon -like peptide 2 analogue, 
teduglutide, on intestinal adaptation in short bowel sy ndrome. J Pediatr Gastroenterol Nutr, 58,
694-702.
US Department of Health and Human Services, National Institutes of Health & National Cancer 
Institute 2010. Common Terminology  Criteria for Adverse Events (CTCAE ).
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL  
Family  Impact Module: preliminary  reliability  and validity . Health Qual Life Outcomes, 2, 55.
Wales, P. W., de Silva, N., Kim, J., L
ecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population- based estimates of incidence and mortality  rates. J Pediatr Surg, 39,
690-5.
For non-commercial use only
Shire CONFIDENTIAL Page 84
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
12 APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 85
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
APPENDIX 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol 11 May 2016 Global
Amendment 1 22 Nov 2016 Global
Amendment 1.1 09 Jan 2017 [LOCATION_006] Specific
Amendment 2 17Mar 2017 Global
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319453].Protocol Signature [CONTACT_319504] [CONTACT_319431] -teduglutide treatment 
period, visits will take place approximately every 12 w eeks.Synopsis
Sections 3.1, 3.1.3 , 7.1.3
Figure 3 -1
The study design flow chart has been edited for clarity. Synopsis
Figure 3 -1
The collection of all actual and prescribed enteral nutrition data has 
been removed to reduce the burden on the subjects and investigators. 
Enteral nutrition data are not required as the efficacy endpoints are 
limited to parenteral support parameters.Syno psis
Table 1 -2, Table 1 -3, Table 1 -4
Sections 3.1.3 , 7.1.2, 7.1.3, [IP_ADDRESS], 
[IP_ADDRESS], 7.1.6, [IP_ADDRESS], [IP_ADDRESS]
Exclusion criterion [ADDRESS_393832] been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to [ADDRESS_393833] been refined.Table 1 -1
Sections 7.1.1, [IP_ADDRESS], [IP_ADDRESS]
For non-commercial use only
Shire CONFIDENTIAL Page 86
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319469]. 
Also, review of diaries has been removed from the screening visit and 
added to the pretreatment visit.Table 1 -2, Table 1 -3, Table 1 -4
Sections 7.1.2, [IP_ADDRESS], [IP_ADDRESS], 7.1.6, 
[IP_ADDRESS]
The requirement for urine specimen collection has been revised so that 
a lack of urinalysis will not constitute a protocol deviation for any 
pediatric subjects (not only for subjects w earing diapers).Table 1 -2, Table 1 -3, Table 1 -4
Section [IP_ADDRESS]
Clarification has been made that the first no -teduglutide treatment visit 
after the screening visit will occur within 2 to 12 w eeks of the screening 
(formerly within 12 w eeks of s creening). Synopsis
Table [ADDRESS_393834] been clarified for visits during the no -teduglutide and 
teduglutide treatment periods.Table 1 -3, Table 1 -4
Section 7.1.3
‘Specific’ has been deleted from ‘positive/specific anti -teduglutide 
antibodies’ to eliminate the redundancy. By [CONTACT_108], positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative. Table 1 -3 
Sections [IP_ADDRESS], 9.8.1
For consistency within the protocol, sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol. Table 1 -2, Table 1 -3, Table 1 -4
Sections 3.1.3, 7.1.3, [IP_ADDRESS]
Removal of former footnote j on fecal occult blood test for clarity. Table 1 -4
Clarification has been made on circumstances when the CxW28 visit 
may be combined with the next pretreatment or EOS/ET visit.  Table 1 -4
Section 7.1.5
The text on PS support requirements over time in pediatric subjects 
with SBS has been clarified, and text on intestinal adaptation has been 
refined.Section 1.1
Status of current teduglutide approvals for use has been updated. Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced w ith ‘additional teduglutide 
treatment’ a nd ‘PN/IV’ with ‘PS’ for clarity and consistency w ith other 
studies.Synopsis
Sections 3.1, 3.1.[ADDRESS_393835] been clarified.Sections 4.8.1, 4.8.2
Withdraw al by [CONTACT_7078]/guardian has been added as reason for 
discontinuation.Section 4.8.[ADDRESS_393836] if deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study 
drug has been clarified.Section 6.4
For non-commercial use only
Shire CONFIDENTIAL Page 87
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319470].Section 7.2.2
Clarification has been made on the collection of medical history and 
SBS history.Synopsis
Sections 3.1.3, 7.1.2, [IP_ADDRESS]
A new section which describes the adverse event (AE) collection during 
the prospective period has been added to the study evaluations and 
procedures. Section [IP_ADDRESS]
Clarification has been made that local laboratory results are not 
requir ed to be entered in the eCRFs. (formerly Section [IP_ADDRESS])Section [IP_ADDRESS]
Collection of urine sodium and urine osmolality has been removed. Section [IP_ADDRESS]
Clarification has been made that the serum sample will not be collected 
at the pretreatment visit if the subject met a follow -up period escape 
criterion. (formerly Section [IP_ADDRESS])Section [IP_ADDRESS]
Nutritional support and diaries (formerly in Section [IP_ADDRESS]) have been 
moved under separate sections (Sections [IP_ADDRESS] and [IP_ADDRESS], 
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that 
only available diary data will be review ed at each clinic and telephone 
visit.Sections [IP_ADDRESS] ,[IP_ADDRESS] 
Performance of dipstick specific gravity tests by [CONTACT_319455]. It is now at the discretion of the investigator for all subjects, 
not just those in diapers. This change is to align with s tandard medical 
practice.Section [IP_ADDRESS]
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety sections of the protocol. Only 
nonserious AEs related (instead of possibly related ) to teduglutide need 
to be reported. No changes to the protocol w ere made for the reporting 
of all AEs of special interest or any serious adverse events, regardless 
of relationship to teduglutide, that occurred during the retrospective 
period.Section 8.[ADDRESS_393837] been made to the language on dose 
interruption.Sections 8.4, 8.4.1
Unscheduled saf ety follow  up assessments (including visits conducted 
after EOS) are not to be recorded. How ever, clarification has been made 
that they are to be collected where requested.Section 9.1
Clarification has been made that the interim analysis will be conducted 
on all retrospective data, and other interim analyses may also be 
conducted if needed.Section 9.4
For non-commercial use only
Shire CONFIDENTIAL Page 88
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319471] (DMC) 
Charter for the schedule of DMC reviews.Section 9.[ADDRESS_393838] been m ade to the guidelines for nutritional 
support management during the study.Appendix 2
Amendment Number 1.1 Amendment Date
09 Jan 2017United -Kingdom -Specific
Description of Change and Rationale Section(s) Affected by [CONTACT_319442] a contraceptive method in the 
study protocol as requested by [CONTACT_319443] ([LOCATION_006]) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.Section 4.7.1
For non-commercial use only
Shire CONFIDENTIAL Page 89
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
APPENDIX 2 GUIDELINES FOR NUTRI TIONAL SUPPORT MA NAGEMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered f or managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical evaluations
Serum electrol ytes
Blood urea nitrogen /creatinine levels
Changes in stool frequency  or volume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte changes or imbalance
Skin breakdown 
Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the stud y.
Nutritional support constituents m ay be adjusted at the discretion of the investigator.
During the [ADDRESS_393839]’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.
If there is a change in enteral nutrition (EN) or other food or fluid intake, the investigator 
should consider this when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 90
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 91
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Figure A -2 Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 92
SHP633 -303 Protocol Am endment 2
Teduglutide 17 Mar 2017
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
PROTOCOL: SHP633 -303
TITLE: A Retrospective and Prospective, Open -label, Long -term Safet y and 
Efficacy  Study  of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED- C13-003
DRUG: Teduglutide
IND: IND# [ADDRESS_393840] NO.: 2016-000863-17
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_393841] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Amendmen
t 3: 16 May 2018
Amendment 2: 17 Mar 2017
Amendment 1.1: 09 Jan 2017 ([LOCATION_008] -Specific)
Amendment 1: 22 Nov 2016
Original Protocol: [ADDRESS_393842] party without the express written consent of Shire.
For non-commercial use only
Shire CONFIDENTIAL Page2 
SHP633-303 Protocol Amendment 3 
Teduglutide 16May2018 
PROTOCOL SIGNATURE [CONTACT_64783]'s (Shire) Approval 
Signature: 
, MD PhD 
 
I Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-303. I Date: ·
1 
I 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-Cl3-[ADDRESS_393843] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however; permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) 
For non-commercial use only

Shire CONFIDENTIAL Page 3
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 3 Amendment Date
16 May 2018Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319472] 
.Emergency Contact [CONTACT_319473], a new escape criterion was added, allow ing 
those who had escaped during the follow -up period of a previous 
teduglutide treatment to omit the follow -up period during subsequent 
teduglutide treatment cycles.
For subjects who previously escaped the follow -up period, CxW24 
assessments can be combined with the next pretreatment visit assessment s.Study Synopsis ; Table 1-4 , Figure 
3
-1; Section 3.1; Section 4.6; 
Section 6.2.3 ; Section  [IP_ADDRESS] ; 
Section [IP_ADDRESS]; Section 7.1.5; 
Section [IP_ADDRESS]
Clarified language that all concomitant procedures are to be captured, not 
just gastrointestinal procedures .Table 1 -2; Table 1 -3; Table 1 -4, 
Section 5.1; Section 7.1.2 ; 
Section 7.1.3 ; Section [IP_ADDRESS] ; 
Section [IP_ADDRESS] ; Section 7.1.6
Updated the information on the clinical studies with teduglutide in pediatric 
subjects to include the r esults of TED -C14-006. Section 1.3
Added new PK simulation data to further support dosing. Section 3.1
Deleted text that was duplicated in other sentences of sections. Section 5.1
Deleted biological therapy (eg, antitumor necrosis factor) from the tab le of 
prohibited treatments as it was included in error.Table 5-[ADDRESS_393844] of laboratory tests. Table 7-1
Clarified that if a child is unable to complete a quality of life questionnaire 
(due to developmental delay or other illness) it will not constitute a 
protocol deviation.Section [IP_ADDRESS]
Minor editorial changes and corrections to typographical errors (w hich do 
not modify content and /or intent of the original document) were made.Throughout protocol
See Appendix [ADDRESS_393845] IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required b y Protocol within 24 hours to the Shire Global Drug Safet y Department. Applicable 
fax numbers and e -mail address can be found on the form (sent under separa te cover). A cop y of 
this form must also be sent to the Shire Medical Monitor by  [CONTACT_3719] e -mail using the details 
below.
, MD PhD
Email: 
Fax: 
For protocol -or safety- related issues, the investigator must cont actQuintiles Medical 
Support:
Primary contact [CONTACT_319460]
, MD, 
Mobile: 
US Toll Free number: 
Phone:  (medical emergenci es –US)
Email: 
Primary contact [CONTACT_319474]
, MD, 
Mobile: 
Phone: 
Phone:  (medical emergencies –EU)
Email: 
In addition, the investigator may also contact [CONTACT_317344]:
, MD PhD, 
Phone: 
Mobile: 3
Email: 
 non mmercial use only

Shire CONFIDENTIAL Page [ADDRESS_393846] 
(marketed or investigational) does not meet expectations (eg, inadequ ate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs rela ted to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E
-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire (U SA)
For non-commercial u  only

Shire CONFIDENTIAL Page [ADDRESS_393847] Background .................................................................................................26
1.3 Clinical Studie s with Teduglutide in Pediatric Subjects ..........................................27
2STUDY OBJECTIVES AND PURPOSE ..............................................................................28
2.1 Rationale for the Study .............................................................................................28
2.2 Study  Objectives ......................................................................................................28
2.2.1 Primary  Objectives .........................................................................................28
2.2.2 Secondary  Objectives .....................................................................................28
3STUDY DESIGN ...................................................................................................................29
3.1 Study  Design and Flow Chart ..................................................................................29
3.1.1 Informed Consent/Assent and Eligibility .......................................................31
3.1.2
Retrospective Data Collection ........................................................................31
3.1.3 Prospective Data Collection and Treatment ...................................................31
3.2 Duration and Study  Completion Definition .............................................................33
4STUDY POPUL ATION.........................................................................................................34
4.1 Study  Inclusion Eligibility  Criteria ................................ ................................ .......... 34
4.2 Study  Exclusion Eligibility  Criteria .........................................................................34
4.3 Teduglutide Eligibility  Criteria ................................................................................34
4.4 Teduglutide Treatment Inclusion Criteria ................................ ................................ 34
4.5 Teduglutide Treatment Exclusion Criteria ...............................................................35
4.6 Follow -up Period Escape Criteria ............................................................................36
4.7 Reproductive Potential .............................................................................................36
4.7.1 Female Contraception ................................ ................................ ..................... 36
4.8 Discontinuation of Subjects ................................ ................................ ..................... 37
For non-commercial use only
Shire CONFIDENTIAL Page 7
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
4.8.1 Teduglutide Discontinuation ..........................................................................37
4.8.2 Study  Withdrawal ...........................................................................................37
4.8.3 Reasons for Discontinuation ...........................................................................38
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................[ADDRESS_393848](s) ...........................................................[ADDRESS_393849] Compliance ..................................................................................................43
7
STUDY PROCEDURES........................................................................................................44
7.1 Study  Schedule .........................................................................................................44
7.1.1
Retrospective Data Collection ........................................................................44
7.1.2 Screening ........................................................................................................45
7.1.3
Visits for Subjects Not Receiving Teduglutide ................................ .............. 46
7.1.4 Visits for Subjects Receiving Teduglutide Treatment................................ ....46
[IP_ADDRESS] Pretreatment Visit ................................ ................................ ................... 46
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24) .....................................47
7.1.5 Teduglutide Follow -up Period ................................ ................................ ........ 49
7.1.6 Study  Completion/Earl y Termination Visit (EOS/ET Visit) ..........................50
7.2 Study  Evaluations and Procedures
................................ ................................ ........... 50
7.2.1 Retrospective Data Collection ................................ ................................ ........ 50
[IP_ADDRESS] Growth (Height, W eight, and Head Circumference) .............................50
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed ................................ ................ 51
For non-commercial use only
Shire CONFIDENTIAL Page 8
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
[IP_ADDRESS] Parenteral Support Prescribed ................................................................51
[IP_ADDRESS] Adverse Events .......................................................................................51
7.2.2
Prospective Data Collection ...........................................................................51
[IP_ADDRESS] Demographics, Medical History , and SBS History ................................51
[IP_ADDRESS] Physical Examination .............................................................................51
[IP_ADDRESS]
Adverse Event Collection.......................................................................51
[IP_ADDRESS] Vital Signs, Bod y Weight, Height, Head Circumference and Bod y 
Mass I ndex .............................................................................................52
[IP_ADDRESS] Clinical L aboratory  Tests .......................................................................52
[IP_ADDRESS] Serum Sampling .....................................................................................53
[IP_ADDRESS] Pregnancy  Testing ..................................................................................54
[IP_ADDRESS] Antibody  Testing ....................................................................................54
[IP_ADDRESS] Volume of Blood ....................................................................................54
[IP_ADDRESS] Gastrointestinal -specific Testing ............................................................55
[IP_ADDRESS] Nutritional Support .................................................................................56
[IP_ADDRESS] Diaries ....................................................................................................56
[IP_ADDRESS] Health
-related Quality  of L ife Assessments ...........................................57
8ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................60
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................60
8.1.1 Severity  
Categorization ..................................................................................61
8.1.2 Relationship Categorization ............................................................................61
8.1.3 Outcome Categorization .................................................................................62
8.1.4 Symptoms of the Disease under Study ...........................................................62
8.1.5 Clinical L aboratory  and Other Safet y Evaluations (Prospective Period 
of Observation Only )
......................................................................................63
8.1.6 Pregnancy .......................................................................................................63
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Onl y)..........................................................................................[ADDRESS_393850] ...........................................................................67
8.4
Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only ).........................................................................................................................[ADDRESS_393851] (Prospective Period of 
Observation Onl y)..........................................................................................68
8.4.2 Dose Interruption Criteria Based on Drug -Induced L iver Injury  
(Prospective Period of Observation Onl y)......................................................69
8.5 Early Termination of t he Clinical Study  (Prospective Period of Observation 
Only )
.........................................................................................................................69
9DATA MANAGEMENT AND STATISTICAL METHODS
...............................................70
9.1 Data Collection .........................................................................................................70
9.2 Clinical Data Management .......................................................................................70
9.3 Statistical Analy
sis Process ......................................................................................70
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................70
9.5 Sample Size Calculation and Power Consid erations ................................................71
9.6 Study  Population ......................................................................................................71
9.7 Efficacy  Anal yses.....................................................................................................71
9.7.1 Efficacy  Endpoints ..........................................................................................71
9.8 Safety  Anal yses........................................................................................................72
9.8.1 Safety  Endpoints .............................................................................................72
9.9 Other Anal yses.........................................................................................................73
9.9.1 Health
-related Quality  of L ife Anal yses.........................................................73
10SPONSOR’S AND INVESTI GATOR’S RESPO NSIBILIT IES...........................................74
10.1
Sponsor’s Responsibilities .......................................................................................74
10.1.1 Good Clinical Practice Compliance ................................................................74
10.1.2 Indemnity /Liability  and Insurance ..................................................................74
10.1.3 Public Posting of Study  Information ..............................................................74
10.1.4 Submission of Summary  of Clinical Study  Report to Competent 
Authorities of Member States Concerned and Ethics Committees ................75
10.1.5 Study  Suspension, Termination, and Completion ..........................................75
10.2
Investigator’s Responsibilities ................................ ................................ ................. 75
10.2.1 Good Clinical Practice Compliance ................................................................75
10.2.2 Protocol Adherence and Investigator Agreement ...........................................76
10.2.3 Documentation and Retention of Records ......................................................76
[IP_ADDRESS] Case Report Forms .................................................................................76
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ................................ ................................ .............................. 76
[IP_ADDRESS] Audit/I nspection ................................ ................................ ..................... 77
For non-commercial use only
Shire CONFIDENTIAL Page 10
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
[IP_ADDRESS] Financial Disclosure ...............................................................................[ADDRESS_393852] or Ethics Committee ...........................................78
10.4 Privacy  and Confidentiality ......................................................................................79
10.5 Study  Results / Publication Policy ...........................................................................[ADDRESS_393853]  OF TABLES
Table 1-1 Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................[ADDRESS_393854] 
Annually ........................................................................................................55
Table 7
-3 Developmentally Appropriate PedsQL™Generic Core Scales .....................[ADDRESS_393855] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study report
CTCAE Common Terminology Criteria for Adverse Events
DILI drug-induced livery injury
DMC data monitoring committee
DPP-[ADDRESS_393856]
IV intravenous
IWRS interactive web -based response system
MedDRA Medical Dictionary for Regulatory Activities
NCI National Cancer Institute
NDA new drug application
NTT no-teduglutide treatment
For non-commercial use only
Shire CONFIDENTIAL Page 13
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
PedsQL Pediatric Quality of Life Inventory
PS parenteral support
PT/INR prothrombin time/international norm alized ratio
QD once daily
SAE serious adverse event
SAP statistical analysis plan
SBS short bow el syndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_393857] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization -Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page 14
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
STUDY  SYNOPSIS
Protocol num ber: SHP633 -303 Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open -label, Long -term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bow el Syndrome Who Completed TED -C13-003
Number of subjects (total and for each treatm ent arm):
Approximately [ADDRESS_393858] of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED -C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the [LOCATION_002] (US) and the [LOCATION_008] ([LOCATION_006]) w ill participate in 
this extension study.
Study period (planned):
October 2016 -September 2019Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith short 
bowel syndrome (SBS) who completed TED -C13-003.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED -C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open -label, long -term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED -C13-[ADDRESS_393859] of care (SOC) treatment arm in 
TED -C13-003.
Investigational product, dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible ped iatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED -C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects completed the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of
specific safety and efficacy measures that were completed in the course of the subject’s standard medical care 
betw een the date of the TED -C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) i s signed for this study. In addition to this retrospective data collection, prospective 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review  and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393860]’s standard medical care betw een the date of the TED -C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after 
informed consent/assent is obtained for this study. The following retrospective data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Grow th (height, head circumference [up to 36 months of age], w eight)
End dates for adverse events (AEs) ongoing at the time of TED -C13-003
All nonserious AEs related to teduglutide treatment
All adverse events of special interest ( AESIs)
All serious adverse events (SAEs)
Prospective Data Collection andTreatment
Additional scre ening visit procedures for prospective data collection assessments can be found in Table 1 -2.These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. The parenteral suppo rt prescription w ill also be collected at screening.
Additionally, intake diaries will be dispensed at the screening visit for collection of actual parenteral support (PS) 
volume and hours per day (Section [IP_ADDRESS]). Diary data for PS volume will be collec ted for at least 2 w eeks after 
the ICF (and if applicable, the informed assent) is signed for this study.
Subjects not receiving teduglutide treatment (ie, in a no -teduglutide treatment [NTT] period), w ill be seen 
approximately every 12 weeks for safety, p arenteral support (PS) requirements, and quality of life. Diary data for 
PS volume will be collected for at least [ADDRESS_393861] NTT visit after the screening visit 
will occur within 2 to 12 w eeks of the screening visit. At any p oint after screening, including during an NTT period, 
subjects who meet ≥[ADDRESS_393862], and parent or legal guardian agrees to proceed with teduglu tide therapy .
After the pretreatment visit, subjects who meet ≥1 of the teduglutide treatment inclusion criteria, and meet none of 
the teduglutide treatment exclusion criteria, w ill start a 28 -week cycle, consisting of 24 w eeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up (no treatment) period (Figure 3 -1). During 
the 28 -week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and w eekly during the follow -up period (betw een Weeks 24 and 28). Safety and PS requirements will be evaluated 
at every visit, and quality of life assessments will be made approximate ly every [ADDRESS_393863] may "escape" the follow -up period 
early and proceed immediately to another pretreatment visit. Follow ing completion of the [ADDRESS_393864] w ill proceed to an NTT visit or another pretreatment visit within approximately 12 w eeks.
At all site visits and telephone contacts, safety will be monitored and nutritional support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 w eeks. To m aintain 
consistency across centers, all attempts should be made to follow  the nutritional support adjustment guidelines 
(developed w ith SBS expert input and provided in the protocol) for d ecisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine and stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation (Appendix 2).
For non-commercial use only
Shire CONFIDENTIAL Page 16
SHP633 -303 Protocol Amendment 3
Teduglutide 16 May 2018
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy.
Eligi ble subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approximately 
1week afte r adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects 
discontinue teduglutide at Week 24 and enter a 4 -week follow-up (no -treatment) period, during which phone visits will be 
performed weekly ( solid grey line s). If an escape criterion is met at Week 24 or during the follow -up period, subjects may 
proceed directly to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet allof the study inclusi on criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study -related procedures.
2.Subject completed the TED -C13-003 study (including subjects in the standard of care treatment arm).
3.Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Cri teria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_393865] (and/or parent or 
legal guardian, as appropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria :
1.Subject is receiving PS and unable to significantly reduce PS or ad vance enteral feeds (eg, 10% or less 
change in PS or advance in feeds) for at least 3 months prior to and during the teduglutide pretreatment 
visit, as assessed by [CONTACT_093]. Transient instability for events such as interruption of central access 
ortreatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the event.
2.Subject w as previously treated w ith teduglutide and at least 1 of the following criteria is satisfied:
a.Increasing PS requirements follow ing teduglutide discont inuation
For non-commercial use only
Shire CONFIDENTIAL Page 17
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319475]
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319391] (EN) following teduglutide discontinuation
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361]
e.Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <10 kg at the pretreatment visit
2.Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.History of cancer in the previous 5 years except surgically curat ive skin cancers
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10cm, and endoscopic proced ures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle
6.Clinically significant intestinal stricture or obstruction
7.Clinically significant, active or recurrent pancreatic or biliary disease
8.Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_319476]  50mL/min/1.[ADDRESS_393866] repair, or patent ductus arteriosus ligation
11.Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, Smoflipid, 
or teduglutide) w ithin 3 months or 5.5 half -lives of the experiment al drug, whichever is longer, prior to 
the pretreatment visit and for the duration of the 28 -week cycle 
12.Treatment with analogs of glucagon -like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP -2) (not 
including teduglutide), insulin -like growth factor -1 (IGF -1), or grow th hormone, within 3 months 
preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_393867], closely -related 
compounds, or any of the stated ingredients
15.Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16.Pregnant or lactating female subjects
17.Sexually active female subjects of child -bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents completion of the study, or interferes with analysis of the study results
For non-commercial use only
Shire CONFIDENTIAL Page 18
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Follow -up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interrupted 
or omitted and the subject may proceed directly to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319392]
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319364]
4.Severe diarrhea related to teduglutide discontinuation
5.The subject escaped during the follow -up period of a previous teduglutide treatment cycle within 
SHP633 -303.
Maximum duration of subject involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed informed consent (and i f 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple [ADDRESS_393868] has access (as nee ded) to teduglutide. The subject’s maximum duration of participation is expected to be 
approximately [ADDRESS_393869] has not 
withdrawn early from the study for any reason prior to completin g end of study (EOS) visit.
Planned duration of no -teduglutide treatm ent periods: variable, depending on disease course
Planned duration of the teduglutide pretreatm ent visit: 1-21 days
Planned teduglutide treatment cycle duration :28 w eeks. Each cycle con sists of 24 w eeks of 
teduglutide treatment followed by a 4 -week follow -up period (no treatment)
Endpoints and statistical analysis:
The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analy sis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED -C13-003) and/or first exposure to 
teduglutide. The following efficacy endpoints will be analyzed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research Endpoints
Health e conomics and outcomes research endpoints will be analyzed at approximately 12 -week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 w eeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period . The beginning of each treatment cycle (CxD1) w ill be an 
additional baseline.
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores:
oFood and drink limits
oDiarrhea
For non-commercial use only
Shire CONFIDENTIAL Page 19
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Safety Endpoints
The follow ing safety endpoints will be analyzed from the beginning of the prospective study period:
Adverse events
Vital signs, including body temperature, heart rate, and blood pressure
Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy
The follow ing safety endpoints will be analyzed from the end of the core study (TED -C13-003) to the beginning of 
the prospective study period:
 Adverse events related to teduglutide
 All SAEs
 All Adverse Events of Special Interest (Section 8.3)
The follow ing safety endpoints will be analyzed relative to the baseline of the core study (TED- C13-003):
 Z-scores for height (or length), w eight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; how ever, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by [CONTACT_195837]. Adverse events 
will also be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_300192].
Sample Size Justification
As this is an extension study, the maximum number of subjects was determined by [CONTACT_319435] -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 20
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
STUDY  SCHEDULES
Table 1-1 Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment Note
Informed consent/assent Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study -related 
procedures, including retrospective data collection.Study eligibility
WeightaThe last representative value for w eight during each [ADDRESS_393870] all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator -initiated trials, 
compassionate use, and named -patient access programs.
Parenteral support (PS) 
prescribedaThe last representative PS prescription during each 12 -week interval throughout 
the retrospective period and at the beginning and end of any teduglutide 
treatment will be collected. Data collected should include weekly prescribed 
volume, calories, average hours per day, and days per w eek of prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED -C13-[ADDRESS_393871]
Serious adverse events (SAEs)
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
aThe first 12 -week interval begins at TED -C13 -003 EOS visit.
Note: Retrospective data are defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED -C13 -003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent ) is signed for this study. Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospective data
collection, only assessments in this table will be completed. Se e Section 7.1.1 for further details on collection of retrospective 
data.
For non-commercial use only
Shire CONFIDENTIAL Page 21
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Table 1-2 Schedule of Events for Screening and End of Study or Early Termination
ScreeningEnd of Study or Early 
Termination
Visit Type Site Site
Informed consent/assent X
Study eligibility X
Dem ographics, medical history, SBS historyaX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriabX
Adverse events X X
Concomitant medications and procedures X X
Physical examination and vital signs, including weight X X
Height and head circumferencecX X
Revie w intake and output diariesdX
Record PS prescription and adjust as neededeX X
Safety laboratory testsfX
PedsQL Generic Core Scale/ PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-ScalesX
Antibodies to teduglutidegX
Fecal occult blood testingh(X)
Colonoscopy or sigmoidoscopyi(X)
Pregnancy testingj(X)
EOS =end of study; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child-bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
aIf the subject has any changes to the medical history and SBS history that had been collected at the baseline of the 
TED -C13 -003 study, then the updated medical history and SBS history will be collected.
bSubjects who meet ≥[ADDRESS_393872], 
and parent or legal guardian agrees to proceed with teduglutide therapy ( Table 1-4).
cHead circumference willbe measured in subjects 36 months of age and younger.
dThe intake diary should be completed daily for a minimum of 2 weeks prior to t he EOS/ET visit. The output diary should be 
completed daily over a 48 -hour period of nutritional stability before the EOS/ET visit.
eParenteral support prescription will be collected at the screening visit. Parenteral support adjustments should be made af ter 
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix [ADDRESS_393873] of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis wil l not 
constitute a protocol deviation.
g Required for all teduglutide -exposed subjects.
h Fecal occult blood testing should be performed on teduglutide -exposed subjects on an annual basis, approximately every 
48-60weeks at a minimum.
i The need for colonoscopy/sigmoidoscopy in response to a positive FOBT result during a no -teduglutide treatment period is at 
the discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscopy/sigmoidoscopy at 5 year intervals or more often as needed. See Section [IP_ADDRESS] for details.
jPregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 22
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Table 1-3 Schedule of Events for No Teduglutide Treatment Period
Visit Number NTx
Visit Type Site
Visit FrequencyaEvery 12 weeks
Window (days)b±[ADDRESS_393874] as neededfX
Safety laboratory testsgX
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutideh(X)
Fecal occult blood testingiAnnually
Colonoscopy or sigmoidoscopyj(X)
Serum samplekEvery 24 w eeks
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
aThe first NTx visit after the screening visit must occur within [ADDRESS_393875] NTx visit in the current no -teduglutide treatment period.
c Subjects who meet ≥[ADDRESS_393876], 
and parent or legal guardian agree to proceed with teduglutide therapy ( Table 1-4).
dHead circumference will be measured in subjects [ADDRESS_393877] actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool output should be recorded in the output diary over a 48 -hour period of nutritional stability before every clinic 
visit. See Section [IP_ADDRESS] for more detail.
fParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix [ADDRESS_393878] follow -up samples collected 
every 12 weeks during the study until a negative result is obtained.
i Fecal occult blood testing should be performed on teduglutide -exposed subjects on an annual basis, approximately every 
48-60weeks at a minimum.
j The need for colonoscopy /sigmoidoscopy in response to a positive fecal occult blood test during a no -teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide-exposed subjects will undergo colonoscopy /sigmoidoscopy after 
they have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receiv e 
teduglutide will undergo colonoscopy /sigmoidoscopy at 5-year intervals or more often as needed. See Section [IP_ADDRESS] for 
details.
k Lack of collection of serum samples will not constitute a protocol deviation.
Note: (X) denotes conditional requirement for a given assessment if the s ubject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 23
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -
up
Visit Number Pxa Cx
D1Cx
W1Cx
W2Cx
W4Cx 
W6Cx 
W9Cx 
W12Cx 
W16Cx W20CxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  
(days)d -21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteriaX Xe
Phone contact [CONTACT_319408] [ADDRESS_393879] as 
neededhX X X X X X X X X X X X X
Safety 
laboratory testsi XjX X X X X X X X X X (X) X
For non-commercial use only
Shire CONFIDENTIAL Page 24
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -
up
Visit Number Pxa Cx
D1Cx
W1Cx
W2Cx
W4Cx 
W6Cx 
W9Cx 
W12Cx 
W16Cx W20CxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  
(days)d -21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
PedsQL 
Generic Core 
Scale/ Family 
Impact Module/ 
GI Symptoms 
Module Sub -
ScalesX X X
Antibodies to 
teduglutidej X X X X
Fecal occult 
blood testingX X X
Colonoscopy /
Sigmoidoscopyk (X) (X) (X)
Pregnancy 
testingl X X X X X X X X X
Serum samplemX X
Evaluate escape 
criterian XpX X
Dispense study 
drugo X X X X X X X X X
eCRFs=electronic case report forms; EOS=end of study; EOT=end of treatment; ET = early termination; FOBT=fecal occult blood t est; FOCBP=females of child -bearing potential; FU=follow -up; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life I nventory; PS=parenteral support; PT/I NR= prothrombin time/internationa l normalized ratio; SBS=short bowel syndrome; SC=subcutaneous; 
Scr=screening; TED=teduglutide; Tx=treatment
aIf the first pretreat ment visit (P1) follows the screening visit, it must occur within 12 weeks of screening. 
b Phone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are t he same as those described for CxW25 -27(except for evaluation of escape 
criteria).
cThe investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur within [ADDRESS_393880] is completing the study at the CxW28 visit, the EOS/ET visit ( Table 1-2) will take place in lieu of the CxW28 visit.
dVisit windows are relative to the CxD1 visit.
e Eligibility will need to be reconfirmed prior to the first dose in the cyc le. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs obtained at t he CxD1 
visit are not required to determine teduglutide treatment eligibility.
For non-commercial use only
Shire CONFIDENTIAL Page 25
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -
up
Visit Number Pxa Cx
D1Cx
W1Cx
W2Cx
W4Cx 
W6Cx 
W9Cx 
W12Cx 
W16Cx W20CxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  
(days)d -21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±[ADDRESS_393881] actual PS volume and hours per day. I ntake diaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except at pretreatment visit), 
for 1 week following PS a djustment, and daily during the 4 -week follow -up period. Urine and stool output should be recorded in the output diary over a 48 -hour period of nutritional stability before 
every clinic visit, and within 1 week of implementing a change in the PS prescription. See Section [IP_ADDRESS] for more detail.
hParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment provided in Appendix [ADDRESS_393882] PT/I NR at the pretreatment visit. Additional collection will occur if a potential drug -induced liver 
injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis w ill not constitute a protocol deviation.
j Samples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are re ceiving teduglutide (CxW12 and CxW24) must be drawn at least 14 hours 
after dosing.
k The teduglutide -naïve subjects age 12 and old er will undergo colonoscopy /sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any age with newly positive 
FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, a nal fissure) will undergo a colonoscopy /sigmoidoscopy prior to receiving teduglutide. If newly 
positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the end of a teduglutide tr eatment cycle (CxW24/EOT), colonosco py/sigmoidoscopy will be performed. 
The need for colonoscopy /sigmoidoscopy in response to positive FOBT results at CxW12 is at the discretion of the investigator. Teduglutide -exposed subjects who have received the equivalent of 2 
treatment cycles (48 weeks of study drug exposure) will undergo colonoscopy /sigmoidoscopy . See Section [IP_ADDRESS] for details.
l A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be adminis tered at all other visits acco rding to the study schedules, or if pregnancy is 
suspected, or as specified per protocol upon withdrawal of the subject from the study.
m Lack of collection of serum samples will not constitute a protocol deviation.
n If escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investigator.
o The first SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observed for hypersensitivity 
reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. Se e Section 6.2.[ADDRESS_393883] occur within 7 days of the CxW24 visit.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 26
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
1 BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital ab normalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 y ear and older with SBS ( Khan et al., 
2015; Wales et al., 2004 ). Unlike the adult population, the majority  of cases of SBS in pediatr ic 
subjects are due to congenital anomalies or catastrophic events that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on par enteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 y ears of the initial diagnosis ( Khan et al., 2015). 
Nevertheless, despi[INVESTIGATOR_3062], many  pediatric subjects remain dependent 
on PS. Complications of long -term PS include liver disease, catheter -related blood stream 
infections, central line-associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality  of life is poor ( Squires et al., 
2012). Accelerating the adaptive process and achieving enteral autonomy  is an urgent goal for all 
patients with SBS who are dependent on PS ( Khan et al., 2015
; Squires et al., 2012 ).
Intestinal adaptation is driven by  [CONTACT_319436] ( Drucker 
and Yusta, 2014 ). Chief among these is hormones glucagon- like peptide 2 (GL P-2), which is 
secreted from L- type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Resection of these region s may  impair the adaptive response by  [CONTACT_319410] -2.
1.[ADDRESS_393884] Background
Teduglutide is a novel, recombinant analog of naturally  occurring human GLP -2 that 
regulates the functional and structural integrit y of the cells lining the g astrointestinal (GI) 
tract. Teduglutide is a 33 -amino acid peptide that differs from native GLP -2 in the substitution 
ofglycine for alanine at the second position at the N -terminus. As a result, teduglutide 
demonstrates resistance to degradation b y dipept idyl peptidase 4 (DPP -4) and therefore 
maintains a longer elimination half -life (t 1/2) in adults of approximately  2 hours compared to 
thenative peptide, which has a t 1/2 of approximately 7 minutes. Teduglutide has been shown 
inanimal studies and previous human clinical trials to increase villus height and crypt depth in 
the intestinal epi[INVESTIGATOR_2130], thereb y increasing the absorptive surface area of the intestines 
(Tappenden et al., 2013 ; Thymann et al., 2014). The European Commission granted a 
centralized marketing authorization valid throughout the European Union (EU) for teduglutide 
(REVESTIVE™) on [ADDRESS_393885] 2012 and a New Drug Application (NDA) for teduglutide 
(GATTEX®) was approved by  [CONTACT_24623] (US) Food and Drug Administration (FDA) on 
21December 2012 for the treatment of adult patients with SBS who are dependent on PS. 
Teduglutide has also been approved for use in adult patients with SBS in Canada and 
Switzerland. 
For non-commercial use only
Shire CONFIDENTIAL Page 27
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
On29Jun2016, theEuropean Commission granted anextension oftheMarket Authorization for 
teduglutide ( REVESTIVE ™) for the treatment of patients aged 1 year and above with SBS; patients 
should be stable following a period of intestinal adaptation.
1.3 Clinical Studies with Teduglutide in Pediatric Subjects
One Phase 3 stud y, TED -C13-003, was completed in pediatric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1 -17. Thirty -seven pediatric subjects received teduglutide at doses of 
0.0125, 0.025, or 0.05 mg/kg/day  for [ADDRESS_393886] of care (SOC) cohort. There were clear dose -dependent 
effects of teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 
0.0125 mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at 
Week 12 of 37%, includi ng complete independence from PS support in [ADDRESS_393887], and a 
reduction of 3.94 hours per day  infusion time. In the 0.05 mg/kg/day  cohort there was a 
reduction in PS volume at Week 12 of 39%, including complete independence from PS support 
in 3 subjects, an d a reduction of 4.18 hours per day infusion time. Teduglutide was generall y safe 
and well tolerated b y pediatric subjects in all dosing cohorts. There were no deaths during the 
study  and no treatment-emergent serious adverse events (TESAEs) related to teduglutide were 
reported. No discontinuations from study were due to adverse events (AEs).
TED -C14-006 is a recently  completed study  of pediatric subjects through 17 y ears which 
included 2 treatment arms: a teduglutide treatment arm and a SOC treatment arm. Subjects in 
both arms participated in a [ADDRESS_393888] 
medical therap y for SBS; while those in the teduglutide treatment arm received daily  
subcutaneous (SC) injections of teduglutide (study  drug) in addition to standard medical therapy . 
The subjects enrolling in the teduglut ide treatment arm were randomized 1:1 in a double -
blinded 
manner into 2 parallel dose groups: 0.025 mg/kg/day  or 0.05 mg/kg/day  of teduglutide 
administered subcutaneously  for 24 weeks. Compared to the SOC , treatment of pediatric subjects 
with SBS with teduglutide resulted in clinicall y meaningful reductions in PN/IV volume, 
calories, day s per week, and hours per day .A total 10% of subjects who received teduglutide 
achieved enteral autonomy  within 24 weeks despi[INVESTIGATOR_319393]/IV for several 
years. Teduglutide treatment also resulted in increases in EN volume and caloric intake as well 
as plasma citrulline. Although the differences in efficacy  between the 0.025 and 0.05 mg/kg dose 
groups were small, a consistently  greater effect was seen in the 0.05 mg/kg dose in all efficacy  
parameters. The PK properties were well characterized in this population and were consistent 
with the prior [ADDRESS_393889] version of the investigator’s brochure for the overall risk/benefit 
assessmen t and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393890] -time treatment of 
teduglutide -naïve subjects who participated in the SOC treatment arm in TED- C13-003.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED -C13-003.
2.2.2 Secondary Objectives
The secondary  objective of this study is to evaluate the long- term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page 29
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
3 STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safet y and 
efficacy  of teduglutide in pediatric subjects who completed the TED -C13-003 study  (the core 
study ). At the time of entry  into the TED- C13-[ADDRESS_393891] 30% of the ir caloric or fluid needs, and 
had not been able to significantly  reduce PS for at least 3 months prior to enrollment. During the 
core stud y, pediatric subjects in the teduglutide treatment arm were entered into a 
0.0125 mg/kg/day , 0.025 mg/kg/day , or 0.05 mg/kg/day  dose cohort based on the timing of their 
enrollment in the study . The cohorts were filled in a sequential manner.
Approximately  [ADDRESS_393892] meet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen approximately  every  12 weeks for safety , parenteral support (PS) requirements, and 
quality  of life. At any  point during an NTT period, subjects who meet ≥[ADDRESS_393893], and 
parent or legal guardian agrees to proceed with teduglutide therap y.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatme nt in this extension 
study and thus long -term follow -up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these pe diatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analy sis suggested that pediatric patients, ages 1 -17 years-old, are likel y to require the same 
dose as used in adults, namely  0.05 mg/kg/day  (Mouksassi et al., 2009 ). In this extension study ,
all subjects who enter a teduglutide treatment cy cle will receive 0.05 mg/kg SC QD.
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily. The completed pediatric studies (TED -C13-003 and 
TED -C14-006) demonstrated that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day 
was associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
For non-commercial use only
Shire CONFIDENTIAL Page 30
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
studies as well as the pediatric (core) study (TED -C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults ( O'Keefe et al., 2006 ).
Further PK simulation was conducted based on the population PK model previously established 
and a virtual population of 1000 pediatric patients created based on Cen ters for Disease Control 
(CDC) growth charts in the target age group (4 to 12 months) and taking into consideration 
body weights of pediatric patients with SBS enrolled in study TED -C13-003 (approximately 15% 
lower than healthy subjects in the same age gro up). Monte Carlo simulations for all age groups 
were performed according to the SC dosing regimens of 0.0125, 0.025 and 0.05 mg/kg every 
24hours. Rich concentration
-time profiles were simulated with the customized population PK 
model to derive the exposur e metrics area under the concentration curve at steady state (AUC ss) 
and maximum concentration at steady state (C max,ss). Following 0.05 mg/kg daily SC 
administration, the median C max,ss of teduglutide in infants (24.9 ng/mL) was within 20% of that 
observe d in the 2 to 4 and 4 to 6 years age groups (26.9 and 29.4 ng/mL, respectively); and 
approximately ~28% lower than that in adult patients with SBS. The clinical package in 
conjunction with C maxwas considered to support teduglutide dose selection since AUC ss was 
previously shown not to correlate with efficacy. Thus, the 0.05 mg/kg dose is proposed for testing 
in all age groups.
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED -C14-[ADDRESS_393894] may  be evaluated immediately  for 
additional teduglutide treatment. Subjects who clinically  deteriorate or stop improving at any  
time after the end of the follow
-up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED- C13-[ADDRESS_393895] 
deteriorated quickly after treatment interruption (ie, escaped from a prior follow -up period) may 
be evaluated immediately for eligibility for additional treatment when they reach the Week [ADDRESS_393896]’s standard medical care between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form (I CF) (and if 
applicable, informed asse nt) is signed for this study . In addition to this retrospective data 
collection, prospective study  assessments of safety  and efficacy  will be completed as a part of 
this study .
For non-commercial use only
Shire CONFIDENTIAL Page 31
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
3.1.1 Informed Consent/Assent and Eligibility
The review and signing of the I CF (and if applicable, informed assent) for this study , must be 
completed before an y other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study ; however subjects may  
consent to retrospec tive data collection onl y. Subjects may not consent to the prospective data 
collection only . After informed consent/assent is obtained, study  eligibility  will be assessed for 
all subjects.
3.1.[ADDRESS_393897]’s standard medical care between the date of the 
TED -C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study . Retrospective data collection may  begin any  time after informed consent/assent is 
obtained for this study . The following data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Growth (height, head circumference [up to 36 months of age], weight)
End dates for adverse events (AEs) ongoing at the time of TED -C13-
003
All nonserious AEs related to teduglutide
All adverse events of special interest (AESIs)
All serious adverse events (SAEs)
3.1.3 Prospective Data Collection and Treatment
Additional screening visit procedures for prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history  and short bowel sy ndrome history . The parenteral support prescription will 
also be c ollected at screening. Additionally , intake diaries will be dispensed at the screening visit 
for collection of actual PS volume and hours per day  (Section [IP_ADDRESS]). Diary  data for PS 
volume will be collected for at least 2 weeks after the I CF (and if appl icable, the informed 
assent) is signed for this study .
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen approximately  
every  [ADDRESS_393898] NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. 
For non-commercial use only
Shire CONFIDENTIAL Page 32
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Atanypoint after screening, including during an NTT period, subjects who meet ≥[ADDRESS_393899], and parent or legal guardian agrees to proceed with teduglutide therapy .
After the pretreatment visit, subjects who meet ≥1 of the teduglutide treatment incl usion criteria, 
and meet none of the teduglutide treatment exclusion criteria, will start a 28 -week cy cle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily , followed by  a 
4-week follow -up (no treatment) period ( Figure 3 - 1). Durin g the 28 -week cy cle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately 
1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 
24), and weekl y during the fol low-up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safet y will be monitored and nutritional support will be 
reviewed and adjusted as needed. Quality  of life assessments will be made approximately  every  
12 weeks. To maintain consistency  across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regarding PS reduction and advances in enteral feeds based on weig ht 
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation ( Appendix 2 ).
Rationale: Measures of long -term safety  will include adverse events, growth parameters, and 
anti-drug antibodies. Measure of long term efficacy  will include durability of effect as measured 
by [CONTACT_319411] (Pediatric Quality  of 
Life Inventory  [PedsQL ], PedsQL  Famil y Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary  endpoint in pi[INVESTIGATOR_9205] 3 adult clinical 
trials and the completed Phase 3 pediatric stud y (TED- C13-003), and will be used as an endpoint 
in this extension study . In previous clinica l studies, a reduction of this magnitude was associated 
with a reduction in the number of days per week of PS, and increases in enteral intake. Reduction 
in volume and time of PS due to improved enteral absorption may  provide a pediatric subject 
with oppor tunities for more age -appropriate activities including oral rehabilitation. Quality  of life 
assessments will be performed in this study  to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account th e 
patient population and the pharmacologic effect of teduglutide, GI -specific screening tests, 
including fecal occult blood testing and colonoscopy /sigmoidoscopy , which are commonl y part 
of the routine care of these subjects, will be performed to ensure sa fety. This study  captures 
long-term safet y data on poly ps and other colonic mucosal changes in teduglutide- exposed 
subjects using the surveillance strategy proposed in Section [IP_ADDRESS].
For non-commercial use only
Shire CONFIDENTIAL Page 33
SHP633 -303 Protocol Amendment 3
Teduglutide 16 May 2018
Figure 3-1 Study Desi gn Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for tedugluti de therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approxim ately 1 week after 
adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide 
at Week 24 and enter a 4 -week follow -up (no-treatment) period, during which phone visits will be performed weekly (solid grey 
lines ). If an escape criterion is met at Week [ADDRESS_393900] has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study Inclusion Eligibility  
Criteria. The stud y will continue for at least [ADDRESS_393901] has access (as needed) 
to teduglutide. The su bject’s maximum duration of participation is expected to be approximately  
[ADDRESS_393902] 
(last safet y contact), whichever is later. The stud y completion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393903] and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed assent) before any  study -related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_393904] will not be considered eligible for the study  without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completing any  
study -related procedures. 
2.Subject completed the TED -C13-003 study  (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully  adhere to study  requirements as 
defined in this protocol.
4.2 Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study .
4.3 Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_393905] (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.[ADDRESS_393906] is receiving PS and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or le ss change in PS or advance in feeds) for at least 3 months prior to and 
during the teduglutide pretreatment visit, as assessed by  [CONTACT_093]. Transient 
instability  for events such as interruption of central access or treatment for sepsis is 
allowed i f the PS returns to within 10% of baseline prior to the event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.Increasing PS requirements following teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, followed b y 
cessation of improvement after teduglutide discontinuation
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319394] (EN) following teduglutide discontin uation
d.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319367]
e.Severe diarrhea related to teduglutide discontinuation
For non-commercial use only
Shire CONFIDENTIAL Page 35
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_393907]
3.History  of cancer in the previous 5 y ears except surgically  curative skin cancers
4.Serial transverse enteroplasty  or other major intestinal surgery  within 3 months 
preceding the teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week 
cycle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairm ent or injury , 
including the following laboratory  values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dy sfunction shown by  [CONTACT_319476] 
50mL/min/1.[ADDRESS_393908] repair, or 
patent ductus arteriosus ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine, 
Omegaven, 
Smoflipid, or teduglutide) within 3 months or 5.5 half -lives of the 
experimental drug, whichever is longer, prior to the pretreat ment visit and for the 
duration of the 28- week cy cle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon -like peptide -2 
(GLP-2) (not including teduglutide), insulin -like growth factor- 1 (IGF -1), or growth 
hormone, within 3 months preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_393909], 
closely -related com pounds, or any  of the stated ingredients
15.Known history  of alcohol or other substance abuse within 1 y ear prior to the 
pretreatment visit
16. Pregnant or lactating female subjects 
For non-commercial use only
Shire CONFIDENTIAL Page 36
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
17.Sexually  active female subjects of child -bearing potential unwilling to use appr oved 
contraception during teduglutide treatment and for 30 day s after the treatment period 
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the study, or interfe res with 
analysis of the study  results
4.[ADDRESS_393910] may  proceed directly  to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319395]
3.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319370]
4. Severe diarrhea related to teduglutide discontinuation
5.The subject escaped during the follow -up period of a previous teduglutide treatment 
cyclewithin SHP633-303.
4.[ADDRESS_393911]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be e ither:
Premenarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta- human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pretreatment visit .Females of 
child- bearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable methods of contraception.
For non-commercial use only
Shire CONFIDENTIAL Page 37
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Acceptable methods of contraception are:
True abstinence: Abstention of sexual activity  that is in line with the preferred and usual 
lifesty le of the subject. (Periodic abstinence [eg, calendar, ovulation, sy mptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception). 
Intrauterine devices plus condoms
Double- barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually  active during t he study , they  should use [ADDRESS_393912] wishes to remain in the study, the evaluations listed for the EOT visit are to be 
performed. A 4- week follow -up period will ensue, consisting of weekl y telephone visits 
(CxW25 -27) and the week 28 clinic visit (CxW28). The subject would then enter an NTT period 
and could be evaluated for subsequent teduglutide treatment eligibility  according to the study  
schedules. 
Comments (spontaneous or elicited) or complaints made b y the subject must b e recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case re port form (eCRF) and source documents, as 
described in Section 4.8.[ADDRESS_393913] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_319477] -up.
If a subject withdraws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completel y as possible. 
Subjects who withdraw from the study  will not be replaced.
For non-commercial use only
Shire CONFIDENTIAL Page 38
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdraw n for more than [ADDRESS_393914] clinically  relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
Adverse event
Protocol deviation
Lack of efficacy
Physician decision
Withdrawal by  [CONTACT_1130]
Withdrawal by  [CONTACT_7078]/guardian
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y)
Death
Other
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_393915] (office visit or telephone contact). At least [ADDRESS_393916]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations, and return an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page 39
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
5 CONCOMITANT TREATMENT
5.1 Concomitant M edications and Procedures
Concomitant treatment will be collected for the prospective period onl y and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this 
study . Concomitant medications and procedures will be assessed at each site visit, and include all 
nonstudy  treatments (medications, herbal treatments, vitamins, invasive and diagnostic 
procedures). Concomitant treatment information must be recorded on the appropriate eCRF 
page. Details of medication changes and/or dosages will be recorded on the eCRF.
5.1.[ADDRESS_393917] medical therapy for SBS should be continued.
5.1.2 Prohibited Treatment
At the time of screening, any  teduglutide treatment being received through any  mechanism 
other than part icipation in this study  (eg, by  [CONTACT_78150]-label prescription, participation in an 
investigator -initiated trial, compassionate access program, etc) must be discontinued. I n such 
cases, there is no minimum duration of interruption of teduglutide treatment before p retreatment 
evaluations can be performed.
The mechanism of action of teduglutide may  increase enteral absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, digox in), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narrow therapeutic range, are given at 
dosages that are h igher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1 Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- [ADDRESS_393918] is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2). In addition to the active ingredient 
(teduglut ide), each vial of teduglutide contains L -
histidine, mannitol, monobasic sodium 
phosphate monohy drate, and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.[ADDRESS_393919](s)
6.2.[ADDRESS_393920] Management
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory  management and supply  ordering, investigational product expi[INVESTIGATOR_49093], and return of investigational product. Please refer to the S tudy Manual for 
additional details regarding the IWRS.
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, an d site personnel will receive training.
6.2.[ADDRESS_393921], and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit ( Table 1-4).
6.2.[ADDRESS_393922] will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily . The initial dose will be calculated based on 
body  weight measured at the teduglutide pretreatment visit, and adjusted as needed, based on 
body  weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment peri od, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administered b y SC injection once dail y (QD) into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393923] 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
At the end of each [ADDRESS_393924] may  proceed directly  to another Pretreatment visit to assess treatment 
eligibility  for another cy cle (Section 4.6). Following the completion of the [ADDRESS_393925](s) container.
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing 7 vials of study  drug will be supplied and these will be labeled in 
accordance with applicable regulatory  requir ements. Sterile water for injection sy ringes and 
other ancillary  components will also be provided separately  and will be labeled in accordance 
with the applicable regulatory  requirements.
All study  drug used in this study  will be manufactured, tested, labe led, and released according to 
current legal requirements and Good Manufacturing Practice.
For non-commercial use only
Shire CONFIDENTIAL Page 42
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
6.3.2 Packaging
Teduglutide will be provided in a 3 mL  sterile, single -use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL ) will be provided in a prefilled s yringe.
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.[ADDRESS_393926] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refrigerated at a temperature between 2 -8°C (35.6 -46.4°F) until dispensed to 
a subject. Once dispensed to a subject, the study  drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2 -25°C, or 35.6- 77°F). Parent/legal guardian 
will be instructed to keep the subject’s study  drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study  drug may  be refrigera ted. The study  drug is for single use onl y, and should be used within 
[ADDRESS_393927] is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  [CONTACT_10179], such that both minimum and maximum thermometric values over a specific time period 
can be recorded a nd retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispen sed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharmacy or nominated member of the stud y 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigatio nal product bottle/carton labels, as they  are distributed.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393928] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be use d in any  unauthorized situation.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protoco l and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study  protocol. All dispensed 
study  medication will be documented in the interactive respons e technology  system and/or other 
investigational product record (eg, investigation product accountability  form). The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects.
All used and unused study  drug vials must be re turned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may  
dispense the unused study  drug vials to the same subject. All original containers, whether empty  
or containing study  drug will be returned to the pharmacy . Returned study  drugs will NOT be 
relabeled or reassigned for use b y other subjects. Contents of the study drug containers will not 
be combined. All used and unused vials must be returned to the distribution cent er according to 
the sponsor’s instruction. No vial/kit may  be destroy ed on site without approval by  [CONTACT_456].
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_393929] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -evident sealed container (eg, bo ttles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability  form.
Compliance with study  drug is calculated from subject diaries. Of those subjects eli gible for 
teduglutide treatment, subjects who have received 80% of the planned doses administered will be 
assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 44
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
7 STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures and assessments to be performed for subjects throughout the study  are 
outlined in the Schedule of Assessments ( Table 1 -1, Table 1-2, Table 1 -3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing an y study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obtain written informed 
consent (and if applicable, assent) from the subject ( Table 1-1).
7.1.1 Retrospective Data Collection
Retrospective data a re defined as specific safet y and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form (I CF) (and i f 
applicable, informed assent) is signed for this study . Retrospective PS and growth data will be 
captured in [ADDRESS_393930] retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent onl y to retrospective data collection, only 
assessments in Table 1-1 will be completed. The fo llowing data will be collected for the 
retrospective portion of the study :
Informed consent, and informed assent (if applicable)
Study  eligibility  is determined
A screen failure is a subject who has given informed consent and failed to meet 
the study  inclu sion eligibility  criteria. Subjects cannot be rescreened once they  
have been designated as a screen failure.
Prior teduglutide use (as prescribed)
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and st op dates, dose, route, and frequency . Prescription 
data includes teduglutide treatment in investigator- initiated trials, compassionate 
use, and named -patient access programs.
Collect start and end dates when a subject’s t eduglutide use was interrupted.
Parenteral support (as prescribed)
The last representative PS prescription during each 12- week interval throughout 
the retrospective period and at the beginning and end of any  teduglutide treatment 
will be collected. Usuall y, the prescription at the end of th e interval will represent 
the status of intestinal adaptation. 
For non-commercial use only
Shire CONFIDENTIAL Page 45
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
However, transient alterations inPSrelated toloss of central venous access or 
acute illness are not representative of intestinal adaptation. When such events 
occur at the end of a 12 -week interval, earlier, more representative PS prescription 
data should be recorded.
Data collected should include weekl y prescribed volume, calories, average hours 
per day , and day s per week of prescribed PS. Hours per day  should be averaged 
over the day s wher e PS is prescribed.
Growth (height, head circumference, and weight)
The last representative value for height, during each 12 -week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subje cts 36 months of age and y ounger at the time the data 
were collected, if available.
The investigator should use his/her clinical judgment to select values that reflect 
the true growth trajectory.
Adverse events
All nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal 
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study . The details of data collection and safety  reporting for these events 
can be found in Section 8.
End dates for AEs ongoing at the end of TED -C13-003 will be collected.
7.1.2 Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1
-2, 
and as detailed below:
Informed consent, and informed assent (if applicable)
Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the study  inclusion eligibility  criteria . Subjects cannot be 
rescreened once they  have been designated as a screen failure.
Demographics, updates to medical history  and SBS history
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomita nt medications and concomitant procedures
Physical examination and vital signs, including weight
Height and head circumference
Record PS prescription and adjust as needed
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393931] occur within 12 weeks of screening for a pretrea tment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
7.1.3 Visits for Subjects Not Receiving Teduglutide
While outside of the 28- week teduglutide -treatment cy cle, subjects will be followed 
approximately  every  12weeks for safety  and efficacy  asse ssments. No- teduglutide treatment 
visits are numbered sequentially  (NT1, NT2, etc.), even if interrupted by  [CONTACT_319415]. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outl ined in Table 1 - 3 and described below.
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomitant medications, and concomitant procedures
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed
Safety  laboratory  tests (ie, clinical chemistry , hematology , and urinaly sis)
PedsQL  Generic Core Scale/PedsQL Family  Impact 
Module/PedsQL Gastrointes tinal Symptoms Module Sub -Scales
Antibodies to teduglutide, if and when required
Fecal occult blood testing, as indicated (see Section [IP_ADDRESS])
Colonoscopy /sigmoidoscopy , as indicated (see Section [IP_ADDRESS])
Serum sample, as indicated
Teduglutide treatment may be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may  proceed to the pretreatment visit immedi ately to determine 
eligibility .
7.1.4
Visits for Subjects Receiving Teduglutide Treatment
[IP_ADDRESS] Pretreatment Visit
Subjects who meet at least 1 of the teduglutide treatment inclusion criteria during the screening 
visit or during the NTT period may  proceed to the pretrea tment visit immediately . Similarly , 
subjects who meet escape criteria at cy cle Week 24 or during the teduglutide follow -up period 
may proceed to the pretreatment visit immediately .
For non-commercial use only
Shire CONFIDENTIAL Page 47
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
In general, pretreatment assessments may  occur over a period of up to 21 da ys. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performed as in Table 1-4 and as 
described below:
Evaluate teduglutide eligibility  (treatment inclusion/exclusion criteria)
Dispense intake and output diaries
Adverse events, concomitant medications, and concomitant procedures
Fecal occult blood testing
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as indicated
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries 
Record PS prescription and adjust as needed.
Safety  laboratory  tests
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit include 
prothrombin time [PT] international normalized ratio [I NR]. Subsequent prothrombin 
time/international normalized ratio [ PT/INR] measurement is only  required to evaluate 
for suspected drug -induced liver injury  [DILI]).
Pregnancy  testing (serum), if applicable
Serum sample
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open- label teduglutide treatment period will comprise [ADDRESS_393932] administration (Visit CxD1).
Visit CxD1
Assessments and procedures at this visit will be performed as outlined Table 1 -4and as 
described below:
Two weeks of intake diary data are required before drug is administered at CxD1.
Confirm teduglutide treatment eligibility
Dispense intake and output diaries
Adverse events, concomitant medications, and concomitant procedure s
For non-commercial use only
Shire CONFIDENTIAL Page 48
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed
Safety  laboratory  tests
Quality  of life measurements
Antibodies to teduglutide
Pregnancy  testing (urine), if applicable
Dispense study  drug
Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cy cle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1
-4and as 
described below:
Dispense and review intake and output diaries (every  effort should be made to complete 
2weeks of intake diary  entries prior to each clinic visit and to complete 48 hours of 
output diary  entries during a period of nutritional stability  prior to each clinic visit)
Physical examination and vital signs, including weight
Record PS prescription and adjust as needed
Safety  laboratory  tests
Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)
Study  drug dispensation (except for CxW24)
Adverse events, concomitant medications and concomitant procedures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
Height and head circumference
Antibodies to teduglutide
Fecal occult blood testing (FOBT)
GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated
Quality  of life measurements
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testi ng and lack of collection will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393933] 1 escape criterion is met at the 
CxW24 visit and the pre treatment assessments occur within 7 day s of the CxW24 visit.
Phone Visits
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outli ned in Table 1 -4and described 
below:
Review intake and output diaries
Safety  laboratory  tests (clinical chemistry  and urinaly sis)
Record PS prescription and adjust as needed
Obtain AEs, concomitant medications, and concomitant procedures
Evaluate escape c riteria
7.1.5 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks (Weeks 25 -28 of the cy cle). Phone visits 
will occur on cy cle Weeks 25, 26, and [ADDRESS_393934] may
proceed directl y to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW24 or CxW28 visits with the next pretreatment visit if at least [ADDRESS_393935] is completing the study  at the CxW28 visit, the 
EOS/ET visit (Section 7.1.6 ) will take place in lieu of the CxW28 visit. Otherwise, following 
completion of the [ADDRESS_393936] will proceed to an NTT visit within 
approximately  12 weeks.
At Cy cle Week 28 (CxW28), subjects will return to the study  site. In addition to the assessments 
performed at Weeks 25 -27, the following procedures will be performed at CxW28 onl y:
Dispense and review intake and output diaries
Physical examination and vital signs, including weight
Antibodies to teduglutide
Pregnancy  testing (urine), if applicable
Evaluate escape criteria
For non-commercial use only
Shire CONFIDENTIAL Page 50
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
7.1.6 Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-[ADDRESS_393937] discontinues the study prematurel y, the as sessments for the EOS/ET 
visit are to be performed as completel y as possible (see Section 4.8.2).
Adverse events, concomitant medications, and concomitant procedures
Physical examination and vital signs, including weight
Height and head circumference
Revie
w intake and output diaries (the intake diary should be completed daily  for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary  should be completed 
daily  over a 48- hour period of nutritional stability  before the EOS/ET visit)
Record PS prescri ption and adjust as needed
Safety  laboratory  tests
Fecal occult blood testing, as indicated
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy , as indicated
Quality  of life measurements
Antibodies to teduglutide
Pregnancy  testing, as needed
7.[ADDRESS_393938]'s completion of the TED -C13-003 study  and the 
date the ICF (and if applicable, assent) is signed for the SHP633 -303 study.
[IP_ADDRESS] Growth (Height, Weight, and Head Circumference)
Retrospective bod y height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z -score, weight z -score, bod y mass index (BMI), and BM I z-score will be calculated b y 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be described as needed in the statistical analy sis plan (SAP) .
For non-commercial use only
Shire CONFIDENTIAL Page 51
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed
Any retrospective teduglutide prescription start and stop dates, dose, route, and frequency  will be 
recorded on the appropriate eCRF page.
[IP_ADDRESS] Parenteral Supp ort Prescribed
Retrospective parenteral support entries consist of [ADDRESS_393939] 
representative prescription from the interv al should be used (see Section 7.1.1 ). In addition, PS 
prescriptions at the beginning and end of an y retrospective teduglutide treatment must be 
recorded. The PS prescription includes weekl y volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
[IP_ADDRESS] Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESI s) and all serious adverse events (SAEs), regardless of causal attribution to teduglutide that 
occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safet y reporting are provided in Section 8.
The end dates for AEs that were ongoi ng at the end of TED -C13-
003 will be collected.
7.2.2 Prospective Data Collection
[IP_ADDRESS] Demographics, Medical History, and SBS History
Demographics, updates to medical history , and updates to SBS history  will be obtained at 
screening. Medical history  for purposes of t his extension study  will consist of updates to the 
medical history  collected at the start of the TED- C13-[ADDRESS_393940] has an y 
changes to the SBS history  since the baseline visit of the TED -C13-003 study , that information 
(updated SBS hist ory) will also be collected.
[IP_ADDRESS] Physical Examination
Physical examinations will be performed according to the study  schedules. Any  new clinicall y 
significant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF.
[IP_ADDRESS] Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had an y health problems since your last visit?”). 
Adverse events are collected from t he time informed consent is signed. (see Section 8, Adverse 
and Serious Adverse Events Assessment.)
For non-commercial use only
Shire CONFIDENTIAL Page 52
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
[IP_ADDRESS] Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index
Vital signs will be measured according to the study  schedules. Measurements will in clude 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body  temperature 
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same arm, 
and in the same position throughout the stud y).
Body weight will a lso be recorded in the eCRF; subjects should be weighed on the same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit.
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
[IP_ADDRESS] Clinical Laboratory Tests
Safety laboratory  tests to be performed at site visits consist of clinical chemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1 -2, Table 1-3, and 
Table 1-4). Scheduled laboratory  testing will be processed b y a central lab. All laboratory  assay s 
will be performed according to the central laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out-of- range clinical laboratory  
values for clinical significa nce, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical condition, may , at the discretion of the investigator or spons
or, 
be repeated as soon as possible until confirmed, explained, or resolved.
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_393941] of clinical chemistry  and urinal ysis and may  be processed by  [CONTACT_319438] a local laboratory . Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate an y new clini cally significant changes, they must be reported as an 
adverse event (see Section 
8.1). Urine specimen collection should be attempted as part of the 
safet y labs, but lack of urinalysis will not constitute a protocol deviation.
New clinicall y significant la bs should be reported as AEs.
For non-commercial use only
Shire CONFIDENTIAL Page 53
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
The following clinical laboratory assessments will be performed according to the study  
schedules:
Table 7-[ADDRESS_393942] of Laboratory Tests 
Hematology :
Hematocrit
Hemoglobin
Platelet count
Red blood cell count
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio
Urinalysis :
Blood
Glucose
Leukocytes
Microscopic analysis
pH
Protein
Specific gravity
Pregnancy tests (females of childbearing potential):
Serum β -HCG (screening)
Urine β -HCG (all other visits)Biochemistry :
Albumin
Alkaline phosphatase
Alanine aminotransferase
Amy lase
Aspartate aminotransferase
Bicarbonate
Bilirubin (total, direct, and indirect)
Blood urea nitrogen
Calcium (total)
Chloride
Cholesterol
C-reactive protein
Creatinine
Estimated Glomerular Filtration Rate 
(Schwartz formula)
Gamma -glutamyl transferase
Glucose
Lipase
Magnesium
Phosphorus
Potassium
Sodium
Triglycerides
Uric acid
[IP_ADDRESS] Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times:
At the pretreatment visit. If the subject arrived at the pretreatment visit by [CONTACT_319478], the serum sample will not be repeated at the pretreatment visit, because 
it will have been collected recentl y at the CxW24 visit.
At the CxW24 (EOT) visit
During NTT: Approximately  every  24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 54
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sample and/or extracted material will otherwise be stored 
for up to [ADDRESS_393943] their 
sample and/or extracted material destro yed. An y results alread y generated from the samples will 
not be removed fr om an y anal yses that have already  been performed.
[IP_ADDRESS] Pregnancy Testing
A serum pregnancy  test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy  tests will be administered at all other visits according to the study  schedules, or if 
pregnancy  is suspected, or as specified per protocol upon withdrawal of the subject from the 
study .
[IP_ADDRESS] Antibody Testing
Blood samples will be drawn for the anal ysis of antibodies to teduglutide according to the 
Schedule of Assessments ( Table 1-2, Table 1 -3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least [ADDRESS_393944] follow- up blood draws for antibodies to teduglutide every  12 weeks while 
on study  until a negative result is obtained.
[IP_ADDRESS] Volume of Blood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study . The volumes of blood to be drawn from each subject will vary  depending on 
clinical status. Approximate volumes of blood to be drawn from each sub ject annuall y are shown 
in Table 7-2.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393945] Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Parameters 1 2 2
Antibodies 2 8 16
Serum storage samples 3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volum e): 138
Subjects Not Receiving Teduglutide Treatmentb
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samples 3 2 6
Total mL per 4 “No Teduglutide Treatment” Visits 48 -week period: 24
β-hCG=beta -human chorionic gonadotropin; NTT= no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bSubjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti -teduglutide 
antibodies will require blood samples for antibody testing every [ADDRESS_393946] negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/p eriod, if they  require the same t ype of tube, the assessments should be combined. Blood 
volume estimates do not include safet y labs performed after PS adjustment, and anti -teduglutide 
antibody  testing during no- teduglutide treatment.
[IP_ADDRESS] Gastrointestinal- speci fic Testing
Fecal Occult Blood Testing
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week [ADDRESS_393947] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past and 
are therefore not teduglutide -naïve) on a roughl y annual basis (approximately every 48 -60 
weeks). Actions to be taken in response to a positive FOBT are described below.
Colonoscopy or Sigmoi doscopy
Teduglutide -naïve subjects age 12 and older will undergo colonoscopy  or sigmoidoscopy  at the 
pretreatment visit if one has not been performed within 1 y ear.
For non-commercial use only
Shire CONFIDENTIAL Page 56
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Subjects of an y age with newly positive FOBT results at the pretreatment visit for which a 
readil y detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscop y or 
sigmoidoscop y prior to receiving teduglutide. If newly positive FOBT results (for which a 
readil y detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy  or sigmoidoscopy  will be performed. The need for 
colonoscop y or sigmoidoscopy in response to positive FOBTs at an y other point during the 
study , or to reevaluate persistently  positive FOBTs is at th e discretion of the investigator.
Teduglutide -exposed subjects who have received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will undergo colonoscopy  or sigmoidoscopy . While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy  or sigmoidoscopy at 5 y ear intervals or 
more often as needed.
Upper endoscop y ma y be performed along with any colonoscop y or sigmoidoscopy at the 
investigator’s discretion. If a pol yp is found, adherence to current pol yp follow -up guidelines is 
recommended. Subjects with unresected GI pol yps, poly posis conditions, premalignant change 
or malignancy  in the GI tract will be excluded from teduglutide treatment.
[IP_ADDRESS] Nutritional Support
Nutritional support includes PS, EN , and other food and fluids. Advances in ENand/or 
reductions to PS will be based on clinical status, including weight, linear growth, hy dration 
status, and safet y laboratory  results. Intake and output diaries will include data to be considered 
in the adju stment of each subject’s nutritional support. Guidelines for nutritional support 
management and weaning algorithms are provided in Appendix 2 .
[IP_ADDRESS] Diaries
Study drug administration diary
A study  drug administration diary  will record administration of tedugluti de. This diary  should be 
completed b y the subject (or parent/legally authorized representative, as applicable) dail y during 
the teduglutide treatment periods (between visits CxD1 and CxW24).
Intake Diary
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary  
2 weeks prior to ALL scheduled prospective site visits (except at pretreatment visit). During the 
24-week teduglutide treatment period, the intake diary  will also be completed for 1 week 
following PS adjustments. The intake diary  will also be completed dail y during the 4 -week 
follow -up period. The following data will be captured in the intake diaries:
Parenteral support volume and infusion duration
Site personnel will determine the actual PS daily  calories based on diary  entries
For non-commercial use only
Shire CONFIDENTIAL Page 57
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Output Diary
Urine and stool output should be recorded in the output diary  over a 48- hour period of nutritional 
stability  before every  clinic vis it; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cy cle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
Toilet -trained subjects (who do not we ar diapers)
Measure and record all urine output in mL  or cc 
Nontoilet- trained subjects (who wear diapers)
Measure and record the weight of all urine -only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL  or 1 cc
At the discretion of the investigator, the parent or legal guardian may  be asked to collect 
the first void after the daily  PS infusion to measure specific gravit y
Stool data (includes diapers with mixed urine and stool):
Toilet -trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency  using the 
Bristol Stool Form Scale (see Output diary )
Nontoilet- trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diap ers with mixed urine and 
stool) as stool output and score the stool consistency  using the Bristol Stool Form Scale 
(see Output diary ). Stool volume will be calculated using the formula: 1 g (scale 
weight)=1 mLor 1 cc
All ostomy  output volume should be rec orded. Ostomy  output will not be scored using the 
Bristol scale.
All available diary  data will be reviewed by  [CONTACT_319479].
[IP_ADDRESS] Health -related Quality of Life Assessments
Throughout the stud y, health -related quality  of life assessments will be performed using the 
PedsQL  Generic Core Scales. Each PedsQL age- appropriate form takes less than 4 minutes to 
complete. The scales in clude self -reports for pediatric subjects and adolescents aged 5to 18 years 
and prox y-reports from parents of pediatric subjects aged 2 to 18 years.If a child is unable to 
complete the age -appropriate questionnaire (eg, due to developmental delay or other illness) it 
will not constitute a protocol deviation, but the parent should continue to complete the 
appropriate parent -specific forms.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393948] mon th, and parent -report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
Pediatric Quality of Life Generic Core Scale (PedsQL™), Acute version
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed by  [CONTACT_319416] 7 -3at the time points as outlined in Table 1-2, Table 1 -3,and Table 1 -4.
Table 7-3 Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects 
(ages 8 -12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18)aSubject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inv entory
a The Child Self Report and Parent Proxy -Report for Teens (ages 13 -18) w ill also be completed for subjects older 
than 18 years of age
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5-7), Pediatric subjects (ages 8 -12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393949] Module (PedsQL™), Acute version
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-2, Table [ADDRESS_393950] of pediatric chronic health conditions on parents and the family  (Varni et al., 2004 ). 
The 36- item PedsQL Family  Impact Module consists of 6 scales mea suring parent self- reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure parent -
reported family  functioning as follows: 1) Dail y Activities (3 items), and 2) Family  Relationships 
(5 items). The PedsQL Family  Impact Module should take the parent or legal guardian 
approximately  5-10 minutes to complete.
PedsQL Gastrointestinal Symptoms Module (PedsQL™), Acute version
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58- item module, comprised 
of 10 different s ymptom scales that assess gastrointestinal sy mptom -related quality  of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Sy mptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
clinically  relevant and appropriate for the s ymptoms experienced in this pediatric study  
population, and therefore, are the onl y scales used in this study . The scales will be completed by  
[CONTACT_319418] [ADDRESS_393951] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (invest igational) product (ICH 
Guidance E2A 1995).
Retrospective period of observation
For the retrospective data collection period (the interval between the EOS visit of the core stud y 
until signing the ICF [and informed assent, if applicable] for SHP633 -303), i nvestigators will be 
asked if they  are aware of any  nonserious AEs related to teduglutide that occurred during this 
time and an y AESIs or any SAEs, regardless of relationship to teduglutide, that occurred during 
this time. The following guidance is given f or defining a treatment -related event:
The temporal relationship between the event and the administration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product.
The event cannot be explained b y the subject’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date
 the event is recorded for this stud y 
in the eCRF.
Prospective period of observation
All prospect ive AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until the defined follow- up period stated in Section 7.1.5. This includes events 
occurring during the screening phase of the stud
y, regardless of whether or not investigational 
product is administered. Where possible, a diagnosis rather than a list of s ymptoms should be 
recorded. If a diagnosis has not been made, then each s ymptom should be listed individually . All 
AEs should be captured on the appropriate AE page s in the eCRF and in source documents. In 
addition to untoward AEs, unexpected benefits outside the investigational product indication 
should also be captured on the AE eCRF.
All prospective AEs must be followed to closure (the subject’s health has returne d to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the stud y. 
For non-commercial use only
Shire CONFIDENTIAL Page 61
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Closure indicates thatanoutcome isreached, stabilization achieved (the investigator does not 
expect any  further improvement or worsening of the event), or the event is otherwise explained. 
When appropriate, medical tests and examinations are performed so that resolution of event(s) 
can be documented.
8.1.[ADDRESS_393952] b e 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE that is usually  transient and may  require only  minima l treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of d aily living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
In consideration of whether a treatment -emergent adverse event (TEAE) might lead to dose 
interruption (Section 8.4.1) or early  termination of the study  (Section 8.5), severe TEAEs will 
also be graded according to the National Cancer Institu
te’s (NCI) Common Terminology  Criteria 
for Adverse Events (CTCAE) severit y grading criteria ( US Department of Health and Human 
Servic es et al., 2010 ).
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibi lity that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested , for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
For non-commercial use only
Shire CONFIDENTIAL Page 62
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by  [CONTACT_423]’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Not RelatedThe event can be readil y explained by  [CONTACT_11260]’s underl ying medical condition, concomitant therapy , or 
accident and no pla usible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study  drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged b y the investigator.
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline.
8.1.[ADDRESS_393953] be recorded during the course of the study  in the eCRF. Outcomes 
are as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study ; however, significant worse ning of the s ymptoms should be 
recorded as an AE.
For non-commercial use only
Shire CONFIDENTIAL Page 63
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
8.1.5 Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory  or vital sign can represent an AE if the change is 
clinically  relevant or if, during the study , a shift of a parameter is observed from a normal value 
to an abnormal value, or a further worsening of an alread y abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
If, during the study , there are abnormal clinical laboratory  values or vital signs which were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg,concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefor e represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported for the retrospective observation period from the EOS visit of 
the core stud y until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, informed assent,) in the SHP633 -[ADDRESS_393954] be reported within 24 hours to the 
Shire Global Drug Safety Department using the Shire Investigational and Marketed Products 
Pregnancy  Report Form. A copy  of the Shire Investigational and Marketed Products Pregnancy 
Report Form (and an y applicable follow -up reports) must also be sent to the Shire Medical 
Monitor using the details specified in the emergency  contact [CONTACT_1739]. 
In the event a subject becomes pregnant after signing the ICF and assent ( if applicable ), 
teduglutide administration must be discontinued immediately .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. For pregnancy  reports during the prospective period of observation, it is 
the responsibility  of the investigator to obtain this information within 30 calendar day s after the 
initial notification and approximately  30 calendar day s postpartum. For pregnancies occurring 
during the retrospective period of observation (ie, befo re signing the informed consent for 
SHP633 -303), the initial notification date will be the date the pregnancy  is recorded for this 
study  and outcome and infant condition information may  be collected any time postpartum.
For non-commercial use only
Shire CONFIDENTIAL Page 64
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Pregnancy  complications such as spont aneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for Serious Adverse Events and Non- serious AEs as Required b y the Protocol. Note: An elective 
abortion is not c onsidered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Adverse Event Form for SAEs and 
Non-serious AEs as required by  [CONTACT_89191] a s well as the Shire Investigational and Marketed 
Products Pregnancy  Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
8.1.7
Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633- 303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective pe riod of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they  result in an AE/SAE as described in Section 8.2. Note: The 24 -hour reporting 
requirement for SAEs does not apply  to reports of abuse, misuse, o verdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse –
Persistent or sporadic intentional intake of investigational product when used 
for a non -medical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may  be detrimental to the individual and/or society
Misuse –Intentional use of investigational product other than as directed or indicated 
at an y dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed b y the protocol)
Overdose –Administration of a dose greater than the allocated dose of the study  
medication or at a frequency  greater than the dosing interval speci fied b y the protocol
Medication Error –An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, medication errors are reportable to the 
sponsor only  as defined below.
 Cases of subjects missing doses of the investigational product are not 
considered reportable as medication errors
 Medication errors should be collected/reported for all products under 
investigation
 The administration and/or use of an expi[INVESTIGATOR_319396] a s a reportable medication error
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393955] provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y-authorized representative/caregiver.
8.[ADDRESS_393956] awareness of the event. Note: The 24 -hour 
reporting requirement for SAEs does not apply  to reports of abuse, misuse, overdose, or 
medication errors (see Section 8.1.7) unless they  result in an SAE.
All adverse events of special interest, as defined in Section 8.3, expe rienced during the 
prospective period of observation must be reported by  [CONTACT_319480] [ADDRESS_393957] complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Nonserious AEs as Required b y Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source d ocuments (Note: Source documents are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global Drug Safet y
Department. A cop y of the completed Shire Clinical Study Adverse Event Form for Serious 
Adverse Events (SAEs) and Nonser ious AEs as Required by  [CONTACT_1738] (and any  applicable 
follow -up reports) must also be sent to the Shire Medical Monitor or designee using the details 
specified in the emergency  contact [CONTACT_1739].
8.2.3 Serious Adverse Event Definition
Aserious adverse event (SAE) is any  untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose: 
Results in death
Is life -threatening. Note: The term 'life -threatening' in the definition of "serious" re fers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
For non-commercial use only
Shire CONFIDENTIAL Page 66
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Requires inpatient hospi[INVESTIGATOR_8686]. Note: 
Hospi[INVESTIGATOR_602], which are the result of elective or previousl y scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospi[INVESTIGATOR_230476](s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based upon appropriate medical judgment, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treat ment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
For the retrospective data collection pe riod (the interval between the EOS visit of the core study  
until signing the ICF [and informed assent, if applicable] for SHP633 -303), investigators will be 
asked if they  are aware of any  SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is recorded for this study  in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Drug Safety Department and the Shire Medical Monitor within [ADDRESS_393958] 
awareness of the event, and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to stud y drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow -up period stated in Section 
7.1.5. These SAEs must be reported to the Shire 
Global Drug Safet yDepartment and the Shire Medical Monitor within [ADDRESS_393959] 
awareness of the event, as per Section 8.2.2. 
In addition, any
 SAE(s) considered “related” to the investigational product and discovered by  [CONTACT_10194] y interval after the study  has completed must be reported to the Shire Global 
Drug Safet yDepartment within [ADDRESS_393960]’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the tim e of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investi gational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solel y as a result of the 
subject’s death.
8.2.[ADDRESS_393961], Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notify ing the 
relevant regulatory  authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notify ing activ e sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authority of all SAEs that occur at his o r her site as required.
8.[ADDRESS_393962]
An AESI  is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
[CONTACT_319481].
The AEs of special interest that require expedited regulatory  reporting include the following:
Growth of pre -existing poly ps of the colon
Benign neoplasia of the GI tract including the hepatobiliary  system
Tumor -promoting ability (eg, benign and/or malignant neoplasia of any  kind, not limited 
to those of the GI or hepatobiliary  system)
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393963] a wareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4 Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 8.5apply onl y to d ose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attem pts should be made to contact [CONTACT_103]/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059], AEs, a lapse in investigational product delivery , etc.
Study  drug must be discontinued if an y of the following events occur:
Pregnancy
Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319447]. This does not include the presence of anti- teduglutide antibodies, mild 
injection site reactions or mild sy mptoms that according to the investigator do not pose a 
significant risk to the subject.
An AE that is of NCI CTCAE severit y Grade 3 or 4 and considered to be related to study 
drug administration
Confirmed DILI related to teduglutide (see Section 8.4.2)
8.4.[ADDRESS_393964] (Prospective Period of Observation 
Only)
The investigational product must be discontinued if the subject experienced an AE that is of 
severit y ≥Grade [ADDRESS_393965]. 
In consideration of whether a TEAE might lead to dose interruption, severe TEAEs will also be 
graded according to the NCI  CTCAE severit y grading criteria ( US Department of Health and 
Human Services et al., 2010 ). All such TEAEs should be discussed with the Shire Medical 
Monitor or desig nee as soon as possible. The length of the dose interruption, a
nd whether 
teduglutide administration resumes or is permanently  discontinued, depends on the clinical 
situation.
For non-commercial use only
Shire CONFIDENTIAL Page 69
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
8.4.2 Dose Interruption Criteria Based on Drug -Induced Liver Injury 
(Prospective Perio d of Observation Only)
Teduglutide administration for an individual subject may  need to be interrupted if the subject has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following crite ria:
ALT or AST >8x ULN
ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)
ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory  values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_393966] should be followed closely to determine the trajectory  of the 
laboratory  abnormalities and to evalu ate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cy tomegalovirus IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti -smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as isc hemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investigator in consultation 
with the Shire Medical Monitor.
Teduglutide administration must be permanentl y discontinued if DILI is co nfirmed and deemed 
related to stud y drug.
8.5 Early Termination of the Clinical Study (Prospective Period of Observation Only)
The data monitoring committee (DMC )may recommend stoppi[INVESTIGATOR_319397]:
≥2subjects develop the same event of CTCAE severity  Grade [ADDRESS_393967]
or
1subject develops an event of CTCAE severity Grade [ADDRESS_393968]
For non-commercial use only
Shire CONFIDENTIAL Page 70
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
9 DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection procedu res will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safet y follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2 Clinical Data Management
Data a re to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for om issions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical da tabase, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Process
The study  will be anal yzed by  [CONTACT_10196]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4 Planned Interim Analysis, and Data Monitoring Committee
An interim anal ysis of all retrospective data will be conducted. Other interim analy ses may  also 
be conducted if needed.
A DMC will be involved in the management of this study . The DMC members will review the 
data approximately  every 3 months according to the DMC Charter. The DMC re view will 
include all cumulative safety  data (ie, AEs, laboratory  assessments, phy sical examinations, etc.) 
from study  assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investiga tional 
product.
The DMC for this study  will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393969] may not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hired by  [CONTACT_456], or members of 
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine whe ther the study  should be modified or temporaril y or 
permanentl y stopped.
9.5 Sample Size Calculation and Power Considerations
As this is an extension study , the maximum number of subjects was determined by  [CONTACT_319407] -C13-003.
9.6 Study Population
The safet ypopulation includes all enrolled subjects in the study . The safet y population will be 
used for both safet y and efficacy anal yses.
9.7 Efficacy Analyses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical sum maries will include 
number of subjects and percentages.
9.7.1 Efficacy Endpoints
Efficacy  endpoints will be anal yzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each stud y visit, relative to the baseline of the core study  (TED -C13-003) and/or 
first exposure to teduglutide. The following efficacy  endpoints will be analy zed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Complete weaning off PS
Change in day s per week of PS
For non-commercial use only
Shire CONFIDENTIAL Page 72
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
9.8 Safety Analyses
Safety  data, including laboratory  tests and vital signs assessments, will be summarized by  [CONTACT_765]. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
for quantitative safet y data as well as for the difference from baseline, if applicable. Frequency  
counts will be compi[INVESTIGATOR_319374] y data.
9.8.1 Safety Endpoints
The following safet y endpoints will be analy zed from the beginning of the prospective study  
period:
Adverse events
Vital signs, including body  temperature, heart rate, and blood pressure
Laboratory  safet y data (ie, clinical chemistry , hematology , and urinaly sis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -
specific testing including fetal occult blood testing and colonoscopy  or 
sigmoidoscop y
The following safet y endpoints will be analy zed from the end of the core study  (TED -C13-003) 
to the beginning of the prospective study  period:
Adverse events related to teduglutide
All SAEs
All AESI s (Section 8.3)
The following safet y endpoints will be analy zed relative to the baseline of the core study  
(TED -C13-003):
Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
BMI
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activ ities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by [CONTACT_319425]. Serious adverse events will be further 
summarized by  [CONTACT_230535]. Adver se events related to 
investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly 
summarized/listed.
For non-commercial use only
Shire CONFIDENTIAL Page 73
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dictionary  (WHO -
DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history  (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by  [CONTACT_6657].
For clinical laboratory  tests, vital signs, body  weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglut ide will be used to summar ize the presence of antibodies.
Additional safet y parameters and measures will include change in bod y weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weigh t z-score, BMI, and BMI z -score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseli ne at each 
scheduled visit.
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses
Health economics and outcomes research endpoints will be analy zed at approximately  12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective stud y period. The beginning of 
each treatment cy cle (CxD1) will be an additional baseline.
Change in Pediatric Quality  of Life Inventory  (PedsQL) score
Change in PedsQL Family  Impact Module score
Change in PedsQL Gastrointestinal Sy mptoms Module Sub
-Scales scores:
Food and drink limits
Diarrhea
For non-commercial use only
Shire CONFIDENTIAL Page 74
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
10 SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_393970] been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH GCP Guideline E6 (1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulation s and guidelines. Records and data may additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is respo nsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitab le clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on app licable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
For non-commercial use only
Shire CONFIDENTIAL Page 75
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
10.1.5 Study Suspension, Termination, and Completion
The s ponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally ,the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as required b y 
Article 10 (c) of Directive 20 01/20/EC.
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_393971] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potentia l for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator [INVESTIGATOR_319387]. Agreement with the final CSR is documented by  [CONTACT_319426] (single -site study ) or coordinating principal investigator (multicenter 
study ), in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 (1995). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393972] met 
protocol eligibility  criteria. Investigators 
arerequired to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and R etention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
Electronic case rep ort forms should be approved by  [CONTACT_319427].
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are uncle ar or contradictory , queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be recorded in the subject’s medical records.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_393973] permit authorized representatives of the sponsor, the respective na tional,
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the 
eCRF entries against the source documents. The consent form includes a statement b y 
which thesubject agrees to the monitor/auditor from the sponsor or its representatives, 
national or local regulatory  authorities, or the IRB/EC, having access to source data 
(eg,subject’s medical file, appointment books, original laboratory  reports, X -rays etc.). 
Nonstudy  site personnel will not disclose any  personal information or personal medical 
information.
These records must be made available wi thin reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
European Medicines Agency  (EMA), [LOCATION_006] Medicines and Healthcare products Regulatory  
Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  [CONTACT_1779], for example, the US FDA (as well as other US 
national and local regulatory  authorities), the European Medicines Agency  (EMA), the 
Medicines and Healthcare products Regulatory  Agency , other regulatory  authoriti es, the sponsor 
or its representatives, and the I RB/EC for each site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_319482] , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, c ompensation in the form of equipment, 
retainer forongoing consultation or honoraria; an y proprietary interest in investigational 
product; anysignificant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 
2(b) (1998).
10.[ADDRESS_393974]’s legall y-authorized representative, as applicable, is requested to sign 
and date the subject informed consent form or a certified translation if appli cable, after the 
subject has received and read (or been read) the written subject information and received an 
explanation of what the study  involves, including but not limited to: the objectives, potential 
benefits and risk, inconveniences, and the subject ’s rights and responsibilities. A cop y of the 
informed consent and assent documentation (ie, a complete set of subject information sheets and 
fully  executed signature [CONTACT_1787]) must be given to the subject or the subject’s legall y-authorized 
representative, a s applicable. This document may  require translation into the local language. 
Signed consent forms must remain in each subject’s study  file and must be available for 
verification at an y time.
Within the source documents, site personnel should document instr uction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
The principal investigator [INVESTIGATOR_1682] a cop y of the co nsent form, and assent form 
where applicable, that was reviewed by  [CONTACT_1201]/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the sponsor, prior to the st art of the study unless it is agreed to 
and documented (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally , if the I RB/EC requires modification of the sample subject information and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_393975] or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to t he IRB/EC for review, and all 
must be approved prior to site initiation .
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating principal investigator [INVESTIGATOR_10157], according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendme nts to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For non-commercial use only
Shire CONFIDENTIAL Page 79
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_1683]/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_393976] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_317364] (or de signee).
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives
review their medical records and data collected during the stud y. These records and data may, in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the spon sor may  develop, register, or 
market SHP633; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: t o 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of all q ualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase [ADDRESS_393977] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_10206], the principal inve stigator will own (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty
-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements,
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  [CONTACT_10207] y publication of study results, or necessary for other scholars to verify such stud y 
results. Notwi thstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_393978] publication of the study  results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163]. If such a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_10209] 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  resu lts, an investigator may  individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwise required by  [CONTACT_10210], or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights t o authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 81
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
11 REFERENCES
Drucker, D. J.and Yusta, B. 2014. Phy siology  and pharmacology  of the enteroendocrine 
hormone glucagon- like peptide -2. Annu Rev Physiol, 76, 561 -83.
Khan, F. A., Squires, R. H., L itman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., 
Sudan, D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W.and Duggan, C. 
2015. Predictors of Enter al Autonomy  in Children with I ntestinal Failure: A Multicenter 
Cohort Study . J Pediatr, 167, 29 -34.e1.
Mouksassi, M. S., Marier, J. F., Cy ran, J.and Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon -like 
peptide-2 analog in neonates and infants with short- bowel sy ndrome. Clin Pharmacol 
Ther, 86, 667-71.
O'Keefe, S. J., Buchman, A. L ., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P. B.and Shaffer, 
J. 2006. Short bowel sy ndrome and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol, 4, 6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. 
A., Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs
-Lask y, M. and Belle, S. H. 
2012. Natural history  of pediatric intestinal failure: initial report from the Pediatric 
Intestinal Failure Consortium. J Pediatr, 161, 723- 8.e2.
Tappenden, K. A., Edelman, J.and Joelsson, B. 2013. Teduglutide enhances structural adaptatio n 
of the small intestinal mucosa in patients with short bowel sy ndrome. J Clin 
Gastroenterol, 47, 602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B.and Sangild, P. T. 2014. Acute effects of the glucagon -like peptide 2 
analogue, teduglutide, on intestinal adaptation in short bowel sy ndrome. J Pediatr 
Gastroenterol Nutr, 58, 694-702.
US Department of Health and Human Services, National Institutes of Healthand National Cancer 
Institute 2010. Common Terminology  Criteria for Adverse Events (CTCAE).
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E.and Dixon, P. 2004. The 
PedsQL  Famil y Impact Module: preliminary reliability  and validity . Health Qual Life 
Outcomes, 2, 55.
Wales, P. W., de 
Silva, N., Kim, J., L ecce, L., To, T.and Moore, A. 2004. Neonatal short bowel 
syndrome: population- based estimates of incidence and mortality  rates. J Pediatr Surg,
39, 690-5.
For non-commercial use only
Shire CONFIDENTIAL Page 82
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
12 APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 83
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
APPENDIX 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol 11 May 2016 Global
Amendment 1 22 Nov 2016 Global
Amendment 1.1 09 Jan 2017 [LOCATION_006] Specific
Amendment 2 17 Mar 2017 Global
Amendment 3 16 May 2018 Global
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2 Amendment Date
17 Mar 2017Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319456]. Emergency Contact [CONTACT_7171]; 
Section 8.1.6 ; Section 8.2.2 ; Section 
8.2.4
Revised teduglutide treatment inclusion criterion #[ADDRESS_393979] been enough to assess efficacy are eligible to receive 
treatment in Study SHP633 -303. Study Synopsis; Section 4.4
Revised teduglutide treatment exclusion criterion #[ADDRESS_393980] of experimental drugs exempt of a washout period 
before initiating teduglutide treatment in Study SHP633 -303. Study Synopsis; Section 4.5; Section 
5.1.[ADDRESS_393981] pretreatment visit (P1) follows the screening visit, it must 
occur w ithin 12 w eeks of screenin g.Table 1 -4
To qualify the language on abstinence as a contraceptive method in the 
study protocol as requested by [CONTACT_319443] ([LOCATION_006]) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.Section 4.7.1
Clarification that ancillary components, in addition to sterile w ater for 
injection syringes, will also be provided and labeled in accordance w ith 
the applicable regulatory requirements.Section 6.3.1
A footnote was added in Table 7 -3 to clarify that subjects older than 
18years of age will continue to use the Child Self Report and Parent 
Proxy -Report for Teens (ages 13 -18) when completing the Pediatric 
Quality of Life Generic Core Scale (PEDSQL™).Section [IP_ADDRESS] (Table 7 -3)
For non-commercial use only
Shire CONFIDENTIAL Page 84
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2 Amendment Date
17 Mar 2017Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319483] a severe 
treatment -emergent adverse event (TEAE) that might lead to dose 
interruption (Section 8.4.1) or early termination of the study 
(Section 8.5) w ill also be graded according to the National Cancer 
Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) severity grading criteria, in addition to the standard severity 
categorization. These events are no longer limited to only the events 
described in Table 8 -1, entitled “CTCAE Cr iteria for Adverse Events 
that May Lead to Dose Interruption (Prospective Period of Observation 
Only). Therefore, Table 8 -1 has been deleted.Section 8.1.1 ; Section 8.4; Section 
8.4.1 ; Table 8 -1 (deleted)
Revised the criteria for early termination of the study as requested by 
[CONTACT_319457] 06 Jan 2017: stoppi[INVESTIGATOR_3418] w ere 
extended to all NCI CTCAE Grade [ADDRESS_393982], and no longer limited to the 
events described in Table 8 -1, entitled “CTCAE Criteria for Adverse 
Events that May Lead to Dose Interruption (Prospective Period of 
Observation Only).Section 8.5
Amendment Number 1.1 Amendment Date
09 Jan 2017United -Kingdom -Specific
Description of Change and Rationale Section(s) Affected by [CONTACT_319442] a contraceptive method in the 
study protocol as requested by [CONTACT_319443] ([LOCATION_006]) Medicines 
and Healthcare products Regulatory Authority (MHRA) in their letter 
dated 29th December 2016.Section 4.7.1
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319453].Protocol Signature [CONTACT_319504] [CONTACT_319431] -teduglutide treatment 
period, visits will take place approximately every 12 w eeks.Synopsis
Sections 3.1, 3.1.3, 7.1.3
Figure 3 -1
For non-commercial use only
Shire CONFIDENTIAL Page 85
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319484]. Synopsis
Figure 3 -1
The collection of all actual and prescribed enteral nutrition data has 
been removed to reduce the burden on the subjects and investigators. 
Enteral nutrition data are not required as the efficacy endpoints are 
limited to parenteral support parameters.Synopsis
Table 1 -2, Table 1 -3, Table 1 -4
Sections 3.1.3, 7.1.2, 7.1.3, [IP_ADDRESS], 
[IP_ADDRESS], 7.1.6, [IP_ADDRESS], [IP_ADDRESS]
Exclusion criterion [ADDRESS_393983] been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to [ADDRESS_393984] been refined.Table 1 -1
Sections 7.1.1, [IP_ADDRESS], [IP_ADDRESS]
Com pletion and review of intake and output diaries have been clarified. 
Also, review of diaries has been removed from the screening visit and 
added to the pretreatment visit.Table 1 -2, Table 1 -3, Table 1 -4
Sections 7.1.2, [IP_ADDRESS], [IP_ADDRESS], 7.1.6, 
[IP_ADDRESS]
The requirement for urine specimen collection has been revised so that 
a lack of urinalysis will not constitute a protocol deviation for any 
pediatric subjects (not only for subjects w earing diapers).Table 1 -2, Table 1 -3, Table 1 -4
Section [IP_ADDRESS]
Clarification has been made that the first no -teduglutide treatment visit 
after the screening visit will occur within 2 to 12 w eeks of the screening 
(formerly within 12 w eeks of s creening). Synopsis
Table [ADDRESS_393985] been clarified for visits during the no -teduglutide and 
teduglutide treatment periods.Table 1 -3, Table 1 -4
Section 7.1.3
‘Specific’ has been deleted from ‘positive/specific anti -tedugluti de 
antibodies’ to eliminate the redundancy. By [CONTACT_108], positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative. Table 1 -3 
Sections [IP_ADDRESS], 9.8.1
For consistency within the protocol, sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol. Table 1 -2, Table 1 -3, Table 1 -4
Sections 3.1.3, 7.1.3, [IP_ADDRESS]
Removal of former footnote j on fecal occult blood test for clarity. Table 1 -4
For non-commercial use only
Shire CONFIDENTIAL Page 86
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319485]28 visit 
may be combined with the next pretreatment or EOS/ET visit.Table 1 -4
Section 7.1.5
The text on PS support requirements over time in pediatric subjects 
with SBS has bee n clarified, and text on intestinal adaptation has been 
refined.Section 1.1
Status of current teduglutide approvals for use has been updated. Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced w ith ‘additional teduglutide 
treatment’ and ‘PN/IV’ with ‘PS’ for clarity and consistency w ith other 
studies.Synopsis
Sections 3.1, 3.1.[ADDRESS_393986] been clarified.Sections 4.8.1, 4.8.2
Withdraw al by [CONTACT_7078]/gu ardian has been added as reason for 
discontinuation.Section 4.8.[ADDRESS_393987] if deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study 
drug ha s been clarified.Section 6.4
Paragraph on the purpose of prospective data collection has been 
deleted for clarity.Section 7.2.2
Clarification has been made on the collection of medical history and 
SBS history.Synopsis
Sections 3.1.3, 7.1.2, [IP_ADDRESS]
A new section which describes the adverse event (AE) collection during 
the prospective period has been added to the study evaluations and 
procedures. Section [IP_ADDRESS]
Clarification has been made that local laboratory results are not 
required to be entered in the eCRFs. (formerly Section [IP_ADDRESS])Section [IP_ADDRESS]
Collection of urine sodium and urine osmolality has been removed. Section [IP_ADDRESS]
Clarification has been made that the serum sample will not be collected 
at the pretreatment visit if the subject met a follow -up period escape 
criterion. (formerly Section [IP_ADDRESS])Section [IP_ADDRESS]
Nutritional support and diaries (formerly in Section [IP_ADDRESS]) have been 
moved under separate sections (Sections [IP_ADDRESS] and [IP_ADDRESS], 
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that 
only available diary data will be review ed at each clinic and telephone 
visit.Sections [IP_ADDRESS], [IP_ADDRESS] 
For non-commercial use only
Shire CONFIDENTIAL Page 87
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319486]. It is now at the discretion of the investigator for all subjects, 
not just those in diapers. This change is to align with standard medical 
practice.Section [IP_ADDRESS] 
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety secti ons of the protocol. Only 
nonserious AEs related (instead of possibly related ) to teduglutide need 
to be reported. No changes to the protocol w ere made for the reporting 
of all AEs of special interest or any serious adverse events, regardless 
of relationsh ip to teduglutide, that occurred during the retrospective 
period.Section 8.[ADDRESS_393988] been made to the language on dose 
interruption.Sections 8.4, 8.4.1
Unscheduled safety follow  up assessments (including visits conducted 
after EOS) are not to be recorded. How ever, clarification has been made 
that they are to be collected where requested.Section 9.1
Clarification has been made that the interim analysis will be conducted 
on all retrospective data, and other interim analyses may also be 
conducted if needed.Section 9.4
The protocol now  refers to the data monitoring committee (DMC) 
Charter for the schedule of DMC reviews.Section 9.[ADDRESS_393989] been made to the guidelines for nutritional 
support management during the study.Appendix 2
For non-commercial use only
Shire CONFIDENTIAL Page 88
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
APPENDIX 2 GUIDELINES FOR NUTRI TIONAL SUPPORT MANAG EMENT 
DURING THE STUDY
Nutritional supp ort adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutr itional support 
(PS and/or oral/enteral feeding) in terms of volume and calori es during the treatment period.
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical eva luations
Serum electrol ytes
Blood urea nitrogen /creatinine levels
Changes in stool frequency  or volume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte changes or imbalance
Skin breakdown 
Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the stud y.
Nutritional support constituents may  be adjusted at t he discretion of the investigator.
During the [ADDRESS_393990]’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.
If there is a change in EN or other food or fluid intake, the i nvestigator should consider this 
when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 89
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 90
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Figure A -2 Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diap ers
For non-commercial use only
Shire CONFIDENTIAL Page 91
SHP633 -303 Protocol Am endment 3
Teduglutide 16 May 2018
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
PROTOCOL: SHP633 -303
TITLE: A Retrospective and Prospective, Open -label, Long -term Safet y and 
Efficacy  Study  of Teduglutide in Pediatric Subjects with Short Bowel 
Syndrome Who Completed TED- C13-003
DRUG: Teduglutide
IND: IND# [ADDRESS_393991] NO.: 2016-000863-17
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_393992] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Amendment 4: [ADDRESS_393993] 2019
Amendment 3: 16 May  2018
Amendment 2: 17 Mar 2017
Amendment 1.1: 09 Jan 2017 ([LOCATION_008] -Specific)
Amendment 1: 22 Nov 2016
Original Protocol: [ADDRESS_393994] party without the express written consent of Shire.
For non-commercial use only
Shire CONFIDENTIAL Page2 
SHP633-303 Protocol Amendment 4 
Teduglutide 01Oct2019 
PROTOCOL SIGNATURE [CONTACT_64783]'s (Shire) Approval 
Signature: 
 
[CONTACT_319505]'s Acknowledgement 
I have read this protocol for Shire Study SHP633-303. • Date: 
Title: A retrospective and prospective, open-label, long-term safety and efficacy study of 
teduglutide in pediatric subjects with short bowel syndrome who completed TED-C13-[ADDRESS_393995] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the 
study, without written authorization from the sponsor. It is, however, permissible to provide 
the information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good 
Clinical Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at 
any time for whatever reason; such a decision will be communicated to me in writing. 
Conversely, should I decide to withdraw from execution of the study I will communicate my 
intention immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) 
For non-commercial use only

Shire CONFIDENTIAL Page [ADDRESS_393996] 2019
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION   
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number [ADDRESS_393997] 2019Global
Description of Change and Rationale Section(s) Affected by 
[CONTACT_319487] S ponsor Medical Monitor w as updated to 
. 
(Administrative letter dated [ADDRESS_393998] 2018)
The fax number of the S ponsor Medical Monitor w as removed. 
(Administrative letter dated 15 Jan 2019)Emergency Contact 
[CONTACT_319488] w as updated to reflect Quintiles ’current name ,
IQVIA ,and  email address as Emergency Contact 
[CONTACT_319489] 2020. Study Synopsis
Clarification of the follow -up period escape criteria and their use in combining the 
CxW24 and pretreatment visits w as added.
(Clarification Memo dated 09 Apr 2019)Study Synopsis , 
Section 4.[ADDRESS_393999] dose of teduglutide in the study even if the EOS/ET occurs within that timeframe.Table 1 -2, Section 7.1.6 ,
Section 8.1
An optional qualitative interview  to be conducted by [CONTACT_319490] 14 days after 
completion of the end of study/early termination visit was added. A single individual 
telephone intervie w will be conducted with English -speaking parents (or legal 
guardians) of subjects and subjects aged 12 years or older who prov ide informed 
consent (and if applicable, informed assent) to participate in the interview. These 
interviews will be performed in selected countries participating in this trial.Table 1 -2, Section 7.1.7 , 
Section [IP_ADDRESS] , 
Section 9.9.2 , Appendix 3, 
Appendix 4
Noted that stored serum samples should be omitted for subjects weighing less than 
15kg and whenever local blood volume limitations are exceeded.Table 1-3, Table 1-4, 
Section [IP_ADDRESS] , Table 7-[ADDRESS_394000] at a dose or frequency greater than 0.05 mg/kg subcutaneous once daily. An 
overdose occurs if any of the follow ing criteria are met: 
More than 0.05 mg/kg is g iven at any one time
Consecutive doses are spaced less than 12 hours apart
Any more than 0.05 mg/kg given in one day (a day is defined as beginning at 
12:00 AMand ending at 11:59 PM)Section 8.1.[ADDRESS_394001] 2019
Summary of Change(s) Since Last Version of Approved Proto col
Amendment Number [ADDRESS_394002] 2019Global
Description of Change and Rationale Section(s) Affected by 
[CONTACT_319491] w ere updated to specify events leading to an 
interruption of teduglutide treatment and events leading to a permanent 
discontinuation of teduglutide treatment. 
Investigational product must be interrupted if any of the follow ing events occur:
An AE of special interest
An AE that is of NCI CTCAE severity Grade 3 or 4 and related to teduglutide
Intestinal obstruction
Biliary obstruction related to teduglutide
Pancreatic duct obstruction related to teduglutide
Heart fa ilure with severe fluid overload related to teduglutide 
Investigational product must be permanently discontinued if any of the following 
events occur:
Pregnancy
Severe hypersensitivity, such as anaphylaxis determined by [CONTACT_319492] s tudy drug. This does not include the presence of anti -teduglutide 
antibodies, mild injection site reactions or mild symptoms that according to the 
investigator do not pose a significant risk to the subject.
Confirmed drug -induced liver injury (DILI) relate d to teduglutide 
Any malignancy
These clarifications were made for consistency with other teduglutide studies. Section 8.4, Section 8.4.1
Minor editorial changes and corrections to typographical errors (w hich do not modify 
content and/or intent of the original document) were made.Throughout the protocol
See Appendix [ADDRESS_394003] IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Nonserious AEs as 
Required b y Protocol within 24 hours to the Shire Global Drug Safet y Department. Applicable 
fax numbers and e -mail address can be found on the form (sent under separate cover). A co py of 
this form must also be sent to the S ponsor Medical Monitor by  e-mail using the details below.
, MD
Email: 
For protocol -or safet y-related issues, the investigator must contact [CONTACT_319493]:
Primary  contac t for [LOCATION_002] and backup contact [CONTACT_319494]
, MD, 
Mobile: 
US Toll Free number: 
Phone:  (medical emergencies –US)
Email: 
Primary  contact [CONTACT_319474]
, MD, 
Mobile: 
Phone: 
Phone:  (medical emergencies –EU)
Email: 
In addition, the investigator may  also contact [CONTACT_941] S ponsor Medical Monitor (8:00 to 20:[ADDRESS_394004] Time):
, MD, 
Mobile: 
Email: 
r n ommercial use only

Shire CONFIDENTIAL Page [ADDRESS_394005](s) will be returned to the 
sponsor for inspection and anal ysis.
A product quality  complaint includes any  instances where there is an allegation or report relating 
to Shire licensed or investigational products, received in writing, electronically , or orall y, which 
indicates an impact to a product’s strength, identity, safet y, purit y, or quality, or which suggests 
that the product did not meet the criteria defined in the regulatory  applications, licenses, or 
marketing authorizations for the product. Examples of investigational product quality  complaints 
include, but are not limited to, the following:
Unit issues Capsule fill empty  or overage
Bottle/vial fill shortage or overage
Capsule/tablet damaged/broken
Syringe/vial cracked/brokenSyringe leakage
Missing components
Product discoloration
Device malfunction
Labeling Label missing
Leaflet or Instructions For Use 
(IFU) missing 
Label illegibleIncomplete, inaccurate, or 
misleading labeling
Lot number or serial number missing
Packaging Damaged packaging (eg, secondary , 
primary , bag/pouch)
Tampered seals
Inadequate or faulty  closureMissing components within package
Foreign 
materialContaminated product
Particulate in bottle/vial
Particulate in packaging
Please report the product quality complaint using the “Product Quality  Complaint Data 
Collection Form” via the email address:
Telephone number (provided for reference if needed):
Shire, Lexington, MA ([LOCATION_003])
For instruction on reporting AEs related to product complaints see Section 8.
For non-commercial use only

Shire CONFIDENTIAL Page [ADDRESS_394006] Background .................................................................................................27
1.3 Clinical Studies with Teduglutide in Pediatric Subjects ..........................................28
2STUDY OBJECTIVES AND PURPOSE ..............................................................................29
2.1 Rationale for the Study .............................................................................................29
2.2 Study  Objectives ......................................................................................................29
2.2.1 Primary  Objectives .........................................................................................29
2.2.2 Secondary  Objectives .....................................................................................29
3STUDY DESIGN ...................................................................................................................30
3.1 Study  Design and Flow Chart ..................................................................................30
3.1.1 Informed Consent/Assent and Eligibility .......................................................[ADDRESS_394007] 2019
4.8.1 Teduglutide Discontinuation ..........................................................................38
4.8.2 Study  Withdrawal ...........................................................................................38
4.8.3 Reasons for Discontinuation ...........................................................................39
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................[ADDRESS_394008](s) ...........................................................[ADDRESS_394009] Compliance ..................................................................................................44
7 STUDY PROCEDURES........................................................................................................45
7.1 Study  Schedule .........................................................................................................45
7.1.1 Retrospective Data Collection ........................................................................45
7.1.2 Screening ........................................................................................................46
7.1.3 Visits for Subjects Not Receiving Teduglutide ..............................................47
7.1.4 Visits for Subjects Receiving Teduglutide Treatment ....................................47
[IP_ADDRESS] Pretreatment Visit ...................................................................................47
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24) .....................................48
7.1.5 Teduglutide Follow -up Period ................................
........................................50
7.1.6 Study  Completion/Earl y Termination Visit (EOS/ET Visit) ..........................51
7.1.7 Qualitative Interview ......................................................................................51
7.2 Study  Evaluations and Procedures ...........................................................................51
7.2.1 Retrospective Data Collection ................................
........................................51
[IP_ADDRESS] Growth (Height, Weight, and Head Circumference) ............................. [ADDRESS_394010] 2019
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed ................................................52
[IP_ADDRESS] Parenteral Support Prescribed ................................................................52
[IP_ADDRESS] Adverse Events .......................................................................................52
7.2.2 Prospective Data Collection ...........................................................................52
[IP_ADDRESS] Demographics, Medical History , and SBS History ................................52
[IP_ADDRESS] Physical Examination .............................................................................52
[IP_ADDRESS] Adverse Event Collection.......................................................................53
[IP_ADDRESS] Vital Signs, Bod y Weight, Height, Head Circumference and Bod y 
Mass I ndex .............................................................................................53
[IP_ADDRESS] Clinical L aboratory  Tests .......................................................................53
[IP_ADDRESS] Serum Sampling ................................
.....................................................54
[IP_ADDRESS] Pregnancy  Testing ..................................................................................55
[IP_ADDRESS] Antibody  Testing ....................................................................................55
[IP_ADDRESS] Volume of Blood ....................................................................................55
[IP_ADDRESS] Gastrointestinal -specific Testing ............................................................56
[IP_ADDRESS] Nutritional Support .................................................................................57
[IP_ADDRESS] Diaries ....................................................................................................57
[IP_ADDRESS] Health- related Quality  of L ife Assessments ...........................................59
[IP_ADDRESS] Qualitative Interviews ................................
............................................60
8ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................64
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................64
8.1.1 Severity  Categorization ..................................................................................65
8.1.2 Relationship Categorization ............................................................................65
8.1.3 Outcome Categorization .................................................................................66
8.1.4 Symptoms of the Disease under Study ...........................................................66
8.1.5 Clinical L aboratory  and Other Safet y Evaluations (Prospective Period 
of Observation Only ) ......................................................................................67
8.1.6 Pregnancy .......................................................................................................67
8.1.7 Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Onl y)..........................................................................................[ADDRESS_394011] ...........................................................................71
8.4 Dose Interruption of Individual Subjects (Prospective Period of Observation 
Only ).........................................................................................................................[ADDRESS_394012] (Prospective Period of 
Observation Onl y)..........................................................................................73
8.4.2 Dose Interruption Criteria Based on Drug- Induced L iver Injury  
(Prospective Period of Observation Onl y)......................................................73
8.5 Early Termination of the Clinical Study  (Prospective Period of Observation 
Only ).........................................................................................................................74
9DATA MANAGEMENT AND STATISTICAL METHODS...............................................75
9.1 Data Collection .........................................................................................................75
9.2 Clinical Data Management .......................................................................................75
9.3 Statistical Analysis Process ......................................................................................75
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................75
9.5 Sample Size Calculation and Power Considerations................................................76
9.6 Study  Population ......................................................................................................76
9.7 Efficacy  Anal yses.....................................................................................................76
9.7.1 Efficacy  Endpoints ..........................................................................................76
9.8 Safety  Anal yses........................................................................................................77
9.8.1 Safety  Endpoints .............................................................................................77
9.9 Other Anal yses.........................................................................................................78
9.9.1 Health- related Quality  of L ife Anal yses.........................................................78
9.9.2 Qualitative Interviews .....................................................................................78
10SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES...........................................79
10.1 Sponsor’s Responsibilities .......................................................................................79
10.1.1 Good Clinical Practice Compliance ................................................................79
10.1.2 Indemnity /Liability  and Insurance ..................................................................79
10.1.3 Public Posting of Study  Information ..............................................................79
10.1.4 Submission of Summary  of Clinical Study  Report to Competent 
Authorities of Member States Concerned and Ethics Committees ................80
10.1.5 Study  Suspension, Termination, and Completion ..........................................80
10.2 Investigator’s Responsibilities .................................................................................80
10.2.1 Good Clinical Practice Compliance ................................
................................80
10.2.2 Protocol Adherence and Investigator Agreement ...........................................81
10.2.3 Documentation and Retention of Records ......................................................81
[IP_ADDRESS] Case Report Forms .................................................................................[ADDRESS_394013] 2019
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................81
[IP_ADDRESS] Audit/I nspection .....................................................................................82
[IP_ADDRESS] Financial Disclosure ...............................................................................[ADDRESS_394014] or Ethics Committee ...........................................83
10.4 Privacy  and Confidentiality ......................................................................................84
10.5 Study  Results / Publication Policy ...........................................................................[ADDRESS_394015]  OF TABLES
Table 1-1 Schedule of Events for Retrospective Data Collection Period 
(Required for All Subjects) ...........................................................................[ADDRESS_394016] 
Annually ........................................................................................................56
Table 7-3 Developmentally Appropriate PedsQL™Generic Core Scales .....................[ADDRESS_394017] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study report
CTCAE Common Terminology Criteria for Adverse Events
DILI drug-induced livery injury
DMC data monitoring committee
DPP-[ADDRESS_394018] 2019
Abbreviations Definitions
NTT no-teduglutide treatment
PedsQL Pediatric Quality of Life Inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once daily
SAE serious adverse event
SAP statistical analysis plan
SBS short bow el syndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_394019] 2019
STUDY  SYNOPSIS
Protocol num ber: SHP633 -303 Drug: Teduglutide
Title of the study: A Retrospective and Prospective, Open -label, Long -term Safety and Efficacy Study of 
Teduglutide in Pediatric Subjects with Short Bow el Syndrome Who Completed TED -C13-003
Number of subjects (total and for each treatm ent arm):
Approximately [ADDRESS_394020] of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
completed the TED -C13-003 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 17 investigational sites in the [LOCATION_002] (US) and the [LOCATION_008] ([LOCATION_006]) w ill participate in 
this extension study.
Study period (planned):
October 2016 -December 2020Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith short 
bowel syndrome (SBS) who completed TED -C13-003.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS who completed 
TED -C13-003.
Rationale:
This is a Phase 3, retrospective and prospective, open -label, long -term extension study to evaluate the safety and 
efficacy of teduglutide in pediatric subjects with SBS who completed the TED- C13-[ADDRESS_394021] of care (SOC) treatment arm in 
TED -C13-003.
Investigational product, dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED -C13-003 study (the core study). 
To evaluate efficacy and safety from the time subjects com pleted the core study to the time they enter this extension 
study, retrospective data collection is planned for this study. The retrospective data collection will consist of 
specific safety and efficacy measures that were completed in the course of the subject’s standard medical care 
betw een the date of the TED -C13-003 end of study (EOS) visit and the date the informed consent form (ICF) (and 
if applicable, informed assent) is signed for this study. In addition to this retrospective data collection, prospec tive 
study assessments of safety and efficacy will be completed as a part of this study.
Informed Consent/Assent and Eligibility
The review  and signing of the ICF (and if applicable, informed assent) for this study, must be completed before any 
other study procedure. Subjects will be encouraged to consent to participate in the prospective and retrospective 
portions of this study; however subjects may consent to retrospective data collection only. Subjects may not consent 
to the prospective data collection only. After informed consent/assent is obtained, study eligibility will be assessed 
for all subjects.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394022]’s standard medical care betw een the date of the TED -C13-003 EOS visit and the date the ICF (and if 
applicable, informed assent) is signed for this study. Retrospective data collection may begin any time after 
informed consent/assent is obtained for this study. The following retrospective data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Grow th (height, head circumference [up to 36 months of age], w eight)
End dates for adverse events (AEs) ongoing at the time of TED -C13-003
All nonserious AEs relate d to teduglutide treatment
All adverse events of special interest ( AESIs)
All serious adverse events (SAEs)
Prospective Data Collection andTreatment
Additional screening visit procedures for prospective data collection assessments can be found in Table 1 -2.These 
procedures include but are not limited to, collection of demographics, and updates to medical history and short 
bowel syndrome history. The parenteral support prescription w ill also be collected at screening.
Additionally, intake diaries will be d ispensed at the screening visit for collection of actual parenteral support (PS) 
volume and hours per day (Section [IP_ADDRESS]). Diary data for PS volume will be collected for at least 2 w eeks after 
the ICF (and if applicable, the informed assent) is signed f or this study.
Subjects not receiving teduglutide treatment (ie, in a no -teduglutide treatment [NTT] period), w ill be seen 
approximately every 12 weeks for safety, parenteral support (PS) requirements, and quality of life. Diary data for 
PS volume will be collected for at least [ADDRESS_394023] NTT visit after the screening visit 
will occur within 2 to 12 w eeks of the screening visit. At any point after screening, including during an NTT period, 
subjects who meet ≥[ADDRESS_394024], and parent or legal guardian agrees to proceed with teduglutide therapy .
After the pretreatment visit, subjects who meet ≥1 of the teduglutide treatme nt inclusion criteria, and meet none of 
the teduglutide treatment exclusion criteria, w ill start a 28 -week cycle, consisting of 24 w eeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up (no treatment) period (Figure 3 -1). During 
the 28 -week cycle, clinic visits will occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required 
approximately 1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 24), 
and w eekly during the follow -up period (betw een Weeks 24 and 28). Safety and PS requirements will be evaluated 
at every visit, and quality of life assessments will be made approximately every [ADDRESS_394025] may "escape" the follow -up period 
early and proceed immediately to another pretreatment visit. Follow ing completion of the [ADDRESS_394026] w ill proceed to an NTT visit or another pretreatment visit within approximately 12 w eeks.
At all site visits and telephone contacts, safety will be monitored and nutritional support will be reviewed and 
adjusted as needed. Quality of life assessments will be made approximately every 12 w eeks. To m aintain 
consistency acr oss centers, all attempts should be made to follow  the nutritional support adjustment guidelines 
(developed w ith SBS expert input and provided in the protocol) for decisions regarding PS reduction and advances 
in enteral feeds based on weight gain, urine a nd stool output, and clinical stability. Departure from the guidelines, 
however, is not considered a protocol deviation (Appendix 2).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394027] 2019
Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy.
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and 
efficacy assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approximately 
1week after adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects 
discontinue teduglutide at Week 24 and enter a 4 -week follow-up (no -treatment) period, during which phone visits will be 
performed weekly ( solid grey lines ). If an escape criterion is met at Week 24 or during the follow -up period, subjects may 
proceed directly to another pretreatment visit.
Study Inclusion Criteria:
The subject will be considered eligible for the study if they meet allof the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study -related procedures.
2.Subject completed the TED -C13-003 study (including subjects in the standa rd of care treatment arm).
3.Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol.
Study Exclusion Criteria:
There are no exclusion criteria for this study.
Teduglutide Treatment Eligibility Criteria:
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_394028] (and/or parent or 
legal guardian, as app ropriate) must agree to proceed with treatment.
Teduglutide Treatment Inclusion Criteria :
1.Subject is receiving PS and unable to significantly reduce PS or advance enteral feeds (eg, 10% or less 
change in PS or advance in feeds) for at least 3 months prior to and during the teduglutide pretreatment 
visit, as assessed by [CONTACT_093]. Transient instability for events such as interruption of central access 
or treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the event.
2.Subject w as previously treated w ith teduglutide and at least 1 of the following criteria is satisfied:
a.Increasing PS requirements follow ing teduglutide discontinuation
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394029] 2019
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319475]
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319391] (EN) following teduglutide discontinuation
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361]
e.Severe diarrhea related to teduglutide discontinuation
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <10 kg at the pretreatment visit
2.Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract
3.History of cancer in the previous 5 years except surgically curative skin cancers
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle
6.Clinically significant intestinal stricture or obstruction
7.Clinically significant, active or recurrent pancreatic or biliary disease
8.Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laborat ory values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_319476]  50mL/min/1.[ADDRESS_394030] repair, or patent ductus arteriosus ligation
11.Participat ion in a clinical study using an experimental drug (other than glutamine, Omegaven, Smoflipid, 
or teduglutide) w ithin 3 months or 5.5 half -lives of the experimental drug, whichever is longer, prior to 
the pretreatment visit and for the duration of the 28 -week cycle 
12.Treatment with analogs of glucagon -like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP -2) (not 
including teduglutide), insulin -like growth factor -1 (IGF -1), or grow th hormone, within 3 months 
preceding the teduglutide pretreatment visit
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_394031], closely -related 
compounds, or any of the stated ingredients
15.Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit
16.Pregnant or lactating female subjects
17.Sexually active female subjects of child -bearing potential unwilling to use approved contraception 
during teduglutide treatm ent and for 30 days after the treatment period
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents completion of the study, or interferes with analysis of the study results
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394032] 2019
Follow-up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interrupted 
(if the subject meets 1or more of escape criteria 1 to 4 during the follow -up period) or omitted (if the subject 
meets escape criterion 5 at the CxW24 visit) and the subject may proceed directly to the pretreatment visit, if 
≥1of the following criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319398]
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319399]
4.Severe diarrhea related to teduglutide discontinuation
5.The subject escaped during the follow -up period of a previous teduglutide treatment cycle within 
SHP633 -303. In this case, the CxW24 visit may be combined w ith the next cycle pretreatment visit.
Maximum duration of subject involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed informed consent (and if 
applicable, informed assent), and meets all of the Study Inclusion Criteria. Subjects may participate in multiple 
NTT periods and/or multiple [ADDRESS_394033] has access (as needed) to teduglutide. T he subject’s maximum duration of participation is expected to be 
approximately [ADDRESS_394034] has not 
withdrawn early from the study for any reason prior to completing end of study (EOS) v isit.
Planned duration of no -teduglutide treatm ent periods: variable, depending on disease course
Planned duration of the teduglutide pretreatm ent visit: 1-21 days
Planned teduglutide treatment cycle duration :28 w eeks. Each cycle consists of 24 w eeks of 
teduglutide treatment followed by a 4 -week follow -up period (no treatment)
Endpoints and statistical analysis:
The safety population includes all enrolled subjects. The safety population will be used for both safety 
and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED -C13-003) and/or first exposure to 
teduglutide. The f ollowing efficacy endpoints will be analyzed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research Endpoints
Health economics and outco mes research endpoints will be analyzed at approximately 12 -week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 w eeks for subjects not on teduglutide), 
relative to the baseline of the prospective study period. The beginning of each treatment cycle (CxD1) will be an 
additional baseline.
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores:
oFood and drink limits
oDiarrhea
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394035] 2019
Safety Endpoints
The follow ing safety endpoints will be analyzed from the beginning of the prospective study period:
Adverse events
Vital signs, including body temperature, heart rate, and blood pressure
Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing, including fetal occult blood testing and colonoscopy or sigmoidoscopy
The follow ing safety endpoints will be analyzed from the end of the core study (TED- C13-003) to the beginning of 
the prospective study period:
 Adverse events related to teduglutide
 All SAEs
 All Adverse Events of Special Interest (Section 8.3)
The follow ing safety endpoints will be analyzed relative to the baseline of the core study (TED -C13-003):
 Z-scores for height (or length), w eight, head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; how ever, 95% confid ence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For c ategorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis
Safety data, including laboratory tests and vital signs assessments, will be summarized by [CONTACT_765]. Adverse events 
will a lso be collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well 
as for the difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_300192].
Sample Size Justification
As this is an extension study, the maximum number of subjects was determined by [CONTACT_319435] -C13-003.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394036] 2019
STUDY  SCHEDULES
Table 1-1 Schedule of Events for Retrospective Data Collection Period (Required for All 
Subjects)
Assessment Note
Informed consent/assent Informed consent (and if applicable, informed assent) must be obtained and 
study eligibility must be determined prior to performing any other study -related 
procedures, including retrospective data collection.Study eligibility
WeightaThe last representative value for w eight during each [ADDRESS_394037] all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency. Prescription 
data includes teduglutide treatment in investigator -initiated trials, 
compassionate use, and named -patient access programs.
Parenteral support (PS) 
prescribedaThe last representative PS prescription during each 12 -week interval throughout 
the retrospective period and at the beginning and end of any teduglutide 
treatment will be collected. Data collected should include weekly prescribed 
volume, calories, average hours per day, and days per w eek of prescribed PS.
End dates for adverse events 
(AEs) ongoing at the end of 
TED -C13-[ADDRESS_394038]
Serious adverse events (SAEs)
AEs=adverse events; CRFs=case report form; EOS=end of study; ICF=informed consent form; PS=parenteral support; 
SAEs=serious adverse events
aThe first 12 -week interval begins at TED -C13 -003 EOS visit.
Note: Retrospective data are defined as specific safety and efficacy assessments that were completed during the retrospective 
observation period, defined as the interval between the date of the TED -C13 -003 end of study (EOS) visit and the date the 
informed consent form (ICF) (and if applicable, informed assent ) is signed for this study. Failure to collect retrospective data 
because data are unavailable will not be considered a protocol deviation. For subjects who consent only to retrospective data
collection, only assessments in this table will be completed. Se e Section 7.1.[ADDRESS_394039] 2019
Table 1-2 Schedule of Events for Screening and End of Study or Early Termination
ScreeningEnd of Study or Early 
Termination
Visit Type Site Site
Informed consent/assent X
Study eligibility X
Dem ographics, medical history, SBS historyaX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriabX
Adverse events X Xl
Concomitant medications and procedures X X
Physical examination and vital signs, including weight X X
Height and head circumferencecX X
Revie w intake and output diariesdX
Record PS prescription and adjust as neededeX X
Safety laboratory testsfX
PedsQL Generic Core Scale/ PedsQL Family Impact 
Module/ PedsQL Gastrointestinal Symptoms Module 
Sub-ScalesX
Antibodies to teduglutidegX
Fecal occult blood testingh(X)
Colonoscopy or sigmoidoscopyi(X)
Pregnancy testingj(X)
Qualitative interviewkX
EOS =end of study; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child -bearing potential; 
GI=gastrointestinal; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=short bowel syndrome
aIf the subject has any changes to the medical history and SBS history that had been collected at the baseline of the 
TED -C13 -003 study, then the updated medical history and SBS history will be collected.
bSubjects who meet ≥[ADDRESS_394040], 
and parent or legal guardian agrees to proceed with teduglutide therapy ( Table 1 -4).
cHead circumference willbe measured in subjects 36 months of age and younger.
dThe intake diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be 
completed daily over a 48 -hour period of nutritional stability before the EOS/ET visit.
eParenteral support prescription will be collected at the screening visit. Parenteral support adjustm ents should be made after 
review of any available intake and output diaries and the safety lab data according to the guidance for nutrition support 
adjustment provided in Appendix [ADDRESS_394041] of clinical c hemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis wil l not 
constitute a protocol deviation.
g Required for all teduglutide -exposed subjects.
h Fecal occult blood testing should be performed on teduglutide -exposed subjects on an annual basis, approximately every 
48-60weeks at a minimum.
i The need for colonoscopy/sigmoidoscopy in response to a positive FOBT result during a no -teduglutide treatment period is at 
the discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscopy/sigmoidoscopy at 5 year intervals or more often as needed. See Section [IP_ADDRESS] for details.
jPregnancy testing is required for FOCBP at an ET visit if the subject has not had a pregnancy test at least 30 days after study 
drug discontinuation.
k Optional interview to be conducted by [CONTACT_1382] 14 days after completion of the EOS/ET visit (see Se ction [IP_ADDRESS] ). 
lAEs will be collected for [ADDRESS_394042] dose of teduglutide in the study even if the EOS/ET occurs within that 
timeframe.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394043] 2019
Table 1-3 Schedule of Events for No Teduglutide Treatment Period
Visit Number NTx
Visit Type Site
Visit FrequencyaEvery 12 weeks
Window (days)b±[ADDRESS_394044] as neededfX
Safety laboratory testsgX
PedsQL Generic Core Scale/PedsQL Family Impact 
Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutideh(X)
Fecal occult blood testingiAnnually
Colonoscopy or sigmoidoscopyj(X)
Serum samplekEvery 24 w eeks
PedsQL=Pediatric Quality of Life Inventory; PS= parenteral support
aThe first NTx visit after the screening visit must occur within [ADDRESS_394045] NTx visit in the current no- teduglutide treatment period.
c Subjects who meet ≥[ADDRESS_394046], 
and parent or legal guardian agree to proceed with teduglutide therapy ( Table 1-4).
dHead circumference will be measured in subjects [ADDRESS_394047] actual PS volume and hours per day, completed daily during the 2 weeks preceding each clinic visit. 
Urine and stool outpu t should be recorded in the output diary over a 48-hour period of nutritional stability before every clinic 
visit. See Section [IP_ADDRESS] for more detail.
fParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix [ADDRESS_394048] follow -up samples collected 
every 12 weeks during the study until a negative result is obtained.
i Fecal occult blood testing should be performed on teduglutide -exposed subjects on an annual basis, approximately every 
48-60weeks at a minimum.
j The need for colonoscopy /sigmoidoscopy in response to a positive fecal occult blood test during a no -teduglutide treatment 
period is at the discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy /sigmoidoscopy after 
they have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receiv e 
teduglutide will undergo colonoscopy /sigmoidoscopy at 5-year intervals or more often as needed. See Section [IP_ADDRESS] for 
details.
k Lack of collection of serum samples will not constitute a protocol deviation.   Stored serum samples should be omitted for 
subjects weighing less than 15 kg and whenever local blo od volume limitations are exceeded.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394049] 2019
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Visit Number Pxa Cx
D1Cx
W1Cx
W2Cx
W4Cx 
W6Cx 
W9Cx 
W12Cx 
W16Cx W20CxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  
(days)d -21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate 
teduglutide 
eligibility 
(inclusion and 
exclusion) 
criteriaX Xe
Phone contact [CONTACT_319408] [ADDRESS_394050] as 
neededhX X X X X X X X X X X X X
Safety 
laboratory testsi XjX X X X X X X X X X (X) X
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394051] 2019
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Visit Number Pxa Cx
D1Cx
W1Cx
W2Cx
W4Cx 
W6Cx 
W9Cx 
W12Cx 
W16Cx W20CxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  
(days)d -21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
PedsQL 
Generic Core 
Scale/ Family 
Impact Module/ 
GI Symptoms 
Module Sub -
ScalesX X X
Antibodies to 
teduglutidej X X X X
Fecal occult 
blood testingX X X
Colonoscopy /
Sigmoidoscopyk (X) (X) (X)
Pregnancy 
testingl X X X X X X X X X
Serum samplemX X
Evaluat e escape 
criterian XpX X
Dispense study 
drugo X X X X X X X X X
eCRFs=electronic case report forms; EOS=end of st udy; EOT=end of treatment; ET=early termination; FOBT=fecal occult blood test; FOCBP=females of child -bearing potential; FU=follow -up; 
GI=gas trointestinal; PedsQL=Pediatric Quality of Life I nventory; PS=parenteral support; PT/I NR= prothrombin time/international norm alized ratio; SBS=short bowel syndrome; SC=subcutaneous; 
Scr=screening; TED=teduglutide; Tx=treatment
aIf the first pretreatment v isit (P1) follows the screening visit, it must occur within 12 weeks of screening. 
b Phone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are t he same as those described for CxW25 -27 (except for evaluation of escape 
criteria).
cThe investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur within [ADDRESS_394052] is completing the study at the CxW28 visit, the EOS/ET visit ( Table 1 -2) will take place in lieu of the CxW28 visit.
dVisit windows are relative to the CxD1 visit.
e Eligibility will need to be reconfirmed prior to the first dose in the cycl e. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs obtained at th e CxD1 
visit are not required to determine teduglutide treatment eligibility.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394053] 2019
Table 1-4 Schedule of Events for Teduglutide Treatment Period
Period Pretreat ment Teduglutide Treat ment Follow -up
Visit Number Pxa Cx
D1Cx
W1Cx
W2Cx
W4Cx 
W6Cx 
W9Cx 
W12Cx 
W16Cx W20CxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  
(days)d -21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±[ADDRESS_394054] actual PS volume and hours per day. I ntake diaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except at pretreatment visit), 
for 1 week following PS ad justment, and daily during the 4 -week follow -up period. Urine and stool output should be recorded in the output diary over a 48 -hour period of nutritional stability before 
every clinic visit, and within 1 week of implementing a change in the PS prescriptio n. See Section [IP_ADDRESS] for more detail.
hParenteral support adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment provided in Appendix [ADDRESS_394055] PT/I NR at the pret reatment visit. Additional collection will occur if a potential drug -induced liver 
injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis w ill not constitute a protocol deviation.
j Samples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are re ceiving teduglutide (CxW12 and CxW24) must be drawn at least 14 hours 
after dosing.
k The teduglutide -naïve subjects age 12 and old er will undergo colonoscopy /sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any age with newly positive 
FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, a nal fissure) will undergo a colonoscopy /sigmoidoscopy prior to receiving teduglutide. If newly 
positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the end of a teduglutide tr eatment cycle (CxW24/EOT), colonosco py/sigmoidoscopy will be performed. 
The need for colonoscopy /sigmoidoscopy in response to positive FOBT results at CxW12 is at the discretion of the investigator. Teduglutide -exposed subjects who have received the equivalent of 2 
treatment cycles (48 weeks of study drug exposure) will undergo colonoscopy /sigmoidoscopy . See Section [IP_ADDRESS] for details.
l A serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit. Urine pregnancy tests will be adminis tered at all other visits acco rding to the study schedules, or if pregnancy is 
suspected, or as specified per protocol upon withdrawal of the subject from the study.
m Lack of collection of serum samples will not constitute a protocol deviation.   Stored serum samples should be omitted for subjects weighing less than [ADDRESS_394056] SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observ ed for hypersensitivity 
reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) o f the first teduglutide dose must be specified and recorded in the eCRF. See Section 6.2.[ADDRESS_394057] occur within 7 days of the CxW24 visit.
Note: (X) denote s conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394058] 2019
1 BACKGROUND INFORMATI ON
1.1 Indic ation and Current Treatment Options
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there ar e a few hundred pediatric subjects 1 y ear and older with SBS ( Khan et al., 
2015; Wales et al., 2004 ). Unlike the adult population, the majority of cases of SBS in pediatr ic 
subjects are due to congenital anomalies or catastrophic events that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on par enteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 y ears of the initial diagnosis ( Khan et al., 2015). 
Nevertheless, despi[INVESTIGATOR_3062], many  pediatric subjects remain dependent 
on PS. Complications of long -term PS include liver disease, catheter -related blood stream 
infections, central line-associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality  of life is poor ( Squires et al., 
2012). Accelerating the adaptive process and achieving enteral autonomy  is an urgent goal for all 
patients with SBS who are dependent on PS ( Khan et al., 2015; Squires et al., 2012 ).
Intestinal adaptation is driven by  [CONTACT_319436] ( Drucker 
and Yusta, 2014 ). Chief among these is hormones glucagon- like peptide 2 (GL P-2), which is 
secreted from L- type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Resection of these region s may  impair the adaptive response by  [CONTACT_319410] -2.
1.[ADDRESS_394059] Background
Teduglutide is a novel, recombinant analog of naturally  occurring human GLP -2 that 
regulates the functional and structural integrit y of the cells lining the g astrointestinal (GI) 
tract. Teduglutide is a 33 -amino acid peptide that differs from native GLP -2 in the substitution 
ofglycine for alanine at the second position at the N -terminus. As a result, teduglutide 
demonstrates resistance to degradation b y dipept idyl peptidase 4 (DPP -4) and therefore 
maintains a longer elimination half -life (t 1/2) in adults of approximately  2 hours compared to 
thenative peptide, which has a t 1/2 of approximately 7 minutes. Teduglutide has been shown 
inanimal studies and previous human clinical trials to increase villus height and crypt depth in 
the intestinal epi[INVESTIGATOR_2130], thereb y increasing the absorptive surface area of the intestines 
(Tappenden et al., 2013 ; Thymann et al., 2014). The European Commission granted a 
centralized marketing authorization valid throughout the European Union (EU) for teduglutide 
(REVESTIVE™) on [ADDRESS_394060] 2012 and a New Drug Application (NDA) for teduglutide 
(GATTEX®) was approved by  [CONTACT_24623] (US) Food and Drug Adm inistration (FDA) on 
21Dec2012 for the treatment of adult patients with SBS who are dependent on PS. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394061] 2019
Teduglutide has also been approved for use in adult patients with SBS in Canada and 
Switzerland. On 29Jun2016, theEuropean Commission granted anextension oftheMarket
Authorization for teduglutide (R EVESTIVE ) for the treatment of patients aged 1 y ear and above 
with SBS; patients should be stable following a period of intestinal adaptation.
1.3 Clinical Studies with Teduglutide in Pediatric Subjects
One Phase 3 stud y, TED -C13-003, was completed in pediatric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1 -17. Thirty -seven pediatric subjects received teduglutide at doses of 
0.0125, 0.025, or 0.05 mg/kg/day  for [ADDRESS_394062] of care (SOC) cohort. There were clear dose -dependent 
effects of teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 
0.0125 mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at 
Week 12 of 37%, includi ng complete independence from PS support in [ADDRESS_394063], and a 
reduction of 3.94 hours per day  infusion time. In the 0.05 mg/kg/day  cohort there was a 
reduction in PS volume at Week 12 of 39%, including complete independence from PS support 
in 3 subjects, an d a reduction of 4.18 hours per day infusion time. Teduglutide was generall y safe 
and well tolerated b y pediatric subjects in all dosing cohorts. There were no deaths during the 
study  and no treatment-emergent serious adverse events (TESAEs) related to teduglutide were 
reported. No discontinuations from study were due to adverse events (AEs).
TED -C14-006 is a recently  completed study  of pediatric subjects through 17 y ears which 
included 2 treatment arms: a teduglutide treatment arm and a SOC treatment arm. Subjects in 
both arms participated in a [ADDRESS_394064] 
medical therap y for SBS; while those in the teduglutide treatment arm received daily  
subcutaneous (SC) injections of teduglutide (study  drug) in addition to standard medical therapy . 
The subjects enrolling in the teduglut ide treatment arm were randomized 1:1 in a double -blinded 
manner into 2 parallel dose groups: 0.025 mg/kg/day  or 0.05 mg/kg/day  of teduglutide 
administered subcutaneously  for 24 weeks. Compared to the SOC, treatment of pediatric subjects 
with SBS with teduglutide resulted in clinicall y meaningful reductions in PN/IV volume, 
calories, day s per week, and hours per day . A total 10% of subjects who received teduglutide 
achieved enteral autonomy  within 24 weeks despi[INVESTIGATOR_319393]/IV for several 
years. Teduglutide treatment also resulted in increases in EN volume and caloric intake as well 
as plasma citrulline. Although the differences in efficacy between the 0.025 and 0.05 mg/kg dose 
groups were small, a consistently  greater effect was seen in the 0.05 mg/kg dose in all efficacy  
parameters. The PK properties were well characterized in this population and were consistent 
with the prior [ADDRESS_394065] version of the investigator’s brochure for the overall risk/benefit 
assessmen t and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394066] 2019
3 STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safet y 
andefficacy  of teduglutide in pediatric subjects who completed the TED- C13-003 study  
(thecore study ). At the time of entry  into the TED- C13-[ADDRESS_394067] 30% of the ir 
caloric orfluid needs and had not been able to significantly  reduce PS for at least 3 months 
prior to enrollment. During the core stud y, pediatric subjects in the teduglutide treatment 
armwere entered into a 0.0125 mg/kg/day , 0.025 mg/kg/day , or 0.05 mg /kg/day  dose cohort 
based on the timing of their enrollment in the study. The cohorts were filled in a sequential 
manner.
Approximately  [ADDRESS_394068] m eet ≥1 of the teduglutide treatment inclusion criteria and none of the teduglutide treatment 
exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no teduglutide treatment period” [NTT]), 
will be seen approximately  every  12 weeks for safety , parenteral support (PS) requirements, and 
quality  of life. At any  point during an NTT period, subjects who meet ≥[ADDRESS_394069], and 
parent or legal guardian agrees to proceed with teduglutide therap y.
Rationale: Some pediatric subjects may have a durable beneficial effect after 12 weeks of 
teduglutide treatment in the core study or 24 weeks of teduglutide treatmen t in this extension 
study and thus long -term follow -up without additional teduglutide treatment may be appropriate. 
However, there may be some pediatric subjects who deteriorate or stop improving after 
discontinuation of teduglutide treatment. In these ped iatric subjects, additional teduglutide 
treatment may be beneficial.
Dose Selection
Analy sis suggested that pediatric patients, ages 1 -17 years-old, are likel y to require the same 
dose as used in adults, namely  0.05 mg/kg/day  (Mouksassi et al., 2009 ). In this extension study , 
all subjects who enter a teduglutide treatment cy cle will receive 0.05 mg/kg SC QD.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394070] 2019
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily. The completed pediatric studies (TED -C13-003 and 
TED -C14-006) demonstrated that teduglutide dosing at 0.025 mg/kg/day and 0.05 mg/kg/day 
was associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
studies as well as the pediatric (core) study (TED -C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults ( O'Keefe et al., 2006 ).
Further PK simulation was conducted based on the population PK model previously established 
and a virtual population of 1000 pediatric patients created based on Cen ters for Disease Control 
(CDC) growth charts in the target age group (4 to 12 months) and taking into consideration 
body weights of pediatric patients with SBS enrolled in study TED -C13-003 (approximately 
15% lower than healthy subjects in the same age group). Monte Carlo simulations for all age 
groups were performed according to the SC dosing regimens of 0.0125, 0.025 and 0.05 mg/kg 
every 24 hours. Rich concentration -time profiles were simulated with the customized population 
PK model to derive the exposur e metrics area under the concentration curve at steady state 
(AUC ss) and maximum concentration at steady state (C max,ss). Following 0.05 mg/kg daily SC 
administration, the median C max,ss of teduglutide in infants (24.9 ng/mL) was within 20% of that 
observe d in the 2 to 4 and 4 to 6 years age groups (26.9 and 29.4 ng/mL, respectively); and 
approximately ~28% lower than that in adult patients with SBS. The clinical package in 
conjunction with C maxwas considered to support teduglutide dose selection since AUC ss was 
previously shown not to correlate with efficacy. Thus, the 0.05 mg/kg dose is proposed for testing 
in all age groups.
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED -C14-[ADDRESS_394071] may  be evaluated immediately  for 
additional teduglutide treatment. Subjects who clinically  deteriorate or stop improving at any  
time after the end of the follow- up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED- C13-[ADDRESS_394072] 
deteriorated quickly after treatment interruption (ie, escaped from a prior follow -up period) may 
be evaluated immediately for eligibility for additional treatment when they reach the Week [ADDRESS_394073]’s standard medical care between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form (I CF) (and if 
applicable, informed asse nt) is signed for this study . In addition to this retrospective data 
collection, prospective study  assessments of safety  and efficacy  will be completed as a part of 
this study .
3.1.1 Informed Consent/Assent and Eligibility
The review and signing of the I CF (and if applicable, informed assent) for this study , must be 
completed before an y other study procedure. Subjects will be encouraged to consent to 
participate in the prospective and retrospective portions of this study ; however ,subjects may  
consent to retrospe ctive data collection onl y. Subjects may not consent to the prospective data 
collection only . After informed consent/assent is obtained, study  eligibility  will be assessed for 
all subjects.
3.1.[ADDRESS_394074]’s standard medical care between the date of the 
TED -C13-003 EOS visit and the date the ICF (and if applicable, informed assent) is signed for 
this study . Retrospective data collection may  begin any  time after informed consent/assent is 
obtained for this study . The following data will be collected:
Teduglutide use (as prescribed)
Parenteral support (as prescribed)
Growth (height, head circumference [up to 36 months of age], weight)
End dates for advers e events (AEs) ongoing at the time of TED- C13-003
All nonserious AEs related to teduglutide
All adverse events of special interest (AESIs)
All serious adverse events (SAEs)
3.1.3 Prospective Data Collection and Treatment
Additional screening visit procedures fo r prospective data collection assessments can be found in 
Table 1-2. These procedures include but are not limited to, collection of demographics, updates 
to medical history  and short bowel sy ndrome history . The parenteral support prescription will 
also be collected at screening. Additionally , intake diaries will be dispensed at the screening visit 
for collection of actual PS volume and hours per day  (Section [IP_ADDRESS]). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394075] 2 weeks after the ICF (and if applicable, 
the informed assent) is signed for this study .
Subjects not receiving teduglutide treatment (ie, in an NTT period), will be seen approximately  
every  [ADDRESS_394076] NTT visit after the screening visit 
will occur within 2 to 12 weeks of the screening visit. At anypoint after screening, including
during an NTT period, subjects who meet ≥[ADDRESS_394077], and parent or legal 
guardian agrees to proceed with teduglutide therapy .
After the pretreatment visit, subjects who meet ≥1 of the teduglutide treatment inc lusion criteria, 
and meet none of the teduglutide treatment exclusion criteria, will start a 28 -week cy cle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily , followed by  a 
4-week follow -up (no treatment) period ( Figure 3 - 1). Duri ng the 28 -week cy cle, clinic visits will 
occur at Weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately 
1 week after adjustments in PS during the teduglutide treatment period (between Weeks 1 and 
24), and weekl y during the follow -up period (between Weeks 24 and 28).
At all site visits and telephone contacts, safet y will be monitored, and nutritional support will be 
reviewed and adjusted as needed. Quality  of life assessments will be made approximately  every  
12 weeks. To mainta in consistency  across centers, all attempts should be made to follow the 
nutritional support adjustment guidelines (developed with SBS expert input and provided in the 
protocol) for decisions regarding PS reduction and advances in enteral feeds based on we ight 
gain, urine and stool output, and clinical stability. Departure from the guidelines, however, is not 
considered a protocol deviation ( Appendix 2 ).
Rationale: Measures of long -term safety  will include AEs, growth parameters, and anti -drug 
antibodies. Measure of long -term efficacy  will include durability  of effect as measured by  
[CONTACT_319495] (Pediatric Qualit y of Life 
Inventory  [PedsQL ], PedsQL  Famil y Impact Module). A reduction in PS volume of at least 
20% at end of treatment (EOT) was used as the primary  endpoint in pi[INVESTIGATOR_9205] 3 adult clinical 
trials and the completed Phase 3 pediatric stud y (TED- C13-003) and will be used as an endpoint 
in this extension study . In previous clinical studies, a r eduction of this magnitude was associated 
with a reduction in the number of days per week of PS and increases in enteral intake. Reduction 
in volume and time of PS due to improved enteral absorption may  provide a pediatric subject 
with opportunities for more age -appropriate activities including oral rehabilitation. Quality  of life 
assessments will be performed in this study  to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the 
patient popul ation and the pharmacologic effect of teduglutide, GI-specific screening tests, 
including fecal occult blood testing and colonoscopy /sigmoidoscopy , which are commonl y part 
of the routine care of these subjects, will be performed to ensure safet y. This stud y captures 
long-term safet y data on poly ps and other colonic mucosal changes in teduglutide- exposed 
subjects using the surveillance strategy proposed in Section [IP_ADDRESS].
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394078] 2019
Figure 3-1 Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy.
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approximately 1 week af ter 
adjustments in PS during the intervening weeks between Weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide 
at Week 24 and enter a 4 -week follow -up (no-treatment) period, during which phone visits will be performed weekly ( solid grey 
lines). If an escape criterion is met at Week [ADDRESS_394079] has provided signed informed 
consent (and if applicable, informed assent), and meets all of the Study Inclusion Eligibility  
Criteria. The stud y will continue for at least [ADDRESS_394080] has access (as needed) 
to teduglutide. The subject’s maxim um duration of participation is expected to be approximately 
[ADDRESS_394081] 
(last safet y contact), whichever is later. The stud y completion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394082] and/or parent or legal guardian must review and sign the informed consent (and if 
applicable, informed ass ent) before an y stud y-related procedures specified in the protocol are 
performed. Teduglutide treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_394083] will not be considered eligible for the study  without me eting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completing any  
study -related procedures. 
2.Subject completed the T ED-C13-003 study  (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully  adhere to study  requirements as 
defined in this protocol.
4.2 Study Exclusion Eligibility Criteria
There are no exclusion criteria for this study .
4.3 Teduglutide Eligibility Criteria
Subjects are eligible for teduglutide treatment if ≥[ADDRESS_394084] (and/or parent or legal guardian, as appropriate) must agree to proceed with 
treatment.
4.[ADDRESS_394085] is receiving PS and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and 
during the teduglutide pretreatment visit, as assessed by  [CONTACT_093]. Transient 
instability  for events such as interruption of central access or treatment for sepsis is 
allowed if the PS returns t o within 10% of baseline prior to the event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.Increasing PS requirements following teduglutide discontinuation
b.Decreased PS requirement during prior teduglutide treatment, followed by  
[CONTACT_319412]
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319394] (EN) following teduglutide discontinuation
d.Deteri orating fluid or electroly te status despi[INVESTIGATOR_319367]
e.Severe diarrhea related to teduglutide discontinuation
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394086] 2019
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_394087] inal surgery  within 3 months 
preceding the teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5.Intestinal or other major surgery  planned or schedu led to occur during the 28 -week 
cycle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairment or injury , 
including the following laboratory  values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dy sfunction shown by  [CONTACT_319476] 
50mL/min/1.[ADDRESS_394088] repair, or 
patent ductus arteriosus ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine, 
Omegaven, S moflipid, or teduglutide) within 3 months or 5.5 half -lives of the 
experimental drug, whichever is longer, prior to the pretreatment visit and for the 
duration of the 28- week cy cle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon -like peptide -2 
(GLP-2) (not including teduglutide), insulin -like growth factor- 1 (IGF -1), or growth 
hormone, within 3 months preceding the teduglutide pr etreatment visit
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_394089] 2019
17.Sexually  active female subjects of child -bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 day s after the treatment period 
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the study, or interferes with 
analysis of the study  results
4.6 Follow -up Period Escape Criteria
At the discretion of the investigator, the follow- up period may  be interrupted (if the subject 
meets 1 or more of escape criteria 1 to 4 during the follow -up period) or omitted (if the subject 
meets escape criterion 5 at the CxW24 visit) and the subject may  proceed directly  to the 
pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319395]
3.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319400]
4. Severe diarrhea related to teduglutide discontinuation
5.The subject escaped during the follow -up period of a previous teduglutide treatment 
cycle within SHP633- 303. I n this case, the CxW [ADDRESS_394090]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:
Premenarchal and either Tanner Stage 1 or less than ag e 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta- human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pretreatment visit .Females
ofchild- bearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable methods of contraception.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394091] 2019
Acceptable methods of contraception are:
True abstinence: Abstention of sexual activity  that is in line with the preferred and usual 
lifesty le of the subject. (Periodic abstin ence [eg, calendar, ovulation, sy mptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception). 
Intrauterine devices plus condoms
Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually  active during the study , they  should use [ADDRESS_394092] wishes to remain in the study , the evaluations listed for the EOT visit are to be 
performed. A 4- week follow -up period will ensue, consisting of weekl y telephone visits 
(CxW25 -27) and the week 28 clinic visit (CxW28). The subject would then enter an NTT period 
and could be evaluated for subsequent teduglutide treatment eligibility  according to the study  
schedules. 
Comments (spontaneous or elicited) or complaints made b y the subject must be recorded in the 
source documents. The reason for permanent treatment discontinuation, dates of investigational 
product administered (including last date of treatment), and amount of investigational product 
taken must be recorded in the electronic case report form (eCRF) and source documents, as 
described in Section 4.8.[ADDRESS_394093] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_319445] -up.
If a subj ect withdraws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completel y as possible. 
Subjects who withdraw from the study will not be replaced.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394094] 2019
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than [ADDRESS_394095] clinically  relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
Adverse event
Protocol deviation
Lack of efficacy
Physician decision
Withdrawal by  [CONTACT_1130]
Withdraw al by  [CONTACT_7078]/guardian
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y)
Death
Other
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_394096] (office visit or telephone contact). At least [ADDRESS_394097]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations, and return an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394098] 2019
5 CONCOMITANT TREATMENT
5.1 Concomitant Medications and Procedures
Concomitant treatment will be collected for the prospective period onl y and refers to all 
treatment being taken on or after the date the ICF (and if applicable, assent) is signed for this 
study . Concomitant medications and procedures will be assessed at each site visit, and include all 
nonstudy  treatments (medications, herbal treatments, vitamins, invasive and diagnostic 
procedures). Concomitant treatment information must be recorded on the appropriate eCRF 
page. Details of medication changes and/or dosages will be recorded on the eCRF.
5.1.[ADDRESS_394099] medical ther apy for SBS should be continued.
5.1.2 Prohibited Treatment
At the time of screening, any  teduglutide treatment being received through any  mechanism 
other than participation in this study  (eg, by  [CONTACT_78150]-label prescription, participation in an 
investigator -initiated trial, compassionate access program, etc) must be discontinued. I n such 
cases, there is no minimum duration of interruption of teduglutide treatment before pretreatment 
evaluations can be performed.
The mechanism of action of teduglutide may  increase ente ral absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, digoxin), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1 Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- [ADDRESS_394100] is teduglutide, which is a white lyophilized powder to be reconstituted before 
use with sterile water for injection (Section 6.3.2). In addition to the active ingredient 
(teduglutide), each vial of teduglutide contains L -histidine, mannitol, monobasic sodium 
phosphate monohy drate, and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is 
provided in the current SHP633 investigator’s brochure.
6.1.[ADDRESS_394101](s)
6.2.[ADDRESS_394102] Management
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory  manage ment and supply  ordering, investigational product expi[INVESTIGATOR_49093], and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS.
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.[ADDRESS_394103], and/or parent/guardian agree 
to proceed w ith treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pretreatment visit ( Table 1-4).
6.2.[ADDRESS_394104] will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body  weight measured at the teduglutide pretreatment visit, and adjust ed as needed, based on 
body  weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor.
Following reconstitution, teduglutide will be administer ed by [CONTACT_319496] y (QD) into 
1 of the 4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394105] 
4 hours during their initial dosing visit. The site of a dministration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
At the end of each [ADDRESS_394106] may  proceed directly  to another Pretreatment visit to assess treatment 
eligibility  for another cy cle (Section 4.6). Following the completion of the [ADDRESS_394107](s) container.
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing [ADDRESS_394108] 2019
6.3.2 Packaging
Teduglutide will be provided in a 3 mL  sterile, single -use, glass vial containing 5 mg or 1.25 mg 
teduglutide. Sterile water (0.5 mL ) will be provided in a prefilled s yringe.
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in
advance b y the sponsor.
6.3.[ADDRESS_394109] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refrigerated at a temperature between 2 -8°C (35.6 -46.4°F) until dispensed to 
a subject. Once dispensed to a subject, the study  drug can be stored refrigerated or up to a 
controlled room temperature (acceptable range of 2 -25°C, or 35.6- 77°F). Parent/legal guardian 
will be instructed to keep the subject’s study  drug and sterile water diluent at controlled room 
temperature. If there are concerns that the controlled room temperature cannot be maintained, the 
study  drug may  be refrigerated. The study  drug is for single use onl y, and should be used within 
[ADDRESS_394110] is maintained within an established temperature range. The investigator is res ponsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calib rated chart recorder, or b y manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon ea ch recording. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pha rmacy  or nominated member of the study  
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394111] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be reco rded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any  unauthorized situation.
The investigator has overall responsibility  for administering/dispensing investig ational product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applic able study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
for teduglutide treat ment following the procedures set out in the study  protocol. All dispensed 
study  medication will be documented in the interactive response technology  system and/or other 
investigational product record (eg, investigation product accountability  form). The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigato r or his/her designee may  
dispense the unused study  drug vials to the same subject. All original containers, whether empty  
or containing stud y drug will be returned to the pharmacy. Returned stud y drugs will NOT be 
relabeled or reassigned for use b y other subjects. Contents of the study  drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may  be destroy ed on site without approval by  [CONTACT_456].
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_394112] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -evident sealed container (eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability  form.
Compliance with study  drug is calculated from subject diaries. Of those subjects eligible for 
teduglutide treatment, subjects who have received 80% of the planned doses administered will be 
assessed as b eing compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394113] 2019
7 STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures and assessments to be performed for subjects throughout the study  are 
outlined in the Schedule of Assessments ( Table 1 -1, Table 1-2, Table 1 -3, and Table 1-4) and 
must be referred to in conjunction with the instructions provided in this section.
Prior to performing an y study-related procedures (including those related to screening and 
retrospective data collection), the investigator or his/her designee must obt ain written informed 
consent (and if applicable, assent) from the subject ( Table 1-1).
7.1.1 Retrospective Data Collection
Retrospective data are defined as specific safet y and efficacy assessments that were completed 
during the retrospective observation period, defined as the interval between the date of the 
TED -C13-003 end of study  (EOS) visit and the date the informed consent form (I CF) (and if 
applicable, informed assent) is signed for this study . Retrospective PS and growth data will be 
captured in [ADDRESS_394114] retrospective data because data are unavailable will not be considered a 
protocol deviation. For subjects who consent onl y to retrospective data collection, only 
assessments in Table 1-1 will be completed. The following data will be collected for the 
retrospective portion of the study :
Informed consent, and informed assent (if ap plicable)
Study  eligibility  is determined
A screen failure is a subject who has given informed consent and failed to meet 
the study  inclusion eligibility  criteria. Subjects cannot be rescreened once they  
have been designated as a screen failure.
Prior teduglutide use (as prescribed)
Collect all teduglutide prescriptions during the retrospective data collection 
period, including start and stop dates, dose, route, and frequency . Prescription 
data includes teduglutide treatment in investigator- initiated trials , compassionate 
use, and named -patient access programs.
Collect start and end dates when a subject’s teduglutide use was interrupted.
Parenteral support (as prescribed)
The last representative PS prescription during each 12- week interval throughout 
the retrospective period and at the beginning and end of any  teduglutide treatment 
will be collected. Usuall y, the prescription at the end of the interval will represent 
the status of intestinal adaptation. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394115] 2019
However, transient alterations inPSrelated toloss of central venous access or 
acute illness are not representative of intestinal adaptation. When such events 
occur at the end of a 12 -week interval, earlier, more representative PS prescription 
data should be recorded.
Data collected should include weekl y prescribed volume, calories, average hours 
per day , and day s per week of prescribed PS. Hours per day  should be averaged 
over the day s where PS is prescribed.
Growth (height, head circumference, and weight)
The last representative value for height, during e ach 12 -week interval throughout 
the retrospective data collection period will be captured. Head circumference 
should be provided for subjects 36 months of age and y ounger at the time the data 
were collected, if available.
The investigator should use his/he r clinical judgment to select values that reflect 
the true growth trajectory.
Adverse events
All nonserious AEs related to teduglutide treatment, as well as all adverse events 
of special interest (AESIs) and all serious adverse events, regardless of causal
relationship to teduglutide treatment, will be collected for the retrospective period 
of the study . The details of data collection and safety  reporting for these events 
can be found in Section 8.
End dates for AEs ongoing at the end of TED -C13-003 will be collected.
7.1.2 Screening
The screening visit (Scr) assessments and procedures will be performed as outlined in Table 1-2, 
and as detailed below:
Informed consent, and informed assent (if applicable)
Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the study  inclusion eligibility  criteria. Subjects cannot be 
rescreened once they  have been designated as a screen failure.
Demographics, updates to medical history  and SBS history
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomitant medications and concomitant procedures
Physical examination and vital signs, including weight
Height and head circumference
Record PS prescription and adju st as needed
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394116] occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
7.1.3 Visits for Subjects Not Receiving Teduglutide
While outside of the 28- week teduglutide -treatment cy cle, subjects will be followed 
approximately  every  12weeks for safety  and efficacy  assessments. No -teduglutide treatment 
visits are numbered sequentially  (NT1, NT2, etc.), even if interrupted by  [CONTACT_319497]. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outlined in Table 1 -3and described below.
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclu sion criteria
Adverse events, concomitant medications, and concomitant procedures
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed
Safety  labor atory  tests (ie, clinical chemistry , hematology , and urinaly sis)
PedsQL  Generic Core Scale/PedsQL Family  Impact 
Module/PedsQL Gastrointestinal Symptoms Module Sub -Scales
Antibodies to teduglutide, if and when required
Fecal occult blood testing, as indicated (see Section [IP_ADDRESS])
Colonoscopy /sigmoidoscopy , as indicated (see Section [IP_ADDRESS])
Serum sample, as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal guardian , as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may  proceed to the pretreatment visit immediately  to determine 
eligibility .
7.1.4 Visits for Subjects Receiving Teduglutide Treatment
[IP_ADDRESS] Pretreatment Visit
Subjects who meet at least [ADDRESS_394117] 2019
In general, pretreatment assessments may  occur over a period of up to 21 day s. The teduglutide 
pretreatment visit (Px) assessments and procedures will be performed as in Table 1-4 and as 
describ ed below:
Evaluate teduglutide eligibility  (treatment inclusion/exclusion criteria)
Dispense intake and output diaries
Adverse events, concomitant medications, and concomitant procedures
Fecal occult blood testing
Gastrointestinal -specific testing, includi ng colonoscopy  or sigmoidoscopy  as indicated
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries 
Record PS prescription and adjust as needed.
Safety  laboratory  tests
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit include 
prothrombin time [PT] international normalized ratio [I NR]. Subsequent prothrombin 
time/international normalized ratio [PT/I NR] measurement is only  required to evaluate 
for suspecte d drug -induced liver injury  [DILI]).
Pregnancy  testing (serum), if applicable
Serum sample
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open- label teduglutide treatment period will comprise [ADDRESS_394118] administration (Visit CxD1).
Visit CxD1
Assessments and procedures at this visit will be performed as outlined Table 1 -4and as 
described below:
Two weeks of intake diary data are required before drug is administered at CxD1.
Confirm teduglutide treatment eligibility
Dispense intake and output diaries
Adverse events, concomitant medications, and concomitant procedures
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394119] 2019
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed
Safety  laboratory  tests
Quality  of life measurements
Antibodies to teduglutide
Pregnancy  testing (urine), if applicable
Dispense study  drug
Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cy cle Weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-4 and as 
described below:
Dispense and review intake and output diaries (every  effort should be made to complete 
2weeks of intake diary  entries prior to each clinic visit and to complete 48 hours of 
output diary  entries during a period of nutritional stability  prior to each clinic visit)
Physical examination and vital signs, including weight
Record PS prescription and adjust as needed
Safety  laboratory  tests
Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)
Study  drug dispensation (except for CxW24)
Adverse events, concomitant medications and concomitant proc edures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
Height and head circumference
Antibodies to teduglutide
Fecal occult blood testing (FOBT)
GI-specific testing, including colonoscop y or sigmoidoscopy  as indicat ed
Quality  of life measurements
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394120] 1 escape criterion is met at the 
CxW24 visit and the pretreatment assessments occur within 7 day s of the CxW24 visit.
Phone Visits
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1 -4and described 
below:
Review intake and output diaries
Safety  laboratory tests (clinical chemistry  and urinaly sis)
Record PS prescription and adjust as needed
Obtain AEs, concomitant medications, and concomitant procedures
Evaluate escape criteria
7.1.5 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks ( Weeks 25 -28 of the cy cle). Phone visits 
will occur on cy cle Weeks 25, 26, and [ADDRESS_394121] may  
proceed directl y to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW24 or CxW28 visits with the next pretreatment visit if at least [ADDRESS_394122] is completing the study  at th e CxW28 visit, the 
EOS/ET visit (Section 7.1.6 ) will take place in lieu of the CxW28 visit. Otherwise, following 
completion of the [ADDRESS_394123] will proceed to an NTT visit within 
approximately  12 weeks.
At Cy cle Week 28 (CxW28), subjects will return to the study  site. In addition to the assessments 
performed at Weeks 25 -27, the following procedures will be performed at CxW28 only :
Dispense and review intake and output diaries
Physical examination and vital signs, including weight
Antibodies to teduglutide
Pregnancy  testing (urine), if applicable
Evaluate escape criteria
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394124] 2019
7.1.6 Study Completion/Early Termination Visit (EOS/ET Visit)
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-[ADDRESS_394125] discontinues the study prematurel y, the assessments for the EOS/ET 
visit are to be performed as completel y as possible (see Section 4.8.2).
Adverse events -AEs will be collected for [ADDRESS_394126] dose of teduglutide in 
the study  even if the EOS/ET occurs within that timeframe
Concomitant medications and concomitant procedures
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries (the intake diary should be completed daily  for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary  should be completed 
daily  over a 48- hour period of nutritional stability  before the EOS/ET visit)
Record PS prescription and adjust as needed
Safety  laboratory  tests
Fecal occult blood testing, as indicated
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy , as indicated
Quality  of life measurements
Antibodies to tedugluti de
Pregnancy  testing, as needed
7.1.7 Qualitative Interview
An optional qualitative interview will be conducted by  [CONTACT_319490] 14 day s after 
completion of the EOS/ET visit (see Section [IP_ADDRESS]). A single individual telephone interview 
will be conducted wit h English -speaking parents (or legal guardians) of subjects and subjects 
aged 12 years or older and who provide informed consent (and if applicable, informed assent) to 
participate in the interview. These interviews will be performed in selected countries.
7.[ADDRESS_394127]'s completion of the TED -C13-003 study  and the 
date the ICF (and if applicable, assent) is signed for the SHP633- [ADDRESS_394128] 2019
[IP_ADDRESS] Growth (Height, Weight, and Head Circumference)
Retrospective bod y height (or length [cm]) and weight (kg) data will be recorded in the eCRF, if 
available. Head circumference (in cm for subjects ≤36 months of age) will also be recorded. A 
height z -score, weight z -score, bod y mass index (BMI), and BM I z-score will be calculated b y 
the sponsor using the retrospective height and weight data. Procedures for these calculations will 
be desc ribed as needed in the statistical analy sis plan (SAP) .
[IP_ADDRESS] Prior Teduglutide Treatment Prescribed
Any retrospective teduglutide prescription start and stop dates, dose, route, and frequency  will be 
recorded on the appropriate eCRF page.
[IP_ADDRESS] Parenteral Support Prescribed
Retrospective parenteral support entries consist of [ADDRESS_394129] 
representative prescription from the interval s hould be used (see Section 7.1.1 ). In addition, PS 
prescriptions at the beginning and end of an y retrospective teduglutide treatment must be 
recorded. The PS prescription includes weekl y volume, calories, hours per day, and days per 
week. Prescription data will be recorded in the eCRF.
[IP_ADDRESS] Adverse Events
Nonserious AEs related to teduglutide treatment and all adverse events of special interest 
(AESI s) and all serious adverse events (SAEs), regardless of causal attribution to teduglutide that 
occurred during the retrospective data collection period will be reported using the sponsor's 
report forms. Select data will be recorded in the eCRF. Additional details of AE collection and 
safet y reporting are provided in Section 8.
The end dates for AEs that were ongoing at the end of TED- C13-003 will be collected.
7.2.2 Prospective Data Collection
[IP_ADDRESS] Demographics, Medical History, and SBS History
Demographics, updates to medical history , and updates to SBS history  will be obtained at 
screening. Medical history  for purposes of this extension study  will consist of updates to the
medical history  collected at the start of the TED- C13-[ADDRESS_394130] has an y 
changes to the SBS history  since the baseline visit of the TED -C13-003 study , that information 
(updated SBS history ) will also be collected.
[IP_ADDRESS] Physical Examination
Physical examinations will be performed according to the study  schedules. Any  new clinicall y 
significant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394131] 2019
[IP_ADDRESS] Adverse Event Collection
At each stud y visit, su bjects will be questioned in a general way  to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had an y health problems since your last visit?”). 
Adverse events are collected from the time informed consent is signed. (see Section 8, Ad verse 
and Serious Adverse Events Assessment.)
[IP_ADDRESS] Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index
Vital signs will be measured according to the study  schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pu lse (beats per minute), and body  temperature 
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same arm, 
and in the same position throughout the stud y).
Body weight will also be recorded in the eCRF; subjects should be weighe d on the same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit.
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
[IP_ADDRESS] Clinical Laboratory Tests
Safety  laboratory  tests to be performed at site visits c onsist of clinical chemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1 -2, Table 1-3, and 
Table 1-4). Scheduled laboratory  testing will be processed b y a central lab. All laboratory  assay s 
will be performed acc ording to the central laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out-of- range clinical laboratory  
values for clinical significance, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical condition, may , at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, e xplained, or resolved.
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_394132] of clinical chemistry  and urinal ysis and may  be processed by  [CONTACT_319438] a local laboratory . Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate an y new clinicall y significant changes, they must be reported as an
AE(see Section 8.1). Urine specimen collection should be attempted as part of the safety  labs, 
but lack of urinal ysis will not constitute a protocol deviation.
New clinicall y significant labs should be reported as AEs.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394133] 2019
The following clinical laboratory  assessments will be performed according to the study  
schedules:
Table 7-[ADDRESS_394134] of Laboratory Tests 
Hematology :
Hematocrit
Hemoglobin
Platelet count
Red blood cell count
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio
Urinalysis :
Blood
Glucose
Leukocytes
Microscopic analysis
pH
Protein
Specific gravity
Pregnancy tests (females of childbearing potential):
Serum β -HCG (teduglutide pretreatment visit )
Urine β -HCG (all other visits)Biochemistry :
Albumin
Alkaline phosphatase
Alanine aminotransferase
Amy lase
Aspartate aminotransferase
Bicarbonate
Bilirubin (total, direct, and indirect)
Blood urea nitrogen
Calcium (total)
Chloride
Cholesterol
C-reactive protein
Creatinine
Estimated Glomerular Filtration Rate 
(Schwartz formula)
Gamma -glutamyl transferase
Glucose
Lipase
Magnesium
Phosphorus
Potassium
Sodium
Triglycerides
Uric acid
[IP_ADDRESS] Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times:
At the pretreatment visit. If the subject arrived at the pretreatment visit by [CONTACT_319478], the serum sample will not be repeated at the pretreatment visit, because 
it will ha ve been collected recentl y at the CxW24 visit.
At the CxW24 (EOT) visit
During NTT: Approximately  every  [ADDRESS_394135] 2019
The seru m sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sample and/or extracted material will otherwise be stored 
for up to [ADDRESS_394136] their 
sample and/or extrac ted material destro yed. An y results alread y generated from the samples will 
not be removed from an y anal yses that have already  been performed.
[IP_ADDRESS] Pregnancy Testing
A serum pregnancy  test is performed on all FOCBP at the teduglutide pretreatment visit. Urine 
pregnancy  tests will be administered at all other visits according to the study  schedules, or if 
pregnancy  is suspected, or as specified per protocol upon withdrawal of the subject from the 
study .
[IP_ADDRESS] Antibody Testing
Blood samples will be drawn for the anal ysis of antibodies to teduglutide according to the 
Schedule of Assessments ( Table 1-2, Table 1 -3, and Table 1-4). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least [ADDRESS_394137] follow- up blood draws for antibodies to teduglutide every  12 weeks while 
on study  until a negative result is obtained.
[IP_ADDRESS] Volume of B lood
Efforts will be made to minimize the amount of blood drawn from all pediatric subjects enrolled 
in this study . The volumes of blood to be drawn from each subject will vary  depending on 
clinical status. Approximate volumes of blood to be drawn from eac h subject annuall y are shown 
in Table 7-2.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394138] Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Parameters 2 2 4
Antibodies 2 8 16
Serum storage samplesb3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volume): 140
Subjects Not Receiving Teduglutide Treatmentc
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samplesb3 2 6
Total mL per 4 “No Teduglutide Treatment” Visits 48 -week period: 24
β-hCG=beta -human chorionic gonadotropin; NTT= no-teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bStored serum samples should be omitted for subjects weighing less than [ADDRESS_394139] negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same t ype of tube, the assessments should be combined. Blood 
volume estimates do not include safet y labs performed after PS adjustment, and anti -teduglutide 
antibody  testing during no- teduglutide treatment.   Stored serum samples should be omitted for 
subjects weighing less than 15 kg and whenever local blood volume limitations are exceeded.  
Maximum blood volume at an y given visit occurs when the pretreatment and Week 24 visits are 
combined (8.5 mL) .  
[IP_ADDRESS] Gastrointestinal- specific Testing
Fecal Occult Blood Testing
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, Week 12, 
and Week [ADDRESS_394140] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past 
andare therefore not teduglutide -naïve) on a roughly  annual basis (approximately  every  
48-60 weeks) . Actions to be taken in response to a positive FOBT are described below.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394141] 2019
Colonoscopy or Sigmoidoscopy
Teduglutide -naïve subjects age 12 and older will undergo colonoscopy  or sigmoidoscopy  at the 
pretreatment visit if one has not been performed within 1 y ear.
Subjects of an y age with newly positive FOBT results at the pretreatment visit for which 
areadil y detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscop y 
orsigmoidoscopy prior to receiving teduglutide. If newl y positive FO BT results (for which 
areadil y detectable cause cannot be identified) are obtained at the end of a teduglutide 
treatment cycle (CxW24/EOT), colonoscopy  or sigmoidoscopy  will be performed. The 
need forcolonoscop y or sigmoidoscop y in response to positive F OBTs at any  other point 
during the study , or to reevaluate persistently  positive FOBTs is at the discretion of the 
investigator.
Teduglutide -exposed subjects who have received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will unde rgo colonoscopy  or sigmoidoscopy . While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy  or sigmoidoscopy at 5 y ear intervals or 
more often as needed.
Upper endoscop y ma y be performed along with any colonoscop y or sigmoidoscopy
attheinvestigator’s discretion. If a pol yp is found, adherence to current polyp 
follow -up guidelines is recommended. Subjects with unresected GI poly ps, poly posis 
conditions, premalignant change or malignancy in the GI tract will be excluded from 
tedugl utide treatment.
[IP_ADDRESS] Nutritional Support
Nutritional support includes PS, EN, and other food and fluids. Advances in EN and/or 
reductions to PS will be based on clinical status, including weight, linear growth, hy dration 
status, and safet y laboratory  results. Intake and output diaries will includ e data to be considered 
in the adjustment of each subject’s nutritional support. Guidelines for nutritional support 
management and weaning algorithms are provided in Appendix 2 .
[IP_ADDRESS] Diaries
Study Drug A dministration D iary
A study  drug administration diary  will record administration of teduglutide. This diary  should be 
completed b y the subject (or parent/legally authorized representative, as applicable) dail y during 
the teduglutide treatment periods (between visits CxD1 and CxW24).
Intake Diary
Intake diaries wi ll be used to collect and evaluate each subject’s nutritional support. 
Thesubject/parent/guardian will complete the appropriate fields of the PS section of 
theintake diary  2 weeks prior to ALL scheduled prospective site visits (except at pretreatment 
visit). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394142] 2019
During the24-week teduglutide treatment period, theintake diary willalsobecompleted for
1week following PS adjustments. The intake diary will also be completed daily  during the 
4-week follow -up period. The following data will be captured in the intake diaries:
Parenteral support volume and infusion duration
Site personnel will determine the actual PS daily  calories based on diary  entries
Output Diary
Urine and stool output should be recorded in the output diary  over a 48- hour period of nutritiona l 
stability  before every  clinic visit; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cy cle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
Toilet -trained subjects (who do not wear diapers)
Measure and record all urine output in mL  or cc 
Nontoilet- trained subjects (who wear diapers)
Measure and record the weight of all urine -only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL  or 1 cc
At the discretion of the investigator, the parent or legal guardian may  be asked to collect 
the first void after the daily  PS infusion to measure specific gravit y
Stool data (includes diapers with mixed urine and st ool):
Toilet -trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency  using the 
Bristol Stool Form Scale (see Output diary )
Nontoilet- trained subjects (who wear diapers)
Record the weight of di apers containing stool (including diapers with mixed urine and 
stool) as stool output and score the stool consistency  using the Bristol Stool Form Scale 
(see Output diary ). Stool volume will be calculated using the formula: 1 g (scale 
weight)=[ADDRESS_394143] 2019
[IP_ADDRESS] Health -related Quality of Life Assessments
Throughout the study, health-related quality of life assessments will be performed using the 
PedsQL Generic Core Scales. Each PedsQL age-appropriate form takes les s than 4 minutes to 
complete. The scales include self-r eports for pediatric subjects and adolescents aged 5 to 18 years 
and proxy-reports from parents of pediatric subjects aged 2 to 18 years. If a child is unable to 
complete the age-appropriate questionnaire (eg, due to developmental delay or other illness) it 
will not constitute a protocol deviation, but the parent should continue to complete the 
appropriate parent -s
pecific forms.
Field trials have shown that the internal consistency  reliability  of the Pe dsQL  was excellent, with 
alphas for the generic core scales in both self -and proxy -report greater than the 0.[ADDRESS_394144] month, and parent -report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
Pediatric Qu ality of Life Generic Core Scale (PedsQL™), Acute V ersion
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed b y either the parent or legal guardian and subject 
as indicated in Table 7 -3at the time points as outlined in Table 1-2, Table 1 -3,and Table 1 -4.
Table 7-3 Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects 
(ages 8 -12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18)aSubject and Parent or Legal Guardian
PedsQL=Pediatric Quality of Life Inventory
a The Child Self Report and Parent Proxy -Report for Teens (ages 13 -18) will also be completed for subjects older than [ADDRESS_394145] 2019
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Generic Core Scale is composed of 
21items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items).
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5-7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
Pediatric Quality of Life Family Impact Module (PedsQL™), Acute Version
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-2, Table [ADDRESS_394146] of pediatric chronic health conditions on parents and the family  (Varni et al., 2004 ). 
The 36- item PedsQL Family  Impact Module consists of 6 scales measuring parent self-reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 
3)
Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure 
parent -reported family  functioning as follows: 1) Daily  Activities (3 items), and 2) Family  
Relationships (5 items). The PedsQL Family  Impact Module should take the parent or legal 
guardian approximately  5-10minutes to complete.
PedsQL Gastrointestinal Symptoms Module (PedsQL™), Acute V ersion
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58- item module, comprised 
of 10 different s ymptom scales that assess gastrointestinal sy mptom -related quality  of li fe: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Sy mptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
clinically  relevant and appropriate for the s ymptoms experienced in this pediatric study  
population, and therefore, are the onl y scales used in this study . The scales will be completed by  
[CONTACT_319418] 7 -3at the time points 
outlined in Table 1-2, Table 1 -3,and Table 1 -4.
[IP_ADDRESS] Qualitative Interviews
The objective of the qualitative interviews i s to elicit the key  symptoms and impacts of 
importance associated with SBS as well as the effect of teduglutide in relation to sy mptoms and 
impact experienced during the clinical study  as described by  [CONTACT_319498].  In addition, the interviews with caregivers will elicit concepts on aspects of caregiver 
burden associated with caring for their children with SBS requiring PS and the impact of 
teduglutide on the caregiver burden experienced during the stud y.  
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394147] 2019
The interviews will be offered to English -speaking parents or legal guardians of subjects and 
subjects aged 12 years or older in selected countries. At the qualified subjects’ clinic sites, 
subjects and caregivers will be provided with a description of the qualitative intervi ew and be 
offered the opportunit y to participate. Subjects and caregivers who agree to participate will be 
asked to provide written informed consent (for caregiver interviews) and written assent and 
parental permission (for subject interviews) using forms developed specifically  for the 
interviews.
The format will be a single individual telephone interview using a semistructured interview 
guide. Each interview will be approximately  45 minutes and will be completed within 14 day s 
after completion of the EOS/E T visit. Subjects and caregivers will be interviewed individually 
and separatel y, will be instructed to take the interview at a private setting.
Two interview guides have been developed, one for the caregiver interviews (Appendix 3 ) and 
one for the subject interviews ( Appendix 4 ). Interview guides for [LOCATION_006] sites will be reviewed b y a 
native speaker of the local dialect. The guides will begin with a brief overview of the interview 
process and very  general q uestions intended to get the participants talking about their 
experiences (and the impacts of these experiences) associated with SBS prior to entering the 
study . These questions will then be followed by  a thorough probing of subject and caregiver 
experienc e during the study  and the importa nce of the treatment outcomes. Topi[INVESTIGATOR_319401]:
Subjects: SBS- related s ymptoms and impacts 
oSymptoms due to SBS
oSymptoms due to parenteral support
oImpact of SBS on dail y activities, physical functioning ,and social functioning
oImpact of parenteral support on daily  activities, phy sical functioning ,and social 
functioning
Subjects: experience of teduglutide treatment in relation to SBS sy mptoms and impacts 
during the stud y
oChanges of SB S-related sy mptoms relating to teduglutide
oChanges of parenteral support- related s ymptoms relating to teduglutide
oChanges o fdaily activities, physical functioning ,and social functioning relating 
to teduglutide
Caregivers: 
oSBS-related s ymptoms and impact s described as an observer
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394148] 2019
Symptoms due to SBS 
Symptoms due to parenteral support
Impact of SBS on dail y activities, physical functioning ,and social 
functioning
Impact of parenteral support on daily  activities, phy sical functioning ,and 
social functionin g
oChanges in SBS -related sy mptoms and impacts in relation to teduglutide 
treatment during the study  described as an observer
Changes of SBS -related sy mptoms relating to teduglutide 
Changes of parenteral support- related s ymptoms relating to teduglutide
Changes o fdaily activities, physical functioning ,and social functioning 
relating to teduglutide
oDescription of care provided and impacts on caregivers of pediatric patients with 
SBS requiring parenteral support
Impact on ability  to complete activities of daily living
Impact on emotional and social functioning
Financial impact
oChanges of caregiver impact in relation to teduglutide treatment during the study
Impact on ability  to complete activities of dail y living
Impact on emotional and social functioning
Financial impact
To limit bias, the interviewer will begin b y asking open- ended questions designed to identify  the 
symptoms associated with SBS and their impact, as well as any  perceived treatment benefits in 
these areas and the meaningfulness of these changes from the perspective of the parent/legal 
guardian and/or subject. Site personnel will obtain consent, assent, and permission for those 
individuals that agree to participate in the qualitative interviews.
All interviews will be conducted b y experienced moderators and will be audio recorded. 
Interviews with subjects and caregivers from [LOCATION_006] sites will be conducted by a moderator 
who isanative speaker. The content of the interview will be transcribed, and the audio 
recording will be destroyed to protect patient privacy . All personal information will be removed 
from the transcripts. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394149]  
subjects and caregivers describe their/their child’s treatment experiences and observations during 
the clinical trial as well as their perceptions of treatment benefit over the trial period. 
Should an interviewer become aware of an y potential AEduring the telephone interview, the 
interviewer will share the relevant information with the subject’s clinical site staff within [ADDRESS_394150] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
labora tory finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995).
Retrospective Period of O bservation
For the retrospec tive data collection period (the interval between the EOS visit of the core study  
until signing the ICF [and informed assent, if applicable] for SHP633 -303), investigators will be 
asked if they  are aware of any  nonserious AEs related to teduglutide that oc curred during this 
time and an y AESIs or any SAEs, regardless of relationship to teduglutide, that occurred during 
this time. The following guidance is given for defining a treatment -related event:
The temporal relationship between the event and the admini stration of the investigational 
product is compelling and/or follows a known or suspected response pattern to that 
product.
The event cannot be explained b y the subject’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Adverse event forms will be used to collect information from Investigators about retrospective 
AEs. Select information from these forms will be captured on the appropriate pages in the eCRF.
For SAEs, report as per Section 8.2. Where applicable, first awareness for events with an onset 
during the retrospective period of observation will be the date the event is recorded for this stud y 
in the eCRF.
Prospective Period of O bservation
All prospective AEs will be collected from the time the ICF (and informed assent, if applicable) 
is signed until [ADDRESS_394151] be followed to closure (the subject’s health has returned to his/her 
baseline status or all variables have returned to normal), regardless of whether the subject is still 
participating in the stud y. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394152] 2019
Closure indicates thatanoutcome isreached, stabilization achieved (the investigator does not 
expect any  further improvement or worsening of the event), or the event is otherwise explained. 
When appropriate, medical tests and examinations are performed so that resolution of event(s) 
can be documented.
8.1.[ADDRESS_394153] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recor ded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
In consideration of whether a treatment -emergent adve rse event (TEAE) might lead to dose 
interruption (Section 8.4.1) or early  termination of the study  (Section 8.5), severe TEAEs will 
also be graded according to the National Cancer Institute’s (NCI) Common Terminology  Criteria 
for Adverse Events (CTCAE) sev erity grading criteria ( US Department of Health and Human 
Services et al., 2010 ).
8.1.2 Relationship Categorization
A phy sician/investig ator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational produ ct. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394154] 2019
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by  [CONTACT_423]’s medical condition, othe r therapi[INVESTIGATOR_014], or 
accident.
Not RelatedThe event can be readil y explained by  [CONTACT_11260]’s underl ying medical condition, concomitant therapy , or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
Adverse events that are related to study  drug that are not resolved at EOT will be followed until 
the event resolves or stabilizes, as judged b y the investigator.
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline.
8.1.[ADDRESS_394155] be recorded during the course of the study  in the eCRF. Outcomes 
are as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study; however, significant worsening of the s ymptoms should be 
recorded as an AE.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394156] 2019
8.1.5 Clinical Laboratory and Other Safety Evaluations (Prospective Period of 
Observation Only)
A change in the value of a clinical laboratory  or vital sign can represent an AE if the change is 
clinically  relevant or if, during the study , a shift of a parameter is observed from a norma l value 
to an abnormal value, or a further worsening of an alread y abnormal value. When evaluating 
such changes, the extent of deviation from the reference range, the duration until return to the 
reference range, either while continuing treatment or after the end of treatment with the 
investigational product, and the range of variation of the respective parameter within its 
reference range, must be taken into consideration.
If, during the study, there are abnormal clinical laboratory values or vital signs w hich were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefore represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported for the r etrospective observation period from the EOS visit of 
the core stud y until the informed consent/assent of the current study.
All pregnancies are to be reported for the prospective observation period from the date the ICF is 
signed (and if applicable, infor med assent,) in the SHP633- [ADDRESS_394157] be reported within 24 hours to the 
Shire Global Drug Safety Department using the Shire Investigat ional and Marketed Products 
Pregnancy  Report Form. A copy  of the Shire Investigational and Marketed Products Pregnancy 
Report Form (and an y applicable follow -up reports) must also be sent to the Sponsor Medical 
Monitor using the details specified in the em ergency  contact [CONTACT_1739]. 
In the event a subject becomes pregnant after signing the ICF and assent (if applicable), 
teduglutide administration must be discontinued immediately .
Every  effort should be made to gather information re garding the pregnancy  outcome and 
condition of the infant. For pregnancy  reports during the prospective period of observation, it is 
the responsibility  of the investigator to obtain this information within 30 calendar day s after the 
initial notification an d approximately  30 calendar day s postpartum. For pregnancies occurring 
during the retrospective period of observation (ie, before signing the informed consent for 
SHP633 -303), the initial notification date will be the date the pregnancy  is recorded for thi s 
study  and outcome and infant condition information may  be collected any time postpartum.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394158] 2019
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adv erse Event Form 
for Serious Adverse Events and Non- serious AEs as Required b y the Protocol. Note: An elective 
abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study Adverse Event Form for SAEs and 
Non-serious AEs as required by  [CONTACT_319499]. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error (Prospective Period of 
Observation Only)
Abuse, misuse, overdose, or medication errors (as defined below) that occur prior to signing the 
informed consent for SHP633 -303 will not be collected.
Abuse, misuse, overdose, or medication error (as defined below) during the prospective period of 
observation must be reported to the sponsor according to the SAE reporting procedure whether 
or not they  result in an AE/ SAE as described in Section 8.2. Note: The 24 -hour reporting 
requirement for SAEs does not apply  to reports of abuse, misuse, overdose, or medication errors 
unless these result in an SAE.
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse – Persistent or sporadic intentional intake of investigational product when used 
for a non -medical purpose (eg, to alter one’s state of consciousness or get high) in a 
manner that may  be detrimental to the individual and/or soci ety
Misuse –Intentional use of investigational product other than as directed or indicated 
at an y dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed b y the protocol)
Overdose –Administra tion of the investigational product at a dose or frequency  
greater than 0.05 mg/kg subcutaneous once dail y. An overdose occurs if any of the 
following criteria are met: 
More than 0.05 mg/kg is given at an y one time
Consecutive doses are spaced less than 1 2 hours apart
Any more than 0.05 mg/kg given in one day  (a day  is defined as beginning at 
12:00 AM and ending at 11:59 PM)
Medication Error –An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, m edication errors are reportable to the 
sponsor only  as defined below.
Cases of subjects missing doses of the investigational product are not considered 
reportable as medication errors
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394159] 2019
Medication errors should be collected/reported for all products under 
investigation
The administration and/or use of an expi[INVESTIGATOR_319372] a reportable medication error
All investigational product provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y-authorized represe ntative/caregiver.
8.[ADDRESS_394160] awareness of the eve nt. Note: The 
24-hour reporting requirement for SAEs does not apply  to reports of abuse, misuse, overdose, or 
medication errors (see Section 8.1.7) unless they  result in an SAE.
All adverse events of special interest, as defined in Section 8.3, experienced during the 
prospective period of observation must be reported by  [CONTACT_319500] S ponsor Medical Monitor within [ADDRESS_394161] complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Nonserious AEs as Required b y Protocol and verify the accuracy of the information 
recorded on the form with the corresponding source documen ts (Note: Source documents are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global Drug Safet y
Department. A cop y of the completed Shire Clinical Study Adverse Event Form for Serious 
Adverse Events (SAEs) and Nonserious A Es as Required by  [CONTACT_1738] (and any  applicable 
follow -up reports) must also be sent to the S ponsor Medical Monitor or designee using the 
details specified in the emergency  contact [CONTACT_1739].
8.2.3 Serious Adverse Event Definition
Aserious adverse event (SAE) is any  untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose: 
Results in death
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394162] 2019
Is life -threatening. Note: The term 'life -threatening' in the definition of "serious" re fers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatient hospi[INVESTIGATOR_8686]. 
Note: Hospi[INVESTIGATOR_602], which are the result of elective or previously  scheduled surgery  
for pre -existing conditions, which have not worsened after initiation of treatment, should 
not be classified as SAEs. For example, an admission for a previousl yscheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting from 
a hospi[INVESTIGATOR_230476](s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based upon appropriate medical judgment, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treat ment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
For the retrospective data collection pe riod (the interval between the EOS visit of the core study  
until signing the ICF [and informed assent, if applicable] for SHP633 -303), investigators will be 
asked if they  are aware of any  SAEs, regardless of relationship to teduglutide, that occurred 
during this time. Where applicable, first awareness for events with an onset during the 
retrospective period of observation will be the date the event is recorded for this study  in the 
eCRF. An SAE that occurred during the retrospective data collection period must be reported to 
Shire Global Drug Safety Department and the S ponsor Medical Monitor within [ADDRESS_394163] 
awareness of the event and reported as per Section 8.2.2.
For the prospective period of observation, all SAEs (regardless of relationship to stu dy drug 
administration) are collected from the time the subject signs the informed consent/assent until the 
defined follow -up period stated in Section 7.1.5. These SAEs must be reported to the Shire 
Global Drug Safet yDepartment and the S ponsor Medical Monitor within [ADDRESS_394164] 
awareness of the event, as per Section 8.2.2. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by  [CONTACT_10194] y interval after the study has completed must b e reported to the Shire Global 
Drug Safet yDepartment within [ADDRESS_394165]’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not co ntribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action wa s previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational produ ct action of “withdrawn” should not be selected solel y as a result of the 
subject’s death.
8.2.[ADDRESS_394166], Ethics Committee, and Site 
Reporting 
The sponsor and/or clinical contract research organization (CRO) is responsible for notify ing the 
relevant regulatory  authorities, and US central institutional review boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notify ing active sites of all related, un expected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
8.[ADDRESS_394167]
An AESI  is an AE (serious or nonserious) of scientific and medical concern specific to the 
sponsor’s product or program and for which ongoing monitoring and immediate notification by 
[CONTACT_230013].
The AEs of special interest that require expedited regulatory  reporting include the following:
Growth of pre -existing poly ps of the colon
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394168] 2019
Benign neoplasia of the GI tract including the hepatobiliary  system
Tumor -promoting ability (eg, benign and/or malignant neoplasia of any  kind, not limited 
to those of the GI or hepatobiliary  system)
For AESIs experienced during the retrospective or prospective period of observation, the sponsor 
must be informed within [ADDRESS_394169] awareness as per the SAE notification instructions 
described in Section 8.2.2 even if the event does not fulfill the seriousness criteria.
8.4 Dose Interruption of Individual Subjects (Prospective Period of Observation Only)
Sections 8.4 and 8.5apply onl y to dose interruption, permanent discontinuation, and adverse 
events that occur during the prospective period of observation.
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to conta ct the 
sponsor/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059], AEs, a lapse in investigational product delivery , etc. The length of 
dose interruption, and whether teduglutide adminis tration resumes or is permanently  
discontinued, depends on the clinical situation.
Investigational product must be interrupted if any of the following events occur:
An AE of special interest (see Section 8.3)
An AE that is of NCI CTCAE severit y Grade 3 or 4 and related to teduglutide
Intestinal obstruction
Biliary  obstruction related to teduglutide
Pancreatic duct obstruction related to teduglutide
Heart failure with severe fluid overload related to teduglutide
Investigational product must be permanentl y discontinued if an y of the following events occur:
Pregnancy
Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319447]. This does not include the presence of anti- teduglutide antibodies, mild 
injection site rea ctions or mild sy mptoms that according to the investigator do not pose a 
significant risk to the subject.
Confirmed DILI related to teduglutide (see Section 8.4.2)
Any malignancy
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394170] (Prospective Period of Observation 
Only)
The investigational product must be interrupted if the subject experienced an AE that is of 
severit y ≥Grade [ADDRESS_394171]. 
In consideration of whether a TEAE might lead to dose interruption, severe TEAEs will also be 
graded according to the NCI  CTCAE severit y grading criteria ( US Department of Health and 
Human Services et al., 2010 ). All such TEAEs should be discussed with the S ponsor Medical 
Monitor or designee as soon as possible. The length of the dose interruption, and whether 
teduglutide administration resumes or is permanently  discontinued, depends on the clinical 
situation.
8.4.2 Dose Interruption Criteria Based on Drug -Induced Liver Injury 
(Prospective Period of Observation Only)
Teduglutide administration for an individual subject may  need to be interr upted if the subject has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following criteria:
ALT or AST >8x ULN
ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
(ALT or A ST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)
ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory  values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_394172] should be followed closely to determine the trajectory  of the 
laboratory  abnormalities and to evaluate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cy tomegalovirus IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclea r, anti -smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed a t the discretion of the investigator in consultation 
with the S ponsor Medical Monitor.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394173] be permanentl y discontinued if DILI is confirmed and deemed 
related to stud y drug.
8.5 Early Termination of the Clinical Study (Prospective P eriod of Observation Only)
The data monitoring committee (DMC) may  recommend stoppi[INVESTIGATOR_319397]:
≥2subjects develop the same event of CTCAE severity  Grade [ADDRESS_394174]
or
1subject develops an event of CTCAE severity Grade [ADDRESS_394175] 2019
9 DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by [CONTACT_103365]. A study  monitor will visit each site and review retrospective data in accordance 
with the monitoring plan. Data collection procedures will be discussed with the site at the site 
initiation visit and/or at the investigator’s meeting. Unscheduled safet y follow up assessments 
(including visits conducted after EOS) are not to be collected unless requested.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Pr ocess
The study  will be anal yzed by  [CONTACT_10196]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitio ns for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications.
9.4 Planned Interim Analysis, and Data Monitoring Committee
An interim anal ysis of all retrospective data will be conducted. Other interim analy ses may  also 
be conducted if needed.
A DMC will be involved in the management of this s tudy. The DMC members will review the 
data approximately  every 3 months according to the DMC Charter. The DMC review will 
include all cumulative safety  data (ie, AEs, laboratory  assessments, phy sical examinations, etc.) 
from study  assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product.
The DMC for this study  will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394176] may not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hired by  [CONTACT_456], or members of 
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stopp ing, modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine whether the study  should be modified or temporaril y or 
permanentl y stopped.
9.5 Sample Size Calculation and Power Considerations
As this is an extension study , the maximum number of subjects was determined by  [CONTACT_319407] -C13-003.
9.6 Study Population
The safet y population includes all enrolled subjects in the study . The safet y population will be 
used for both safet y and efficacy anal yses.
9.7 Efficacy Anal yses
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1 Efficacy Endpoints
Efficacy  endpoints will be anal yzed at the end of each teduglutide tr eatment period (Week 24 or 
EOT), and at each stud y visit, relative to the baseline of the core study  (TED -C13-003) and/or 
first exposure to teduglutide. The following efficacy  endpoints will be analy zed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Complete weaning off PS
Change in day s per week of PS
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394177] 2019
9.8 Safety Analyses
Safety data, including laboratory  tests and vital signs assessments, will be summarized by  [CONTACT_765]. 
Adverse events will also be collected and summarized. Descriptive statistics will be calculated 
for quantitative safet y data as well as for the difference from baseline, if applicable. Frequency  
counts will be compi[INVESTIGATOR_319374] y data.
9.8.1 Safety Endpoints
The following safet y endpoi nts will be analy zed from the beginning of the prospective study  
period:
Adverse events
Vital signs, including body  temperature, heart rate, and blood pressure
Laboratory  safet y data (ie, clinical chemistry , hematology , and urinaly sis)
Urine output
Stool o utput
Antibodies to teduglutide
Gastrointestinal -specific testing including fetal occult blood testing and colonoscopy  or 
sigmoidoscop y
The following safet y endpoints will be analy zed from the end of the core study  (TED -C13-003) 
to the beginning of the prospective study  period:
Adverse events related to teduglutide
All SAEs
All AESI s (Section 8.3)
The following safet y endpoints will be analy zed relative to the baseline of the core study  
(TED -C13-003):
Z-scores for height (or length), weight, head circumference (up to 36 months of age), and 
BMI
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by [CONTACT_319425]. Serious adverse events will be further 
summarized by  [CONTACT_230535]. Adverse events related to 
investigational product, AEs leading to withdrawal, SAEs, and deaths will be similarly 
summarized/listed.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394178] 2019
Prior and concomitant medications will be coded using the World Health Organization -Drug 
Dictionary  (WHO -DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior medications will be summarized. Medical history  (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by  [CONTACT_6657].
For clinical laboratory  tests, vital signs, body  weight, and fluid b alance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each sche duled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies.
Additional safet y parameters and measures will include change in bod y weight, h eight (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z -score, BMI, and BMI z -score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and per centage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses
Health economics and outcomes research endpoints will be analy zed at approximately  12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects 
not on teduglutide), relative to the baseline of the prospective stud y period. The beginning of 
each treatm ent cy cle (CxD1) will be an additional baseline.
Change in Pediatric Quality  of Life Inventory  (PedsQL) score
Change in PedsQL Family  Impact Module score
Change in PedsQL Gastrointestinal Sy mptoms Module Sub- Scales scores:
Food and drink limits
Diarrhea
9.9.[ADDRESS_394179] 2019
10 SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsib ilities
10.1.[ADDRESS_394180] been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulati ons, I CH GCP Guideline E6 (1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behal f of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulat ory authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guide lines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394181] 2019
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies a nd within 1 y ear for nonpediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as required b y 
Article 10 (c) of Directive 2001/20/EC.
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_394182] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and approp riately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifi cations necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and subinvestigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the invest igator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator [INVESTIGATOR_319387]. Agreement with the final CSR is documented by  [CONTACT_319426] (single -site study ) or coordinating principal investigator (multicenter 
study ), in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 (1995). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394183] met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency with final reports and summaries as required by  (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the invest igator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
Electronic case report forms should be approved by [CONTACT_319427].
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory , queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be recorded in the subject’s medical records.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394184] permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the 
eCRF entries against the source documents. The consent form includes a statement b y 
which thesubject agrees to the monitor/auditor from the sponsor or its representatives, 
national or local regulatory authorities, or the IRB/EC, having access to source data 
(eg,subject’s medical file, appointment books, orig inal laboratory  reports, X -rays etc.). 
Nonstudy  site personnel will not disclose any  personal information or personal medical 
information.
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a proper ly authorized representative of any  regulatory  agency  (eg, the US FDA, 
European Medicines Agency  (EMA), [LOCATION_006] Medicines and Healthcare products Regulatory  
Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  [CONTACT_1779], for example, the US FDA (as wel l as other US 
national and local regulatory  authorities), the European Medicines Agency  (EMA), the 
Medicines and Healthcare products Regulatory  Agency , other regulatory  authorities, the sponsor 
or its representatives, and the I RB/EC for each site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_10204] , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, 
retainer forongoing consultation or hon oraria; an y proprietary interest in investigational 
product; anysignificant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 
2(b) (1998).
10.[ADDRESS_394185]’s legall y-authorized representative, as applicable, is requested to sign 
and date the subject informed consent form or a certified translation if applicable, after the 
subject has received and read (or been read) the written subject infor mation and received an 
explanation of what the study  involves, including but not limited to: the objectives, potential 
benefits and risk, inconveniences, and the subject’s rights and responsibilities. A cop y of the 
informed consent and assent documentation (ie, a complete set of subject information sheets and 
fully  executed signature [CONTACT_1787]) must be given to the subject or the subject’s legall y-authorized 
representative, as applicable. This document may  require translation into the local language. 
Signed consent forms must remain in each subject’s study  file and must be available for 
verification at an y time.
Within the source documents, site personnel should document instruction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
The principal investigator [INVESTIGATOR_1682] a cop y of the consent form, and assent form 
where applicable, that was reviewed b y the IRB/EC and whic h received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the sponsor, prior to the start of the study  unless it is agreed to 
and documented (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally , if the I RB/EC requires modification of the sample subject information and 
consent documen t provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_394186] or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site initiation .
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating principal investigator [INVESTIGATOR_10157], according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator a greement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not b e released until the sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394187] 2019
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_1683]/EC apprised of the 
progress of the stud y and of an y changes ma de to the protocol, but in any  case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_394188] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_317364] (or designee).
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
review their medical records and data collected during the stud y. These records and data may, in 
addit ion, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP633; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of sub jects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that laboratory  results have been assign ed to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines 
(eg,Good Publication Practices 2) when forming a publication steering committee, which is 
done for large, multicenter Phase [ADDRESS_394189] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  informati on existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_10206], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her publications. To the e xtent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publication” refers to a ny public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  [CONTACT_10207] y publication of study results, or necessary for other scholars to verify such stud y 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_394190] publication of the study results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163]. If such a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_10209] 18- month period after co nclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accord ance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwise required by  [CONTACT_10210], or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394191] 2019
11 REFERENCES
Drucker, D. J. and Yusta, B. 2014. Ph ysiology  and pharmacology  of the enteroendocrine 
hormone glucagon- like peptide -2. Annu Rev Physiol, 76, 561-83.
Khan, F. A., Squires, R. H., L itman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., 
Sudan, D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. and Duggan, C. 
2015. Predictors of Enteral Autonomy  in Children with I ntestinal Failure: A Multicenter 
Cohort Study . J Pediatr, 167, 29- 34.e1.
Mouksassi, M. S., Marier, J. F., Cy ran, J.and Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon -like 
peptide-2 analog in neonates and infants with short- bowel sy ndrome. Clin Pharmacol 
Ther, 86, 667-
71.
O'Keefe, S. J., Buchman, A. L ., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P. B. and Shaffer, 
J. 2006. Short bowel sy ndrome and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol, 4, 6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. 
A., Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs
-Lasky, M. and Belle, S. H. 
2012. Natural history  of pediatric intestinal failure: initial report from the Pediatric 
Intestinal Failure Consortium. J Pediatr, 161, 723- 8.e2.
Tappenden, K. A., Edelman, J.and Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel sy ndrome. J Clin 
Gastroenterol, 47, 602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Ve gge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. and Sangild, P. T. 2014. Acute effects of the glucagon- like peptide 2 
analogue, teduglutide, on intestinal adaptation in short bowel sy ndrome. J Pediatr 
Gastroenterol Nutr, 58, 694-702.
US Department of Health and Human Services, National Institutes of Health and National 
Cancer Institute 2010. Common Terminology  Criteria for Adverse Events (CTCAE).
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. and Dixon, P. 2004. The 
PedsQL  Famil y Impact M odule: preliminary  reliability  and validity . Health Qual Life 
Outcomes, 2, 55.
Wales, P. W., de Silva, N., Kim, J., L ecce, L., To, T. and Moore, A. 2004. Neonatal short bowel 
syndrome: population
-based estimates of incidence and mortality  rates. J Pediatr Surg,
39, 690-5.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394192] 2019
APPENDIX 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol [ADDRESS_394193] 2019 Global
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 3 Amendment Date
16 May 2018Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319472] 
.Emergency Contact [CONTACT_319473], a new escape criterion was added, allow ing 
those who had escaped during the follow -up period of a previous teduglutide 
treatment to omit the foll ow-up period during subsequent teduglutide 
treatment cycles. 
For subjects who previously escaped the follow -up period, CxW24 
assessments can be combined with the next pretreatment visit assessments.Study Synopsis; Table 1 -4, 
Figure 3-1; Section 3.1; Sect ion 4.6; 
Section 6.2.3; Section [IP_ADDRESS]; 
Section [IP_ADDRESS]; Section 7.1.5; 
Section [IP_ADDRESS]
Clarified language that all concomitant procedures are to be captured, not 
just gastrointestinal procedures.Table 1 -2; Table 1 -3; Table 1 -4, 
Section 5.1; Section 7.1 .2; 
Section7.1.3; Section [IP_ADDRESS]; 
Section [IP_ADDRESS]; Section 7.1.6
Updated the information on the clinical studies with teduglutide in pediatric 
subjects to include the results of TED -C14-006. Section 1.3
Added new PK simulation data to further support dosing. Section 3.1
Deleted text that was duplicated in other sentences of sections. Section 5.1
Deleted biological therapy (eg, antitumor necrosis factor) from the table of 
prohibited treatments as it was included in error.Table [ADDRESS_394194] of laboratory tests. Table 7 -1
Clarified that if a child is unable to complete a quality of life questionnaire 
(due to developmental delay or other illness) it will not constitute a protocol 
deviation.Section [IP_ADDRESS]
Minor editorial changes and corrections to typographical errors (w hich do 
not modify content and/or intent of the original document) were made.Throughout protocol
For non-commercial use only

Shire CONFIDENTIAL Page [ADDRESS_394195] 2019
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2 Amendment Date
17 Mar 2017Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319456]. Emergency Contact [CONTACT_7171]; 
Section 8.1.6; Section 8.2.2; 
Section 8.2.4
Revised teduglutide treatment inclusion criterion #[ADDRESS_394196] been enough to assess efficacy are eligible to receive treatment 
in Study SHP633 -303. Study Synopsis; Section 4.4
Revised teduglutide treatment exclusion criterion #[ADDRESS_394197] of experimental drugs exempt of a washout period before 
initiating teduglutide treatment in Study SHP633 -303. Study Synopsis; Section 4.5; 
Section 5.1.[ADDRESS_394198] pretreatment visit (P1) follow s the screening visit, it must occur 
within 12 w eeks of screening.Table 1 -4
To qualify the language on abstinence as a contraceptive method in the 
study protocol as requested by [CONTACT_319443] ([LOCATION_006]) Medicines and 
Healthcare products Regulatory Authority (MHRA) in their letter dated 
29th December 2016.Section 4.7.1
Clarification that ancillary components, in addition to sterile w ater for 
injection syringes, will also be provided and labeled in accordance w ith 
the applicable regulatory requ irements.Section 6.3.1
A footnote was added in Table 7 -3 to clarify that subjects older than 
18years of age will continue to use the Child Self Report and Parent 
Proxy -Report for Teens (ages 13 -18) when completing the Pediatric 
Quality of Life Generic C ore Scale (PEDSQL™).Section [IP_ADDRESS] (Table 7 -3)
Revised the text on severity categorization to specify that a severe 
treatment -emergent adverse event (TEAE) that might lead to dose 
interruption (Section 8.4.1) or early termination of the study (Section 8.5) 
will also be graded according to the National Cancer Institute’s (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE) severity 
grading criteria, in addition to the standard severity categorization. These 
events are no longer limited t o only the events described in Table 8 -1, 
entitled “CTCAE Criteria for Adverse Events that May Lead to Dose 
Interruption (Prospective Period of Observation Only). Therefore, Table 
8-1 has been deleted.Section 8.1.1; Section 8.4; 
Section 8.4.1; Table 8 -1 (deleted)
Revised the criteria for early termination of the study as requested by [CONTACT_319501] 06 Jan 2017: stoppi[INVESTIGATOR_319402] [ADDRESS_394199], and no longer limited to the events described 
in Table 8 -1, entitled “CTCAE Criteria for Adverse Events that May 
Lead to Dose Interruption (Prospective Period of Observation Only).Section 8.[ADDRESS_394200] 2019
Amendment Number 1.1 Amendment Date
09 Jan 2017United -Kingdom -Specific
Description of Change and Rationale Section(s) Affected by [CONTACT_319442] a contraceptive method in the 
study protocol as requested by [CONTACT_319443] ([LOCATION_006]) Medicines and 
Healthcare products Regu latory Authority (MHRA) in their letter dated 
29th December 2016.Section 4.7.1
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319502] S ponsor medical monitor has been changed to Medical 
Director for clarity.Protocol Signature [CONTACT_319504] [CONTACT_319431] -teduglutide treatment 
period, visits will take place approximately every 12 w eeks.Synopsis
Sections 3.1, 3.1.3, 7.1.3
Figure 3 -1
The study design flow chart has been edited for clarity. Synopsis
Figure 3 -1
The collection of all actual and prescribed enteral nutrition data has been 
removed to reduce the burden on the subjects and investigators. Enteral 
nutrition data are not required as the efficacy endpoints are limited to 
parenteral support parameters.Syno psis
Table 1 -2, Table 1 -3, Table 1 -4
Sections 3.1.3, 7.1.2, 7.1.3, [IP_ADDRESS], 
[IP_ADDRESS], 7.1.6, [IP_ADDRESS], [IP_ADDRESS]
Exclusion criterion [ADDRESS_394201] been refined: 
exclusion/prohibition of treatment with growth hormone has b een 
extended to [ADDRESS_394202] been refined.Table 1 -1
Sections 7.1.1, [IP_ADDRESS], [IP_ADDRESS]
Com pletion and review of intake and output diaries have been clarified. 
Also, review of diaries has been removed from the screening visit and 
added to the pretreatment visit.Table 1 -2, Table 1 -3, Table 1 -4
Sections 7.1.2, [IP_ADDRESS], [IP_ADDRESS], 7.1.6, 
[IP_ADDRESS]
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394203] 2019
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319503] s been revised so that a 
lack of urinalysis will not constitute a protocol deviation for any pediatric 
subjects (not only for subjects wearing diapers).Table 1 -2, Table 1 -3, Table 1 -4
Section [IP_ADDRESS]
Clarification has been made that the first no -teduglutide treatment visit 
after the screening visit will occur within 2 to 12 w eeks of the screening 
(formerly within 12 weeks of screening). Synopsis
Table [ADDRESS_394204] been clarified for visits during the no -teduglutide and 
teduglut ide treatment periods.Table 1 -3, Table 1 -4
Section 7.1.3
‘Specific’ has been deleted from ‘positive/specific anti -teduglutide 
antibodies’ to eliminate the redundancy. By [CONTACT_108], positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative. Table 1 -3 
Sections [IP_ADDRESS], 9.8.1
For consistency within the protocol, sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol. Table 1 -2, Table 1 -3, Table 1 -4
Sections 3.1.3, 7.1.3, [IP_ADDRESS]
Removal of former footnote j on fecal occult blood test for clarity. Table 1 -4
Clarification has been made on circumstances when the CxW28 visit may 
be combined with the next pretreatment or EOS/ET visit. Table 1 -4
Section 7.1.5
The text on PS support requirements over time in pediatric subjects w ith 
SBS has been clarified, and text on intestinal adaptation has been refined.Section 1.1
Status of current teduglutide approvals for use has been updated. Sections 1.2, 3.1
The term ‘rechallenge’ has been replaced w ith ‘additional teduglutide 
treatment’ and ‘PN/IV’ with ‘PS’ for clarity and consistency w ith other 
studies.Synopsis
Sections 3.1, 3.1.[ADDRESS_394205] been clarified.Sections 4.8.1, 4.8.2
Withdraw al by [CONTACT_7078]/guardian has been added as reason for 
discontinuation.Section 4.8.[ADDRESS_394206] if deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study drug 
has been clarified.Section 6.4
Paragraph on the purpose of prospective data collection has been deleted 
for clarity.Section 7.2.2
Clarific ation has been made on the collection of medical history and SBS 
history.Synopsis
Sections 3.1.3, 7.1.2, [IP_ADDRESS]
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394207] 2019
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_64737]
A new section which describes the adverse event (AE) collection during 
the prospective period has been added to the study evaluations and 
procedures. Section [IP_ADDRESS]
Clarification has been made that local laboratory results are not required 
to be entered in the eCRFs. (form erly Section [IP_ADDRESS])Section [IP_ADDRESS]
Collection of urine sodium and urine osmolality has been removed. Section [IP_ADDRESS]
Clarification has been made that the serum sample will not be collected at 
the pretreatment visit if the subject met a follow -up period escape 
criterion. (formerly Section [IP_ADDRESS])Section [IP_ADDRESS]
Nutritional support and diaries (formerly in Section 7. 2.2.9) have been 
moved under separate sections (Sections [IP_ADDRESS] and [IP_ADDRESS], 
respectively) for clarity. Information on study drug administration diary 
has been added in the diary section. Clarification has been made that only 
available diary data will b e reviewed at each clinic and telephone visit.Sections [IP_ADDRESS], [IP_ADDRESS] 
Performance of dipstick specific gravity tests by [CONTACT_319433]. 
It is now at the discretion of the investigator for all subjects, not just 
those in diapers. This change is to align with standard medical practice.Section [IP_ADDRESS] 
Reporting of AEs during the retrospective period has been clarified and 
corrected for consistency across safety section s of the protocol. Only 
nonserious AEs related (instead of possibly related ) to teduglutide need 
to be reported. No changes to the protocol w ere made for the reporting of 
all AEs of special interest or any serious adverse events, regardless of 
relationship to teduglutide, that occurred during the retrospective period.Section 8.[ADDRESS_394208] been made to the language on dose interruption. Sections 8.4, 8.4.1
Unscheduled safety follow  up assessments (including visits conducted 
after EOS) are not to be recorded. How ever, clarification has been made 
that they are to be collec ted where requested.Section 9.1
Clarification has been made that the interim analysis will be conducted 
on all retrospective data, and other interim analyses may also be 
conducted if needed.Section 9.4
The protocol now refers to the data monitoring com mittee (DMC) 
Charter for the schedule of DMC reviews.Section 9.[ADDRESS_394209] 2019
APPENDIX 2 GUIDELINES FOR NUTRI TIONAL SUPPORT MANAG EMENT 
DURING THE STUDY
Nutritiona l support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managin g nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period.
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical evaluations
Serum electrol ytes
Blood urea nitrogen /creatinine levels
Changes in stool frequency  or volume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deteri oration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte changes or imbalance
Skin breakdown 
Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the stud y.
Nutritional support constituents m ay be adjusted at the discretion of the investigator.
During the [ADDRESS_394210]’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.
If there is a change in EN or other food or fluid intake, the investigator should consider this 
when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394211] 2019
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394212] 2019
APPENDIX 3 CAREGIVER INTERVIEW GUIDE
Exit Interv iews With Caregiv ers
Follow ing Participation in a
Short Bow el Sy ndrome Clinical T rial
1.Introduction (5Minutes)
Introduce interviewers
Confirm caregiver’s first name [CONTACT_319506] w
We are interested in learning more about your child’s symptoms and impacts due to short 
bowel syndrome and parenteral support. W e would also like to understand your experiences 
caring for your child as well as you and your child’s experiences with regard to treatment 
during the clinical trial.
The information you share with us will help the study sponsors learn more about potential 
treatment benefits of the clinical trial drug.
As we go along, please feel comfortable to speak openly an d share your opi[INVESTIGATOR_319403]. 
There are no wrong answers. You are the expert.
Unless you report a side effect potentially related to a medication that our study sponsors 
produce during today’s call, your name [CONTACT_319507] e 
with us.
If you doreport a side effect during today’s call, I have to let the study sponsors know. I 
may ask you some follow -up questions to fully understand the nature of the experience 
so I can fully communicate information to the study sponsor.
**REMEMBER TO TURN ON THE AUDIO RECORDER ONCE CONSENT I S PROVIDED. 
INTERVIEWER WILL VERBALLY NOTE STUDY ID AND INTERVIEW DATE**
2.History and Symptoms (10 minutes)
Just briefly, please tell us about your child’s history with SBS.
How old is your child?
How long has your child had SBS?
How long has your child received parenteral support?
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394213] 2019
What symptoms of SBS does your child experience? W hat symptoms due to parenteral 
support does your child experience? Are there other symptoms your child experienced in the 
past but doesn’t experience currently? W hat are those? [Probe for complete list and write 
down each symptom provided by [CONTACT_2299]; for each symptom, probe to understand 
whether due to SBS, parenteral support, or both]
Symptom 1: ________________________________
Symptom 2: _______ _________________________
Symptom 3: ________________________________
Symptom 4: ________________________________
Symptom 5: ________________________________
[If not provid ed spontaneously by [CONTACT_2299], specific symptoms will be probed.]
Now we would like to discuss other symptoms that some patients or caregivers have described 
to see whether or not they are things your child has experienced as well.
As I read each sym ptom, please let me know if your child has experienced this symptom in 
relation to his or her SBS or parenteral support. [Only read those symptoms not already 
provided by [CONTACT_2299]; probe to understand whether due to SBS, parenteral support, or 
both]
Pain/discomfort
Fatigue
Frequent need to empty bowels/bag
Diarrhea
Of the symptoms you have described which would you say is the most bothersome for your 
child? W hy?
3.Impacts (10 minutes)
How does your child’s SBS and parenteral support affect his or her life? [Probe for complete 
list and write down each impact provided by [CONTACT_18629]; probe to understand whether 
impact of SBS, parenteral support, or both]
Impact 1: ________________________________
Impact 2: ________________________________
Impact 3: ________________________________
Impact 4: ________________________________
Impact 5: ____________________________ ____
[If not provided spontaneously by [CONTACT_2299], specific impacts will be probed.]
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394214] 
described to see whether or not they are things your child has experienced as well.
As I read each impact, please let me know if you have experienced this in relation to your 
child’s SBS and parenteral support. [Only read those impacts not already provided by [CONTACT_2416]. For endorsed impacts, ask the participant to describe the ir experiences with the 
impact and whether they feel it is due to SBS or parenteral therapy or both]
Daily activities, including school if applicable
-Need to know/plan for bathroom facilities when leaving home
Physical functioning
Social functioning
Emotio nal functioning
Sleep
Of the impacts you have described, which would you say is the most bothersome to your 
child? W hy?
4.Clinical Trial Experiences (10 minutes)
Now we would like to talk about your experience during the clinical trial.
What were your expectations of treatment prior to entering the clinical trial?
Thinking back to before you started the clinical trial, what were some of the reasons you 
decided to enroll your child in the trial?
Were there specific symptoms/issues which you most wanted t reatment to help? W hich 
ones? W hy?
How frequently was your child receiving parenteral therapy at the beginning of the trial? 
[Probe on how many times a week, for how many hours, and when administered] .
What improvements, if any, have you noticed in your child since starting the study? [Have 
caregivers describe each improvement reported]
Improvement 1: ________________________________
Improvement 2: ________________________________
Improvement 3: ________________________________
Improvement 4: ________________________________
Improvement 5: ________________________________
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394215] 2019
What were the biggest improvements you noticed? How important, if at all, were these 
improvements to you?
Were there smaller or other improvements that you noticed that were also meaningful to 
you? If so, please describe these improvements. [Add these improvements to the list above]
I would lik e to review each of the improvements that you noticed. Thinking about [a 
symptom from the list] , how would you describe them before the study? [Probe mild, 
moderate , or severe , as applicable]
How would you describe them after the study? [Probe none , mild, moderate , or severe , as 
applicable]
[If not reported] Were there any improvements in your child’s parenteral therapy during the 
study? How important, if at all, was this change to you? [Probe to capture current parenteral 
frequency]
Of all of the improveme nts we have talked about, which do you think was the most important 
to your child? Why? W hich was the most important to you? W hy?
How would you describe the change in your child’s SBS overall after participating in the 
study? [Probe: very much better , much better , a little better, no change , a little worse , much 
worse , or very much worse]
5.Caregiver Experiences (10 minutes)
Now we would like to talk about your experience as a caregiver of a child with SBS.
How has having a child with SBS impacted your life? [Probe for complete list and write down 
each impact provided by [CONTACT_18629]; probe to understand whether impact of SBS, 
parenteral support, or both]
Impact 1: __________________ ______________
Impact 2: ________________________________
Impact 3: ________________________________
Impact 4: ________________________________
Impact 5: ________________________________
[If not provided spontaneously by [CONTACT_2299], specific impacts will be probed.]
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394216] experienced as well.
As I read each impact, please let me know if you have experienced this in relation to caring 
for your child with SBS [Only read those impacts not already provided by [CONTACT_2299]. For 
endorsed impacts, ask participants to des cribe their experiences with the impact and 
whether they feel it is due to their child’s SBS, parenteral therapy for the SBS, or both.]
Caregiver’s daily activities
-Need to know/plan for bathroom facilities when leaving home with child
Caregiver’s physical functioning
Caregiver’s emotional functioning
Caregiver’s social functioning
Caregiver’s sleep
Financial impact
Of the impacts you have described which would you say is the most bothersome for you? 
Why?
Which, if any, of the above do you feel was improved during your child’s participation in the 
clinical trial? How important, if at all, was this improvement?
6.Closing
Is there anything else you would like to add about your child’s SBS?
Thank you for taking the time to meet with us today. Your inpu t has been very helpful and will 
also be helpful for the patients that will participate in further research on SBS. Thank you again.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394217] INTERVIEW GUIDE
Exit Interv iews With Pediatric Subjects
Follow ing Participation in a
Short Bow el Syndrome Clinical T rial
7.Introduction (5Minutes)
Introduce interviewers
Confirm subject’s first name [CONTACT_319508] a nd format of the intervie w
We are interested in learning more about your symptoms and impacts due to short bowel 
syndrome and parenteral support (the nutrition and fluids you get because of your short 
bowel). W e would also like to understand your experienc es during the study you were in. 
The information you share with us will help the study sponsors learn more about potential 
treatment benefits of the clinical trial drug.
As we go along, please feel free to speak openly and share your opi[INVESTIGATOR_319403]. Ther e are 
no wrong answers. You are the expert.
Unless you report a side effect that might be related to a medication that our study sponsors 
produce during today’s call, your name [CONTACT_319509].
If you doreport a si de effect during today’s call, I have to let the study sponsors know. I 
may ask you some follow -up questions to fully understand what happened so I can fully 
share this with the study sponsor.
**REMEMBER TO TURN ON THE AUDIO RECORDER ONCE CONSENT I S PROVID ED. 
INTERVIEWER WILL VERBALLY NOTE STUDY ID AND INTERVIEW DATE**
8.History and Symptoms (15 minutes)
Just briefly, please tell us about history with SBS.
How old are you? 
How long have you had SBS?
How long have you been getting parenteral support? [Confirm participant understanding 
of term and use term if understood/used or use the participant preferred term throughout 
the interview]
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394218] 2019
What symptoms of SBS do you experience? W hat symptoms due to parenteral support do 
you experience? Are there other symp toms you have had in the past but do not experience 
today? W hat are those? [Probe for complete list and write down each symptom provided by 
[CONTACT_2299]; for each symptom, probe to understand whether due to SBS, parenteral 
support, or both]
Symptom 1: ________________________________
Symptom 2: ________________________________
Symptom 3: ________________________________
Symptom 4: _______________ _________________
Symptom 5: ________________________________
[If not provided spontaneously by [CONTACT_2299], specific symptoms will be probed.]
Now we would like to discuss other symptoms that some patients have described to see 
whether or not they are things you have experienced as well.
As I read each symptom, please let me know if you have experienced this symptom in 
relation to your SBS or parenteral support. [Only read those symptoms not already provided 
by [CONTACT_2299]; probe to understand whether due to SBS, parenteral support, or both]
Pain/discomfort
Fatigue
Frequent need to empty bowels/bag
Diarrhea
Of the symptoms you have described which would you say is the most bothersome for you? 
Why?
9.Impacts (15 minu tes)
How does your SBS and parenteral support affect your life? [Probe for complete list and 
write down each impact provided by [CONTACT_2299]; probe to understand whether impact of 
SBS, parenteral support, or both]
Impact 1: ____ ____________________________
Impact 2: ________________________________
Impact 3: ________________________________
Impact 4: ________________________________
Impact 5: ________________________________
[If not provided spontaneously by [CONTACT_2299], specific impacts will be probed.]
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394219] experienced as well.
As I read each impact, please let me know if you have experienced this in relation to your 
SBS and parenteral support. [Only read those impacts not already provided by [CONTACT_2416]. For endorsed impacts, ask the part icipant to describe their experiences with the 
impact and whether they feel it is due to SBS or parenteral therapy or both]
Daily activities, including school if applicable
-Need to know/plan for bathroom facilities when leaving home
Physical functioning
Social functioning
Emotional functioning
Sleep
Of the impacts you have described, which would you say is the most bothersome to? W hy?
10. Clinical Trial Experiences (10 
minutes)
Now we would like to talk about your experience during the clinical trial.
What did you think the study would be like before you started it? 
Thinking back to before you started the study, what were some of the reasons you decided 
to be a part of the study? 
Were there specific symptoms/issues which you most wanted treatment to help ? Which 
ones? W hy?
How frequently were you child receiving parenteral therapy at the beginning of the trial? 
[Probe on how many times a week, for how many hours, and when administered] .
What improvements, if any, have you noticed since you started the stud y? [Have 
participants describe each improvement reported]
Improvement 1: ________________________________
Improvement 2: ________________________________
Improvement 3: ________________________________
Improvement 4: ________________________________
Improvement 5: ________________________________
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_394220] 2019
What were the biggest improvements you noticed? How important, if at all, were these 
improvements to you?
Were there smaller or other improvements that you noticed that were also meaningful to 
you? If so, please describe these improvements. [Add these improvements to the list above]
I would like to review each of the impro vements that you noticed. Thinking about [a 
symptom from the list] , how would you describe them before the study? [Probe mild, 
moderate , or severe , as applicable]
How would you describe them after the study? [Probe none , mild, moderate , or severe , as 
appli cable]
[If not reported] Were there any improvements in your parenteral therapy during the study? 
How important, if at all, was this change to you? [Probe to capture current parenteral 
frequency]
Of all of the improvements we have talked about, which do yo u think was the most important 
to you? W hy? 
How would you describe the change in your SBS overall after being in the study? [Probe: 
very much better , much better , a little better, no change , a little worse, much worse , or very 
much worse ]
11. Closing
Is there anything else you would like to add about your SBS?
Thank you for taking the time to meet with us today. Your input has been very helpful and will 
also be helpful for the patients that will participate in further research on SBS. Thank you agai n.
For non-commercial use only